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ABSTRACT
Poor growth is a significant problem in children with chronic renal failure. Poor
nutrition and metabolic abnormalities contribute to poor growth, and in addition
disturbances of growth hormone (GH) and its mediator insulin-like growth factor-I
(IGF-I) have been described. Growth rates usually decline further once dialysis is
required, and whilst growth rate may improve following renal transplantation in some
children, this is not universal, and may not be sustained. Final adult height is reduced in
children who require dialysis or transplantation during childhood.
It is on this background that recombinant human growth hormone (rhGH) is
being used more commonly in children with chronic renal failure. The basis of this
thesis is a multi-centre study looking at the safety and efficacy of the use of rhGH in
10 infants with chronic renal failure (CRF), 29 children with CRF, 14 children on
peritoneal dialysis (PD), 8 on haemodialysis (HD) and in 22 children following renal
transplantation. All of the children were followed during one year of rhGH treatment
except the transplanted children who were randomised either to receive 2 years of
rhGH treatment or to receive no treatment in the first year and rhGH in the second
year. RhGH treatment (liu/kg/week) improved short to medium term growth in all of
these groups of children. Comparison between groups and factors predictive of the
magnitude of response to rhGH are described, as are the effects of rhGH during the
pubertal years.
The main safety issues which are addressed are the effects of rhGH on renal
function, immune function, renal bone disease, and the effects on glucose and lipid
metabolism. Patients with acromegaly, where there is overproduction ofGH, have
large kidneys that have an increased glomerular filtration rate (GFR). In a setting of
impaired renal function, a stimulus to increase GFR could result in hyperfiltration,
which is thought to be one mechanism for progression of chronic renal impairment.
Renal function was measured in the CRF and transplanted children; there was no
significant change in the CRF group, but an increase was seen in the transplanted
group after 1 week and 6 months which returned to baseline by one year. These
findings and the effects of rhGH on blood pressure, renal size and protein excretion are
discussed in detail.
v
There are well established links between GH and the immune system,
particularly in smaller mammals. In man, GH and IGF-I receptors are found on
peripheral blood lymphocytes, and in vitro studies indicate a role for GH in
lymphopoiesis and granulopoiesis. Minor changes in lymphocyte subsets have been
reported with GH replacement in children with GH deficiency. Children with renal
transplants are immunosuppressed, and any increase in immune activity could result in
rejection of the graft. Flow cytometry studies demonstrated little change in lymphocyte
subsets, and markers of T lymphocyte activation in the CRF and transplanted patients
during rhGH treatment. Overall there was no increase in the incidence of rejection
episodes in the transplanted children during rhGH treatment. These results are
decribed in detail.
Carbohydrate and lipid metabolism are already disturbed in chronic renal
failure, and could be altered further by rhGH treatment. Fasting glucose was
unchanged by rhGH treatment, but fasting insulin increased transiently. Fasting
cholesterol and triglyceride levels were already increased in many children before the
start of treatment, and with the exception of the CRF group, in whom a small but
significant increase in triglyceride was seen, there was little change during the study.
The implications of these findings are discussed, as are the effects of rhGH on bone
metabolism. Calcium was unchanged during treatment, but significant increases in
phosphate and alkaline phosphatase were seen. Parathyroid hormone increased during
rhGH treatment in the CRF groups.
Abnormalities of the GH / IGF-I axis are found in chronic renal failure; indeed
a state of GH resistance has been described. Detailed studies ofGH, IGF-I and its
binding proteins (IGFBPs) were undertaken to investigate the mechanisms ofGH
resistance and the effects of rhGH treatment both before and after renal
transplantation. Roles for different IGFBPs in the mechanism of short stature before
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CAPD continuous ambulatory peritoneal dialysis
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GFR glomerular filtration rate
GH growth hormone
GHD growth hormone deficiency
GHRH growth hormone releasing hormone
HbAlc glycosylated haemoglobin
HD haemodialysis
HLA human leucocyte antigen
HV height velocity
height SDS height standard deviation score
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rhGH recombinant human growth hormone
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RTA renal tubular acidosis
SD standard deviation
SDS standard deviation score
SDS-PAGE sodium dodecyl sulphate polyacrylamide gel
electrophoresis
SE standard error
WCC white cell count
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WLB western ligand blot
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Foreword
Short stature has long been recognised as an important complication of chronic renal
failure. For many children with renal disease it is the one visible sign that they are ill.
Many factors, such as nutrition and electrolyte disturbances are involved, and
conservative management goes some way toward improving poor growth. However
many children with chronic renal failure remain short, and renal replacement therapy
does not always improve the situation. Some children grow well following renal
transplantation, but unfortunately this is not the case for all children. Dialysis, whether
it be haemodialysis or peritoneal dialysis, may improve well-being and weight gain, but
rarely results in catch up growth. More often the height drifts down through the
centiles.
It is on this background that recombinant human growth hormone therapy has been
introduced for children with chronic renal failure. High levels of endogenous growth
hormone had initially suggested that the growth hormone / insulin-like growth factor-I
axis was not involved in short stature of chronic renal failure, however in 1983 Mehls
was able to demonstrate increased growth in uraemic rats given growth hormone
(Mehls el al. 1983). These studies resulted in preliminary trials of growth hormone in
children with chronic renal failure in the late 1980's and early 1990's. The beneficial
results of these early studies increased the use of rhGH in short children with chronic
renal failure. However, it remained necessary to investigate the safety of growth
hormone treatment in these children, and to establish whether all children benefit
equally from the use of growth hormone therapy.
This thesis reports the results of the British Association for Paediatric Nephrology
(BAPN) multi-centre trial of recombinant human growth hormone therapy in chronic
renal failure, which was co-ordinated by myself. Supplementary to the trial, further
more detailed studies were undertaken to look at specific safety aspects of growth
hormone treatment. I undertook these studies at the three London paediatric
xxx




Short stature is a significant problem for children with renal disease. Many factors
contribute to the poor growth which complicates chronic renal failure (CRF), renal
tubular problems, renal transplantation, and the use of corticosteroids in patients with
renal disease. In certain conditions it is possible to study the isolated effect of one
factor, e.g. acidosis in renal tubular acidosis, but more often there are many factors at
play, and the relative importance of each is difficult, if not impossible, to assess. Age
at the onset of renal problems is also an important factor, such that conditions which
present in infancy are more likely to cause short stature than those which present in
later life. Some renal conditions are particularly likely to be associated with growth
failure. Examples of such conditions are infantile cystinosis and congenital nephrotic
syndrome.
This chapter will outline normal growth during childhood, describe the patterns of
growth in children with CRF, and will then go on to describe the aetiology of poor
growth in renal disease, and the treatment options that are available. The rationale for
the use of recombinant human growth hormone (rhGH) in this situation will be
described, as will the initial results and the concerns of using rhGH in CRF. The term
CRF refers to patients with a glomerular filtration rate (GFR) of less than 75
ml/min/1.73m2, most of whom will be receiving conservative management only. As
used this term also includes children with end stage renal failure (ESRF) (GFR of less
than 10-15 ml/min/1.73m2) most of whom will have received a renal transplant or be
on dialysis. In this thesis the term chronic renal insufficiency (CRI) is used to describe
those children with CRF who are being treated conservatively. This term is also used




The rate of growth varies throughout childhood (Tanner et al. 1965), and can be
divided into three stages, namely infancy, midchildhood and puberty.
Infancy
At the time of birth mean length is 50 cm and height velocity (HV) is at its greatest.
Height velocity declines sharply during the first two years of life, although the rate of
growth is relatively fast compared with later childhood. Approximately 26 cm of
length are added during the first year of life, with a further 10 cm being gained during
the second year of life. By the age of two years, a child has reached half of its final
adult height, so that one third of post-natal growth has occurred in the first two years
of life. Growth at this time is influenced mainly by nutrition (Betts and Magrath
1974), although there is a contribution from growth hormone (GH) (Albertsson
Wikland et al. 1990).
Midchildhood
The rate of growth is relatively constant during midchildhood, gradually slowing
down to a nadir of approximately 5 cm/yr before puberty. Growth during this time is
due to the influence of GH.
Puberty
The pubertal growth spurt occurs on average after the age of 10 years in girls, and
after 12 years in boys, and during puberty approximately 30 cm are added to final
adult height. During the pubertal growth spurt, GH secretion increases under the
influence of sex steroids.
Assessment of Growth
When assessing growth in children, it is necessary to consider both the statural height
already attained and the rate of growth at the time of study. Short stature is assumed
when the height is below the 3rd centile for age and sex, although by this definition
2
3% of normal children are included. Maintaining a position on any centile, even the
3rd centile, requires a normal height velocity; when height velocity decreases the child
falls away from the centiles. To return to the normal range requires a height velocity
greater than expected for age, so called catch-up growth.
Growth is expressed in cm per year (cm/yr), however as growth is seasonal, and
affected by intercurrent illness or stress, it is necessary to leave a suitable interval
between measurements to allow accurate estimation of annualised height velocity.
This is particularly so for children who are growing poorly. Height needs to be
measured at the same time of day, by trained personnel using suitably accurate
equipment, such as a wall-mounted stadiometer. In the first two years of life
recumbent length is measured. During this time the occipito-frontal head
circumference has been shown to be a good measure of brain growth (Winick and
Rosso 1969; Proyer and Thelander 1968).
For comparison of height and height velocity data, standard deviation scores (SDS)
are used in preference to centiles.
Height SDS = Patient's height - mean height for age and sex
standard deviation for age and sex
A height SDS of zero approximates to the 50th centile and a height SDS of -2 is
equivalent to a height on the 3rd centile. Height velocity SDS (HVSDS) is calculated
in a similar fashion. The increase in height SDS is denoted as A height SDS.
Another factor which has to be taken into consideration during the assessment of
growth is the bone age. Bone age reflects skeletal maturation and is an indicator of
growth potential. A delayed bone age implies that the child may continue to grow for
a relatively longer period of time.
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Genetic factors influence height and must be considered in the assessment of a child's
height. The parental heights should be measured and the mid-parental height
ascertained. The final adult height for a boy should lie within 10 cm of this
measurement, and for a girl within 9 cm (Tanner et al. 1970).
Growth in Chronic Renal Failure
Poor growth is a major problem in renal disease. Approximately 60% of children with
CRI have a height below the normal range (Rizzoni et al. 1984; Rees et al. 1989).
The situation is even worse for children on dialysis; the European Dialysis and
Transplant Association (EDTA) registry data report a mean height SDS of -4.2 for
boys and -3.8 for girls of all ages who are on dialysis (Rizzoni et al. 1991).
Transplantation results in good catch up growth in some children (Klare et al. 1991;
Broyer et al. 1992; Maxwell et al. 1998a), but there are many who remain below the
3rd centile. A study in Holland found that the mean final adult height SDS was -2.5
for men and women who had received renal transplants in childhood (Hokken-
Koelega et al. 1994a), and disappointingly the North American Pediatric Renal
Transplant Co-operative Study (NAPRTCS) found that catch-up growth occurred
only in children aged less than 7 years at the time of transplantation (Tejani et al.
1993).
Short stature is a particular problem for children with congenital renal disease who are
more affected than children with acquired renal disease occurring later in childhood
(Betts and Magrath 1974). The type of renal disease is also important; children with
inherited tubular problems are often very stunted (Potter and Greifer 1978). For
many, but not all conditions, growth declines as renal function deteriorates (Betts and
Magrath 1974), but with good supportive management normal growth rates can be
maintained (Polito et al. 1987). In any one child there are multiple factors operating,
and their relative importance is often difficult, if not impossible, to determine. The
child's age is very important when considering the effects of renal failure on growth.
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Infancy
Children with congenital renal disease and those with problems commencing in
infancy are most at risk of short stature (Betts and Magrath 1974). As described
above, growth is fastest in infancy; ill health at this time results in a rapid loss of
stature. Antenatal diagnosis of renal problems has allowed these infants to be followed
from birth; growth is most affected in the first six months of life, when height SDS
can decline by as much as 0.6 SD each month (Rizzoni et al. 1984). The children
described in this study had a normal birth weight and length. Birth weight is usually
normal, but a number of children with renal dysplasia are small at birth (Rees et al.
1989). Data on birth length are more scarce.
Similar observations of poor growth in infancy in renal disease have been reported by
a number of groups (Jones et al. 1982; Kleinknecht et al. 1983; Rizzoni et al. 1984;
Warady et al. 1988; Rees et al. 1989; Abitol et al. 1993). Taking these reports
together, height SDS at presentation is negatively correlated with age; mean height
SDS for those presenting in the first month was -0.6 SD (Warady et al. 1988), while
those presenting at 1 year had a mean height SDS of -2.9 (Rees et al. 1989).
Growth in infancy is highly dependent on nutrition (Betts and Magrath 1974), and
provision of adequate calories can improve growth (Strife et al. 1986). Many of these
infants have tubular dysfunction, and correction of electrolyte, base and fluid loss
results in a marked improvement in growth (Rees et al. 1989). Each of these factors is
discussed in detail below. In this age group, catch-up growth can be achieved in some
infants with good conservative management and intensive nutritional support (Rees et
al. 1989).
In addition to poor growth, ESRF in infancy has been described as causing an
encephalopathy, manifest by reduced cognitive ability, microcephaly and reduced
motor function (Rotondo et al. 1982; McGraw and Haka-Ikse 1985; Polinsky et al.
1987). Renal replacement therapy can alleviate this, with a slight improvement
occurring on peritoneal dialysis (Warady et al. 1988), and a more marked
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improvement being seen after renal transplantation (Nevins 1987; So et al. 1987;
Davis et al. 1990; Najarian et al. 1990).
Midchildhood
After the first one to two years of life, children with CRF grow at a normal rate, so
that the child remains below but parallel to the 3rd centile. Catch-up growth is rare.
Rees et al found that after infancy, intensive conservative management only resulted
in a slow improvement in growth (Rees et al. 1989). At presentation to the clinic,
61% of the children described were below the normal range for height; at the end of
the study period, 53% remained below the 3rd centile.
During childhood, there is no definite correlation between growth in patients with
CRF and absolute GFR (Rees et al. 1989). Growth tends to be along the centiles at
this stage (Betts and Magrath 1974; Claris-Appiana et al. 1989), and the growth rate
remains relatively normal until either ESRF or puberty is reached. Growth on dialysis
is less than that observed during conservative management (Kleinknecht et al. 1980).
Children with a later onset of renal problems often show a slowing down of growth in
the initial stages of the illness, then grow along a lower centile when their condition is
more stable.
Puberty
Puberty is associated with development of secondary sexual characteristics and an
increase in growth rate. The onset of the pubertal growth spurt, which is taken as the
time of minimum HV prior to the growth spurt, is delayed by an average of
approximately two and a half years in both sexes in renal failure (Schaefer et al.
1990). Interestingly the absolute height at which this occurs is similar to that in
normal controls, but the peak velocity achieved during puberty is reduced to
approximately 75% of that of controls. In addition the duration of the pubertal growth
spurt is attenuated; on average it is reduced by one year in boys and by one and a half
years in girls. These factors combine to result in a reduction in expected height gain
during puberty, from 30 to 17 cm in boys and from 29 to 14 cm in girls (Schaefer et
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al. 1990). Bone age at the end of puberty was less than expected; little growth
occurred after a mean bone age of 15.6 years in boys and 14.7 in girls in this study
(Schaefer et al. 1990). Growth potential is therefore lost during puberty.
Much of the data regarding pubertal growth and development are derived from
studies which combine children on different treatment modalities. In the study
described above the majority of children were receiving either conservative
management or dialysis at the onset of puberty, but treatment modality changed in a
number of children such that by the end of puberty most children had received a renal
transplant (Schaefer et al. 1990). This course is not unusual in children with renal
disease, so data on the effects of different treatment modalities on pubertal growth are
hard to come by. Broyer described 17 children on haemodialysis, of whom 10 were of
a pubertal age; the pubertal growth spurt was absent or severely depressed in all 10
children (Broyer et al. 1974). There is an ongoing multi-national study of growth and
development during puberty in renal disease which may be able to provide these data
(Scharer et al. 1990).
Traditionally growth during puberty in children with renal transplants has been
described as poor, with some authors reporting little growth in those with a bone age
over 12 years (Grushkin et al. 1973; Rees et al. 1988). Since the introduction of
cyclosporin A and the subsequent reduction in steroid dosage, normal patterns of
pubertal growth have been described (Maxwell et al. 1998a).
Sexual maturation is also delayed by approximately two and a half years in renal
disease (Scharer et al. 1990). Progression through puberty is generally normal,
although temporary maturational delay has been reported (Schaefer and Mehls 1994).
Secretion of luteinising hormone is reduced in uraemic adolescents (Scharer et al.
1990) and adults (Rodger et al. 1985), but normal in transplanted patients (Scharer et
al. 1990; Rodger et al. 1985). The effects of uraemia in childhood on future fertility
are not known. Preliminary data suggest that sperm counts are reduced in men with
renal transplants who developed ESRF in childhood (Scharer et al. 1989; Schaefer et
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al. 1991a). In contrast testicular atrophy occurring in adult men who develop ESRF is
reversed by successful renal transplantation (Phadke et al. 1970; Rodger et al. 1985).
Final Adult Height
The ultimate test of the management of growth is final adult height. There are only a
few studies which provide this information. Changes in management over the last two
decades, and an increase in the proportion of younger patients now surviving, do
however limit the applicability of such data to the present time. The EDTA registry
report a mean adult height SDS of -2.0 for boys and -1.3 for girls, in children who
commenced renal replacement therapy before the age of 15 years and who were alive
in 1984 (Rizzoni et al. 1986a). This report excluded patients with cystinosis and
oxalosis, who are more severely stunted. Patients requiring renal replacement therapy
before the age of ten were shorter than those who started between the ages of ten and
fifteen. Patients who remained on dialysis were shorter than those who received renal
transplants (Rizzoni et al. 1986a).
Final adult height SDS was less severely retarded at -0.8 in a cohort of 22 patients
who remained on conservative management throughout puberty (Schaefer et al.
1989).
Aetiology of Poor Growth in Renal Disease
Nutrition
Currently much emphasis is attached to the role of inadequate nutrition as a cause of
poor growth in children, and in particular, infants with renal disease. Uraemic rats eat
less than ad libitum fed controls, and gain less weight than pair-fed controls,
suggesting not only a reduced appetite, but also poor utilisation of energy (Chantler et
al. 1974). Calorie supplementation improves but does not normalise growth in
uraemic rats (Adelman and Holliday 1974; Holliday 1975).
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In children with CRF, energy intake has variously been described as being correlated
with (Simmons et al. 1971; Betts and Magrath 1974; Arnold et al. 1983) and not
being correlated with growth (Broyer et al. 1974; Betts et al. 1977; Wass et al.
1977). Betts and Magrath were able to relate reduced calorie intake to poor growth in
CRF; less than 80% of the recommended daily allowance (RDA) for age for energy
intake was associated with a growth rate of less than 75% of that expected for age
(Betts and Magrath 1974). Similarly Simmons et al showed that in children on
haemodialysis, only those with a calorie intake of greater than 70% of normal had
normal growth (Simmons et al. 1971), but Broyer was unable to confirm this in his
haemodialysis population (Broyer et al. 1974). Likewise calorie supplementation has
been shown to improve growth in some groups of children, but not others (Simmons
et al. 1971; Arnold et al. 1983). However Betts, in a prospective study did not find an
improvement in growth with calorie supplements, although energy intake was only
increased by 8.4% (Betts et al. 1977). Arnold, in a two year study, was able to
correlate growth rate and energy intake during the first observational year. During the
second year calorie supplementation was given, and whilst the growth rate increased
towards that expected for age, catch-up growth did not occur. In the second year,
there was no longer a correlation between growth and energy intake. In this study,
intake increased from 73 to 103 % of RDA (Arnold et al. 1983). Sufficient energy
intake therefore appears to be permissive for normal growth, but does not necessarily
accelerate growth. In view of the evidence of poor utilisation of energy in uraemia,
perhaps even higher intakes are needed.
There is evidence that growth can be increased by energy supplementation in infants
with CRF (Rees et al. 1989; Ledermann et al. 1994). Rees was able to show that
catch-up growth can occur in children who present to a paediatric nephrologist before
the age of two (Rees et al. 1989). Similarly in another single centre report, enteral
feeding of 26 infants and young children with congenital renal disease resulted in an
improvement in length SDS from -2.9 to -2.0 after two years (Ledermann et al.
1994). A North American multicentre study however has given disappointing results;
catch up growth occurred in some but not all infants (Abitol et al. 1993). The
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management of small children with CRF continues to remain a challenge. Poor
response to conservative management in some infants has resulted in a trial of the use
of rhGH in this age group (Maxwell et al. 1996a).
The reasons for poor intake are anorexia, vomiting, altered taste sensation and
sometimes inability to ingest adequate calories because of the large volumes of fluid
ingested in some infants who are unable to conserve salt and water. If adequate
nutrition cannot be achieved via the oral route, then nasogastric or gastrostomy
feeding should be instituted. Recurrent episodes of infection or repeated operations
which interrupt feeding programmes contribute to periods of poor growth.
Adequate calories are necessary for growth and anabolism; inadequate intake results
in increased use of protein as an energy source. Inadequate protein intake as a cause
of poor growth is uncommon these days, but was frequently seen in the past (Chantler
1984). Urinary and peritoneal protein losses can be high. Trials of dietary protein
restriction show that growth and weight gain are not affected by restriction of protein
to World Health Organisation safe levels of 0.8-1.1 g/kg/day (Wingen et al. 1991).
Acidosis
The importance of normal acid-base balance to growth is apparent from the study of
children with renal tubular acidosis (RTA). Both proximal and distal RTA present
with growth failure (Nash et al. 1972). Each of the 9 children with proximal RTA
described by Nash presented within the first 18 months of life with failure to thrive
and vomiting. Four children with distal RTA also presented with poor growth, but in
addition had symptoms related to polyuria and polydipsia. In both groups there was a
sharp increase in height velocity upon starting alkali therapy. Thereafter growth
continued at a slower but improved rate. Normal height was achieved in all patients,
with 3 approaching the 50th centile. Height velocity decreased in one patient in whom
the parents temporarily stopped treatment (Nash et al. 1972). McSherry analysed 10
children with distal RTA: 6 had a height below the normal range; 4 were small but
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within the normal range (McSherry 1978). Of the latter 4 patients, 2 were newly
diagnosed neonates and two had previously been shown to be non-acidotic. In the
group as a whole, height was inversely correlated with duration of acidosis. On
starting alkali therapy, height velocity increased two to three fold and all children
achieved a height within the normal range. Mean height was greater than that
predicted from parental heights.
Whilst the evidence in RTA is impressive, direct evidence that acidosis is an important
cause of poor growth in CRF is lacking. Poor growth and acidosis have been shown
to be correlated in some studies (West and Smith 1956), but it is not clear whether
this is a causal association. Correction of acidosis per se has not been demonstrated to
improve growth in CRF.
The mechanism of poor growth in acidosis and improved growth with alkali therapy is
not entirely clear. It may be a direct effect of acidosis, or related to increased
excretion of sodium, potassium and calcium which occurs during acidosis. More
recent work however suggests that the mechanism may be due to an effect on GH
secretion (Caldas and Fontoura 1994). Growth hormone secretion in children with
CRF and RTA was studied in the acidotic and non-acidotic state; mean and peak
spontaneous and provoked GH secretion was reduced in both groups during acidosis.
Levels of the main GH mediator, insulin-like growth factor-I (IGF-I), were also
reduced during acidosis. Growth hormone secretion and IGF-I were no different from
controls in the non-acidotic state (Caldas and Fontoura 1994).
This phenomenon has also been demonstrated in laboratory animals. Experimental
acidosis resulted in reduced GH secretion (Challa et al. 1993a), reduced hepatic
expression ofGH receptor mRNA and hepatic IGF-I mRNA (Challa et al. 1993b) and
reduced chondrocyte expression of IGF-I mRNA (Hanna et al. 1995). Poor growth in
these acidotic animals is partially but not totally due to malnutrition, and cannot be
overcome by either GH or IGF-I treatment (Ordonez et al. 2000).
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It has also been shown that administration of rhGH to human volunteers with
experimentally induced chronic acidosis results in an increase in plasma bicarbonate
from 14.1 mmol/1 to 18.6 mmol/1 (Sicuro et al. 1998). Children who have GH
deficiency (GHD) are more likely to have a lower serum bicarbonate level that
children with short stature due to other causes (Glaser et al. 1998).
Fluid and Electrolytes
Isolated tubular defects resulting in loss of electrolytes are associated with poor
growth ; height velocity increases when these deficiencies are corrected. Such
conditions point to the importance of water and certain electrolytes for growth.
Children with Bartter's syndrome are short and replacement of sodium and potassium
improves growth (Simopoulos 1979). Some of these children have a normal adult
height, while others remain stunted. Similarly, in familial chloridorrhoea, a syndrome
in which there is excessive loss of chloride in the stool, sodium chloride replacement
results in improved growth (Roy and Arant 1981). A salt-depleted diet in rats is
associated with poor growth (Wassner 1991). Approximately 50% of patients with
nephrogenic diabetes insipidus are stunted. Increased fluid intake increases growth
(Vest et al. 1963).
Salt and water loss frequently complicate obstructive uropathy. As with acidosis the
contribution which correction of these deficiencies makes to improved growth in CRF
is difficult to quantify.
Renal Osteodystrophy
Traditionally renal osteodystrophy has been assumed to be an important cause of
growth failure in renal disease (Stickler and Bergen 1973). With florid renal bone
disease complete cessation of growth can occur with destruction of the growth plate,
or slipping of the epiphyses, but fortunately since the advent of activated vitamin D
preparations, this is now an uncommon problem (Malluche and Faugere 1989).
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An early report suggested that 1,25 dihydroxy vitamin D could increase growth
velocity (Chan JCM et al. 1981), but this has not been substantiated by larger studies
(Chesney 1985). Six out of 11 children studied by Chan showed an improvement in
growth; many of these children had marked x-ray changes of renal bone disease prior
to starting vitamin D therapy (Chan JCM et al. 1981). Treatment of uraemic rats with
vitamin D increases but does not normalise growth velocity (Mehls et al. 1978).
Improved growth seems to be limited to those with marked bone disease. However
normal growth can occur in the presence of x-ray changes of renal osteodystrophy.
Anaemia
There is a theoretical role for anaemia in poor growth of renal disease; anaemia is
associated with decreased appetite and recurrent infections. Conditions with marked
anaemia e.g. thalassaemia are associated with poor growth (in the absence of iron
overload), with recurrent transfusions improving growth. Poor oxygenation could be
a rate-limiting step in cell proliferation. It has been difficult to look at the effects of
anaemia in isolation, however the widespread availability of recombinant human
erythropoietin has allowed the problem to be addressed from a different angle. Does
correction of anaemia improve growth? Initial reports were encouraging (Seidel et al.
1991), but a large multi-centre trial study has shown no beneficial effect of
erythropoietin on growth (Schaefer et al. 1991b).
Hormonal Factors
Levels of GH and IGF-I are normal or raised in CRF and it is only relatively recently
that the GH/IGF-I axis has been implicated in short stature of renal disease (Samaan
and Freeman 1970; Rees et al. 1990). Growth hormone is secreted in a nocturnal
pulsatile fashion from the pituitary gland in response to episodic secretion of GH
releasing hormone (GHRH) from the hypothalamus. Somatostatin from the
hypothalamus acts to suppress the secretion of GH. Almost 50% of circulating GH is
bound to a binding protein (growth hormone binding protein - GHBP), which may
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represent a soluble form of the GH receptor (Baumann et al. 1989). Growth hormone
acts on the liver to cause the secretion of IGF-I (Schoenle et al. 1982). This peptide is
highly protein bound; six binding proteins have been identified in man (IGFBPs 1-6).
The main carrier protein is IGFBP-3 which acts as a reservoir for IGF-I (Rosenfeld et
al. 1994). Many of the anabolic actions of GH are mediated by IGF-I, but GH also
acts directly at the growth end-plate to stimulate growth (Isaksson et al. 1982), and
thirdly it stimulates the local production of IGF-I (Nilsson et al. 1990). The relative
contributions of circulating and locally produced IGF-I to growth are not known.
In CRF the control of GH secretion is abnormal; stimulation of the pituitary results in
oversecretion of GH (Tonshoff et al. 1990a). Overnight profiles of GH secretion
show increased pulse amplitude and baseline GH (Schaefer et al. 1991c). The kidney
is involved in clearing GH from the circulation, and this in part may explain the high
baseline levels. GH binding protein is reduced in CRF (Maxwell et al. 1991; Tonshoff
et al. 1997), suggesting a reduction in GH receptors and a state of GH resistance.
Indeed it has been shown by Chan that there is reduced expression of hepatic GH
receptors in uraemic rats, and these animals demonstrate reduced IGF-I mRNA
expression in response to GH (Chan et al. 1993).
Another possible mechanism of growth failure in renal disease is a reduction in the
bioactivity of IGF-I (Saenger et al. 1974). Circulating IGF-I is normal in CRF when
measured by immunoassays, but low when measured by bioassay. IGF-I is lower in
patients on dialysis than in those receiving conservative treatment only (Phillips and
Kopple 1981).
Reduced IGF-I bioactivity has been postulated to be due to increased amounts of
IGFBPs, in particular IGFBP-3 (Blum et al. 1991). It is thought that fragments of
IGFBP-3, which are normally cleared by the kidney, accumulate in renal disease and
bind to and therefore reduce the amount of free IGF-I. Other groups have not found
IGFBP-3 to be significantly elevated in CRF, and other IGFBPs have been implicated
(Baxter and Martin 1986; Hodson et al. 1992; Lee D-Y et al. 1993).
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Steroids
Corticosteroids interfere with growth through a number of mechanisms. Spontaneous
growth hormone secretion is reduced by steroids (Pantelakis et al. 1972), even in
children on alternate day steroids (Rees et al. 1988). Steroids are thought to alter
somatostatin tone (Wehrenberg et al. 1990). Increased GH secretion at the time of
puberty is particularly susceptible to steroid suppression (Rees et al. 1988). IGF-I
bioactivity is reduced in patients on steroids (Unterman and Phillips 1985); bioactivity
falls within 6 hours of the steroid dose but returns to normal within 24 hours. Steroids
may also reduce local IGF-I production; in vitro high levels of Cortisol decrease
skeletal IGF-I synthesis by reducing IGF-I transcription (McCarthy et al. 1990).
Steroids also interfere with collagen synthesis (Hyams et al. 1986). Type I
procollagen is a by-product of collagen synthesis; levels are reduced in children with
inflammatory bowel disease on daily steroids, but not in those on alternate day or on
no steroids.
The relative importance of these mechanisms to poor growth during steroid therapy
remains speculative.
Psychosocial
Emotional deprivation is a recognised cause of poor growth. Children suffering
emotional deprivation have been shown to gain weight and grow when admitted to
hospital (Green et al. 1984). The extra demands of a child with a chronic illness may
be too great for a family already stressed by financial, housing or other worries, and
the child may not receive the care and attention that they need. Rizzoni described an
association between growth and psychological and socio-economic status (Rizzoni et
al. 1986b). Parents may find it difficult to bond with an infant with severe congenital
abnormalities, in whom survival is not assured, developing an ambivalence towards a
child whom they have not expected to survive.
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It is interesting that a small but significant increase in height velocity was seen in the
placebo arm of a double-blind controlled study of the use of growth hormone in CRF
(Hokken-Koelega et al. 1991).
Growth During Different Stages of Chronic Renal failure
ConservativeManagement
Approximately 60% of children with CRI have a height below the normal range (Rees
et al. 1989). Renal dysplasia, with or without obstruction and reflux, is the most
common cause of end stage renal disease in childhood, with growth often being
affected in the first year of life. Intensive nutritional support, orally, by nasogastric
tube or by gastrostomy feeding is imperative, particularly in the first year of life
(Ledermann et al. 1994). After this age the effects of nutritional support are difficult
to disentangle from other aspects of treatment. Calorie supplementation does not
consistently result in improved growth (Betts et al. 1977), but poor growth can be
demonstrated in children with diets deficient in calories (Betts and Magrath 1974;
Simmons et al. 1971). As improved growth is not seen in every infant fed enterally,
the use of rhGH is being evaluated in children of this age group (Fine et al. 1995;
Maxwell et al. 1996c).
Correction of acidosis, fluid and electrolyte abnormalities and avoidance of secondary
hyperparathyroidism and renal osteodystrophy by controlling serum phosphate level,
and by the early use of activated vitamin D, are important aspects of management.
Good conservative management allows normal growth, but catch-up growth is rare
after infancy (Rees et al. 1989).
Dialysis
The use of peritoneal dialysis is becoming more common; of children under 15 on
dialysis in the United Kingdom, approximately 68% are on peritoneal dialysis, and
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32% on haemodialysis (Report of the BAPN, 1995). Home continuous ambulatory
peritoneal dialysis (CAPD) or continuous cycling peritoneal dialysis (CCPD) is the
treatment of choice for chronic dialysis. There are occasions however when
haemodialysis is the only or preferred option. Poor social circumstances, persistent
fluid overload, gastrointestinal abnormalities or previous gastrointestinal surgery may
reduce the feasibility of peritoneal dialysis.
Despite correcting some of the metabolic abnormalities associated with renal failure,
haemodialysis does not improve growth (Broyer et al. 1974). Broyer reported normal
growth in 4 out of 17 children, with a variable reduction in growth rate being seen in
the remainder. Catch-up growth was not seen. Kleinknecht reported a reduction in
mean height SDS of 0.4SD per year in children on haemodialysis (Kleinknecht et al.
1980). Children who grew better could not be distinguished by residual renal function
or dialysis prescription. As is the case for children managed conservatively (Arnold et
al. 1983), energy was permissive for growth on dialysis, but did not induce catch-up
growth (Simmons et al. 1971). Growth studies of children on dialysis tend to be
limited by high rates ofwithdrawal due to transplantation.
Growth during the first year of peritoneal dialysis is reported as being stable, and
better than that observed during haemodialysis (Fennell et al. 1984; Potter et al.
1986). However on more prolonged follow-up, growth rates during peritoneal dialysis
decline (Fine and Mehls 1986).
Growth in infants on peritoneal dialysis receiving enteral feeds is variable (Strife et al.
1986; Warady et al. 1988; Ledermann et al. 2000). Warady reported four infants who
started peritoneal dialysis before one month of age, who at the age of one year had a
mean height SDS of-1.3. Neurological development was within the normal range in 3
and was mildly retarded in one child. Gross motor development was retarded in all
infants. Mean occipito-frontal head circumference SDS was -1.4, with one patient
being below the normal range (Warady et al. 1988). Kohaut reported on 9 infants
commenced on peritoneal dialysis within the first 6 weeks of life (Kohaut et al. 1987);
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mean height SDS was -0.8 at the start of CAPD and -1.7 after 1 year. Mean occipito¬
frontal head circumference SDS did not change during this time; -0.4 before and -0.5
after 1 year of CAPD. Four of the surviving 6 infants who are transplanted are
developmentally normal, 2 are delayed. However Strife reported improved growth in
3 infants on peritoneal dialysis (Strife et al. 1986), and Brewer reported improved
growth in 14 such infants (Brewer et al. 1986). Ledermann reported improved growth
and increased occipito-frontal head circumference SDS in 20 infants on peritoneal
dialysis followed up for 2 years (Ledermann et al. 2000). These are all small studies,
with patients who no doubt differ in their clinical condition. The goal for these infants
is renal transplantation; intensive nutritional management, and dialysis where
necessary, are carried out in an attempt to maintain growth and development until
transplantation is possible.
Renal Transplantation
The preferred mode of renal replacement therapy in childhood is transplantation, and
many centres aim for pre-emptive transplantation. At present approximately 25% of
children are transplanted without prior dialysis (Tejani et al. 1993). Whilst pre¬
emptive transplantation has not been shown to be of benefit in terms of post-
transplant growth, it prevents the child from having a period in their life when growth
is restricted.
Eight percent of transplants performed in the UK in 1992 in children under 15 years
were from live related donors (LRD) (United Kingdom Transplant), in contrast to
North America where 55% are from LRD (Tejani et al. 1993). Data from the North
American Pediatric Renal Transplant Co-operative Study (NAPRTCS) report 5 year
LRD patient survival of 97%, and of 94% for cadaver grafts respectively. Five year
graft survival is 73% for LRD, and 59% for cadaver kidneys (Stablein et al. 1993).
Comparable data from the EDTA reveal almost identical results (Broyer et al. 1993).
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Growth following renal transplantation is variable, and appears to be influenced by
several factors, principally steroid dose and schedule, graft function, and age at
transplantation. Some groups report disappointing growth with catch-up being limited
to children under the age of six or seven (Ingelfinger et al. 1981; Bosque et al. 1983;
Tejani et al. 1993). Others report stable or improved growth with some achieving
almost complete catch-up (van Diemen-Steenvorde et al. 1987; Rees et al. 1988;
Klare et al. 1991; Maxwell et al. 1998a).
The growth suppressive effects of corticosteroids have long been recognised (Lam
and Arneil 1968). The introduction of cyclosporin A has allowed the use of much
lower doses of steroids, resulting in improved growth (Offner et al. 1987; Guest et al.
1991; Ettenger et al. 1991). Perhaps even more significantly, the use of the same total
dose of prednisone in an alternate day regime compared to daily administration,
results in improved growth (Broyer et al. 1992). In one study children who converted
to alternate day steroids had a mean increase in height SDS of 0.5SD per year
compared to a reduction of height SDS by -0.1 in patients who continued on daily
prednisone. All children received alternate day steroids for the second year and
growth rate continued to improve (Broyer et al. 1992). A recent Dutch study has also
found a positive effect of alternate day steroids on growth in the first two years after
transplantation (Hokken-Koelega et al. 1994b), and on final adult height (Hokken-
Koelega et al. 1994a).
Even more impressive increases in height SDS are seen when steroids are withdrawn
completely; Klare reported an increase of 0.8SD in the first year post transplant, with
almost complete catch-up occurring over 4 years (Klare et al. 1991). Tejani also
found an increase in height SDS on discontinuing steroids, but 9 of 23 patients had to
restart prednisone after developing acute rejection episodes (Tejani et al. 1989).
Renal function is a further determinant of growth post transplantation. In a
NAPRTCS report of growth during a two year study period, a reduction in creatinine
of 90 (j.mol/1 was associated with a decrease in height SDS of -0.17 (Tejani et al.
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1993). Pennisi found a reduction in growth rate when the GFR fell below 60
ml/min/1.73m2 (Pennisi et al. 1977). Similarly poor catch-up growth in the first two
years after transplantation has been associated with a GFR of less than 50
ml/min/1,73m2 (Hokken-Koelega el al. 1994b).
Age at transplantation is important; the greatest catch-up growth is seen in infants,
with an improvement in height SDS of 0.8 SD in the first year (Tejani et al. 1993).
Catch-up growth is also reported in midchildhood, but the improvement lessens with
increasing age. There are several reports of poor growth in older children who receive
renal transplants (Ingelfinger et al. 1981; Bosque et al. 1983; Tejani et al. 1993), but
others report normal growth at this age (van Diemen-Steenvorde et al. 1987; Rees et
al. 1988; Klare et al. 1991; Maxwell et al. 1998a).
Most reports agree that growth during puberty is a problem. There is a reduction in
endogenous GH secretion, and peak height velocity during the pubertal growth spurt
is negatively correlated with the cumulative dose of steroid (Schaefer et al. 1990,
1991c). Some authors suggest that improvement in growth after transplantation will
occur only with a bone age of less than 12 years (Grushkin and Fine 1973; Fine and
Ettenger 1988), but a pubertal growth spurt has been demonstrated in some patients
of this age, albeit it of decreased amplitude (Schaefer et al. 1990; Najarian et al.
1990). With the increasing use of low dose, alternate day steroids, some adolescents
can achieve a very normal pubertal growth spurt (Maxwell et al. 1998a).
The management of infants with end-stage disease is more controversial.
Transplantation at this age has been reported to carry a higher operative and post¬
operative morbidity and mortality, with reduced graft and patient survival being
reported by some (Fine and Ettenger 1988), but not all centres (Nevins et al. 1987;
So et al. 1987). Impressive results have been obtained from centres specialising in
transplantation in infants (Nevins et al. 1987; So et al. 1987). In these centres patient
and graft survival are no different to those in older children and adolescents. The best
results are seen with the use of living related donors. Following transplantation,
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impressive catch-up growth is seen in infants (Tejani et al. 1993). Perhaps of greater
importance is the improvement that is seen in indices of mental and motor
development (Davis et al. 1990). There is also a marked improvement in occipito¬
frontal head circumference, suggesting increased brain growth (Winick and Rosso
1969).
European Dialysis and Transplant Association data report a mean height SDS, for
children of all ages on dialysis, of -4.2 in boys and -3.8 in girls (Rizzoni et al. 1991).
The equivalent figures for children with renal transplants were -2.7 and -2.3
respectively. There was little improvement over the 5 years of the study which was
carried between 1985 and 1990. This may be due to an increase in the number of
infants with congenital renal disease who have been taken onto end stage programmes
during this time period. These children are often very short and they may mask any
improvement in the management of growth over the last few years.
Recombinant Human Growth Hormone
In CRF poor growth may persist despite optimum conservative management,
institution of dialysis, and for some children despite renal transplantation. Therefore
the discovery that growth hormone improved growth in uraemic rats (Mehls et al.
1983), led to the first small trials of the use of rhGH treatment in short and poorly
growing patients with CRF on conservative management, on dialysis, and in those
with renal transplants (Lippe et al. 1988; Rees et al. 1990; Tonshoffet al. 1991a).
In addition to promoting growth, GH has many other actions, which can best be
appreciated from the study of patients with GHD, and by studying the response of
these patients to GH replacement. The main action of growth hormone is to stimulate
longitudinal bone growth. Children with GHD are short; patients with gigantism are
abnormally tall. Adult patients with acromegaly show overgrowth of certain bones
resulting in large extremities and characteristic facies.
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There are a number of mechanisms whereby GH is able to stimulate bone growth.
Growth hormone appears to have a direct action on the growth plate. Evidence
supporting this is the presence GH receptors on epiphyseal chondrocytes and
osteoblasts (Werther et al. 1990). Furthermore, GH stimulates DNA synthesis, cell
proliferation and the production of collagen matrix of cultured chondrocytes in vitro
(Lindahl et al. 1986), and when injected into the growth plate of hypophysectomised
rats GH produces longitudinal bone growth (Isaksson et al. 1982).
Growth hormone also acts via its mediator IGF-I; both systemic IGF-I and locally
produced IGF-I stimulate longitudinal bone growth. Schlechter showed that part of
the direct action of GH was due to locally produced IGF-I (Schlechter et al. 1986).
Systemic IGF-I also induces growth as demonstrated by IGF-I treatment of children
with GH receptor deficiency (Wilton 1992). Such treatment results in improved
growth (Wilton 1993). However transgenic mice which over-express GH or GHRH
grow faster than non-transgenic siblings, whilst transgenic mice over-expressing IGF-I
grow at the same rate as litter mates (Ohlsson et al. 1998). Taken together, it would
appear that both GH and IGF-I stimulate bone growth, although the mechanisms
involved seem to be different. One hypothesis proposes that GH stimulates germinal
chondrocytes to differentiate into proliferating chondrocytes which both produce and
respond to local IGF-I in a paracrine or autocrine fashion (Isaksson et al. 1987).
In addition to bone growth, GH is also involved in bone remodelling. Osteoblasts
express GH receptors (Nilsson et al. 1995) and GH stimulates proliferation and
differentiation of osteoblasts (Ernst and Froesch 1988). Growth hormone increases
the synthesis of type 1 collagen, alkaline phosphatase and osteocalcin in vitro (Kassem
et al. 1994), and GH also stimulates the differentiation and activation of osteoclasts
(Maor et al. 1989).
The importance of GH in bone remodelling is evident from the fact that patients with
GHD have a reduced bone mineral content (Lu et al. 1992; Saggese et al. 1993). This
is the case both for GEDD occurring in childhood as shown in the above studies but is
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also true for GHD acquired during adulthood (Holmes et al. 1994). Bone mineral
content continues to be accrued until 25 -30 years of age, however peak bone mineral
mass is related to the duration and timing of the pubertal growth spurt (Finkelstein et
al. 1992). Growth hormone replacement in GHD patients results in an increase in
bone mineral density (Saggese et al. 1996).
The actions of GH are not limited to longitudinal bone growth. Patients with GHD
have truncal obesity and abnormal body composition, with a decreased fat-free mass,
increased body fat and reduced extracellular water. Adult patients with GHD have
abnormal cardiac structure and function, and have cardiovascular risk factors such as
hyperlipidaemia, decreased fibrinolysis and increased atherosclerosis. In GHD there is
decreased psychological well-being and reduced exercise performance. Both GFR and
ERPF are reduced.
There is also altered glucose metabolism. Patients with acromegaly have glucose
intolerance and an increased incidence of diabetes (Sonksen et al. 1967). The actions
ofGH are balanced by those of insulin. Growth hormone reduces peripheral uptake of
glucose and increases hepatic synthesis of glucose (Karlander et al. 1986), whereas
insulin increases the peripheral uptake of glucose. These two forces act in concert to
maintain a constant blood glucose level, despite intermittent carbohydrate loads.
Excess GH secretion or administration of GH results in increased blood glucose
levels, but there is usually an associated increase in insulin secretion which counteracts
these effects (Salomon et al. 1989). Glucose intolerance or diabetes results when
these compensatory mechanisms no longer operate. A further metabolic action of GH
is to cause lipolysis. Growth hormone increases mobilisation of fat and promotes its
use as a source of energy (Rabinowitz et al. 1965). Patients with GHD are short and
fat; GH replacement increases lean body mass and reduces the proportion of body fat.
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Efficacy of Recombinant Human Growth Hormone in Chronic Renal Failure
CRI - Conservative management
Barbara Lippe was the first to report the growth promoting effects of rhGH in
children with CRI (Lippe et al. 1988). Five boys with congenital renal disease, with a
mean age of 4.6 years were treated with rhGH (0.125 mg/kg thrice weekly) for 6
months. Calculated GFR was 18 (6) ml/min/1.73m2, and height SDS -3.0 (1.0).
Height velocity increased from 4.9 (1.4) cm/yr before treatment to 5.0 (1.0) during
the 6 month treatment period. After 6 months of rhGH treatment, there were no
significant changes in calculated GFR (17 (4) ml/min/1.73m2), glucose or insulin
levels. There was no undue advancement in bone age.
Several other small series of children were reported subsequent to this, including an
update of the same 5 patients after they had been treated for 1 year (Koch et al.
1989). Mean 1 year height velocity was 8.9 (1.2) cm/yr, and height SDS increased
from -3.0 (0.7) to -2.4 (0.8) after 1 year. Weight gain increased significantly from 1.5
(0.5) kg per year before the study to 2.8 (0.8), and anthropometric studies showed
that total skinfold thickness had decreased while mean mid-arm muscle circumference
increased, with little overall change in mid-arm circumference. Four of the children
had shown a good response, but in the other child, the increase in height velocity was
only from 6.3 to 7.5 cm/yr with rhGH treatment despite a doubling of the rhGH dose
after 6 months. Interestingly, he was the least stunted and the fastest growing of the
group at the start of the trial.
The same group published data on the longer term effects of rhGH in CRI (Fine et al.
1991a). Six of the nine reported children were treated for 2 years, and 4 for 3 years.
After 2 years of treatment, five of the six children had heights within the normal
range. Height velocity remained above baseline for up to 3 years; mean height SDS in
these 4 patients increased from -2.8 to -1.3 during this time.
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Following these initial encouraging reports, several larger studies were performed. A
Dutch placebo-controlled double-blind, cross-over study involving 20 patients
reported conclusively that rhGH improved short-term growth in prepubertal children
with CRF; an extra 2.9 (CI 2.3 - 3.5) cm of growth over 6 months was attributed to
rhGH treatment (Hokken-Koelega et al. 1991). A larger, but uncontrolled multi¬
centre European Study (Van Es et al. 1991), involving 43 prepubertal children
reported 2 year growth data for 17 children; height SDS increased from -3.1 at
baseline to -1.9 after 2 years. Height velocity increased from 4.5 cm/yr before
treatment to 9.5 cm/yr in the first year and 6.8 cm/yr in the second year. Six children
reached end stage renal failure during the study, but there were no other adverse
effects.
Subsequent studies, including the study reported in this thesis have concentrated on
the safety of the use of rhGH in CRI, in particular the effects on renal function, on
glucose and lipid metabolism, on renal bone disease and on the effects on the immune
system. Factors which predict the magnitude of the response to rhGH have also been
studied. The results of the BAPN study of rhGH in children with CRI are reported in
Chapters 3 and 4 where they are discussed in detail, and compared with data
published since the trial ended.
Dialysis
In 1990 and again in 1991 Tonshoff reported on prepubertal children on dialysis with
growth failure. In the 1991 paper 10 children on dialysis are reported, and as with
children with CRI, one year of rhGH treatment had a salutary effect on growth.
Height velocity increased from 4.2 (0.9 - 5.4) to 7.3 (5.0 - 9.4) cm/yr. Height SDS
one year before the study was -3.1, and changed little in the year before the study, but
increased from -3.2 to -2.7 during rhGH treatment (Tonshoff et al. 1990b, 1991a).
There are fewer reported trials of the use of rhGH in children on dialysis. This is due
in part to the fact that a high proportion of children are withdrawn when they receive
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renal transplants and therefore spend less time on rhGH. However most reports in the
literature are in agreement that the response of children on dialysis is less than that
seen in children with CRI (Schaefer et al. 1994). This is discussed in greater detail in
Chapter 5, where the results of the dialysis arm of the BAPN trial are reported.
Renal Transplantation
The first report of the use of rhGH post renal transplantation was published in the
French literature by Rochiccioli et al in 1986. Increased height velocity was seen in a
pubertal girl with a renal transplant treated with rhGH. Of course it is difficult to be
certain whether the increased growth rate was due to GH or to the endogenous
pubertal growth spurt. The first report in the English literature was published by van
Dop et al in 1989. This group presented growth details of a prepubertal 11 year old
boy, who 3 years after receiving a successful renal transplant had a height velocity of
less than 2 cm/yr. He was receiving prednisolone 8 mg/m2 on alternate days. During a
year of rhGH treatment (2 mg x3/wk) he remained prepubertal and his height velocity
increased to 8.7 cm/yr. Further reports followed shortly thereafter.
The following year a report by Rees et al described 12 children with renal transplants
who received a year of rhGH treatment (30 IU/m2/week in 7 doses). Six children were
prepubertal and 6 were pubertal. Height velocity increased from 2.3 (0.8 - 4.8) to 6.0
(2.8 - 10.9) and 3.1 (0.5 - 6.5) to 5.9 (4.6 - 7.0) cm/yr in these two groups
respectively, but there was no significant change in height SDS (Rees et al. 1990).
The main concern in patients with renal transplants is whether a proposed therapeutic
intervention will affect the graft, either through a change in GFR or by precipitating
rejection episodes. In the study by Rees, the incidence of clinical rejection was no
different in the year of treatment compared with the year before, although renal
function deteriorated in 1 child in each group (Rees et al. 1990). One prepubertal
child had 6 episodes of presumed rejection and her calculated GFR fell from 51 to 11
ml/min/1.73m2 during the study. She had had 5 such episodes in the previous year.
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One adolescent lost his graft after 3 months of rhGH; he was non-compliant with his
medication. The children in the study by Rees were part of a large European multi¬
centre study (van Es et al. 1991). Virtually identical results were seen in this larger
group; furthermore a significant increase in height SDS was seen in the prepubertal
group after 2 years (-3.1 to -2.1, p<0.05). Overall there was no change in GFR, but
individual patients had increases in their serum creatinine (van Es et al. 1991).
Other studies reported similar findings; good short term improvements in growth rate,
with occasional patients showing a rise in creatinine (Tonshoff et al. 1991a; Fine et al.
1991b). These studies however were confusing in their use of different rhGH
regimens and inclusion of both prepubertal and pubertal patients. All used the
equivalent of 30 units per m2 per week, but this was given thrice weekly in the earlier
patients and daily in patients enrolled at a later stage. Some studies included patients
with cystinosis.
Two case reports prompted further concern, and urged for caution in the use of rhGH
post transplantation. Tyden reported 2 children with stable graft function, both of
whom developed biopsy proven acute rejection 5 and 7 months after starting rhGH.
Both of the episodes were reversed by methylprednisolone. One child remained on
rhGH and had a further episode of acute rejection 3 weeks later. Thereafter rhGH
treatment was stopped (Tyden et al. 1990).
Schwartz described a 4.5 year old child who started rhGH 1.75 years after receiving a
renal transplant. Creatinine was stable at 35 pmol/1, and she had suffered no rejection
episodes. Four months later the creatinine increased to 80 pmol/1 and a renal biopsy
showed acute rejection. Treatment with methylprednisolone was given and she was
started on cyclosporin A. Growth hormone treatment was continued. Three months
later the creatinine rose to 159 pmol/1; again acute rejection was seen on a biopsy.
Growth hormone was stopped and after receiving a course of an anti-lymphocyte
preparation (OKT3), the creatinine stabilised between 80 and 97 pmol/1 (Schwartz
and Warady 1992).
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Van Dop reported 8 children who were treated with rhGH. In one patient, creatinine
increased from 160 to 260 p.mol/1 during the first 3 months of rhGH; rhGH treatment
was discontinued and the serum creatinine decreased to 190 pmol/l (Van Dop et al.
1992).
Subsequent reports of acute rejection during rhGH treatment caused further concern
and resulted in larger controlled studies including the BAPN trial reported in this
thesis. This study was designed specifically to look at the safety aspects of the use of
rhGH in CRF and following renal transplantation. The results of the transplant arm of
the BAPN trial are reported in Chapter 6, along with a detailed review of the
literature that has been published since the trial was completed.
Safety of Recombinant Human Growth Hormone
Renal Function
It is well recognised that patients with acromegaly have large kidneys which
hyperfilter (Ikkos et al. 1956), and rhGH given to healthy adults results in an increase
in effective renal plasma flow (ERPF) and GFR (Hirschberg et al. 1989). Transgenic
mice secreting GH also show an increase in ERPF and GFR, and go on to develop
glomerular sclerosis (Doi et al. 1988). Renal failure does not develop in acromegaly
however, in the absence of hypertension and diabetes (Gershberg et al. 1957).
There are a number of mechanisms whereby rhGH could affect renal function. First,
GH, through the action of IGF-I, increases GFR and ERPF in the normal kidney;
micropuncture studies in the rat demonstrate that this is due to an effect on
glomerular haemodynamics (Hirschberg et al. 1991). Second, altered renal function
could be related to hypertrophy of the kidney; prolonged exposure to GH causes renal
enlargement, as seen in acromegaly (Gershberg et al. 1957) and in transgenic mice
secreting high levels of GH (Doi et al. 1988). Hypopituitary mice undergoing
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unilateral nephrectomy have reduced hypertrophy of the remaining kidney (Astarabadi
et al. 1953). Third, transgenic mice with prolonged exposure to GH (but not to IGF-
I) develop glomerulosclerosis and renal failure (Doi et al. 1988). There are growth
hormone receptors on mesangial cells, and receptors for IGF-I on proximal tubular
and mesangial cells (Arnqvist et al. 1988; Aron et al. 1989; Rogers et al. 1989).
Finally, rhGH may have an effect on the immune system, and in renal transplantation
could precipitate acute rejection or cause progression of chronic rejection (Bozzola et
al. 1991).
Metabolic Effects
There are other potential effects of rhGH treatment which require consideration in
CRF patients. Glucose tolerance is altered in uraemia (DeFronzo et al. 1978) and
might be further aggravated by rhGH treatment (Sonksen et al. 1967). There are pre¬
existing lipid abnormalities in renal disease (Querfeld 1993), and GH causes lipolysis
(Rabinowitz et al. 1965). This subject is discussed further in Chapter 10.
Renal Bone Disease
As CRF progresses, there is reduced activation of vitamin D and retention of
phosphate by the kidney. The resultant hypocalcaemia and hyperphosphataemia
stimulate production of parathyroid hormone (PTH) which results in
hyperparathyroidism and renal bone disease. This occurs early, when the GFR is still
approximately 70 - 80 ml/min/1.73m2 (Reichel et al. 1991). Management with dietary
phosphate restriction, and administration of activated vitamin D supplements and
phosphate binders, can prevent hyperparathyroidism.
The clinical manifestations of renal osteodystrophy are more apparent in a growing
child where bone turnover is high compared with adult patients. Hyperparathyroidism
results in osteitis fibrosa, and when this is extensive, slipping of the epiphyses may
occur (Mehls et al. 1975).
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It is conceivable that renal osteodystrophy may prevent or retarded the growth
response to rhGH, or alternatively higher growth rates may aggravate renal bone
disease.
Fluid Retention
Growth hormone treatment in GHD adult patients has been associated with sodium
and water retention resulting in oedema (Salomon et al. 1989). Were this to happen in
children with oliguric renal failure, fluid overload and hypertension would ensue.
Monitoring of blood pressure and examination for signs of fluid overload is therefore
required.
Immune Function
There is a potential for GH to have an effect on immune function. Growth hormone is
by definition a mitogen, and it has known interactions with the immune system
(Bozzola et al. 1991). There is therefore a potential risk of increased rate of transplant
rejection, infection or of increased malignancy. Preliminary studies of rhGH in
children with renal transplants have not reported an increase in the incidence of
rejection episodes, however there are individual case reports to the contrary, as
described above (Tyden et al. 1990; Schwartz and Warady 1992), and further study is
needed to clarify whether rhGH can precipitate acute rejection episodes.
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Chapter 2: British Association for Paediatric Nephrology Trial of
Recombinant Human Growth Hormone in Chronic Renal Failure
Introduction
For many years the role of the GH/IGF-I axis in short stature of CRF was not
appreciated, mainly due to the fact that children with CRF have high levels of
endogenous circulating GH (Samaan et al. 1970). Flowever in 1983, Otto Mehls was
able to demonstrate the beneficial effect of rhGFI in uraemic rats, and shortly
thereafter the first preliminary trials of rhGH in renal failure were undertaken in
children. The results were encouraging; one year of rhGH treatment resulted in an
increase in height velocity. Further study was necessary. Would all patients respond
equally to treatment? Would the increase in height velocity be sustained? Was it safe
to use rhGH in patients with renal failure, in particular was it safe to use rhGH in
children with renal transplants.
To answer some of these questions a multi-centre British trial of rhGH in renal failure
was established in 1991 under the auspices of the BAPN. Four subgroups of children
were studied: those on conservative management (CRI); children on haemodialysis
(HD) or peritoneal dialysis (PD); and children with renal transplants. In addition
infants with renal failure were studied as a separate group. The infants, children with
CRI and the dialysis groups were entered into a prospective one year open-labelled
study, the results of which are given in Chapters 3, 4 and 5 respectively. The
transplanted children were enrolled into a two year randomised controlled open-
labelled study, and are discussed in Chapter 6.
Multi-centre BAPN Trial of rhGH in Children with Chronic Renal Failure
The trial was designed to monitor both the efficacy and safety of the use of rhGH in
CRF. The efficacy parameters studied were height velocity (HV) and change in
standardised height (A height SDS) during treatment. Data were also collected on
renal function, glucose metabolism, renal bone disease and adverse events, in
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particular the occurrence of rejection episodes in the transplanted group. The above
parameters were collected for all of the children entered into British trial.
In addition, all of the patients entered from the three London Paediatric Nephrology
centres (Royal Free Hospital, Guy's and Great Ormond Street) had more detailed
studies performed by myself. These additional studies are outlined in Chapters 7 to 9.
For each of these studies, different subgroups of patients were included; summary
data for each of these groups are given in the relevant chapters. Patient details for all
84 children entered into the trial are given in Table 2.1. More detailed information is
included in the relevant chapters.
Eleven centres in the UK entered children into this trial (Table 2.2). Patient entry and
exclusion criteria are listed below. More detailed descriptions of the four subgroups
are included in the relevant paragraphs. Approval was granted from ethics committees
at all centres. Written informed consent was obtained from all the parents or
guardians. Verbal consent was obtained from the older children.
Inclusion Criteria
Children were considered eligible for entry to the trial if they fulfilled the following
criteria:
• chronic renal failure
• height more than 2 SD below the mean for age and sex or a HV less than
the 25th centile
• at least 2 previous height measurements at the renal clinic over the
preceding 1 year (6 months for infants)
• normal thyroid function
• written informed consent.
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Exclusion Criteria
Children were excluded from the trial for the following reasons:
• HV greater than the 75th centile during the preceding 6 months
• treatment with any form of growth hormone in the past
• a previous malignancy
• a severe congenital abnormality
• diabetes mellitus
• uncontrolled renal bone disease
Additional inclusion criteria for the subgroups are given below.
Infant Group
• CRF with a calculated GFR of less than 50 mls/min/1.73m2 with or without
dialysis
• bone age of less than 2 years
• height SDS less than -2SD or a declining height SDS and no improvement in
growth despite correction of fluid and electrolyte and acid-base balance, bone
disease and diet (including a trial of tube feeding when necessary)
• age less than 1 year at presentation of disease
• two previous height measurements in the last 6 months.
CRI Group
• calculated GFR of less than 50 ml/min/1.73m2 for at least 1 year
• receiving conservative management at a paediatric nephrology centre
Dialysis Group
• haemodialysis (FED) or peritoneal dialysis (PD) for at least 6 months
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Transplanted Group
• functioning renal transplant for more than 1 year
• 2
• minimum calculated GFR of 20 ml/min/1 73m
Both prepubertal children and those already in the early stages of puberty were
enrolled into the subgroups. Prepubertal boys were defined by a testicular volume of
less than 4 ml and girls by breast development less than Tanner stage B2 (Marshall &
Tanner 1969, 1970). Early puberty was defined in boys by a testicular volume
between 4 and 10 ml inclusive, and in girls by stage B2 or B3.
Study Design
The study protocol for all patients is described below. More detailed explanations are
provided for each of the subgroups in the relevant chapters. Patients were assessed for
suitability prior to the trial. If the entry criteria were met, the child was enrolled and a
patient number assigned. For the transplanted children patient numbers were held in
the Pharmacy department. After stratification for pubertal status, randomisation was
performed by opening sealed envelopes numbered in strict sequence. The envelopes
contained details regarding treatment or no treatment.
All children were studied for at least one year; the transplanted children were studied
for 2 years. After the trial was complete, children were able to remain on rhGH
treatment on a named patient basis if they wished. Growth data during subsequent
years of treatment are detailed in the relevant chapters.
Treatment
The dose of rhGH (Genotropin) used was liu/kg/week (0.14iu (0.05mg)/kg/day).
This dose was given as 7 daily subcutaneous injections in the evening. The dose was
adjusted according to weight at 3 monthly intervals. The growth standards of Tanner
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and Whitehouse were used to calculate height SDS, and HVSDS (Tanner et al.
1966). Percentage ideal weight for height (WFH) was calculated 6 monthly.
Study Protocol
On day 1, all patients attended at 09.00 having fasted for at least 4 hours. The patients
were examined, weight measured and blood pressure checked. Height was measured
using a Harpenden stadiometer. Fasting blood samples were taken, and the families
given instruction regarding administration of rhGH. Thereafter children were assessed
3 monthly, when again height, weight, and blood pressure were measured, and fasting
blood samples taken. The occurrence of adverse events was noted.
On each occasion in all children, blood was sampled for estimation of a full blood
count, urea, creatinine, electrolytes including calcium and phosphate, liver function
tests including alkaline phosphatase (ALP), intact parathyroid hormone (PTH),
glucose, insulin, cholesterol, triglycerides and glycosylated haemoglobin (HbAlc), and
if appropriate cyclosporin level. These results are given and discussed in Chapter 10.
Additional blood tests were performed depending on the subgroup. Insulin-like
growth factors and IGFBPs were studied in the CRI and transplanted groups (Chapter
8). Lymphocyte subsets and markers of T cell activation were also measured in these
groups (Chapter 9).
Accurate assessment of renal function was performed in the CRI and transplanted
groups. Clearances of inulin and PAH were performed on day 1, after 1 week and
after 1 year in the CRI group. Inulin clearances were performed on day 1, after 1
week and then 6 monthly for 2 years in the transplanted group. Further details are
given in Chapter 7. Inulin clearance studies were not performed in the infant group.
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Statistical Analysis
Results are expressed as mean (range) or mean (standard deviation) (SD). Where the
distribution was skewed the median values are also given. Within and between group
results were compared using the paired or unpaired Students /-test respectively.
Comparison of change within the treatment and control groups was made by
calculating and comparing the mean (standard error) (SE) change. Frequencies were
compared using the chi-squared test. Analysis of multiple results within the same
group over time was performed by analysis of variance (ANOVA). Correlations were
performed using Pearson's correlation coefficient, and regression by both single and
multiple linear regression analyses. Statistical significance was assumed with a p value
of <0.05.
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Chapter 3: One Year Trial of Recombinant Human Growth Hormone in Infants
with Chronic Renal Failure
Introduction
Poor growth is a particular problem for children with congenital renal disease (Betts
and Magrath 1974). Growth in the first two years of life is greater than at any other
time, such that by the age of two years children have already attained half of their final
adult height (Tanner et al. 1966). Chronic ill health during this time can cause a
reduction in height velocity, resulting in the height declining through the centile lines,
and whilst later growth in the pre-school and early school years is often normal,
catch-up growth rarely occurs (Rees et al. 1989; Ledermann et al. 1999). Chronic ill
health during infancy can therefore result in a loss of height potential.
Optimum conservative management, including provision of adequate calories,
correction of electrolyte disturbance and acid-base abnormalities and prevention of
renal osteodystrophy goes some way towards improving growth; but many children
remain below the normal range (Betts and Magrath 1974; Kleinknecht et al. 1983;
Rizzoni et al. 1984; Polito et al. 1987; Claris-Appiani et al. 1989). Nasogastric or
gastrostomy feeding to ensure adequate nutrition improves growth in some (Strife et
al. 1986; Rees et al. 1989; Ledermann et al. 1999), but not all children (Abitol et al.
1993).
Growth in the first two years of life is strongly influenced by nutrition, however the
influence of growth hormone at this age is now appreciated; infants who are later
diagnosed as having growth hormone deficiency are shorter and lighter than normal
(Albertsson Wikland et al. 1990). The data presented here are from a one year study
of the use of rhGH in infants and young children with CRF, who were not growing
despite good conservative management.
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Methods
Entry criteria are detailed in Chapter 2; the following criteria were also observed:-
• CRF with a glomerular filtration rate of less than 50 mls/min/1.73m2 with
or without dialysis
• a bone age of less than 2 years
• height less than -2SD or a declining height SDS and no improvement in
growth despite correction of fluid and electrolyte and acid-base balance,
bone disease and diet (including a trial of tube feeding when necessary)
• age less than 1 year at presentation of disease
• two previous height measurements in the last 6 months.
Patients
Ten children (3 girls) were enrolled into the study. Two children received renal
transplants after 12 days and 4 months respectively. Growth data are therefore
presented only for the 8 children who completed at least 6 months of rhGH treatment.
Patient details for all 10 children and for the 8 in whom growth data are presented are
given in Table 3.1.
Mean gestational age was 37.2 (34 - 41) weeks (n = 10); three children were < 35
weeks gestation. Birth weight was available for 8 infants; six of the 8 infants had a
birth weight within the normal range; one child was small for dates and one of the two
premature infants had a weight above that expected for gestational age.
Growth data during the preceding 6 months were available for all 10 children. Mean
height SDS 6 months prior to the study was -3.22 (-4.7 to -2.1) and -3.28 (-4.6 to -2)
at entry to the study. Growth data relating to the 8 children completing the study are
given in Table 3.2. Creatinine was measured at each time point during the trial. GFR
was calculated using the Schwartz formula (Schwartz et al. 1976) at 6 monthly
intervals. Metabolic data are reported in Chapter 10.
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Results
Seven of the ten children completed the full year of treatment: three children were
withdrawn after 12 days, 4 and 9.5 months respectively when they received renal
transplants. Growth hormone treatment was stopped at that time. Growth data for the
last of these three children have been annualised and are included in the analysis. No
data are presented for the other two children. Two further children reached end-stage
renal failure and were commenced on peritoneal dialysis, one after 4 months, the other
after 10 months. These children remained on rhGH treatment and completed the study
and their one year growth data have been included. Growth data are given in Table
3.2 and illustrated in Figure 3.1.
Height SDS increased significantly during rhGH treatment; A height SDS during the
first 6 months of treatment at 0.7 (0.1 - 1.0) was greater than in the 6 months
preceding the trial (0.08), p = 0.007. Height velocity did not change significantly, but
there was a significant increase in HVSDS. This discrepancy is explained by the
expected reduction in HV with age that is seen during infancy.
Response to rhGH in this group of patients was related to age, with the greatest
increment in height SDS being seen in the youngest children (Figure 3.2). The growth
response to treatment was unrelated to baseline GFR (r = -0.141).
Weight increased from 9.5 (7.5 - 13.8) kg to 10.6 (8.3 - 12.9) at 6 months and 11.7
(8.9 - 13.8) after 1 year (p = 0.008 v dayl). Weight, expressed as % of the ideal
weight for height, was 98% (79 -118) at the start of the study, and 96% (79 - 127)
after 1 year.
Two children started dialysis during the trial. No other serious adverse events
occurred (Table 3.3).
Creatinine and GFR values are shown in Table 3.4. For the child who received a renal
transplant at 9.5 months, and the the child who went onto dialysis at 10 months, the 9
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month results are used. The child who started dialysis after 4 months of treatment has
been excluded from the creatinine analysis, and for the GFR analysis, a value of zero
has been used for the end of treatment GFR. There was no significant change in
calculated GFR during the study, but there was a significant increase in creatinine.
Discussion
Renal failure in infancy is often complicated by poor growth. Height velocity is
greater in infancy than at any other time during childhood, so ill health at this time
results in a rapid decline in age-related height. This is the rationale behind the use of
rhGH in this age group.
At entry to the trial, the mean height SDS was -3.3 at a mean age of just under two
years, therefore indicating that significant growth delay had occurred over a relatively
short period of time. This finding is supported by a prospective study of growth in
infancy in CRF which reported that the major loss in height and weight SDS occurred
within the first six months (Abitol et al. 1993); this loss can be as great as 0.6 SD per
month (Rizzoni et al. 1984).
Traditionally growth in infancy has been thought to be influenced primarily by
nutrition, but recently growth hormone has been recognised as a contributing factor at
this age (Albertsson Wikland et al 1990). The use of calorie supplements in infants
with CRF, by nasogastric or gastrostomy feeding if necessary, does not consistently
improve growth. (Strife et al. 1986; Abitol et al. 1993). The result of rhGH treatment
in two boys aged less than two years with CRF, was reported in abstract form (Linne
et al. 1992). Both showed a good response to treatment. A later abstract reported
that after 28 months of rhGH treatment both boys had reached their target heights
(Linne et al. 1996).
In the children reported here, mean height SDS did not change in the six months
before the trial, while it increased from -3.3 to -2.2 during the year of rhGH
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treatment. Each child showed an improvement, with four children entering the normal
range. The increment in height SDS represents good catch-up growth, and
interestingly the greatest improvement in height SDS was seen in the youngest
children (Figure 3.2).
Despite the low height SDS before treatment, mean HVSDS was within the normal
range. This suggests that reduction in height SDS had indeed started early.
Furthermore remarkable catch up growth on rhGH was seen despite relatively normal
HVSDS values although most values were within the upper half of the normal range.
Although this is partly an auxiological phenomenon resulting from the high rates of
growth seen in infancy, it appears to be easier to achieve catch-up growth with rhGH
at a younger age compared with later childhood (Rees et al. 1990; Hokken-Koelega
et al. 1991; Fine et al. 1994); a situation which is also reported following renal
transplantation (Ingelfinger et al. 1981; Tejani et al. 1993).
The dramatic changes which occur in HV in the first two years of life complicate
interpretation of growth data within this age group. Change in height SDS was used
as a measure of the growth response, and HVSDS was used to allow comparison of
height velocities at different ages. Ideally comparison should be with a placebo control
group, but ethically this is difficult. With the small number of children involved in this
study, it was decided to treat all children. Height SDS was used as the critertia for
entry to the trial. Comparison of annualised HV at this age can be misleading because
of the changing velocity, yet observing growth for 1 year to obtain an accurate
velocity measurement will only lead to a delay in treatment.
There are limited published data of the use of rhGH in infants and young children.
Fine published data from a controlled trial of rhGH in 30 children aged less than 2.5
years: 19 children received rhGH for 2 years; 11 received placebo (Fine et al. 1995).
Height velocity in the first year was 14.1 cm/yr on rhGH and 9.3 in the placebo group.
In the second year HV was 8.6 on rhGH and 6.9 in the control group. Over the two
year period, A height SDS was 2.0 in the treatment group and -0.2 in the placebo
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group. Height velocity, HVSDS and A height SDS during the study were significantly
increased in the treatment group compared to the control group.
Growth after infancy, in the late pre-school and early school years, is often normal in
CRF (Kleinknecht et al. 1983); it remains to be determined whether or not children
treated in infancy with rhGH can maintain their position within the normal range
without further rhGH treatment. A short course of rhGH treatment in infancy could
possibly achieve as much as a longer course later in childhood. The children reported
by Linne needed to remain on rhGH to sustain a normal height velocity (Linne et al.
1996), however normal growth rates following cessation of rhGH have also been
reported (Warshaw et al. 1997). A larger series described by Fine found that 27% of
children with CRI treated with rhGH maintained their height centile when treatment
was stopped, while 73% had a decceleration in HV (Fine et al. 1996a)
There was no change in calculated GFR in the children who remained on conservative
management. Two of the children were commenced on dialysis; it is difficult to know
whether rhGH treatment was implicated. The group included several children with
severely reduced renal function; several children were on call for renal transplants.
It has been much debated whether growth is related to GFR per se. It has been
reported by one group that growth declines when the GFR falls below 25
mls/min/1.73m2 (Betts and Magrath 1974), and by others that good growth can be
achieved in some children even at a very low GFR (Kleinknecht et al. 1983; Rizzoni
v
et al. 1984). We were unable to find a relationship between growth rate during rhGH
treatment, although growth before treatment tended to be faster in those children with
better renal function (r = 0.640, p = 0.058).
Conclusion
Growth hormone treatment for one year resulted in a marked improvement in height
SDS in a group of infants and young children with CRI. Two children reached end
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stage renal failure and required dialysis. Glomerular filtration rate in the remaining
children was unaffected by rhGH treatment. There were no serious adverse events.
The beneficial results seen in this group of young children suggests that early
treatment with rhGH is worthwhile, however the optimum timing and duration of
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Chapter 4: One Year Trial of Recombinant Human Growth Hormone in
Patients with Chronic Renal Insufficiency
Introduction
Almost two thirds of children with CRF managed conservatively have a height that is
below the normal range (Rizzoni et al. 1984; Rees et al. 1989). As discussed in the
previous chapter, growth is fastest in infancy and then slows down thereafter, such
that many children with CRF grow at a normal rate, but have a height that is well
below the normal range. Optimum conservative management of electrolyte
disturbances, acidosis, anaemia, renal osteodystrophy and the provision of adequate
nutrition improves growth in some but not all children (Claris-Appiani et al. 1995),
however true catch-up growth is rare (Reed et al. 1998). Children who present to a
paediatric nephrologist below the age of 2 years are more likely to show catch-up
growth than those who present at a later age (Rees et al. 1989).
Height velocity often starts to deteriorate when the GFR falls below 50-60
ml/min/1.73m2, and whilst some workers have reported that growth is proportional to
the degree of renal impairment (Betts & Magrath 1974; Claris-Appiani et al. 1989),
others have not found that to be the case (Rizzoni et al. 1984; Rees et al. 1989; Van
Dyck et al. 1999). Even if there is no direct relationship between growth and renal
function, better growth is reported in children with a GFR > 25 ml/min/1,73m2 than in
those with a GFR < 25 ml/min/1.73m2 (Kleinknecht et al. 1983; Polito et al. 1987).
This chapter describes the effects of rhGH in children with CRI receiving conservative
management. The youngest child was 4 years old. All of these children were growing
poorly despite adequate medical management.
Methods
The children met the general inclusion and exclusion criteria described in Chapter 2.
All had CRI with a calculated GFR of less than 50 ml/min/1.73m2 (Schwartz et al.
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1976), and required conservative management only. This was a one year study, with
all participants receiving treatment with rhGH.
GFR was measured by inulin clearance on day 1 and after 1 year in 18 children from
the London paediatric nephrology centres. A Schwartz formula calculated GFR was
used for the remaining 9 CRI children enrolled from other centres (Schwartz et al.
1976).
Patients
Twenty-six prepubertal children and 3 pubertal children with CRI were entered into
the trial. Patient details are given in Table 4.1. Height SDS, HV and HVSDS at the
start of treatment are given in Tables 4.2 and 4.3. Eleven prepubertal children
remained on rhGH after completion of the trial and growth data during this time are
also reported.
Growth data are given only for those children who completed at least six months of
rhGH treatment. Annualised HV during the first year of treatment was compared with
the growth rate during the preceding year.
Results
Prepubertal CRI
Twenty-one of 26 prepubertal children completed 1 year of rhGH; 3 children required
dialysis after 8, 9 and 10 months of rhGH, and 2 children received renal transplants
after 8 and 11 months respectively. There were no other adverse events (Table 4.4).
Two children entered puberty (Tanner stage II) during the study. Height velocity and
HVSDS increased during treatment, and after one year there was a significant
improvement in height SDS as shown in Table 4.2.
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Several of the children remained on rhGH treatment after the trial was complete.
Height velocity (Figure 4.1) and height SDS (Figure 4.2) remained significantly above
baseline values for up to 4 years of treatment. Data from individual patients are shown
in Figure 4.3. After 4 years of rhGH, 5 of 6 children had a height within the normal
range, as did the 3 children who received 5 years of rhGH.
Pubertal CRI Group
All 3 pubertal children completed one year of rhGH treatment. Height velocity and
height SDS increased in 2 of the 3 patients. All 3 children progressed further through
puberty (Table 4.3). Individual height SDS values for these children are shown in
Figure 4.4. Adverse events are shown in Table 4.5. A 15 year old pubertal girl with
CRI developed weakness in both legs due to Guillain-Barre syndrome 3 months into
the trial. Growth hormone treatment was continued and she made a full recovery.
Renal Function
Renal function is described in detail in Chapter 7. Creatinine was 269 (66 - 521)
pmol/l before treatment; 321 (76 - 689) after 6 months and 387 (85 - 889) after 1 year
of rhGH treatment (p < 0.0001, ANOVA). Glomerular filtration rate was 20 (8 - 58)
ml/min/1,73m2 at the start of the study and 17 (0 - 59) after one year (p = 0.14).
Growth Response in All CRI Patients
Data from all 37 patients with CRI on conservative management (8 infants, 26
prepubertal and 3 pubertal patients) were combined and analysed. Age, GFR and pre-
treatment parameters of growth were correlated with growth before starting treatment
and with the growth response to rhGH treatment. Details are shown in Table 4.6.
Before rhGH treatment there was no correlation between statural height and age,
renal function nor pre-treatment HVSDS. Height velocity SDS before treatment was
related to renal function, but not to age (Table 4.6).
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During the first year of treatment the greatest improvement in growth rate was seen in
those who were growing most slowly, Figure 4.5. The greatest increase in height SDS
was seen in the youngest patients, Figure 4.6. None of the parameters of growth
response to rhGH were related to GFR (Table 4.6).
Discussion
This group of children with CRI had a marked improvement in HV during the first
year of rhGH treatment which resulted in a mean increase in height SDS of 0.8 SD.
The greatest increase in height SDS was seen in the youngest children, although it
was the children who were growing the most slowly who had the greatest
improvement in growth rate.
Several children remained on rhGH after the study was complete. Height velocity
remained above baseline for up to 4 years, and most of the children achieved an end of
treatment height that was within the normal range. There are as yet little final adult
height data for children with CRI who have been treated with rhGH, but as there is no
undue advancement in bone age (Fine et al. 1994; Hokken-Koelega et al. 1994c),
final height should be improved. Bone age was measured in our patients, but as these
were read in different centres by different radiologists, and as the data were
incomplete, height and HVSDS were calculated for chronological age.
Prior to rhGH treatment, HVSDS was faster in those with better renal function. As
mentioned before, this point has previously been debated in the literature, with some
authors supporting this finding (Betts and Magrath 1974; Claris-Appiani et al. 1989),
and others refuting it (Rizzoni et al. 1984; Rees et al. 1989; Van Dyck et al. 1999).
The children reported here are a selected group of CRI patients as they were entered
into the study because of poor growth, however even within this group, we found a
relationship between HVSDS and GFR.
55
During rhGH treatment the greatest increase in HVSDS was seen in those children
who were growing most slowly prior to treatment. Similar findings were reported by
the German Study Group for Growth Hormone Treatment in Chronic Renal Failure
(Wuhl et al. 1993; Haffner et al. 1998a). This finding is perhaps not surprising, as the
children growing most slowly may be those with the greatest degree of GH resistance,
which can then be overcome with exogenous rhGH treatment. Similar findings are
reported with rhGH treatment in short normal children (Hindmarsh et al. 1991). In
this latter group, growth rate rather than height was related to GH secretion; those
with the best response to rhGH were those with the lowest rates of GH secretion
(Hindmarsh et al. 1991). Growth hormone secretion is normal in CRJF, but there is
evidence of GH resistance.
A Dutch study of rhGH in CRF reported a different result; they found that the
increase in HVSDS was positively correlated to pre-study HVSDS (Hokken-Koelega
et al. 1991). It is possible that this difference relates to the small number of children in
the Dutch study (n = 16), and the fact that only data for 6 months of treatment are
reported. Furthermore of the initial 20 patients, 11 were on dialysis and only 9 were
receiving conservative management. It is well-recognised that the response to rhGH is
less in children on dialysis than in those on conservative management. The patient
group as a whole was slightly older. Recognising the potential differences between
CRI and dialysis patients, we have reported the results separately.
The greatest increase in statural height (A height SDS) during treatment was seen in
the youngest patients. This finding has also been reported in CRI (Wuhl et al. 1993;
Haffner et al. 1998a), and also in children with GHD (Ranke et al. 1990). This may in
part reflect an auxological phenomenon resulting from the faster growth rate in this
group.
It is rather striking that nearly all studies of patients with CRI report a virtual doubling
ofHV in response to rhGH treatment; most studies report a mean HV of 9-10 cm/yr
during the first year of treatment (Van Es et al. 1991; Tonshoff et al. 1992; Fine et al.
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1994). As in this study, most authors report no relationship between growth response
to treatment and renal function (Rees and Maxwell 1996a). Haffner reported a
positive correlation of both A height SDS and A HVSDS during treatment and GFR
(Haffner et al. 1998a). The difference is difficult to explain, and may partly relate to
differences in patient groups; their group contained both CRI and dialysis patients.
The German Study group also reported a positive correlation with target height. This
same phenomenon has been reported in GHD (Ranke et al. 1990). In GHD it has been
suggested that the normal variation in height may relate to inherited differences in GH
secretion and possibly also to an inherited variability in the response to GH. If this is
indeed the case, it may also be true in CRI. In our study, parental height was
recorded, but for many patients this was estimated rather than measured, and was felt
to be too inaccurate for calculating target height.
Loss of height potential in renal failure occurs mainly during infancy and during the
pubertal years. Two of the three pubertal children in this arm of the trial showed an
increase in HV and height SDS; the other child did not. Children with CRF have a
shortened and attenuated pubertal growth spurt which will reduce final adult height
(Schaefer et al. 1990). The pubertal growth spurt in normal girls contributes 25 cm to
the final height, and in boys the equivalent figure is 28cm (Tanner et al. 1965). If it is
possible to increase pubertal height velocity in children with CRF with the use of
rhGH then this may contribute to a significant increase in final adult height. However
it is important to make sure that this is not achieved at the expense of a shortened
pubertal growth spurt. There have been concerns that this indeed may happen in
pubertal children with GHD treated with rhGH (Darendiler et al. 1990); there is
however no data to suggest that this is the case for rhGH treatment in CRF (Hokken-
Koelega et al. 1994c). Final adult height data in CRI patients are not yet available.
It is becoming clear that an adequate pubertal growth spurt is needed to allow
accumulation of peak bone mass (Finkelstein et al. 1992). This is another
consideration in CRI and rather than allowing these children to go on growing for
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longer and have a late puberty, it may be more appropriate to induce puberty at a
relatively normal time, by priming with small doses of sex hormones. A late puberty
may be associated with a smaller gain in height overall (Tanaka et al. 1996), but a
normally timed puberty may actually result in a greater increase in height gain and
greater accretion of bone mass. This issue was not addressed in the present study, but
needs to be a consideration in any therapeutic intervention aimed at increasing final
adult height.
Height velocity was highest during the first year of treatment and as has been reported
for children receiving rhGH treatment for other indications, there was a waning effect
of rhGH with time (Joss et al. 1983; Wit 1999). Similar results in CRI have
subsequently been reported by other authors (Tonshoff et al. 1994; Fine et al. 1996b).
Most children show catch up growth initially and then grow parallel to the centiles.
Height velocity however remained above baseline for up to 4 years, and it is possible
that this will translate into an improved final height.
There are few reports of growth velocity once rhGH treatment in CRI is stopped.
Fine et al reported the effects of discontinuing rhGH in children who had reached
their target height of mid-parental height (Fine et al. 1996a). Sixteen of the 22
patients reported were re-started on rhGH because of decceleration in growth rate;
mean (SD) height SDS fell from -0.3 (0.8) to -0.7 (0.7) after an average of 9 (3 - 16)
months. Six children remained off rhGH treatment; five of these children maintained
their centile after a mean follow-up of 26 (2.4 - 58) months. Warshaw has reported
one of these five children separately (Warshaw et al. 1997). A boy of 3 years 8
months was treated with rhGH for 21 months. Height SDS increased from -2.3 at
baseline to -0.6 at the end of rhGH treatment. After nearly 5 years off treatment his
height SDS was -0.7. Schaefer however reported catch-down growth in 75% of
children with CRI and those on dialysis when rhGH treatment was stopped (Schaefer
et al. 1999).
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RhGH was well tolerated in this group of patients. One of the pubertal children
developed Guillain Barre Syndrome after 3 months of treatment. Recovery occurred
without stopping rhGH treatment, and it seems unlikely that rhGH treatment was
responsible.
The other adverse events were related to renal function. Two children were on call for
renal transplants and received a graft during the study. Three children had a
deterioration in their GFR and were commenced on peritoneal dialysis, although
overall there was no significant change in GFR. The group as a whole had poor renal
function, so the withdrawals from the study were not unexpected. The effect of rhGH
on GFR is addressed more fully in Chapter 7. The effects of rhGH on lipid and
glucose metabolism are discussed in Chapter 10.
Conclusion
One year of rhGH treatment in a group of children with CRI managed conservatively
resulted in a significant improvement in HV with no adverse effect on GFR. The
greatest increase in height SDS was seen in the youngest children, although the
greatest increase in HVSDS was seen in those who were growing most slowly. In
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Chapter 5: One Year Trial of Recombinant Human Growth Hormone In
Children Undergoing Peritoneal Dialysis and Haemodialysis
Introduction
Growth in children on dialysis tends to be slower than in children with CRI or those
with renal transplants. European Dialysis and Transplant Association (EDTA) registry
data reported a mean height SDS of -4.2 in boys aged one to fifteen years on dialysis,
and a mean height SDS of -2.7 in boys of a similar age with renal transplants (Rizzoni
et al. 1991), and Kleinknecht reported a loss in relative height of 0.4 SD per year in
children receiving long-term haemodialysis (Kleinknecht et al. 1980). Initial reports
suggested that children on peritoneal dialysis grew better than those on haemodialysis
(Fennell et al. 1984), but this has not been substantiated (Fine et al. 1986). What is
clear however is that catch up growth is rare in children receiving dialysis (Broyer et
al. 1974).
Methods
Children were eligible for entry to the trial, if in addition to the general entry criteria
(Chapter 2), they had been treated with either peritoneal dialysis (n=16) or
haemodialysis (n=10) for at least 6 months. All children entering the dialysis arm of
the trial received one year of rhGH treatment. Increase in height SDS and HV during
rhGH treatment were correlated with age and growth parameters at baseline. As some
children were pubertal, HV rather than HVSDS was used.
Patients
Twenty-six children were enrolled into the dialysis study. Twenty-three were
prepubertal and 3 were in early puberty (Testicular volume between 4 and 10 ml, or
Breast stage 2 or 3). Patient details are shown in Table 5.1.
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Results
The results are subdivided into prepubertal peritoneal dialysis, prepubertal
haemodialysis and combined peritoneal and haemodialysis pubertal groups.
Prepubertal Peritoneal Dialysis
Six of the 14 children completed one year of rhGH treatment. Nine children were
withdrawn; 7 received renal transplants (after 2.7, 3.1, 3.2, 3.9, 5.7, 8.0, 11.2 months
respectively), one was withdrawn after developing raised intracranial pressure, and
another stopped treatment 3 weeks early because of a poor response and worsening
renal bone disease. These children are discussed below. The average time spent on
rhGH treatment was 0.7 (0.2 - 1.2) years. All children remained prepubertal.
Growth data for the 9 children who received at least 6 months of rhGH treatment are
shown in Table 5.2. Individual height SDS measurements are shown in Figure 5.1.
Height SDS increased significantly in those children receiving at least 6 months of
rhGH treatment; A height SDS was significantly greater than during the preceding
year. Height velocity was on average 2.5 (0.9 - 2.5) cm greater during rhGH
treatment than during the preceding year.
Eleven adverse events were reported in 7 of the 9 children in the prepubertal
peritoneal dialysis group during the study. Many were almost certainly unrelated to
rhGH treatment, but at least two might be causally related (Table 5.3). Patient 9, a 12
year old girl, developed headaches after 3 months of rhGH treatment. Investigation
revealed raised intracranial pressure for which no cause was found. A diagnosis of
benign intracranial hypertension was made. Growth hormone treatment was
discontinued. She went on to make a full recovery; rhGH treatment was not re¬
started.
Patient 1, a 5 year old child developed worsening renal bone disease. She had a poor
response to therapy. A 7 year old boy on peritoneal dialysis developed a right sided
facial nerve palsy 4 days after starting rhGH followed by a left sided facial nerve palsy
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one month later; both had resolved by the three month visit. The patient had also
become hypertensive, which was thought to be the more likely explanation.
Prepubertal Haemodialysis Patients
Nine prepubertal children on haemodialysis were entered into the trial. Five completed
the trial; four children were withdrawn when they received renal transplants (after 0,
2.2, 2.2 and 6.1 months respectively). The mean time spent on rhGH was 0.6 (0.4)
years. Two children progressed into early puberty during the year of treatment.
There was no significant increase in height SDS or HV during GH therapy. Results
are shown in Table 5.4. Individual height SDS measurements are shown in Figure 5.2.
The change in HV during treatment compared to the previous year was 1.7 (-3.5 to
6.2) cm. The increment in height SDS was less than that seen in the prepubertal
peritoneal dialysis group: 0.1 (0.3) vs. 0.4 (0.2), p = 0.06. Reported adverse events
are shown in Table 5.5. Neither of the adverse events in this group of patients were
considered to be serious.
All Prepubertal Patients
Fifteen prepubertal dialysis patients received at least 6 months of rhGH treatment.
Growth data for this combined group are given in Table 5.6. Height velocity and
height SDS increased significantly, although A height SDS was small 0.3 (-0.2 to 0.3).
Pubertal Dialysis Patients
Height velocity increased in all 3 pubertal patients; height SDS increased in two. All
progressed further into puberty. Individual height SDS values for these children are
shown in Figure 5.3. The mean time on rhGH was 1.0 (0.9 - 1.1) years. Growth data
are shown in Table 5.7. Adverse events and their possible relationship to treatment are
given in Table 5.8. None of these events were considered to be serious.
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Correlations
Combining all of the dialysis patients, HV during rhGH treatment was positively
correlated with pre-treatment HV, (r=0.514, p=0.03), however the greatest increase
in HV during treatment was seen in those children who were growing most slowly
before treatment (r= -0.568, p=0.013), Figure 5.4. Increase in height SDS during
rhGH was not correlated with age (r=0.153) nor with pre-treatment height SDS
(r=0.034).
Discussion
One year of treatment with rhGH improved short term growth in prepubertal children
on dialysis such that height velocity and A height SDS increased significantly.
Comparing the peritoneal dialysis and haemodialysis groups, the children on
peritoneal dialysis had a better response than those on haemodialysis.
It is well recognised that children who are on dialysis grow more slowly than children
with less advanced renal failure (Rizzoni el al. 1986b). There are a number of possible
explanations for this finding. Children with ESRF are more likely to be anaemic, to
have renal osteodystrophy, to be acidotic or to be less well-nourished. There is more
disruption of the GH / IGF-I axis in dialysis patients compared with those with less
advanced renal failure (Blum et al. 1991). Furthermore, children on dialysis tend to be
older then those with CRI, and many have delayed puberty. Growth rate decreases
with age, and growth is at its slowest in the immediate pre-puberty period, which is a
time of natural resistance to the actions of endogenous GH. The older age range may
partly explain why as a group children on dialysis tend to grow more slowly.
Poor growth in children on dialysis has led to the use of rhGH in an effort to improve
growth. The German study group for growth hormone treatment in chronic renal
failure reported the results of a 1 year study involving 14 patients on haemodialysis
and 17 on peritoneal dialysis (Schaefer et al. 1994). These patients were treated with
the same dose of rhGH as used in this study. Height velocity increased in the
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haemodialysis group from 2.9 (1.9) to 5.5 (1.7) and from 3.0 (2.2) to 7.2 (3.2) cm/yr
in the peritoneal dialysis group. The increase in growth rate in the peritoneal dialysis
group was marginally better than in the haemodialysis group (p=0.09). The increments
in height SDS during the first year of rhGH were 0.4 and 0.5 respectively. These
results are similar to our results.
Berard reported the results of three French trials of rhGH in poorly growing children
on haemodialysis (Berard et al. 1998). Combining the results for the first year of
rhGH treatment, HV increased from 3.5 (2.2) to 7.0 (2.4) cm/yr; the corresponding
increase in height SDS was 0.5 (0.5) SD. In the children who remained on rhGH
treatment, HV remained above baseline values for up to 4 years of treatment (Berard
et al 1998). In the BAPN study it was not possible to perform such an analysis as
insufficient numbers of children remained on rhGH after the trial. Most received renal
transplants during or shortly after the study period.
During the first year of rhGH treatment, the fastest growth rate was seen in the
children who were growing fastest at the start of the study, but the greatest increase
in HV was seen in the children who were growing most slowly in the year prior to
treatment. This finding has also been reported by other authors (Berard et al. 1998;
Wuhl et al. 1993). Indeed Berard suggests that the value of treating patients growing
faster than six cm per year is debatable.
In the French study, HV was unrelated to pubertal status (Berard et al. 1998); the
number of patients in our study was insufficient to determine if pubertal status
affected the response to treatment. Each of the 3 pubertal children showed an increase
in height velocity with treatment. This is encouraging, as growth during puberty in
these children can often be very poor, with a delayed and attenuated growth spurt. In
the absence of a control group, it is impossible to differentiate the effects of rhGH
from those of the endogenous pubertal growth spurt.
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The mean increase in height SDS and HV during the first year of treatment was less
than that seen in the CRI group. Other studies have reported that the response to
rhGH treatment in dialysis patients is less than in conservatively managed patients.
Children on dialysis tend to be shorter and to have slower growth velocities than
children with conservatively managed CRI, and so it is disappointing that rhGH
appears to be of less benefit in this group. There are several reasons why children on
dialysis might show a poorer response to rhGH than those being managed
conservatively. Children with ESRF tend to receive rhGH for shorter periods of time,
and may be more likely to have intercurrent illnesses or other medical complications
than children with CRI. Age has been found to be a negative predictive factor in the
response to rhGH in renal failure in some studies (Wuhl et al. 1993), and children on
dialysis tend to be older than those receiving conservative treatment. However one
study compared children aged less than 10 years on dialysis with an age and sex
matched group with CRI, and reported that even if one controls for age, sex, height
and height velocity, children on dialysis still have a poorer response to rhGH than
children with CRI (Wuhl et al. 1996).
A significant adverse effect occurred in one if the prepubertal peritoneal dialysis
patients who developed benign intracranial hypertension. Benign intracranial
hypertension has been reported previously with rhGH treatment (Malozowski et al.
1993, 1995), and it seems to be more common in children with renal conditions being
treated with either rhGH or IGF-I (Guy et al. 1987; Roller et al. 1997) than in
children being treated for other indications. The incidence in renal disease outwith
rhGH treatment is higher than in the general population (Chang et al. 1992). It is a
recognised but rare complication of rhGH treatment, and if children receiving rhGH
treatment complain of headaches or blurred vision, examination, and in particular,
fundoscopy is mandatory.
Renal bone disease or renal osteodystrophy is a frequent problem in children on
dialysis. Renal osteodystrophy may prevent a good response to rhGH, or alternatively
increased growth rates due to rhGH may worsen renal osteodystrophy. One child was
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withdrawn because of worsening renal osteodystrophy, however as the growth
response to rhGH was poor, it seems unlikely to be the cause. The effects of rhGH on
renal bone disease are discussed in more detail in Chapter 10.
Conclusion
In summary, one year of rhGH increased the short term growth rate in children on
longterm dialysis, with children on peritoneal dialysis showing a marginally better
response than those on haemodialysis. The response in both groups was less than that
seen in the CRI and transplanted groups. The children who showed the greatest
improvement in HV were those who were growing most slowly prior to treatment.
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Chapter 6: Randomised Controlled Trial of Recombinant Human Growth
Hormone in Prepubertal and Pubertal Renal Transplant Recipients
Introduction
Short stature persists in some children following renal transplantation, and preliminary
studies have shown a beneficial effect of rhGH (van Dop et al. 1989; Rees et al.
1990). The safety of rhGH in this group is of paramount importance; improved
growth at the expense of graft function is not acceptable. For this reason, this arm of
the trial was conducted in a controlled fashion; children were randomised to rhGH or
no treatment in the first year, with all receiving rhGH in the second year.
In view of the known effects of rhGH, its use post transplantation requires close
monitoring, with particular emphasis on the effect of treatment on renal function
(Hirschberg et al. 1989), the incidence of transplant rejection (Tyden et al. 1990),
renal bone disease (Watkins 1996), and glucose metabolism (Sonksen et al. 1967).
The children in the transplant group were older than the CRI and dialysis patients, and
a greater percentage were approaching or were in the early stages of puberty. The
effect of rhGH on the timing and duration of puberty are not known, therefore
patients were stratified according to pubertal stage at entry into the trial.
Some of the children remained on rhGH therapy after the trial was complete and
follow up data for these children are also reported.
Methods
Twenty-two children with renal transplants were enrolled into a 2 year open-labelled,
prospective and controlled trial of the use of rhGH. Patients were assigned to
prepubertal and pubertal groups, then subsequently randomised to rhGH (treatment
group) or no rhGH treatment (control group) in the first year of the trial, with all
children receiving rhGH in the second year (Figure 6.1). Six children continued on
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rhGH treatment after completion of the trial; data from these children are also
reported (follow up data).
The children were seen on day 1, day 8, and then at 3 monthly intervals for 2 years.
On each occasion, height, weight, blood pressure and blood biochemistry including
urea, creatinine, calcium, phosphate, alkaline phosphatase (ALP), intact parathyroid
hormone (PTH), glucose, insulin and glycosylated haemoglobin (HbAlc) were
checked.
Renal function was monitored every 6 months by clearance of inulin. A rejection
episode was defined as an episode of transplant dysfunction treated with 3 days of
high dose oral prednisolone. The diagnosis was made by the managing clinician. The
children who remained on rhGH were monitored thereafter at 3 monthly intervals.
Children were considered eligible for entry to the trial if they fulfilled the general entry
and exclusion criteria outlined in Chapter 2. In addition, the patients had received
their transplants more than 1 year previously, and had a minimum calculated GFR of
20 ml/min/1.73m2 (Schwartz et al. 1976).
Immunosuppression consisted of azathioprine (60 mg/m2), prednisolone
(approximately 10 mg/m2 on alternate days) and cyclosporin A. The dose of
cyclosporin A was adjusted to maintain plasma trough levels between 50 and 150
ng/ml.
Patients
Fifteen prepubertal (2 girls) and 7 pubertal patients (2 girls) were enrolled and
randomised to receive either rhGH or no rhGH in the first year. Patient details are
given in Table 6.1. Height velocity and HVSDS during the year before the trial are
given in Table 6.2; height SDS at baseline is given in Tables 6.3.
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The mean time since transplantation was 6.5 (2.0 - 11.8) years. Prednisolone dose
was 8.9 (0 - 20.1) mg/m2 on alternate days in the prepubertal and 8.2 (0 - 15.2) in the
pubertal group, equivalent to a daily dose of 0 - 10 mg/m2 of prednisolone. Nine
prepubertal and 4 pubertal children were randomised to receive rhGH in the first year
(treatment group); all children received rhGH in the second year.
Follow up Data
Fourteen children were followed up for 2 years; 3 for 3 years, 2 for 5 years and 1
child was treated for 6 years. Height velocity and calculated GFR were measured
during this time. In addition, the first year of rhGH treatment in all patients was
compared with the growth rate during the preceding year. Age, pre-treatment HV and
height SDS, GFR and steroid dose were correlated with the increase in HV and height
SDS during the first year of treatment. In view of the older age of the patients, HV
during the study was used in preference to HVSDS.
Statistical Analysis
Results are expressed as mean (range) or mean (SD). Within and between group
results were compared using the paired or unpaired Students t-test respectively.
Comparison of change within the treatment and control groups was made by
calculating and comparing the mean (SE) change. Frequencies were compared using
the chi-squared test. Analysis of multiple results within the same group over time was
performed by ANOVA. Correlation's were performed using Pearson's correlation
coefficient, and regression by both single and multiple linear regression analyses.
Statistical significance is assumed with a p value of < 0.05.
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Results
Treatment Group (9 prepubertal, 4pubertal)
Two prepubertal children stopped rhGH; one child returned to dialysis after 11
months, the other developed glucose intolerance after 9 months of treatment. Two
children stopped treatment during the second year: one prepubertal child had started
the trial with poor graft function and received a second graft after 18 months of
rhGH; the other pubertal child had an increase in creatinine and elected to stop rhGH
treatment at the beginning of the second year. Episodes of transplant dysfunction are
shown in Table 6.4.
Control Group (6prepubertal, 3 pubertal)
One pubertal child was withdrawn after 18 months because of a poor response to 6
months of rhGH therapy.
Growth
Prepubertal Patients (n=15)
During the first year of the study HV and HVSDS were greater in the treatment than
control group, Table 6.2. Mean (SE) A height SDS during the first year of study was
0.6 (0.1) in the treatment group and -0.3 (0.2) in the control group, p < 0.001, Table
6.3.
In the treatment group there was no difference between A height SDS in the first and
second years of treatment; 0.6 (0.1) vs. 0.4 (0.2), p = 0.34. Height velocity and
HVSDS were lower in the second year compared to the first year of treatment, Table
6.2. The increase in height SDS during the second year in the treatment group was
greater than that in year 1 in the control group [0.4 (0.2) vs. -0.3 (0.2), p = 0.003],
but HV and HVSDS were not significantly different; p = 0.16 and 0.09 respectively.
In the control group, HV, HVSDS and A height SDS were greater in the second year
on rhGH treatment than in the first year, Tables 6.2 & 6.3.
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Pubertal Patients (n = 7)
The results in the pubertal group were similar to those in the prepubertal group,
however the number of children in the treatment and control groups was small.
During the first year of the trial, HV and A height SDS were significantly greater in
the treatment than control group; the corresponding p value for HVSDS was p =
0.06, Tables 6.2 & 6.3.
In the treatment group, HV, HVSDS and A height SDS remained above pre-treatment
levels in the second year of the study, but were lower than the respective values in the
first year of the trial. Comparing the first and second year data in the control group,
HV, HVSDS and A height SDS were greater in the year 2 than in year 1, but the
values were not statistically significant, Tables 6.2 & 6.3.
Pooled Follow-Up DataforAll Prepubertal Children during rhGH Treatment
When data are pooled for all 15 prepubertal children during their first year of rhGH
treatment, HV, HVSDS and A height SDS all increased significantly compared with
the year before treatment, Table 6.5, Figures 6.2 and 6.3. Height SDS at each time
point is shown in Figure 6.4.
Ten prepubertal children received rhGH for at least 2 years. In these children height
SDS increased from -3.4 (-5.8 to -1.9) on day 1, to -2.4 (-4.4 to -1.2) after 2 years,
p=0.002 (Figure 6.2). Height velocity was 3.9 (0.8 - 6.9) in the year before treatment;
8.2 (3.0 - 10.7) in the first year, p<0.0002 vs. year before; and 6.1 (0.1 - 8.8) during
the second year, p=0.012 compared to the year before treatment (Figure 6.3). The
mean gain in height was 14.8 (3.1 - 18.5) cm in 2 years. Three children received 3
years of rhGH; mean height gain was 22.1 (21.8 - 22.4) cm in 3 yrs. One child
received rhGH for 5 years and another for 6 years (Figure 6.4); HVSDS remained
above pre-treatment values during this time.
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Pooled Follow-Up Datafor All Pubertal Children during rhGH Treatment
Considering all 7 pubertal children, HV, HVSDS and A height SDS all increased
significantly when compared to the year before treatment, Table 6.5 and Figures 6.5
and 6.6. Height SDS at each time point is shown in Figure 6.7. Five of the 7 patients
completed the study, but elected to stop treatment. Four children received 2 years of
rhGH: HV was 5.2 (3.5 - 8.1) before treatment; 9.3 (5.3 - 11.7) in the first year; and
5.8 (4.1 - 8.7) in the second year, values very similar to the prepubertal group. The
average height gain during 2 years of rhGH was 15.0 (9.5 - 19.3) cm.
Regression Analysis
There was no significant difference in the increase in height SDS and HV in the first
year of treatment between the prepubertal and pubertal groups. Combining the results
from all 22 transplanted children, HV in the year before treatment was correlated with
age (r = -0.417, p = 0.05) as was HV during rhGH treatment (r = -0.463, p = 0.03).
Multiple regression analysis revealed prednisolone dose (p = 0.028), Figure 6.8, and
age (p = 0.049) as the strongest negative predictors of A height SDS during rhGH
treatment. Using single regression analysis, HV during treatment was positively
correlated with GFR (r = 0.429, p = 0.016), but this relationship became non¬
significant when the effects of age and prednisolone dose were taken into account.
There was no significant relationship between A height SDS and height SDS on day 1
( r = 0.034) or between A height SDS and HV (r = 0.265) before treatment.
The increase in HV during the first year of rhGH treatment was unrelated to pre-
treatment HV (r = -0.265, p = 0.23), to GFR (r = 0.223), to age (r = -0.199) and to
dose of prednisolone (r = -0.102).
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Weight for Height
At the start of treatment, all children had a WFH > 100%. The two lowest values
(105% and 108%) were in the two children who received no prednisolone therapy.
Percentage WFH decreased during the first year of treatment from 133 (105 - 171)%
at the start of treatment, to 125 (99 - 152)% at 6 months (p < 0.001), and 122 (96 -
152)% at 1 year (p < 0.001). WFH remained significantly reduced after two years 120
(88 - 168)% (p = 0.016).
Renal Function
Results for the prepubertal and pubertal children have been combined. Serum
creatinine in the treatment and control groups did not differ at baseline (p = 0.46),
Table 6.6. The mean (SE) change in creatinine during the first year appeared greater
in the treated group [30.1 (11.7) umol/1] compared with the control group [3.8 (6.2)],
but the difference was not statistically significant (p = 0.11). Creatinine at 1 year was
146 (64 - 317) in the treated group (p = 0.013 vs. day 1), and did not increase further
during the second year of treatment [146 (70 - 402) at 2 years]. Urea decreased
slightly after 1 week of rhGH, but was unchanged thereafter (data not shown).
Results for the prepubertal and pubertal children have been combined; GFR at
baseline was no different in the treated and control groups, p = 0.12, Table 6.6. The
mean change in GFR during the first year was 9.9 (5.4) mls/min/ 1.73m2 in the treated
group (n = 12) and -1.6 (7.6) in the control group, (n = 9), p = 0.22. One child was
withdrawn during the first year because of graft failure. Setting his GFR to zero at the
1 year visit does not significantly alter the change in GFR during the first year; 7.2
(6.0), p = 0.36.
More detailed data relating to individual GFR values during rhGH treatment are
shown in Chapter 7. The mean (range) values for creatinine and GFR for all children
during rhGH treatment are shown in Table 6.7. For those children withdrawn due to
glucose intolerance and poor response, the last available GFR has been used for the
end of treatment value. Where graft failure occurred, a value of zero was used.
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GFR increased significantly during rhGH treatment: 49 (13 - 117) on day 1 and 58
(14 - 133) mls/min/1.73m2 after 6 months, n = 22, p = 0.01. Taking only those
children who completed a full year of rhGH, GFR remained elevated at one year; 51
vs. 59, (n = 19, p = 0.04). However if a value of zero is included for the child who
lost his graft, then the change in GFR becomes non-significant; (n = 20, p = 0.12).
There was no further change in GFR during the second year of rhGH treatment.
Calculated GFR in the children who continued on treatment after the study was
complete, did not change (data not shown).
Presumed Rejection Episodes
In the first year of the trial there were 8 presumed rejection episodes in 5 of the 13
patients in the treatment group and 4 in 2 of 9 patients in the control group (p >0.1).
In the control group there was no difference between the number of episodes in the
first and second years of the trial; 4 in 2 of 9 patients vs. 4 in 2 of 9. Combining the
data from all 22 children, there were 12 episodes in 22 patients in the first year of
treatment, which was no different from the year before rhGH (15 in 22 patients),
p>0.1. Further information relating to these episodes of transplant dysfunction is
given in Table 6.4.
Adverse Events
In addition to the transplant dysfunction described above, two other adverse events
were reported. A 10 year old girl with a renal transplant had an elevated fasting
glucose, insulin, and HbAlc after 9 months of rhGH. These returned to normal when
rhGH was stopped. Several years before, whilst on dialysis, she had pancreatitis and
required a partial pancreatectomy. Glucose tolerance tests before and after withdrawal
from the trial were normal. She went on to develop insulin dependent diabetes, and
chose to re-start rhGH therapy once established on insulin replacement.
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A 13 year old boy in the transplant control group developed worsening of a pre¬
existing idiopathic scoliosis during rhGH which required surgical correction the
following year.
Discussion
This is one of the few controlled trials of rhGH in children with renal transplants to
date. Growth hormone improved growth in both the prepubertal and pubertal
transplant patients. The growth response was equal in the two groups, and improved
growth persisted during the second year of treatment. Comparing the control and
treatment groups, there was no apparent adverse effect on graft function.
The best response to rhGH was seen in the youngest children and in those on the least
steroid, with the strongest predictor being the dose of prednisolone (p=0.029).
Growth in children with renal transplants, who are not on rhGH, has been correlated
with age, GFR and also with steroid therapy (Guest et al. 1991; Tejani et al. 1993).
Children on alternate day steroids grow better than those on daily steroids (Guest et
al. 1991), and peak height velocity during puberty in patients with renal transplants is
inversely correlated with steroid dose (Schaefer et al. 1990), so the relationship
between response to rhGH and steroid dose is not surprising. In another post
transplant study (Ingulli et al. 1993), change in height SDS was greater than 0.4 after
one year of rhGH in 5 of 5 children on no steroid and one child on alternate day
steroids, but only -0.2 (-0.6 to 0.3) in 11 children on daily steroids. Mean creatinine
was the same in both groups. All of our patients were receiving alternate day steroids.
Whether rhGH benefits final height, particularly if it is not started until puberty, has
yet to be determined. In renal failure, puberty is delayed and the magnitude of the
pubertal growth spurt attenuated (Schaefer et al. 1990). Puberty would seem to be an
appropriate time to use rhGH, to induce or mimic the endogenous growth spurt, but
there is concern that treatment might shorten the duration of the pubertal growth
spurt (Darendililer et al. 1990). Some reports have suggested that this may be the
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case in children with renal transplants who receive rhGH (Bartosh et al. 1992;
Benfield et al. 1993), whilst others have demonstrated an increase in height during
adolescence (Fine et al. 1992; Hokken-Koelega et al. 1994d; Maxwell et al. 1996d).
There was no undue advancement in bone age in this study (data not shown), nor in
other reported studies (Hokken-Koelega et al. 1994d). The increase in height SDS
was similar in the prepubertal and pubertal treatment groups in our study, with little
or no change in height SDS in either of the control groups. Longer follow up however
will be necessary to determine if there is a positive effect on final adult height.
Preliminary final height data are becoming available. Janssen assessed final height in
17 renal transplant patients who had received rhGH; the median final height SDS of -
1.8 for males was significantly higher than controls. Six of the 17 patients had a target
height within the predicted range (Janssen et al. 1997). Broyer presented data from 13
children with renal transplants who had received rhGH. Height SDS was -3.5 at the
time of starting rhGH and final height SDS was -1.8. (Broyer M, data presented at 1st
meeting of the International Paediatric Transplantation Association, Venice, August
2000).
Rees has published final adult height data from 6 prepubertal and 6 pubertal renal
transplant recipients. In the prepubertal patients height SDS increased from -3.3 to -
2.9 after 2.7 years of rhGH, and was -3.0 at final height. In the pubertal patients
height increased from -3.4 to -2.6 after 1.4 years of rhGH treatment, and was -2.5 at
final height (Rees et al. 2000). The German group have also presented preliminary
final height data in 38 children with renal transplants who received rhGH treatment.
Height SDS before treatment was -3.2. An increase of+1.5 SD was seen in the males
and of+1.2 was seen in the female patients during treatment. This compares with 50
control patients who had a mean height SDS of -1.5, and whose height SDS changed
by -0.7 in the boys and -0.5 in the girls during an equivalent time period (Haffner D,
data presented at the European Society of Pediatric Nephrology, Helsinki, June
2000). From the preliminary evidence available, rhGH treatment would appear to
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have a beneficial effect on final height, but further data are required before any firm
conclusion can be drawn.
One of the patients developed glucose intolerance during the study. This is a
recognised complication of acromegaly (Sonksen et al. 1967). Patients with renal
disease have peripheral resistance to the actions of insulin (Mak and DeFronzo 1992),
which is aggravated in transplanted patients by the use of corticosteroids (Fennell et
al. 1983). Glucose intolerance during rhGH treatment post transplantation has been
reported previously (Ingulli et al. 1993). Our patient had undergone a partial
pancreatectomy which may have been a contributing factor. For the group as a whole,
the increase in fasting glucose and insulin were transient and during two years of
rhGH there was no increase in HbAlc. In the long term there would appear to be no
adverse effect on glucose tolerance. This issue is discussed further in Chapter 10.
There are several possible mechanisms whereby rhGH or its mediator insulin-like
growth factor-I (IGF-I), might affect graft function: rhGH increases renal plasma flow
and GFR in adults with normal renal function (Hirschberg et al. 1989; Hammerman et
al. 1989); there are known interactions between rhGH and the immune system which
could potentially cause an increase in the rate of rejection episodes (Kelley et al.
1990); and lastly rhGH could have a direct effect on the kidney, as there are growth
hormone receptors on mesangial cells, and receptors IGF-I on proximal tubular and
mesangial cells (Arnquist et al. 1988). Because of the relationship between rejection
episodes and GFR, it is very difficult to study the effects of rhGH on these parameters
in isolation. The effects of rhGH on renal function are discussed at length in Chapter
7.
In renal impairment, an increase in GFR might hasten the progression of decline in
GFR, the so-called hyperfiltration theory (Brenner et al. 1985). There is no evidence
that rhGH adversely affects GFR in children with CRI (Tonshoff et al. 1992; Maxwell
et al. 1995), but few studies of rhGH in renal transplantation have formally assessed
GFR. Most report changes in creatinine or calculated GFR, and an analysis of these
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trials has been inconclusive (Chavers et al. 1995). The data presented here suggest
that 2 years of rhGH treatment does not adversely affect graft function.
However two children were withdrawn from the study because of a deterioration of
renal function. For one patient there was suspicion of non-adherence to
immunosuppression, whilst the other child had an acute rejection episode after 6
months of treatment. His GFR at 1 year was little changed from baseline, but 1 week
later he had a further increase in creatinine and was withdrawn from the study. A third
child received a second renal transplant after 18 months of rhGH. His renal function
had shown a gradual deterioration before and during the trial. The small number of
patients, the variability of the clinical course post transplantation, and the expected
decline in graft function over time hamper interpretation of the data.
There was no apparent untoward effect of rhGH on the incidence of acute rejection.
Some reports suggest rhGH does not affect acute rejection (Rees et al. 1990; Fine et
al. 1992; Hokken-Koelega et al. 1994d, 1996), while others suggest that it does
(Tyden et al. 1990; Schwartz and Warady 1992; Guest et al. 1998). Biopsy proven
acute rejection has been documented in several children at varying intervals after
starting rhGH (Tyden et al. 1990; Johansson et al. 1990; Schwartz and Warady 1992;
Ingulli et al. 1993). None of these were controlled trials. One study suggests that the
risk of rejection is increased by rhGH, but only in children who have had rejection
episodes prior to treatment (Guest et al. 1998). During the first year of rhGH
treatment, 7 of our patients had 12 presumed rejection episodes; all but one had had
presumed rejection episodes in the previous year.
The incidence of rejection episodes in the study is higher than other studies. This is
explained partly by the fact that these were presumed and not biopsy proven episodes,
and therefore likely to be an overestimation. Several patients had chronic rejection at
the start of treatment, and other studies report increases in creatinine during rhGH
when there is biopsy-proven chronic rejection (Johansson et al. 1990; Van Dop et al.
1992; Benfield et al. 1993). It is difficult to determine if rhGH has decreased GFR, if
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there has been an increase in muscle bulk, or if this is the natural progression of
chronic rejection. A recent study of mixed lymphocyte cultures using lymphocytes
from paediatric renal transplant recipients and donor cells, showed that overall, the
addition of rhGH to the culture had little effect, although 3 patients had an augmented
response. These 3 patients had biopsy proven chronic rejection (Benfield et al. 1996).
An ongoing study is addressing the issue of rhGH and rejection in patients with renal
transplants. Fine is conducting a randomised controlled study which requires a renal
biopsy at the start of the study before entry, and requires biopsy confirmation of
rejection episodes (Fine RN, data presented at 1st meeting of the International
Paediatric Transplantation Association, Venice, August 2000). Preliminary results in
38 children in the treatment group and 29 in the control group show no significant
difference between the incidence of rejection in the two groups.
Conclusion
Recombinant human GH improves short term growth in prepubertal and pubertal
children with renal transplants compared to controls. Height velocity during the
second year of rhGH treatment remained above the baseline value in the prepubertal
group. In both groups approximate height gain was 15 cm after 2 years of rhGH
treatment. There was no increase in the incidence of rejection episodes. There was a
significant increase in GFR during the first six months of treatment, but no change
thereafter. With continued use of rhGH, HV decreases toward baseline, but the
growth rate remains above pre-treatment values for up to 6 years .
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Day 1 100 (49 - 152) 114(46 -220) 59 (19- 105) 43 (18 - 70)
6 Months 101 (42- 151) 134 (67 - 357) 66 (10 - 134) 53 (18 - 99)*
1 Year 103 (43 - 144) 146 (64-317) 58 (13 - 117) 49 (0 - 109)
ANOVA p = 0.42 p = 0.04 p = 0.43 p = 0.20
*p = 0.04 vs. Day 1
Table 6.7 Renal function in all transplanted children during their first year of rhGH
treatment
Day 1 6 Months 1 Year ANOVA
Creatinine (n=22) 110(43 -221) 123 (37 - 357) 129 (36 -317) p = 0.06
GFR (n = 22) 49(13 - 117) 58 (14 - 133) 55 (0-113) p = 0.029
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Figure6.2MeanheightSDSintheprepubertalransplantati n s1y rb fore,tstofdyn atyearlyintervalsthe eafteduringrhGHr atm nt,*p<0.01vsy1.
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Chapter 7: Effects Of Recombinant Human Growth Hormone On Renal
Function in Chronic Renal Insufficiency and Following Renal Transplantation
Introduction
It has been known for some time that patients with acromegaly have large kidneys
that hyperfilter (Ikkos et al. 1956; Gershberg et al. 1957). Recombinant human
growth hormone, when given experimentally to adults with normal renal function,
increases GFR and ERPF (Corvilian et al. 1962; Hirschberg et al. 1989; Christiansen
et al. 1991). This effect occurs after several hours, at a time when GH levels have
returned to normal, but levels of IGF-I are elevated (Parving et al. 1978; Hirschberg
et al. 1989). Indeed administration of recombinant human IGF-I has the same effect
(Guler et al. 1989; Hirschberg et al. 1993). Micropuncture studies in the rat
demonstrate that this is due to an effect on glomerular haemodynamics (Hirschberg et
al. 1991).
Growth hormone treatment in patients with CRI results in an increase in IGF-I levels
(Rees et al. 1990), but no change in GFR has been demonstrated, either in adults with
CRI given rhGH experimentally (Haffner et al. 1989) or in children in therapeutic
trials of the use of rhGH in short stature ofCRI (Tonshoff et al. 1992). The effects of
rhGH on ERPF in CRI in man have not been reported. More recently, rhIGF-I has
been shown to increase both GFR and ERPF in adults with moderate CRI (O'Shea et
al. 1993). If hyperfiltration is a mechanism for progression of CRF in man, as appears
to be the case in small mammals (Brenner et al. 1985), then rhGH treatment in
children with CRI could potentially lead to a deterioration in renal function in the
longterm.
There are other mechanisms whereby rhGH could potentially affect renal function.
There are GH and IGF-I receptors on mesangial cells (Arnqvist et al. 1988; Aron et
al. 1989), which could result in expansion of the mesangium and fibrosis. Transgenic
mice with prolonged exposure to GH (but not to IGF-I) develop glomerulosclerosis
and CRF (Doi et al. 1988; Quaife et al. 1989; Kawaguchi et al. 1991). Prolonged
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exposure to GH also causes renal enlargement, as seen in acromegaly (Gerschberg et
al. 1957) and in transgenic mice secreting high levels of GH (Doi et al. 1991).
Hypopituitary mice undergoing unilateral nephrectomy have reduced hypertrophy of
the remaining kidney (Astarabadi et al. 1953).
Many patients with renal transplants have a subnormal GFR, so as with CRI, there are
potential concerns that rhGH treatment might result in a deterioration of renal
function by causing hyperfiltration. In addition rhGH may affect graft function by
other mechanisms. Growth hormone affects the immune system (Bozzola et al. 1991),
and might therefore precipitate acute rejection or cause progression of chronic
rejection (Broyer et al. 1994). Published reports give conflicting results of the effect
of rhGH on renal graft function (Rees et al. 1990; Johansson et al. 1990; Fine et al.
1992; Bartosh et al. 1992; Van Dop et al. 1992; Tonshoff et al. 1993; Benfield et al.
1993; Janssen et al. 1993; Hokken-Koelega et al. 1994d). It is important to make sure
that renal function is not compromised at the expense of improved growth, not least
because graft function itself has been shown to have an effect on growth (Tejani et al.
1993).
Study Aims
The aim of the study was to determine the immediate (hours), short term (1 week)
and the longer term (6 months - 2 years) effects of rhGH on renal function in children
with CRI and in those with renal transplants. In order to do this, urea, creatinine,
GFR, ERPF and proteinuria were measured before starting rhGH treatment,
immediately after receiving the first dose of rhGH, again after 1 week, then 6 monthly
or yearly. Glomerular filtration rate and ERPF were estimated from the clearances of
inulin and para-aminohippuric acid (PAH) respectively. Additionally, in the
transplanted group, the effect of rhGH treatment on the volume of the transplanted
kidney was studied. Weight and blood pressure were monitored throughout.
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Patients
This study was carried out as part of the BAPN trial of rhGH in CRF, as detailed in
Chapter 2. Children attending the London paediatric nephrology centres underwent
additional renal function studies and make up this cohort of patients. Details of the 18
children with moderately severe CRI managed conservatively and 16 with renal
transplants are given in Table 7.1.
All of the patients in the CRI group had all had a GFR of less than 50 ml/in/1,73m2 for
more than 1 year. The transplanted patients had received their grafts more than 1 year
previously and had had stable graft function for the 6 months before the trial. Mean
time from transplantation was 6.5 (2.0 - 11.8) years. Two grafts were from living
related donors; 12 were first grafts, 3 were second grafts, and one was a third
transplant.
Nine children received triple immunosuppression consisting of azathioprine (60
mg/m2/day), cyclosporin A (at a dose sufficient to maintain plasma levels between 50
and 150 ng/ml), and prednisolone. Seven children were immunosuppressed with
azathioprine and prednisolone alone. Prednisolone was given at a mean dose of 9.8
(5.2 - 20.1) mg/ m2 on alternate days in 15 children; one child received 7.6 mg/ m2
daily.
Retrospective growth data and creatinine values were available for all children for the
year preceding entry into the trial.
Study Protocol
Children were seen on day 1 (before treatment), day 8 (after 1 week of rhGH), then 3
monthly up to 1 year. On each occasion blood was sampled in the fasting state for
estimation of urea, creatinine, GH and IGF-I. With the exception of day 1, these
samples were drawn approximately 12 hours after the preceding dose of rhGH.
Height was measured using a wall-mounted stadiometer by the same observer. Blood
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pressure was measured in the sitting position. An early morning urine sample was
obtained for measurement of microalbumin. Three day dietary assessments were made
6 monthly (2 children received overnight nasogastric feeds).
Methods
Glomerular filtration rate and ERPF were estimated by clearance of inulin (Inutest
25%, Laevosan-Gesellschaft GmbH, Linz/Donau) and para-aminohippuric acid (PAH)
(Aminohippurate Sodium 20%, Merck, Sharp and Dohme, West Point, USA)
respectively using a standard clearance with urine collection technique.
The procedure was carried out after an overnight fast. A cannula was inserted in each
arm, a fasting blood sample withdrawn, then a bolus of 50mg/kg inulin and 5 mg/kg
PAH in 50 mis of normal saline given over 3-4 minutes. This was followed by infusion
of a maintenance solution of inulin and PAH in 0.45% saline, calculated so as to
maintain a plasma inulin level of approximately 250 mg/1 (mg inulin per minute =
250/1000 x GFR) and 25 mg/1 PAH (mg PAH per minute = GFR /0.2 x 25/1000).
The maintenance solution was infused at 100 mis/hour, by constant rate infusion
pump (IMED Volumetric Pump 960, IMED, Albington, Oxon).
Diuresis was induced by encouraging the child to drink water, 20 ml/kg for the first
hour, then 10 ml/kg/hour thereafter. As the study lasted for several hours the child
was allowed to eat small non-protein, non-fructose containing snacks. After one hour,
steady state was assumed and the bladder emptied. Eight forty minute urine
collections (collections nos. 1-8) were made with the child being encouraged to
completely empty the bladder on each occasion. A sample of blood was drawn, from
the second cannula, at the midpoint of each collection for inulin, PAH and GH.
Insulin-like growth factor-I was measured during collections 3 and 8. Growth
hormone (0.14 iu/kg) was given by subcutaneous injection on completion of the third
collection.
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For the children attending the Royal Free Hospital (RFH) and the Hospital for Sick
Children, assays were performed at RFH. Inulin was measured spectrophotometrically
using a resorcinol method (Roe et al. 1949), PAH was determined by the Bratton
Marshall reaction (Smith et al. 1954), creatinine by an enzymatic method using an
RA1000 Autoanalyser (Technicon Instruments Co Ltd., Basingstoke, UK) and IGF-I
by radioimmunoassay after acid-ethanol extraction. It is recognised that this method
of extraction does not completely remove IGF binding proteins (Powell et al. 1986),
which can then interfere in the assay. The extent of interference appears to depend on
the particular antibody being used. In our assay, acid chromatography, when
compared to acid-ethanol extraction, gave comparable results in CRI (r = 0.979,
p<0.0001) with acid-ethanol extraction giving slightly lower results (acid-ethanol
extraction = [0.906 x acid chromatography] - 0.049) (See also Chapter 8). Growth
hormone was measured by immunoradiometric assay (Chapter 8). Urinary
microalbumin was measured by an immunoturbidimetric method (Technicon method,
Bayer Diagnostics, UK Ltd). Urinary creatinine was measured enzymatically on the
same urine samples, and the results expressed as the albumin / creatinine ratio.
For the children attending Guy's Hospital, assays were performed at Guy's Hospital.
Inulin was measured enzymatically (Dalton et al. 1987), PAH was determined by the
Bratton Marshall reaction (Smith et al. 1954), and creatinine by an enzymatic method
using an RA1000 Autoanalyser (Technicon Instruments Co Ltd., Basingstoke, UK).
Urine samples were analysed for microalbumin by a two-site ("sandwich") enzyme-
linked immunosorbent assay (Thomlinson et al. 1994). Polyclonal rabbit anti-human
albumin immunoglobulin was used both as the capture antibody and, when conjugated
to horseradish peroxidase, as signal antibody (Dako, High Wycombe, UK). Intra-
assay and inter-assay CV were 4.2% and 11.9% at 10mg/l respectively. The reference
range of 0 - 10 mg/mmol creatinine was obtained from normal children (Thomlinson
et al. 1994).
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Urinary N-acetyl glucosaminidase was measured using an automated
spectrophotometric method with p-nitrophenyl-B-D-glucosaminide as substrate
(Sigma, Poole, Dorset, UK) (Tucker et al. 1975). Intra-assay and inter-assay
coefficients of variation (CV) were 2.5% and 5.8% respectively at 3.9 mmol/p-
nitrophenol/h/mmol creatinine. The reference range of 0 - 100 mmol/p-
nitrophenol/h/mmol creatinine was obtained from normal children (Thomlinson et al.
1994).
CRI Group
These children were studied for 1 year. Inulin clearances were carried out on day 1,
day 8 and at 1 year; on days 1 and 8 rhGH was given at midday rather than in the
evening. On day 1, eight urine collections were made; the first 3 to establish baseline
clearance. Immediately the third collection was complete, the first subcutaneous
injection of rhGH was given and the urine collections continued without interruption.
On day 7 rhGH was given in the evening as usual, then exactly the same procedure as
above was carried out the following morning (day 8), before and after the eighth
injection of rhGH. Baseline clearances (Pre) were taken as the average of the first 3
collections and compared with the average of the last 3 collections (nos. 6-8) (Post)
to look for an immediate effect of rhGH. At 1 year, four forty minute urine collections
were carried out, 12 hours after the last injection of rhGH. Baseline clearances on day
1, day 8 and after a year were compared, to look at the short and long term effects of
rhGH Four of the youngest children had baseline clearance tests only on each of the 3
days; four forty minute urine collections before rhGH on dayl, and at least 12 hours
after the previous dose on day 8 and at 1 year.
Transplanted Group
Inulin and PAH clearances were performed as for the CRI group, however only 4 x
40 minute collections were made on each day. These children were enrolled later than
the CRI group, and it had become clear from the CRI group that there was no
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immediate effect of rhGH on GFR. The collections were performed before rhGH was
given on day 1, and 12 hours after rhGH on the other days. Clearance studies were
performed on day 1, 1 week after starting rhGH, then 6 monthly for 2 years. As this
arm of the trial was a controlled study, 7 of children were randomised to no treatment
in the first year, with all children receiving rhGH treatment in the second year. In the
control year clearance studies were performed six monthly, then immediately before
starting rhGH, after 1 week, and 6 monthly.
Kidney volume was measured yearly using either an ATL Mark IV or Acuson 128
ultrasound machine, with 3.5 or 5 MHz sector probes. When the whole length of the
kidney could not be included in the image, a stand off gel block was used. Repeated
measurements of renal length were made until a maximum was reached. Multiple
depth and width measurements were taken and averaged. Kidney volume (ml) was
estimated using the formula for an ellipse (Dinkel et al. 1985).
Rejection episodes were diagnosed by the clinician in charge, and were assumed to
have occurred when there was an increase in baseline creatinine of more than 10% on
2 occasions, in the absence of a high cyclosporin A level (>150ng/ml; therapeutic
range 50 - 150ng/ml), dehydration, infection or obstruction. Treatment consisted of a
3 day course of oral prednisolone (3mg/kg/day). A renal biopsy was performed if
creatinine did not return to baseline after this treatment.
Statistical Analysis
Within each group, statistical analysis was performed using a paired Student's /-test,
and confirmed using a Wilcoxon matched pairs signed rank sum test. Two-way
ANOVA was used to compare repeated measurements in the same group of patients.
Correlation was performed by Pearsons Correlation and multiple regression analysis.
Within the transplanted group, the treatment and control groups were compared using




Fifteen of the 18 children completed one year of treatment. Three children were
withdrawn from the trial; two required dialysis after 9 months of treatment and the
other received a pre-emptive transplant after 6 months. Data from these children,
whilst they were in the trial, have been included and their HV on treatment annualised.
There were no other serious adverse events. Height velocity increased from 4.5 (1.7-
6.5) cm/yr in the year before treatment to 9.5 (4.8-12.7) whilst on treatment (p <
0.0001).
Fourteen children had clearance studies before and after a subcutaneous injection of
rhGH on days 1 and 8. Eighteen had clearance studies on both days 1 and 8, and 15
had studies on days 1, 8 and after 1 year.
GH and IGF-I
Growth hormone increased approximately 10-fold in the 3-4 hours following the first
subcutaneous injection on both day 1 (Figure 7.1a) and day 8 (Figure 7.1b). Mean
fasting GH increased after 1 week of treatment (Table 7.2), but did not accumulate
further (Table 7.3). IGF-I did not change in the 3-4 hours after injection on either day
1 or day 8 (Table 7.2), but fasting IGF-I was elevated after 1 week and remained so
for the duration of treatment (Table 7.3). Growth hormone and IGF-I results are
discussed further in Chapter 8.
GFR
There was no change in GFR in the 3-4 hours after rhGH injection on either day 1 or
day 8 (Table 7.2). Eighteen patients had baseline clearances before and after one week
of rhGH. There was no change in mean GFR after 1 week of treatment (Table 7.4).
There was also no difference after 1 year in the 15 patients who completed the year of
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study (Table 7.4). Individual values are shown in Figure 7.2. When a value of zero
was substituted for the children who required dialysis, GFR was 16.3 (0 - 59) at 1
year, n=18. This was not significantly different from day 1, p = 0.20.
ERPF
Mean ERPF, as determined by clearance of PAH, was unchanged in the 3-4 hours
following a subcutaneous injection of rhGH, but was significantly increased after 1
week. Individual values are shown in Figure 7.3. Four patients showed an increase in
GFR in addition to an increase in ERPF. This subgroup was not distinguished by
baseline renal function, aetiology of renal disease, basal IGF-I or increase in IGF-I
after one week.
Mean ERPF remained elevated after a year when compared to day 1 but this was not
statistically significant. In the group as a whole, there was a downward trend in
filtration fraction, but individually there was much variation and the decrease was not
significant.
There was no correlation between baseline GFR, ERPF and the change in GFR and
ERPF at 1 week or after 1 year. There was no correlation between absolute IGF-1 or
IGF-I corrected for age and sex, and GFR or ERPF on day 1, day 8 or at 1 year, nor
was there a relationship between the change in either GFR or ERPF and the increase
in IGF-I or IGF-I SDS.
Urea and Creatinine
Plasma urea decreased significantly after one week, but returned to pre-treatment
values by 3 months. Creatinine was unchanged after 1 week, however there was a
significant increase in creatinine after 1 year. Results are shown in Table 7.3
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Blood Pressure
Mean systolic and diastolic blood pressures were unchanged by 1 year of rhGH
treatment (Table 7.3).
Urinary Albumin Excretion
Albuminuria, expressed as an albumin(mg/l) / creatinine(mmol/l) ratio, was unchanged
during the study (0.08 (0.08) on dayl; 0.05 (0.05) on day 8; and 0.10 (0.12) at 1
year) in the 15 children with congenital structural problems. The 3 children with
FSGS had marked proteinuria.
Weight and Dietary Assessments
Weight was unchanged after 1 week (22.2 (13.3 - 37.0) kg on day 1; 22.3 (13.4 -
36.8) on day 8), but increased to 25.7 (15.5 - 39.2) kg after 1 year of treatment (p <
0.0001). Dietary intake of protein did not change during the study period: 2.1 (1.2 -
2.5) gm/kg body weight protein on day 1; 1.9 (1.4 - 2.9) at 6 months; and 1.8 (1.4 -
2.1) at 1 year. Energy intake (kcal/kg body weight) was not affected by treatment: 36
(18 - 59) on day 1; 33 (27 - 47) at 6 months; and 36 (31 - 41) at one year.
Transplanted Group
Fifteen children completed 1 year, 7 completed 18 months and 6 completed 2 years of
rhGH treatment. Patient 6 developed fasting hyperglycaemia associated with a raised
HBAlc after 9 months, at which time rhGH treatment was stopped.
Two children (patients 7 and 11) had poor graft function at the start of the trial; both
had biopsy-proven chronic rejection. Patient 11 received a second graft after 18
months of treatment with rhGH; patient 7 completed 2 years of rhGH but required
haemodialysis six months after completion of the trial. Patient 13 had pyelonephritis
after 18 months of rhGH and a permanent deterioration of graft function during this
127
episode. Patient 16 had hypertension and hyponatraemia after the oral water diuresis
during the inulin clearance study on day 1; subsequent measurement of renal function
was by single injection inulin clearance only.
Height velocity increased significantly in the group receiving rhGH, compared to the
children in the control group. Results are given first for all 22 children during rhGH
treatment; the treatment and control groups in the first year of study are also
compared.
GH and IGF-I
Serum GH and IGF-I levels increased after one week of rhGH and remained elevated
thereafter (Table 7.5). There was no relationship between baseline IGF-I or increase
in IGF-I and the changes in renal function in individual patients.
GFR
Glomerular filtration rate was significantly increased after one week of rhGH; 52 (28)
on day 1 and 57 (29) on day 8 (p = 0.004), Table 7.6. Glomerular filtration rate
remained increased at six months [62 (31), p = 0.013], but not at 1 year [55 (33)],
Figure 7.4. Individual values are shown in Figure 7.5. By ANOVA there was a
significant increase in GFR with time (p = 0.036). There was no further significant
change in GFR in those children treated for 2 years: 53 (17 - 65) ml /min/1.73m2 at 18
mths (n=7); 38 (11 - 51) at 2 years (n=5). Despite an increase in GFR, there was an
increase in plasma creatinine concentration from 110 (43 - 221) umol/1 to 139 (64 -
317) after one year of treatment, p = 0.028 (Table 7.5), presumably because of an
increase in muscle bulk. Blood urea decreased after one week of rhGH, but returned
to pretreatment values by 3 months (Table 7.5).
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ERPF
There was no significant change in ERPF, as measured by clearance of PAH, or
filtration fraction during the year of rhGH treatment, Table 7.6. There was no change
in ERPF in those children who received rhGH for 2 years: 285 (54 - 598) at 18 mths
(n=7); 219 (41 - 469) at 2 years (n=5). Individual patient values are shown in Figure
7.6.
Kidney Volumes
Kidney volume was measured in 10 patients before and during rhGH treatment. Mean
volume was 128 (57 - 221) ml on dayl and 133 (57 - 227) after one year (p=0.14).
The change in kidney volume was no different from that seen in 5 children studied
during the year of no treatment; 114 (76 - 148) on day 1 and 123 (99 - 150) after one
year (p=0.38).
Blood Pressure
There was no significant change in systolic or diastolic BP during rhGH treatment
(Table 7.5).
Urinary Protein Excretion
There was no significant change in albumin excretion during therapy: day 1 mean (SE)
17.3 (11.6) mg/mmol creatinine; 13.8 (6.7) at 6 months; 13.1 (6.1) at 1 year. There
was also no change in the pattern of urinary N-acetyl glucosaminidase excretion: dayl
106 (27) mmol/p-nitrophenol/h/mmol creatinine; 120 (20) at 6 months; 123 (26) at 1
year. Four patients had elevated levels on day 1 which persisted with treatment.
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Dietary Assessments
There was no significant change in mean (SE) dietary protein intake: 1.3 (0.2) g
protein N/kg on dayl; 1.1 (0.3) at 6 mths; 1.3 (0.1) at one year. Energy intake was
likewise unchanged: 38 (5.3) kcal/ kg on day 1; 32 (5.8) after 6 mths; 42 (7.7) at one
year.
Control Data
GFR, ERPF, creatinine and urea did not change in the 7 children studied during their
year of no treatment (Table 7.7). Blood pressure, protein excretion and kidney
volume were also unchanged. Height velocity was 4.5 (2.8 - 7.8) cm/yr in the year
before the trial; 4.1 (1.4 - 5.6) cm/yr in the year of no treatment; and 8.5 (5.3 - 11.1)
cm/yr in these 7 children during the first year on rhGH (p<0.004 vs year of no




Prolonged exposure to consistently high GH levels, such as are found in acromegaly
and diabetes, results in an elevation of ERPF and GFR (Ikkos et al. 1956;
Christiansen et al. 1981). Whilst this might appear be beneficial in CRI, if
hyperfiltration is indeed a mechanism for progression of CRI in man (Brenner et al.
1985), then rhGH treatment in CRI may have a deleterious effect on renal function in
the longer term. Patients with acromegaly do not go on to develop chronic renal
failure (in the absence of diabetes and hypertension) (Gershberg et al. 1957), however
rodents with prolonged exposure to very high levels of GH develop glomerular
sclerosis (Doi et al. 1988; Quaife et al. 1989; Kawaguchi et al. 1991).
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There are a number of mechanisms whereby rhGH could affect renal function. First,
as discussed, GH through the action of IGF-I, increases GFR and ERPF in the normal
kidney; micropuncture studies in the rat demonstrate that this is due to an effect on
glomerular haemodynamics (Hirschberg et al. 1991). Second, altered renal function
could be related to hypertrophy of the kidney; prolonged exposure to GH causes renal
enlargement, as seen in acromegaly (Gershberg et al. 1957) and in transgenic mice
secreting high levels of GH (Doi et al. 1988). Hypopituitary mice undergoing
unilateral nephrectomy have reduced hypertrophy of the remaining kidney (Astarabadi
et al. 1953). Third, transgenic mice with prolonged exposure to GH (but not to IGF-
I) develop glomerulosclerosis and chronic renal failure (Doi et al. 1988). Finally,
rhGH may have an effect on the immune system, and in renal transplantation could
precipitate acute rejection or cause progression of chronic rejection (Bozzola et al.
1991).
In our CRI patients there was no change in GFR during rhGH treatment, confirming a
study in 7 adults with CRI, none of whom showed any change in inulin clearance 24
hours after 3 days of rhGH (Haffner et al. 1989). It also supports the findings of the
rhGH trials in children with CRI, where GFR, as measured by single injection inulin
clearance, was unchanged after 6 months and 1 year (Tonshoff et al. 1992) and where
the change in calculated creatinine clearance after 24 months was no different on
rhGH as compared to placebo (Fine et al. 1994).
Two children reached end-stage disease during treatment and required dialysis. It is
difficult to disentangle the long term effects of rhGH treatment on renal function from
the natural progression of CRI, and it is not known if rhGH treatment affected their
clinical course. Both children had FSGS and a rising creatinine before starting
treatment. One child showed a 50% increase in ERPF after one week of rhGH; the
other showed little change in ERPF. Four children reached end-stage disease in the
year following the trial, so perhaps it was surprising that there was not a decline in
mean GFR during the study.
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Plasma creatinine rose significantly despite a consistent GFR, and presumably reflects
an increase in muscle bulk. Fractional excretion of creatinine was unchanged by rhGH
treatment (results not shown), therefore the increase in plasma creatinine was not due
to a reduction in tubular secretion of creatinine. From our data it is clear that serum
creatinine alone is an inadequate marker of GFR in children with CRI during rhGH
treatment.
None of the previously mentioned studies have looked at the effects of rhGH on
ERPF in CRI in man. After one week of treatment we demonstrated an increase in
mean ERPF, to a degree similar to that seen in individuals with normal renal function
(approximately 25%) (Hirschberg et al. 1989). Three day dietary assessments
confirmed that increased ERPF was not due to an increase in protein intake during the
trial. There was no change in systemic blood pressure, suggesting the increase in
ERPF represents a decrease in renal vascular resistance.
Four children had an increase in GFR as well as ERPF. It was not possible to predict
the renal response to rhGH from baseline characteristics and in the group as a whole
there was no relationship between the increase in circulating IGF-I and the changes in
GFR and ERPF. Autocrine and paracrine actions of IGF-I within the kidney may be as
or even more important than circulating IGF-I in mediating the renal effects of rhGH
(D'Ercole et al. 1984).
These results support a study of four adults with moderate CRI, all of whom showed
an increase in GFR and ERPF in response to subcutaneous twice daily injections of
rhIGF-I for 5 days (O'Shea et al. 1993). Glomerular filtration rate increased between
40-70% with a larger increase in ERPF, such that filtration fraction decreased in each
of the four patients. The degree of renal insufficiency was less than in our patients.
Interestingly in two of these patients clearance of PAH remained elevated 10-12 days
after stopping rhIGF-I, whilst GFR had returned to baseline.
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The same group have since undertaken further placebo-controlled studies of IGF-I
therapy in patients with severe CRI (6-15 ml/min/1.73m2) (Vijayan et al. 1999;
Hammerman et al. 1999). At the end of 31 days patients treated with IGF-I had a
GFR that was 145% of baseline; patients receiving placebo had no change in GFR.
Whilst the increase in GFR would seem most probably to be due to an effect of IGF-I
on glomerular haemodynamics, 14 days after treatment was stopped GFR remained
elevated at 125% of baseline in the treatment group. At this time circulating IGF-I
levels had returned to normal, therefore such changes may represent IGF-I induced
renal hypertrophy (Hammerman et al. 1999).
Micropuncture work in normal rats infused with rIGF-I revealed an increase in GFR
and ERPF due predominantly to an increase in efferent arteriolar dilatation and an
increase in the ultrafiltration coefficient (Hirschberg et al. 1991). The relevance of
these changes in CRI (Miller et al. 1990; Allen et al. 1992) and their application to
man, are not clear, but it is interesting to speculate that changes within the glomerulus
in CRI, dependent on the severity and aetiology of renal disease, may determine the
response, if any, to rhGH or rhIGF-I. Alternatively, as a reduction in renal mass
stimulates IGF-I production during compensatory hypertrophy in rodents (Fagin et al.
1987; Lajara et al. 1989), there may already be increased IGF-I expression in the
kidney in CRI which results in a different response to exogenous rGH or rIGF-I.
Renal hypertrophy per se may be important in the response to prolonged rGH
exposure.
In small mammals, prolonged administration of GH to rats with renal impairment
results in glomerular hypertrophy and glomerular sclerosis (Allen et al. 1992).
Interestingly prolonged exposure to IGF-I causes hypertrophy but not sclerosis of the
glomerulus in transgenic mice with normal renal function (Quaife et al. 1989).
Micropuncture work has shown that glomerular capillary pressure is not raised in
response to IGF-I in the normal rat (Hirschberg et al. 1991), so perhaps the sclerosis
is due to an action of GH which is not mediated via IGF-I-induced haemodynamic
changes (Yang et al. 1993). As mentioned before patients with acromegaly do not
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develop renal disease, despite exposure to high levels of GH. The renal response to
GH in man would appear to be different from that in rodents; indeed the rodent
reduced renal mass model may not be representative ofCRI in man.
Whilst the evidence to date suggests that the renal effects of GH are likely to be due
to an effect of IGF-I on glomerular haemodynamics, it is not inconceivable that GH
increases secretion of PAH by the proximal tubule. While this cannot be discounted
from our data, neither can it be the whole explanation.
Measurement ofGFR
It is obviously important in a study such as this that GFR measurements are as
accurate as possible. Measurement of GFR by standard inulin clearance with urine
collections is the gold standard, but in children it can be a difficult test to perform. It
is not ethical to use bladder catheterisation, yet without it one cannot be sure that the
child has completely emptied their bladder. Ensuring a high urine flow rate with the
use of an oral water diuresis makes it easier to empty the bladder, and so reduces the
risk of error. None of our children had overt bladder dysfunction.
To verify the adequacy of bladder emptying, we also calculated the clearance of inulin
by the constant infusion without urine collection method; at steady state the amount
of inulin infused equals the amount cleared in the urine (Berger et al. 1948; Rose et
al. 1969). There was very close correlation between these methods in our patients
(Maxwell et al. 1994), confirming that bladder emptying was virtually complete. On
33 occasions GFR was measured by both the urine collection and constant infusion
techniques. Glomerular filtration rate, as measured by urine collection, was 20.3 (6.4 -
58.1) ml/min/1.73m2 and by constant infusion 21.1 (6.6 - 55.9). The mean difference




As far back as 1962 Corvilian reported reduced urinary phosphate excretion following
an injection of hGH. There are GH and IGF-I receptors on proximal tubular cells
(Hammerman et al. 1986; Rogers et al. 1989). Treatment with rhGH could also have
an effect on tubular function, as well as glomerular function. As a marker of tubular
function we measured urinary excretion of N-acetyl glucosaminidase, a renal tubular
enzyme. This was unchanged during rhGH treatment, as was the excretion of albumin
in the urine.
Transplanted Patients
The effects of rhGH on renal function are perhaps more pertinent to its use post
transplantation. An improvement in height at the expense of graft function is not
acceptable. In the group of patients studied, GFR increased after one week and six
months of rhGH treatment, and remained elevated, but not significantly so after 1
year. There was no significant change in ERPF or in kidney volume.
The effect of rhGH on GFR after one week is likely to be due to an alteration in
glomerular haemodynamics. It is unlikely that any of the other mechanisms outlined
above would be acting after only one week of treatment. After six months of rhGH,
increased GFR could still be due to altered haemodynamics, or to renal hypertrophy
as a result of treatment. With time, however, other influences, such as progression of
chronic rejection, have to be taken into account. As in CRI, haemodynamic changes in
the transplanted kidney could adversely effect graft function. Despite the increase in
GFR, there was also an increase in serum creatinine, presumably reflecting increased
muscle bulk.
Our results suggest that the transplanted kidney can respond to rhGH in a similar
fashion to the normal kidney, but it seems likely that other factors such as chronic
allograft nephropathy intervene to prevent a sustained increase in GFR. It is therefore
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difficult to predict the longterm effect of rhGH in renal transplantation from a study of
this length. Continued monitoring is required.
An analysis of published studies of rhGH in renal transplantation reported a variable
effect on renal function (Chavers et al. 1995). However few studies have formally
measured GFR in patients with renal transplants during rhGH treatment. One reported
no significant change in GFR, as measured by single dose inulin clearance (Tonshofif
et al. 1993), and the other (Hokken-Koelega et al. 1994d) reported no significant
changes in GFR as measured by inulin clearance. Other studies of rhGH therapy after
renal transplantation quote changes in creatinine or changes in the slope of an inverse
creatinine (1/creatinine) plot; however, changes in creatinine do not always reflect a
change in GFR. Calculated GFR (Schwartz et al. 1976) takes some account of this; a
multicentre European study (Johansson et al. 1990) showed no significant change in
calculated GFR after 1 year. Another study (Benfield et al. 1993) showed no
significant change in creatinine clearance in 19 children after 1 year, another reported
a decrease in creatinine clearance in 5 of 9 patients (Van Dop et al. 1992), and yet
another reported a decrease in calculated GFR in 3 but an increase in the other 2
patients (Bartosh et al. 1992).
Interpretation of these studies is hampered both by the lack of formal measurement of
GFR, and by the heterogeneity within patient groups. Slowly growing children tend to
have poorer renal function. In one study a rise in creatinine of 90 umol/1 was
associated with a decrease in height SDS of -0.17 (Tejani et al. 1993). Moreover,
GFR decreases with the number of rejection episodes and with length of time from
transplantation (Berg et al. 1992), so changes in GFR during a study like this may be
related to factors other than rhGH.
It is even more difficult to determine the effects of rhGH on the incidence of rejection
episodes. Transplant dysfunction that appears clinically to be rejection is treated in our
centres with a 3 day course of high dose oral prednisolone; we proceed to a biopsy
only if there is no response to this treatment. This does not allow assessment of the
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true incidence of rejection, but a similar policy was used in both centres before and
during the trial. The incidence of transplant dysfunction was no different during rhGH
treatment when compared to the year before. From the literature, the use of rhGH has
been associated with biopsy-proven acute rejection in children with previously stable
graft function at variable times after commencing rhGH (Johansson et al. 1990; Tyden
et al. 1990; Fine et al. 1992; Schwartz and Warady 1992), and also with the
progression of chronic rejection (Van Dop et al. 1992; Benfield et al. 1993). In one
report, two children with previously diagnosed chronic rejection had an increase in
serum creatinine after the use of rhGH. The creatinine level decreased on stopping
rhGH, suggesting a functional effect rather than irreversible changes (Jabs et al.
1993).
There have been three major controlled trials including this one, of the use of rhGH
after renal transplantation. None have reported an increase in rejection episdoes, but
risk factors for rejection have been suggested. The Dutch multi-centre study
suggested that the use of alternate day steroids was a risk factor for rejection
(Hokken-Koelega et al. 1994d). The French multi-centre study also reported no
overall increase in rejection episodes, but reported an increase in the number of
rejection episodes in children who had had rejection episodes in the year prior to the
trial (Guest et al. 1998). The issue of transplant rejection is discussed further in
Chapters 6 and 9.
Conclusion
One year of rhGH treatment in patients with CRI resulted in a significant increase in
ERPF after one week, with a return toward baseline values after one year. There was
no change in mean GFR during treatment. In the transplanted group, GFR increased
after one week and six months of treatment, but had returned toward starting values
after one year. There was no change in ERPF. In both groups blood pressure and





































































*p=0.03vsDay1 IGF-Imiaseasuredduringcollections3nd8 GH,FRandERPFrethave agedvalu sofcollection1-36 8













































*p<0.01vsday1,*p=.0001**p0. 5Day FastingGH:normalrange<10mU/l IGF-I:normalrangeisagelated
















































































*p=0.03vsday1,*p< 01 FastingGH:normalrange<10mU/ IGF-I:normalrangeisgrelated
Table7.6































































Figure7.1aGrowthhormone(GH)pr filesaft rthfirstsubcutan ousinjecti nfrhGHd y ofthestudyinCRIgroup.
-2020614822 lime(minutes)









Figure7.3IndividualERPFmeasurementsnthC Ipatientsod y1,aft rwe kdy afrhGHtre tm . *MeanERPFw sincr asedaft r1eekcomparetd y,p=0.03.
Day16MthsYe r82ear TimeonrhGH
Figure7.4GFR(ml/min/13m2)ialltransplant dpat entswhoreceiv d2ye rsofhGHtreat nt, *p=0.01vsday1.
0A1 0612824 RhGHTreatment(months)
Figure7.5
GFR(ml/min/1,73m2)itheransplantedgroupbefor ,ft r1weekd6n hly intervalsduringrhGHtr atme t.
Figure7.6Renalplasmaflow(ERPF)ml/min/1.73 2itheransplantedroupbefo ,ft rweek andt6monthlyintervalsduri grhGHtre tme t.
701
Day16MthsYe r
Figure7.7GFR(ml/min/1.73m2)intheransplanttreatmeMdco trol□roupsdu i g thefirstyearofstudy,*p=0.04v .da1.
Chapter 8: Insulin-Like Growth Factors And Insulin-Like Growth Factor
Binding Proteins in Children with Chronic Renal Insufficiency and Following
Renal Transplantation Before And After TreatmentWith Growth Hormone
Introduction
Poor growth in CRF is attributed to a state of GH resistance, where there are high
levels of GH, but reduced expression of hepatic GH receptors and low normal levels
of its main mediator IGF-I (Blum et al. 1991; Chan et al. 1993). In addition it has
long been recognised that the IGF binding capacity of uraemic serum is high (Powell
et al. 1987). This has been attributed to raised levels of IGFBPs which have a high
affinity for IGFs (Powell et al. 1987, 1993; Lee et al. 1989; Blum et al. 1991). As a
result IGF bioactivity of uraemic serum is low (Phillips et al. 1984; Baxter et al. 1986;
Blum et al. 1991).
To date, six IGFBPs have been described (Ballard et al. 1989; Rosenfeld et al. 1994).
Quantitatively IGFBP-3 is the most important binding protein and acts as a reservoir
for IGF-I in the circulation (Baxter RC et al. 1991). IGFBP-3 fragments are said to
accumulate with increasing renal failure (Blum et al. 1991), and then fall after renal
transplantation (Tonshofif et al. 1996). IGFBP-1 and -2 have also been proposed as
possible inhibitors of growth in renal failure (Burch et al. 1990; Lee PDK et al. 1993;
Cox et al. 1994; Powell et al. 1997a).
Whilst most emphasis has been placed on IGFBP-3 as an inhibitor of growth in renal
failure (Mehls et al. 1990; Blum et al. 1991; Tonshofif et al. 1991b), there is evidence
to suggest that the role of IGFBP-3 is more likely to be one of growth promotion
rather than growth suppression. IGFBP-3 is GH dependent (Wood et al. 1988) and in
vitro can potentiate the action of IGF-I (Blum et al. 1989). IGFBP-3 levels increase
during successful treatment of short stature with rhGH in renal failure (Rees and
Maxwell 1996b).
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To address the role of IGFBPs in short stature of renal failure, two groups of poorly
growing children were studied; a group with conservatively managed CRI, and a
group with renal transplants. Insulin-like growth factors and IGFBPs were measured
before and during a year of rhGH therapy.
Western ligand blot analysis (WLB) allowed semi-quantification of IGFBPs -1 to -4.
In addition IGFBPs -1, -2 and -3 were measured by radioimmunoassay (RIA) or
immunoradiometric assay (IRMA). IGFBP-3 was also measured by western
immunoblot (WIB) analysis using an anti-IGFBP-3 antibody. WIB permits separate
identification of intact IGFBP-3 and IGFBP-3 fragments; IRMA quantifies total
IGFBP-3 (i.e. combined intact and fragments), and WLB detects only intact IGFBP-3.
We also measured the ability of serum from the 2 groups of children to break down
intact recombinant IGFBP-3 into fragments (Guidice et al. 1990; Hossenlopp et al.
1990) so called in vitro IGFBP-3 proteolysis.
The relationship between IGF and IGFBP measurements and age, age-related height
and HV, GFR and steroid dosage before and during the use of rhGH was studied.
Patients
Seventeen children (3 girls) with CRI and 11 (3 girls) with renal transplants being
treated at two paediatric nephrology centres in London were studied. Patient details at
the start of rhGH treatment are given in Table 8.1. Entry criteria were as outlined in
Chapter 2.
In the CRI group, 14 children had congenital structural problems, two had focal
segmental glomerulosclerosis and the other developed renal failure following cardiac
surgery. The transplanted group had received their grafts 5.7 (1.9 - 11.6) years
previously. All were taking azathioprine (60 mg/m2/day) and prednisolone 9.6 (5.2 -
20.1) mg/m2 on alternate days. Four were also on cyclosporin A (at a dose sufficient
to maintain plasma levels of 50-150 ng/ml). Eight had congenital structural problems,
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the remaining 3 children had developed renal failure secondary to cystinosis,
haemolytic uraemic syndrome and glomerulonephritis of unknown aetiology. Height
velocity in cm/yr was available for the year prior to the study.
Methods
The children were seen on day 1, day 8 and then at 3 monthly intervals for 1 year.
Fasting blood samples were drawn on each occasion; before starting rhGH on day 1,
and approximately 12 hours after the previous injection of rhGH on subsequent days.
The blood was centrifuged, separated and the serum stored at -30°C.
IGF-I
Serum IGF-I was measured after acid ethanol extraction of its binding proteins, by
RIA using a polyclonal rabbit antiserum (R557A), raised against highly purified
human IGF-I. The level of detection of the assay was 13 mg/1. The inter-assay CV
was 9.0%, 6.5% and 4.7% at analyte levels of 45, 243 and 698 mg/1 respectively, with
an intra-assay CV of 10.5%,10.1% and 5.1% at 75, 196 and 698 mg/1. We have
previously shown acid ethanol extraction to be comparable to acid chromatography
for measurement of IGF-I in renal disease (Powell et al. 1986; Maxwell et al. 1996b).
Values are reported as age-related SDS.
IGF-II
Serum IGF-II was measured by a non-competitive time resolving immunofluorimetric




IGFBP-3 was measured using a coated-tube IRMA kit (Diagnostic Systems
Laboratories, Webster, Texas, USA). The minimum detection limit was 0.5 mg/1. The
inter-assay CV was 4.2% and 3.1% at 6.0 and 21.1 mg/1; the intra-assay CV was
8.1% and 5.4% at 2.2 and 9.8 mg/1 respectively. This antibody detects both intact
IGFBP-3 and fragments (Powell et al. 1993).
The molar ratio of IGF-I and IGF-II (both 7.6 kDa) to IGFBP-3 (40 Da) was
estimated. As IGFBP-3 circulates in many forms this can only be an approximation.
Western Ligand Blotting (WLB) and Western Immunoblotting (WIB) of
IGFBPs
WLB was performed in all of the children studied. WLB detects IGFBPs 1-4; only the
intact form of IGFBP-3 is recognised. Sodium dodecyl sulphate polyacrylamide gel
electrophoresis (SDS-PAGE) and ligand blot analysis were performed according to
the method of Hossenlopp (Hossenlopp et al. 1986) as previously described
(Flyvbjerg et al. 1992). Two ml of serum was subjected to SDS-PAGE (10%
polyacrylamide) under non-reducing conditions with unlabelled IGF-I (Bachem,
Bubendorf, Switzerland). All samples from each subject were analysed in the same
gel.
The identity of the IGFBPs detected on the WLB was confirmed using specific
immunoblot analysis for IGFBP-1, IGFBP-2, IGFBP-3 and IGFBP-4 (UBI, Lake
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Placid, New York, USA) with S-protein A (specific activity 500 Ci/mmol)
(Amersham International, Amersham, Bucks, UK). IGFBP-3 appears as an intact 38-
42 kDa doublet, a 30 kDa fragment and a smaller fragment of 16 kDa. Sera from 6
children in each group were subjected to IGFBP-3 WIB at each time point in the
study. These children were selected at random by a blinded investigator. Total
IGFBP-3, and each of the fragments were analysed. Pooled control serum from 10
age-matched children (8 boys, 2 girls) was run on the same gel.
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IGFBP-3 Protease Activity
To assess the ability of CRI and transplant sera to break down intact IGFBP-3,
IGFBP-3 protease assays were run in 5 children selected at random by a blinded
investigator, and were performed as previously described (Lamson et al. 1991).
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Recombinant I-IGFBP-3 (30000 cpm) (Diagnostic Systems Laboratories, Webster,
Texas, USA) was incubated for 18 hours at 37°C with 2 ml of serum samples from
each patient then subjected to SDS-PAGE as described above. Electrophoresed gels
were fixed in a solution of 7% acetic acid, dried and autoradiographed. The degree of
proteolysis of each sample was given as the percentage of the optical density per lane
which appeared in the proteolytic cleavage product bands. Pooled control (as above)
and term pregnancy sera were run on each gel.
Quantification ofWLB,WIB and IGFBP-3 Protease Activity
Autoradiographs were quantified by densitometry using a Shimadzu C9001 PC dual
wavelength flying spot scanner. The relative density of the bands was measured as
arbitrary absorbance units per square millimetre (AU/mm ).
IGFBP-2 (RIA)
IGFBP-2 was measured by RIA (Diagnostic Systems Laboratories, Webster, Texas,
USA). The intra-assay and interassay CV were < 5% and < 10% respectively.
IGFBP-1( RIA)
IGFBP-1 was measured by a specific RIA. Purified antigen was obtained from Dr
SLS Drop (Rotterdam, Holland). Tracer was prepared by iodination using the
chloramine T method followed by separation on a Sephadex G75 column. Bound and
free fractions were separated with a solid phase second antibody, donkey anti-rabbit
coated cellulose (SAC-CEL, from IDS, Boldon, Tyne and Wear, UK). Minimum
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detection limit of the assay was 6 mg/1. The inter-assay CV at 55 mg/1 was 6%, and
the intra-assay CV at 35 mg/1 was 4%.
Insulin
Insulin was measured using an immunoenzymometric assay (Enzymun-Test Insulin,
Boehringer Mannheim Gmbh Diagnostica, FRG). The reference range for fasting
subjects is 3-17 mU/1. Inter-assay CV was 9.2% and 4.9% at 19.7 and 92.1 mU/1
respectively. Intra-assay CV was 8.6%, 8.1% and 3.6% at 7.1, 11.4 and 33.0 mU/1.
Statistical Analysis
Comparison of measurements within each group at multiple time points was carried
out by ANOVA. Comparison of results at two time points was performed by a
Student's /-test. Correlation was performed using Pearson's correlation coefficients
and backward multiple regression analysis. Statistical significance was assumed when
a p value of 0.05 or less was obtained.
In the CRI group HV was negatively correlated with age and therefore HVSDS
values were used in the correlations with IGFs and IGFBPs. In the slightly older
transplanted group, the timing of puberty makes the interpretation of HVSDS
difficult, and as HV was unrelated to age, HV was used in preference to HVSDS.
Results
Height velocity and height SDS increased significantly in both groups of children
during treatment with rhGH (Table 8.1). There was no significant change in GFR
during the year of study (Table 8.1).
158
IGF-I
At the start of treatment mean IGF-I SDS values were similar in both groups and
were within the normal range [CRI: -1.06 (-4.16 to 2.47); transplanted group: -1.11 (-
3.92 to 2.27)], Figure 8.1. During treatment, IGF-I SDS increased to a mean value of
3.03 (-1.23 to 8.11) in the CRI group, p < 0.001 vs. day 1, and 6.65 (0.50 to 17.10)
in the transplanted group, p < 0.001 vs. day 1. The average increase in IGF-I SDS
during treatment was significantly greater in the transplanted compared with the CRI
group (p = 0.008). Absolute IGF-I values are given in Tables 8.2a and 8.2b.
IGF-II
At the start of the study, IGF-II SDS values were greater in the CRI group than in the
transplanted group [CRI: 2.65 (0.50 - 7.26); transplanted group: 1.03 (-2.51 to 3.18),
p = 0.02], Figure 8.2. IGF-II SDS increased significantly during treatment in the CRI
group (averaged value during treatment 4.50 (2.27 - 9.58), ANOVA during treatment
p < 0.0001), but not in the transplanted group (averaged value during treatment 1.00
(-1.73 to 4.23), ANOVA during treatment p = 0.31), Figure 8.2. The increase in IGF-
II in the CRI group was evident by 1 week (p < 0.0001). Absolute values for IGF-II
are given in Tables 8.2a and 8.2b.
IGFBP-3
At the start of treatment IGFBP-3 SDS, when measured by IRMA, was within the
normal range in both groups of children [CRI: 0.44 (-0.53 to 2.00) and transplanted
group: 0.28 (-1.06 to 1.38)], Figure 8.3. IGFBP-3 SDS increased significantly during
rhGH treatment, with averaged values of 2.93 (1.53 to 5.57) in the CRI group and
2.12 (0.17 to 4.07) in the transplanted group during the study, p < 0.001 vs. day 1 for
both groups, Figure 8.3. Absolute values of IGFBP-3 by IRMA and the molar ratio of
IGFs to IGFBP-3 are shown in Tables 8.2a and 8.2b. During rhGH treatment, the
ratio IGFs/IGFBP-3 decreased in the CRI group (p = 0.004), despite improved
growth. The ratio did not change in the transplanted group.
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Comparison of IGFBP-3 by IRMA, WLB and WIB
The IRMA assay measures total IGFBP-3 (both intact and IGFBP-3 fragments).
Absolute values of IGFBP-3 by IRMA were similar in the two groups on day 1 of the
study, Tables 8.2a & 8.2b, Figure 8.4. By WLB analysis however, IGFBP-3 was
lower in the transplanted group compared to the CRI group on day 1 (Figure 8.4),
and as WLB detects only intact IGFBP-3, this implied that there was less intact and
more fragmented IGFBP-3 in the transplanted group.
To investigate this finding further, sera from 6 children in each group were randomly
selected by a blinded investigator and subjected to WIB using an IGFBP-3 antibody.
The WIB results are shown as % values in Table 8.3; the absolute data are given in
Figure 8.5. On day 1, total IGFBP-3 when measured by WIB was similar in both
groups (CRI: 49.3 (18.6) AU/mm2; transplanted: 54.5 (18.2), p = 0.64), so
confirming the IRMA findings, and in fact was no different to pooled control serum
(59.9 (22)) run on the same gels. Confirming the discrepancy in day 1 results for
WLB and IRMA, the % IGFBP-3 present as the intact form was less in the
transplanted group compared to the CRI group, and to pooled control serum. There
was no difference between the CRI group and the control sera (p = 0.17), Table 8.3.
On day 1, the % of IGFBP-3 present as the 30 kDa fragment was higher in the
transplanted group compared to both the CRI group and to the control serum, Table
8.3. There was no difference between the CRI and control sera (p = 0.41). In the
transplanted group, the % of 16 kDa fragment was not increased compared to the
CRI group (p = 0.52), but the % was increased in both the transplanted and CRI
groups compared to the control serum. In short, the children with renal transplants
had normal total IGFBP-3, but the % present as intact IGFBP-3 was low. The
children with CRI had a small increase in 16 kDa fragments, but normal amounts of
intact IGFBP-3.
The pattern of intact and fragmented IGFBP-3 in individual patients can also be
expressed as % "in vivo proteolysis", which is the ratio of both 30 and 16 kDa
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IGFBP-3 fragments to total IGFBP-3. On day 1, mean in vivo proteolysis in the
transplanted group was increased compared to both the CRI group and to the control
serum, Table 8.3. In the transplanted group in vivo proteolysis before rhGH treatment
was unrelated to prednisolone dose.
During rhGH treatment
IGFBP-3 values increased during treatment in both groups by all three methods
employed. Comparing the pattern of different forms of IGFBP-3 by WIB, the only
significant change during rhGH treatment was of an increase in % intact IGFBP-3 in
the transplanted group (p = 0.04). Associated with this there was a decrease in in vivo
proteolysis during rhGH treatment in the transplanted group (Day 1 = 70 (10)%, 1
Year = 60 (9)%, p = 0.008). There was no such change in in vivo proteolysis in the
CRI group. A representative immunoblot from one of the transplanted children during
treatment is shown in Figure 8.6.
In vitro IGFBP-3 Protease Activity
Having confirmed a decrease in intact IGFBP-3 in the transplanted group, we went on
to measure the ability of both transplant and CRI sera to induce proteolysis of intact
recombinant IGFBP-3. Protease activity was not increased above control values at the
start of treatment in either of the groups, and was much reduced compared to pooled
term pregnancy serum run on the same gels, Figure 8.7. There was no significant
change in in vitro protease activity in either group during rhGH therapy.
IGFBP-2
On day 1, IGFBP-2 measured by RIA was greater in the CRI than transplanted
groups, p = 0.006, Tables 8.2a & 8.2b, Figure 8.8. IGFBP-2 did not change
significantly during treatment in either group, Tables 8.2a & 8.2b. At the start of the
study, IGFBP-2 when measured by both RIA and WLB was significantly correlated
with the dose of prednisolone (r = 0.623, p = 0.04) and (r = 0.919, p <0.001)
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respectively, Figure 8.9. IGFBP-2 was negatively correlated with GFR (r = 0.-624, p
= 0.04) in the transplanted group, Figure 8.10. In the CRI group, IGFBP-2 was also
inversely proportional to GFR (r = -0.876, p = 0.05), Figure 8.10.
IGFBP-1
In the CRI group on day 1, mean IGFBP-1 was elevated at 244 (74.6 - 424) mg/1,
(normal range is age related but is < 50 mg/1). IGFBP-1 SDS are shown in Figure
8.11. There was a small but significant decrease in IGFBP-1 levels during the year of
rhGH (p = 0.04). Fasting insulin values increased slightly after 1 week (p < 0.01) then
gradually returned to baseline values during the year of treatment, Figure 8.12.
In the transplanted group mean IGFBP-1 SDS was elevated on day 1, but to a lesser
degree than in the CRI group, Figure 8.11. In contrast to the CRI group, there was a
marked decrease in IGFBP-1 after one week of rhGH (p = 0.0025), with the mean
value remaining within the normal range thereafter. Fasting insulin levels rose
significantly, and to a greater degree than in the CRI group, Figure 8.12. The normal
inverse relationship between insulin and IGFBP-1 was preserved in the transplanted
group, with the change in one mirroring the other, however in individual patients
there was no significant correlation between the change in fasting insulin and fasting
IGFBP-1 before treatment (r = 0.20), nor between change in IGFBP-1 and change in
insulin after one week (r = 0.13). The greatest decrease in IGFBP-1 was seen in those
children with the highest pre-treatment IGFBP-1 levels (r = 0.921, p < 0.0001).
There was no correlation between fasting insulin and in vivo proteolysis of IGFBP-3
in either group, either before or after rhGH treatment.
IGFBP-4 (WLB)
There was no difference between IGFBP-4 levels in the two groups on day 1: CRI
group 13.8 (9.4); transplanted group 9.2 (9.1), p = 0.21, Figure 8.13. In both groups
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IGFBP-4 was significantly correlated with IGFBP-1: CRI (r = 0.798, p < 0.0001);
transplanted group (r = 703, p = 0.001). During rhGH treatment, there was a trend
for IGFBP-4 to increase in the CRI group (ANOVA, p = 0.06), but not the
transplanted group. The mean value during treatment in the CRI group was 14.7




Correlations between growth and IGF / IGFBPs in the CRI group, both before and
during rhGH treatment, are shown in Table 8.4. Before treatment, height SDS was
positively correlated with IGF-II SDS (r = 0.593, p = 0.01), Figure 8.14, and with
IGFBP-3 SDS (r = 0.674, p = 0.005), Figure 8.15. HVSDS in the year before
treatment was greater in those children with the highest IGF-I SDS (r = 0.560, p =
0.01), Figure 8.16, and was negatively correlated with IGFBP-1 SDS (r = -0.535, p
0.03), Figure 8.17. During rhGH the increase in height SDS was negatively correlated
with IGF-II SDS during treatment (r = -0.502, p = 0.04).
Transplanted group
Similar correlations between growth and IGFs and IGFBPs for the transplanted group
are shown in Table 8.5. As many of the children were of a pubertal age, calculation of
HVSDS can be problematic. Therefore in this group of children HV rather than
HVSDS was used for the correlations. Height velocity was shown to be independent
of age (Figure 8.18). These growth parameters were not correlated with any of the
variables tested, and in fact the results were similar ifHVSDS was substituted for HV.
The increase in height SDS in the year before treatment was also analysed as this may
be more representative of recent growth. In the year before treatment, the increase in
height SDS was positively correlated with IGF-I SDS (r = 0.579, p = 0.06), and with
GFR (r = 0.611, p = 0.046), but not with prednisolone dose
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Height velocity during treatment was positively correlated with mean IGF-I SDS
during rhGH (r = 0.692, p = 0.02), Figure 8.19. Increase in height SDS during
treatment was positively correlated with IGF-I SDS at the p = 0.06 level.
IGFs / IGFBPs and Renal Function
The relationship between growth factors and renal function is shown in Table 8.6.
IGFBP-2 was negatively correlated with GFR in both groups. In the transplanted
group, IGF-II was also negatively correlated with GFR.
Discussion
These detailed studies of IGFs and IGFBPs in short children with CRI and renal
transplants before and during rhGH revealed interesting findings. In CRI previous
reports have suggested that IGF binding capacity is increased and IGF bioactivity
reduced; IGFBPs are thought to be responsible, with IGFBP-3 proposed as the main
binding involved (Blum et al. 1991). However using 3 different assays, IGFBP-3 was
not elevated in either group, and contrary to previous reports (Blum et al. 1991;
Powell et al. 1993), there was no marked increase in IGFBP-3 fragments in the CRI
group. Indeed there were more fragments and less intact IGFBP-3 in the transplanted
than CRI children, a previously unreported finding.
Also of note in the transplanted group was a correlation between IGFBP-2 and
prednisolone dose, an unexpected finding. Growth retardation is common post
transplantation, and is related to several factors including the dose of steroids (Offner
et al. 1991). In this study, IGFBP-2 when measured by 2 different methods was
correlated with the dose of steroid (Figure 8.9), and it is interesting to speculate that
IGFBP-2 may be involved in the growth inhibition due to steroids. IGFBP-2 is
increased in GH deficiency, insulin deficiency and malnutrition (Hardouin et al. 1987).
GH secretion is reduced in children with renal transplants on steroids (Schaefer et al.
1991) and steroids can induce insulin resistance and catabolism, so perhaps the
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relationship is not altogether surprising. No other IGF or IGFBP measured was
correlated with the dose of prednisolone.
There are a number of factors pointing to IGFBP-2 as an inhibitor of growth; it is
inhibitory in culture systems in vitro (Burch et al. 1990). IGFBP-2 is elevated in CRI,
and height SDS is inversely correlated with IGFBP-2 in CRI (Tonshoff et al. 1995a;
Powell et al. 1997a). It is possible that IGFBP-2 is merely a marker for relative GH
deficiency, although IGFBP-2 was higher in CRI than the transplanted group, and
there was no reduction in IGFBP-2 in either group during rhGH treatment. The
relationship between IGFBP-2 and prednisolone dose is in contrast to the results of
short-term administration of dexamethasone to healthy volunteers, where a reduction
in IGFBP-2 was seen (Miell et al. 1993).
There is more reason to suspect IGFBP-2 is related to growth suppression than
IGFBP-3. In children with CRI and in those on dialysis both IGFBP-2 SDS and
IGFBP-3 SDS are increased, however IGFBP-2 levels are relatively greater than
IGFBP-3 in both groups of children (Tonshoff et al. 1995a, 1996). In experimental
uraemia, increased gene expression of IGFBP-1 and -2 have been reported (Tonshoff
et al. 1995b). IGFBP-3 is GH dependent and indeed in both groups of patients was
positively related to indices of growth. IGFBP-2 was the only IGFBP which was
negatively correlated with GFR in both groups in this study.
In CRI, IGFBP-3 has variously been reported to be elevated (Lee et al. 1989; Blum et
al. 1991; Powell et al. 1993; Tonshoff et al. 1995a) or normal (Baxter et al. 1986;
Hodson et al. 1992; Lee D-Y et al. 1993; Rees and Maxwell 1996b). IGFBP-3 is
higher in children on dialysis than in those with residual native renal function
(Tonshofif et al. 1996), so that differences in residual GFR, and different assays and
methodology may explain this discrepancy. However, the lack of a consistent finding
of elevated IGFBP-3 in children with CRI on conservative management suggests that
IGFBP-3 is not an important factor in short stature of CRI. IGFBP-3 fragments were
slightly elevated compared to control sera, but were less so than in the transplanted
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children, making them an unlikely source of growth suppression. IGFBP-3 is GH
dependent and the significant increase in IGFBP-3 during treatment also go against
IGFBP-3 being a major inhibitor of growth in CRI. IGFBP-3 levels rose by
approximately 50% during rhGH treatment.
IGFBP-3 is a 38-42 kDa glycoprotein which has the ability to bind to an acid-labile
subunit (ALS) to form a high molecular weight complex (150 kDa) which tends to
keep IGF-I in the circulation (Baxter RC et al. 1991). Fragments of IGFBP-3 have
been described, and although these fragments can bind IGF-I, they do so with less
affinity than intact IGFBP-3 (Baxter et al. 1986; Gargosky et al. 1992). Proteolysis of
IGFBP-3 was first demonstrated in the serum of pregnant women and is presumed to
be a mechanism to increase the availability of IGF-I to the foetus (Guidice et al. 1990;
Hossenlopp et al. 1990). Proteolysis can be described in two different ways; in vitro
and in vivo proteolysis. The former describes the ability of serum to break down intact
(recombinant) IGFBP-3 into fragments, and the latter describes the pattern of
fragments present in serum (% of total IGFBP-3 present as fragments).
IGFBP-3 proteolysis has also been reported in malnutrition, after major surgery and in
GH resistant and deficient states (Davies et al. 1991; Holly et al. 1993), and would
appear to be a response to a catabolic state. Glucocorticoids are catabolic, whereas
rhGH is anabolic, and in keeping with this in vivo proteolysis was increased in the
transplanted group before treatment, and there was a significant reduction in in vivo
proteolysis during rhGH. IGFBP-3 in vivo proteolysis is increased in untreated
diabetics, and has been shown to decrease following insulin treatment (Bereket et al.
1995). Whilst we did not demonstrate a correlation between in vivo proteolysis and
insulin levels before rhGH treatment in our patients, there was a reduction in in vivo
proteolysis and an increase in insulin following rhGH treatment.
Reduced intact IGFBP-3 might lead to a reduction in the half-life of circulating IGF-I.
Alternatively an increase in IGFBP-3 fragments, as was found in the transplanted
group, might interfere with the interaction between IGF-I and its receptor, assuming
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the fragments are able to leave the circulation and enter the extra-cellular space.
Either of these mechanisms might contribute to growth retardation in transplanted
children and this may be a mechanism of steroid induced growth retardation in CRF
(Unterman and Phillips 1985), however there was no obvious relationship between in
vivo proteolysis and prednisolone dose, although the numbers are small.
Neither the serum from the transplanted group nor the CRI group was able to
breakdown intact recombinant IGFBP-3 (no in vitro proteolysis). Presumably in the
transplanted group the IGFBP-3 is being broken down elsewhere.
The main determinant of IGFBP-1 is insulin status; levels of insulin and IGFBP-1 are
inversely correlated (Lee PDK et al. 1993). Insulin promotes growth, and levels rise
during rhGH treatment. In this study, the increase in insulin was greater in the
transplanted than CRI group, and there was a greater decrease in IGFBP-1 in the
transplanted group. One explanation for this may be the degree of insulin resistance in
uraemia (Mak and DeFronzo 1992), which could obliterate the normal inverse
relationship between insulin and IGFBP-1. Either resistance to the actions of insulin
or an increase in IGFBP-1 may be related to growth suppression in CRI. IGFBP-1 can
be inhibitory in vitro (Ritvos et al. 1988; Burch et al. 1990). Steroids also can result
in insulin resistance (Fennell et al. 1993), but the normal relationship between insulin
and IGFBP-1 still exists in the transplanted patients.
A correlation was found between IGFBP-4 and IGFBP-1 in both groups, the
significance of which is unclear. IGFBP-4 has been found to be inhibitory in culture
systems (Conover et al. 1993).
Since the work for this thesis was completed, specific antisera to IGFBPs 4-6 have
subsequently become available. IGFBP-6 levels are raised in CRF, in proportion to
the degree of renal failure (Powell et al. 1997b). IGFBP-6 levels were found not to be
related to indices of growth in CRF, to bind IGF-II rather than IGF-I, and to be
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unaffected by rhGH treatment (Powell et al. 1997b). IGFBP-6 may therefore
modulate IGF-II in CRF, but its role in short stature is unclear.
Serum IGFBP-4 is also elevated in CRF but levels are not related to height SDS.
Treatment with rhGH increased IGFBP-4 by 26% (Powell et al. 1999). IGFBP-5 is
not raised in CRF, but levels double with rhGH treatment (Powell et al. 1999).
IGFBP-5 was found to correlate with IGF-I, IGF-II and with growth rates in CRF,
and has been postulated to be involved in the growth response to rhGH (Powell et al.
1999).
Whatever the role of lGFBPs in short stature of renal failure, it is clear that rhGH
treatment results in a substantial increase in IGF-I in both groups and an increase in
IGF-II in the CRI group. Both IGF-I and IGF-II are able to stimulate linear growth in
hypophysectomized rats (Schoenle et al. 1985). Powell recently reported an increase
in free IGF-I in children with CRF receiving rhGH treatment (Powell et al. 1997a).
Comparison of the two groups of patients studied gives useful information. Despite
the same dose of rhGH, the increase in IGF-I (adjusted for age) was lower in the CRI
than in the transplanted group. The findings in CRI are consistent with growth
hormone resistance. Growth hormone levels are high, but the mediator, IGF-I is not
elevated (Powell et al. 1986; Blum et al. 1991). In experimental uraemia, the number
of GH receptors on hepatic cells is reduced (Chan et al. 1993; Tonshoff et al. 1994),
as is expression of IGF-I mRNA (Tonshoff et al. 1995b). There were significant
correlations between indices of growth and age-related IGFs in the CRI group before
treatment. Absolute IGF-I was in the low normal range in our group of CRI patients
and rose 2 fold with rhGH treatment. The dose of rhGH in CRI is twice the
replacement dose used in GHD.
With the same dose of rhGH, the increase in IGF-I SDS in the transplanted group was
significantly greater. Growth hormone secretion is reduced in transplanted patients
receiving steroids (Schaefer et al. 1991), and the greater increase in IGF-I would fit
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with GH 'replacement' rather than overcoming GH resistance. The response to
treatment was positively correlated with IGF-I SDS. Interestingly the growth
response to treatment was similar in both groups.
IGFBP-3 values before treatment, and the increase in IGFBP-3 in response to
treatment, was similar in both groups. This would fit with IGFBP-3 being dependent
on GH rather than IGF-I (Vaccarello et al. 1993). IGF-II was within normal limits in
the transplanted group at baseline, but was elevated in the CRI group and rose further
during rhGH treatment. This discrepancy is difficult to explain, but adds to the
impression that the GH / IGF-I axis is less disturbed in the transplanted than CRI
group. In normal children, both IGF-I and IGFBP-3 correlate with indices of growth
(Blum et al. 1993); this relationship is retained in transplanted children but not in
those with CRI.
Conclusion
Levels of IGFBP-3 in poorly growing children with CRI and renal transplants were
not elevated. There was a reduction in intact IGFBP-3 and an increase in in vivo
proteolysis in the transplanted group. IGFBP-2 was increased in the CRI group, and
in the transplanted group was correlated with the dose of prednisolone and GFR.
IGFBP-1 was elevated in both groups, particularly the CRI group, in whom the usual
inverse relationship with insulin was lost. In CRI IGFBP-1 and IGFBP-2 may be
related to poor growth, whereas in transplanted children poor growth may be related
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Table 8.4 Correlations in the CRI group before and during rhGH treatment
PRE-TREATMENT
Baseline Height SDS r E
IGF-I SDS 0.049 0.85
IGF-II SDS 0.593 0.012
IGFBP-1 SDS 0.100 0.70
IGFBP-2 SDS -0.767 0.13
IGFBP-3 SDS 0.683 0.04
Baseline HVSDS
IGF-I SDS 0.551 0.022
IGF-II SDS -0.052 0.84
IGFBP-1 SDS -0.535 0.027
IGFBP-2 SDS 0.416 0.49
IGFBP-3 SDS 0.241 0.53
DURING TREATMENT
A Height SDS r n
IGF-I SDS -0.185 0.48
IGF-II SDS -0.502 0.041
IGFBP-1 SDS -0.283 0.271
IGFBP-2 SDS -0.267 0.66
IGFBP-3 SDS -0.381 0.31
HVSDS
IGF-I SDS 0.296 0.25
IGF-II SDS -0.169 0.52
IGFBP-1 SDS -0.335 0.19
IGFBP-2 SDS -0.290 0.64
IGFBP-3 SDS 0.331 0.38
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Table 8.5 Correlations in the transplanted group before and during rhGH
treatment
PRE-TREATMENT
Baseline Height SDS r £
IGF-I SDS -0.270 0.42
IGF-II SDS -0.351 0.29
IGFBP-1 SDS -0.128 0.71
IGFBP-2 SDS -0.215 0.52
IGFBP-3 SDS 0.097 0.78
Baseline HVSDS
IGF-I SDS 0.344 0.30
IGF-II SDS -0.260 0.44
IGFBP-1 SDS -0.061 0.86
IGFBP-2 SDS -0.319 0.34
IGFBP-3 SDS -0.216 0.52
DURING TREATMENT
A Height SDS r E
IGF-I SDS 0.577 0.063
IGF-II SDS -0.287 0.39
IGFBP-1 SDS -0.018 0.96
IGFBP-2 SDS -0.254 0.45
IGFBP-3 SDS -0.099 0.77
HVSDS
IGF-I SDS 0.325 0.33
IGF-II SDS -0.172 0.61
IGFBP-1 SDS 0.024 0.94
IGFBP-2 SDS -0.109 0.75
IGFBP-3 SDS -0.131 0.70
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Table 8.6 Correlations between IGFs / IGFBPs and renal function before rhGH
treatment
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Figure 8.5 IGFBP-3 as measured by WIB. Total IGFBP-3 at each time
point is composed of intact protein, a 30kDa fragment and
smaller fragments. At the start of treatment the amount of intact
IGFBP-3 was lower in the transplanted group compared with
controls, * p <0.001, and with the CRI group^ p = 0.03.
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Chapter 9: The Effects Of Recombinant Human Growth Hormone On The
Immune System In Children With Chronic Renal Insufficiency and Renal
Transplants
Introduction
It has long been recognised that there is a link between pituitary hormones and the
immune system. As early as 1930 Smith demonstrated that ablation of the rat anterior
pituitary gland resulted in regression of the thymus gland (Smith 1930), and nearly
forty years later, Pierpaoli showed that the hormone responsible was GH; antiserum
to GH injected into mice with intact pituitary glands also caused thymic atrophy
(Pierpaoli et al. 1968). It is also well recognised that GH is necessary for certain
lymphocyte functions in vitro (Snow et al. 1981), and in animals, experimentally
induced hypopituitarism results in impaired immune function, which can then be
restored with GH replacement (Baroni et al. 1969; Dusquessnoy et al. 1972).
In contrast, with rare exceptions only (Monafo et al. 1991, Fleischer et al. 1980, Tang
et al. 1993), children with GHD are not immunocompromised and have normal
indices of immune function (Abassi and Bellanti 1985; Rapaport et al. 1986; Etzioni
et al. 1988; Bozzola et al. 1989; Petersen et al. 1990; Rapaport et al. 1991; Spadoni
et al. 1991). Growth hormone replacement has been reported to decrease transiently
the % B cells and CD4+ cells, although not to subnormal levels (Rapaport et al. 1986;
Petersen et al. 1990; Rapaport et al. 1991; Spadoni et al. 1991). On the other hand,
some authors report no change in lymphocyte subsets or immune function (Abassi and
Bellanti 1985; Etzioni et al. 1988; Bozzola et al. 1989).
Immune function is altered in CRF, although the majority of children are not clinically
immunocompromised (Drachman et al. 1989). Potentially this could be aggravated by
rhGH treatment. Children with renal transplants receive up to three
immunosuppressant medications, and clearly are immunocompromised, particularly in
the early post transplant period. Any alteration in immune function could potentially
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increase the risk of rejection of the graft (Tyden et al. 1990; Schwartz and Warady
1992), or result in an increased incidence of infection.
We performed immunological studies in two subgroups of children in the BAPN
multi-centre trial of rhGH in CRF (Maxwell et al. 2000). Lymphocyte subsets and
markers of T cell activation were measured before and during rhGH treatment.
Haematological indices were also measured to determine if rhGH treatment affected
red cell, platelet or granulocyte numbers.
Twenty-one children in the BAPN trial of rhGH in CRF were studied. These patients
were being treated in the Paediatric Nephrology departments at the Royal Free and
Guy's Hospitals, London. Eleven children (2 girls) had chronic renal insufficiency and
were being managed conservatively (CRI); 10 (3 girls) children had renal transplants.
Patients
Patient details are given in Table 9.1. GFR was less than 50 ml/min/L73m2 in the CRI
group, and had been so for at least one year. The transplanted patients had stable graft
function, and had received their grafts more than one year previously; the mean time
from transplantation being 5.2 (1.9 - 10.2) years. Immunosuppression consisted of
prednisolone at a mean (range) dose of 10.2 (7.6 - 20.2) mg/m2/alternate day,
azathioprine (60 mg/m2/day) and in 7 children, cyclosporin A at a dose sufficient to
maintain plasma 12 hour trough levels between 50 - 150 ng/ml. No child in either
group received recombinant erythropoietin.
Methods
Lymphocyte subsets, T cell activation markers and full blood counts were measured.
The transplanted children were part of a controlled trial, and therefore had up to 1
year of control data before starting rhGH treatment. Less pre-treatment data were
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available for the CRI group, so the data for the two groups were analysed in a
different fashion.
The children were studied on between 1 and 4 occasions in the year before starting
rhGH (control phase). After commencing rhGH they were seen after 1 week, then at 3
monthly intervals for 1 year (rhGH phase). At each visit the number of episodes of
illness, courses of antibiotics, and rejection episodes were recorded. For the purposes
of the study, a rejection episode was diagnosed by the managing clinician and was
defined as the need for treatment with high dose oral prednisolone for 3 days.
Height was measured using a Harpenden stadiometer. Glomerular filtration rate was
measured by clearance of inulin on day 1 and after 1 year (Maxwell et al. 1995).
At each visit haemoglobin, platelets, total and differential white counts were
measured. Five ml of blood was collected in lithium heparin tubes for estimation of
lymphocyte subsets and markers of T cell activation. The % and absolute number of
lymphocytes, T (TCRa|3) cells, CD4+, and CD8+ cells, B cells and natural killer (NK)
cells were calculated. The number of and % of T cells expressing the 11-2 receptor
(CD25), major histocompatability complex class II antigens (HLA-DR) and another
marker of T cell activation, CD26 (dipeptidylpeptidase), were recorded. These 3
antigens increase during T cell activation at early, intermediate and late times
respectively. Episodes of illness, graft rejection (as diagnosed by the clinician in
charge) were recorded.
Lymphocytes were separated on Lymphoprep (Nygaard, Denmark) and incubated
with T10B9 (TCRaP receptor) together with a second antibody (listed below).
Staining was performed by double fluorescence flow cytometry (Facscan
flowcytometer, Becton Dickinson) using anti-mouse IgMPE and anti-mouse IgGFITC as
second layers. Using the lymphocyte gate determined by forward angle and side
scatter, the % total T cells (TCRaP), TH (CD4+), Tc (CD8+), B (CD19+) and NK
(CD16+CD7+) cells were determined. The absolute number of each lymphocyte subset
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was then calculated from the paired total lymphocyte count. The % T cells expressing
CD25, CD26 and HLA-DR antigens were determined.
Antibodies
Monoclonal antibodies against CD2 (RFT11), CD4 (RFT4), CD7 (RFT2), CD8
(RFT8), CD25 (RFT5), HLA-DR (RFTDR2) were raised in the Department of
Immunology, Royal Free and University College Medical School. The following
antibodies were also used: T10B9 (TCRaP) a kind gift from Professor Thompson,
Kentucky, USA); CD16 (Leul lb, Becton Dickinson); CD26 (Ta-1, Coulter).
Statistical Analysis
As lymphocyte counts vary with age, and because it was not possible to find a control
group exactly matched for age, sex, underlying disease, time from transplantation,
donor source, renal function and medication, the patients acted as their own controls.
In the CRI group, change in the parameters studied was assessed by ANOVA.
Statistical significance was further tested by calculating the confidence interval of the
difference of the mean value at each time point and that on day 1. If the confidence
interval of the difference in means excluded zero, then statistical significance was
confirmed.
Data during rhGH treatment in the transplanted group were analysed in a similar
fashion, but in this group data were also available from the year before rhGH
treatment (control phase). To compensate for day to day variation, the average value
of each subset or activation marker was calculated during both the control and rhGH
phases, and these 2 sets of results were compared using a paired Student's f-test. To
exclude a difference due to the effects of time alone, the change in lymphocyte
numbers and activation markers during each phase was also calculated and compared
by a paired Student's f-test. The summary data are expressed as the mean + SE. Again
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statistical significance was further tested by calculating the confidence interval of the
difference of the mean value at each time point and that on day 1.
A p value of < 0.05 was taken to represent statistical significance. The number of
rejection episodes, dose of prednisolone and time since transplantation were
correlated both with the number of cells of each lymphocyte subset, and the % of T
cells expressing activation markers, using multiple regression analysis.
Results
In the CRI group, 10 of the 11 children completed the study; 1 child reached end
stage renal failure and required dialysis 9 months into the study. Only data prior to
starting dialysis have been used for analysis in this child. Mean HV improved during
the year of rhGH treatment, from 4.1 (1.7 - 6.3) to 9.3 (5.9 - 12.5) cm/yr, p<0.001.
There was no change in GFR during the study: 18 (9 - 59) on day 1 and 19 (5 - 59)
ml/min/1,73m2 at 1 year.
In the transplanted group, 9 of the 10 children completed one year of treatment; one
patient returned to dialysis 11 months after entering the study. Only data relating to
the first 9 months of rhGH treatment in this patient have been included. Height
velocity increased from 4.2 (2.6 - 5.6) cm/yr in the year before rhGH to 8.5 (5.3 -
11.7) cm/yr during treatment, p<0.001. Glomerular filtration rate remained
unchanged; 61 (26 - 93) on day 1 and 61 (24 - 109) ml/min/1.73m2 at 1 year. There
were no serious infective episodes during treatment, and no increased incidence of
infections compared with the year before the trial.
During the year of rhGH treatment, 5 children had 9 episodes of presumed rejection.
None of these episodes coincided with study visits. No anti-lymphocyte preparations
were given. These same 5 children had 12 such episodes in the year preceding rhGH,
giving rejection rates for all 10 children of 1 per 10 patient months in the year before
rhGH and 1 per 13 patient months during rhGH. These rates were not statistically
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different. The other 5 children had no episodes of graft dysfunction before or during
treatment.
I. Haematological Indices
Haemoglobin, total and differential white cell counts and platelet numbers were
measured in each group. Comparison of the baseline values in each group is shown in
Figure 9.1. The only difference between the groups was in the lymphocyte count,
which was significantly lower in the transplanted group, p = 0.05.
During rhGH treatment there was a decrease in haemoglobin in the CRI group, but
there were no other significant changes, Figure 9.2. The data are also shown in Table
9.2a for the CRI group and 9.2b for the transplanted group. In addition for the
transplanted group, the averaged values during the control and treatment phases are
shown in Figure 9.3, and Table 9.3. The mean (SE) changes during both the control
and treatment phases are shown in Table 9.4. There was no difference between the
changes seen before and those seen during rhGH treatment.
II. Lymphocyte Subsets
The total lymphocyte count, T cells, CD4+, CD8+, B cells and NK cells in each group
are shown in Tables 9.3 - 9.5, and Figures 9.2 - 9.8. Values at baseline in each group
are shown in Figure 9.3.
CRI Group
During treatment there was no change in the total number of lymphocytes, but there
was a significant decrease in the number of T cells (ANOVA, p=0.03). This was due
to a decrease in the number of CD4+ T cells (p=0.04), with no significant change in
CD8+ cells (p=0.57). There was no significant change in the number of B cells
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(p=0.13), or in the number ofNK cells (p=0.14). Summary data are shown in Table
9.5a, and individual patient data are shown in Figures 9.4 and 9.5.
Transplanted group
Summary data for the children in the transplanted group during rhGH treatment are
shown in Table 9.5b. Individual values are shown in Figures 9.6 and 9.7.
Comparison of the control and treatment phases is shown in Figure 9.8 and the
changes during the control and treatment phases are given in Table 9.4. There was no
significant difference in the absolute number of total lymphocytes, T cells, CD4+ or
CD8+ cells, between the control and rhGH phases. The B cell count was lower during
rhGH treatment than during the control phase (control: 0.11 (0.07); rhGH: 0.07
(0.06), p = 0.015) (Figure 9.8), but there was no significant difference between the
change in B cell number during each phase (p = 0.72), suggesting an effect due to
time rather than rhGH (Table 9.3). The average TH / Tc ratio in the control phase did
not differ from that in the rhGH phase: 2.32 (0.32) vs. 2.41 (0.53), p = 0.91.
There was no relationship between lymphocyte numbers and rejection episodes, GFR,
or prednisolone dose. There was a trend for a negative correlation between the total
number of lymphocytes and the length of time since transplantation (r = -0.569, p =
0.08).
The 5 children who had rejection episodes before and during rhGH treatment, were
compared with the 5 who had no rejection episodes during the 2 years of study. There
was no significant difference between these 2 groups either before or during rhGH
treatment in terms of the number of each type of lymphocyte subset. There was a
trend for higher CD4 (TH) counts during rhGH treatment in the children with no
rejection episodes (p = 0.06).
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III. T Cell Activation Markers
Surface expression of CD25, CD26 and of HLA-DR antigens showed wide variation
at the start of treatment in both groups. Summary data are given in Tables 9.3, 9.4
and 9.6, and Figures 9.3 and 9.8. Individual values are shown in Figures 9.9 and 9.10.
Mean and median values for CD25 and ULA-DR were similar in both groups. There
was increased expression of CD26 in the transplanted group as compared to the CRI
group (Figure 9.3).
CRI Group
Summary data during rhGH treatment are shown in Table 9.6a, and individual patient
values are depicted in Figure 9.9. There was no significant change in T cell expression
of CD25 or HLA-DR antigens during rhGH treatment. There was increased
expression of CD26 at 3 and 6 months, but not at 1 year. Over the year of treatment,
the change was not significant (p = 0.11). As the number of T cells was reduced
during treatment, there was no change in the absolute number of T cells expressing
CD26 (p = 0.53).
Transplanted Group
Expression of activation markers during rhGH treatment in the 10 transplanted
children is shown in Table 9.6b and Figure 9.10. The averaged values of the number
of T cells expressing activation markers during the control and treatment phases are
given in Figure 9.8.
In the transplanted group surface expression of CD25 was varied, such that at times
during the control phase, between 1 and 42 % of T cells expressed CD25. The
average expression of CD25 was lower during rhGH treatment than during the
control phase. There was however no significant difference between the change in %
T cells expressing CD25 in the control phase compared with the rhGH phase (p =
0.31), suggesting an effect of time alone. There was no significant change in
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expression of CD26 antigen nor of HLA-DR antigens on T cells during either the
control or treatment phases.
Expression of activation markers was unrelated to the number of rejection episodes,
either before or during rhGH treatment. There was no difference between the
expression of CD25, CD26 and HLA-DR antigens between the groups with or
without rejection episodes, either before or during rhGH treatment. During the
control phase, there was no relationship between expression of CD25, CD26 or HLA-
DR antigens and the time from transplantation nor the dose of prednisolone.
Discussion
Concern surrounding the use of rhGH in CRF has arisen from the recognition that
there are links between GH and the immune system, both during development and in
post natal life. The multitude of experimental evidence which has accumulated since
Smith's original work, where he demonstrated involution of the thymus in the rat
following ablation of the anterior hypophysis (Smith 1930), attests to the existence of
bi-directional communication between GH and the immune system.
It is well known that GH stimulates immune function in vitro (Snow et al. 1981), and
the link between GH and the immune system is strong in small mammals (Fabris et al.
1971). The dwarf Snell mouse, which has congenital deficiency of the pituitary due to
a mutation in the Pit-1 gene, has arrested development of the thymus and marked T
cell immunodeficiency (Baroni et al. 1969; Duquessnoy et al. 1972) Growth hormone
replacement not only improves growth but also restores immune competence, and
prevents involution of the thymus and depletion of peripheral lymphoid tissues.
Lymphocyte, erythrocyte, neutrophil and platelet counts are increased with GH
replacement (Murphy et al. 1992). Mice which are transgenic for GH have enlarged
lymphoid organs (Clark et al. 1997).
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In man the link is less strong but peripheral lymphocytes express GH (Kiess et al.
1985) and IGF-I (Eshet et al. 1975) receptors, and in vitro studies indicate a role for
GH in lymphopoiesis (Snow et al. 1981), granulopoiesis (Merchaw et al. 1988) and
erythropoiesis (Golde et al. 1977), and in granulocyte (Weidermann et al. 1991) and
macrophage (Edwards et al. 1988) function. Growth hormone has been shown to
stimulate DNA synthesis in T lymphocytes (Gelato et al. 1993), and to stimulate
proliferative and cytotoxic responses in mixed lymphocyte culture (Snow et al. 1981).
Natural killer cell function is increased by GH (Crist et al. 1987, 1990). Growth
hormone enhances the production of 11-2 and 11-6 by lymphocytes (Berczi et al.
1997). While most reports suggest a stimulatory role for GH and the immune system,
others indicate an inhibitory effect (Kiess et al. 1983). Some of the effects of GH are
mediated by local production of IGF-I (Geffner et al. 1990).
Despite the evidence linking GH and the immune system, GHD in man is not
associated with reduced immunity, with the rare exception of case reports of families
with GHD and agammaglobulinaemia (Monafo et al. 1991),
hypogammaglobulinemia (Fleisher et al. 1980), and also with combined
immunodeficiency (Tang et al. 1993). Most children with GHD have normal indices
of immune function (Abassi and Bellanti 1985; Rapaport et al. 1986; Etzioni et al.
1988; Bozzola et al. 1989; Petersen et al. 1990; Rapaport et al. 1991; Spadoni et al.
1991), although there are occasional reports of a decrease in 11-2 production
(Casanova et al. 1990), a decrease in NK activity (Crist et al. 1987; Kiess et al. 1988;
Bozzola et al. 1990) and decreased B cells in GHD (Gupta et al. 1983).
Most patients with GHD do not have complete absence of GH. However even
patients with the Pit-1 gene mutation, who do have complete GHD, have no evidence
of immunosuppression (Wit et al. 1989). Furthermore, GH and IGF-I (and prolactin)
are also secreted by cells of the immune system in an autocrine fashion (Weigent et al.
1991a; Baxter JB et al. 1991). So complete absence of GH is rare. There is also
overlap or redundancy between the actions of different hormones on the immune
system such that absence of one may not be clinically evident. Therefore in children
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with GHD, there would appear to be subtle and variable changes in laboratory
parameters of immune function, but no clear evidence of clinical immunodeficiency.
There is also no clinical evidence in man that administration of exogenous GH affects
the immune system in vivo. The changes in lymphocyte subsets that are seen with GH
therapy in GHD appear to be minor. Some groups report a transient reduction in % B
cells and % T helper cells (Rapaport et al. 1986; Petersen et al. 1990; Rapaport et al.
1991; Spadoni ei al. 1991), although not to subnormal levels. Other groups report no
change in lymphocyte subsets during GH treatment (Abassi and Bellanti 1985; Etzioni
et al. 1988; Bozzola et al. 1989), but an increase in mitogen stimulated lymphocyte
proliferation has been reported (Abassi and Bellanti 1985).
In CRF the immune system has been variously reported to be normal or depressed.
One study in children with CRF found lymphocyte subsets and mitogen-stimulated
proliferative responses to be normal, although % B cells was lower than controls
(Drachman et al. 1989). This is in contrast to our findings; the number and % of B
cells were well within the normal range for our laboratory. Mean GFR in this study
and that of Drachman, was similar. The same authors report a normal % B cells in
children on dialysis. Whilst this might suggest a dialysable inhibitor of B cells in CRF,
one would then expect a relationship between B cells and GFR. This did not exist in
their study nor was it present in our study.
Other workers describe a state of chronic activation of the immune system in uraemia,
so-called preactivation, with increased expression of IL-2 receptors on T cells and an
increase in soluble IL-2 receptors (shed from the cell surface after binding of IL-2 to
its receptor on activated T cells) (Beaurain et al. 1989). This has not been confirmed
by all groups (Caruana et al. 1992). Indeed in our patients IL-2 receptor expression
was not increased. There was no change with rhGH treatment.
There are few published data looking at the effect of rhGH on lymphocyte subsets or
activation markers in CRI and renal transplantation. Our finding of a reduction in the
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number of CD4+ cells in the CRI group is interesting as the same effect has been
reported with rhGH in GHD (Rapaport et al. 1986; Petersen el al. 1990; Rapaport el
al. 1991; Spadoni el al. 1991). In over 90% of the CRI children however the CD4
count remained within the normal range. The B cell count was not affected. There
was no increased incidence of infections, so the clinical significance for the CRI group
seems slight. In contrast to the other reported studies, we expressed our results as
lymphocyte numbers rather than % subsets, although both variables were calculated.
The total number of lymphocytes was unchanged, therefore the % of T cells and
CD4+ cells also decreased. The lack of a control group for this group of patients
means that it is impossible to exclude that the reduction is due to an effect of time
alone. There was no significant change in the number of lymphocyte subsets in the
transplanted children, however the number of CD4+ cells at the start of treatment was
significantly lower in the transplanted group compared to CRI group, and may explain
the difference.
The findings of three recent publications taken together suggest a potential
mechanism for the rhGH induced changes in lymphocyte subpopulations that have
been reported in GHD. It has been known for some time that lymphocytes have
receptors for GH (Eshet et al. 1975) and are also able to secrete GH (Weigent et al.
1991b). More recently flowcytometry has demonstrated that B cells have a higher
expression of GH receptors than T or NK cells (Badolato el al. 1994). Secondly in
cultures of rat spleen cells, secretion of GH is seen primarily by B cells, T helper cells
and macrophages, while T suppressor cells and NK cells produced only small amounts
of GH (Weigent et al. 1991a). Thirdly addition of rhGH down-regulates the number
of receptors on cultured lymphocytes in a dose-dependent fashion (Smal et al. 1985).
Taking these observations together, GH treatment may reduce the number of GH
receptors on lymphocytes and therefore decrease GH induced proliferation, be that
exogenous or endogenous GH. This sequence of events would predominantly affect B
cells and T helper cells. The lack of effect on B cells in our patients might reflect a
pre-existing effect of the underlying condition or previous treatment on B cell
numbers or function.
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The possible consequence of rhGH treatment in transplanted children are of an
increase in the incidence of infection or rejection. To date there has been no reported
increase in infections with rhGH, but the risk of rejection remains unclear. There are a
number of published studies of rhGH post renal transplantation. There has been no
reported increase in serious infections, but there have been occasional reports of
actual or presumed rejection episodes after starting rhGH treatment (Tyden et al.
1990; Schwartz and Warady 1992). Other studies show no effect on the incidence of
rejection (Bartosh et al. 1992; Fine et al. 1992; Tonshoff et al. 1993; Ingulli et al.
1993; Jabs et al. 1993; Benfield et al. 1993; Janssen et al. 1993; Hokken-Koelega et
al. 1994d).
The overall finding in this, the BAPN trial, was that there was no increase in the
incidence of rejection during rhGH treatment (Maxwell et al. 1998b, Chapter 6). The
Dutch multi-centre study also showed no overall increase in the incidence of rejection,
but suggested that those patients on alternate day steroid were more at risk of
rejection episodes than those receiving daily steroids (Hokken-Koelega et al. 1994d).
All of our patients received alternate day steroids. The most recent and largest multi¬
centre study to be published is that on behalf of the French Society of Pediatric
Nephrology. Whilst overall there was no increased incidence of rejection in those
treated with rhGH compared to controls, there was an increased risk of rejection in
those with a history of 2 or more rejection episodes in the year before treatment. Six
of 17 children with a history of a previous rejection episode had a further episode
during rhGH treatment compared with only 1 of 21 such patients in the control group,
p=0.01 (Guest et al. 1998). In our study, only those children with clinically diagnosed
rejection episodes in the year before rhGH treatment had further rejection episodes
during treatment.
Many of those patients who had rejection episodes would have chronic rejection or
chronic allograft nephropathy. Consequently they will have a lower GFR and less
renal reserve, and are therefore more likely to have fluctuations in creatinine levels. It
is impossible to know if rhGH is causing 'rejection1, or if increased body muscle mass
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is responsible for the elevation in creatinine. Some children undoubtedly had acute
rejection diagnosed by biopsy, but in others the exact mechanism of graft dysfunction
was unknown.
Of interest however is a paper reporting the effects of rhGH on mixed lymphocyte
cultures from renal allograft recipients against donor tissue. Out of the 12 patients
tested, 3 patients had augmented responses when rhGH was added to the culture;
these 3 patients had biopsy proven chronic rejection (Benfield et al. 1996). If rhGH
does stimulate the immune system, then an increase in activation markers would be
expected. No such increase was seen in any of the three T cell activation markers
tested in our study. Indeed it was not possible to distinguish those patients who went
on to develop rejection episodes from those who did not. Expression of activation
markers as tested in our study does not predict who will reject during rhGH treatment
and who will not.
The rejection rate within our transplanted group is high compared to published data.
There are a number of explanations for this. The episodes were presumed rejection, as
not all children underwent renal biopsy, and so the incidence is likely to be higher than
in centres where all suspected rejection is investigated by renal biopsy. However the
same diagnostic criteria for rejection were used for both phases of the trial. Secondly,
our patients are selected in that we have studied only slowly growing children, some
of whom had poor graft function with biopsy evidence of chronic rejection before
receiving rhGH treatment. Thirdly, two children accounted for six of the nine
episodes.
Growth hormone treatment has been reported to increase haemoglobin concentration
in children with short stature due to various conditions (Vihervuori et al. 1994). In
these studies, mean haemoglobin had increased by 0.7 g/dl after 6 months (p < 0.001),
and over 50% of the children had evidence of iron deficiency, presumed to be due to
depletion of iron stores. Insulin-like growth factor-I enhances the actions of
erythropoietin and indeed has erythropoietin-like activity at high doses (Golde et al.
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1977; Kurtz et al. 1988; Aron et al. 1992). The authors also suggest that renal growth
during rhGH therapy could result in increased production of erythropoietin. In a
previous report we were unable to demonstrate any change in the volume of
transplanted kidneys during rhGH treatment (Maxwell et al. 1996b). We were unable
to demonstrate an increase in haemoglobin in either of our groups of patients. None
received erythropoietin before or during the study. Many of our patients had evidence
of anaemia of renal failure at the start of the study. In our patients, lack of
endogenous erythropoietin may be the limiting factor preventing a rise in haemoglobin
during rhGH treatment.
Conclusion
Growth hormone treatment resulted in a slight but significant reduction in CD4+ cells
in the CRI group, but there were no significant changes in lymphocyte subsets in the
transplanted group. There were no consistent changes in T lymphocyte activation
markers in either group. There was no change in the incidence of infection, or
rejection episodes in the transplanted group. It was not possible to distinguish those
children with rejection episodes from those without, either by lymphocyte subset or by













































































































Table 9.3 Mean (SE) total lymphocyte count, lymphocyte subsets and %






Total Lymphocytes 1.88 (0.35) 1.82 (0.34) p = 0.78
T Cells 1.40 (0.26) 1.38 (0.29) p = 0.92
CD4+ Cells 0.80 (0.18) 0.80(0.17) p = 0.99
CD8+ Cells 0.52 (0.12) 0.50 (0.15) p = 0.82
B Cells 0.11 (0.02) 0.07 (0.02) p = 0.015
NK Cells 0.25 (0.14) 0.11 (0.02) p = 0.33
% T Cells Expressing
CD25 15 (3) 7(1) "-hOSII
CD26 38 (7) 34 (5) p = 0.65
HLA-DR 25 (7) 16(5) p = 0.34
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Table 9.4 Mean (SE) change in haemoglobin, total WCC, lymphocyte,
neutrophil and platelet counts, lymphocyte subsets and %






Haemoglobin (g/dl) -0.5 (0.1) -0.3 (0.2) p = 0.57
Total WCC x 109/1 0.9 (0.7) -0.7 (0.6) p = 0.16
Lymphocytes x 109/1 0.0 (0.2) 0.0 (0.3) p = 0.89
neutrophils x 109/1 0.4 (0.9) 0.2 (0.6) p = 0.87
Platelets x 109/1 -7(13) -34 (21) p = 0.39
B Cells -0.04 (0.02) -0.03 (0.02) p = 0.72
NK Cells 0.03 (0.02) -0.19 (0.14) p = 0.24
CD3 -0.19(0.1.) 0.06 (0.24) p = 0.42
CD4 -0.08 (0.05) 4.14(0.21) p = 0.69
CD8 -0.14(0.12) -0.01 (0.10) p = 0.45
% T cells expressing
CD25 -3 (2) -9 (4) p = 0.31
CD26 -4 (5) -0.8 (12) p = 0.56
HLA-DR -14(13) 15(7) p = 0.94
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Chapter 10; The Metabolic Effects Of Recombinant Human Growth Hormone
In Children With Chronic Renal Insufficiency and Renal Transplants
Introduction
Growth hormone has a role in carbohydrate and lipid metabolism, and its use in
supraphysiological doses in CRF requires carefully monitoring. Patients with CRF
already have glucose intolerance and abnormal lipid profiles which might be
exacerbated by rhGH treatment. Growth hormone not only stimulates growth but also
affects bone mineral content. This may be relevant in children with CRF who will have
varying degrees of renal osteodystrophy. This chapter details the effects of rhGH on
glucose metabolism, lipid profiles and on parameters of bone metabolism in each of
the different arms of the trial.
Methods
Different protocols were used for each of the arms of the BAPN study, so the data
collected varied between the groups. Details are given in the appropriate section
below. Children attending the London centres, were seen on day 1, day 8 and then
three monthly. All other children were seen at three monthly intervals for one year
(infants, CRI and dialysis groups) or two years (transplanted children). Within groups
the results are expressed as the mean (SD) at each time point; comparison of groups
are expressed as the mean (SE). Where the distribution of data points was skewed,
the median valued are reported. Analysis of variance was used to assess changes
within each group during treatment. Multiple regression analysis was used to perform
correlations within groups.
Patients
Patient details for each group have already been described in Chapter 3 (infants),
Chapter 4 (CRI), Chapter 5 (dialysis), and Chapter 6 (transplanted patients). The
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results for glucose metabolism, lipids and renal bone disease are reported and
discussed under separate headings below.
I. GLUCOSE METABOLISM
Glucose Metabolism in Chronic Renal Failure
Abnormal glucose metabolism is a common finding in patients with CRF (DeFronzo
et al. 1978; Alvestrand 1997). Several mechanisms contribute, but the most important
is peripheral resistance to the actions of insulin (DeFronzo et al. 1981). The major site
of insulin resistance is skeletal muscle, where a post-receptor defect has been
described (Smith and DeFronzo 1982). Dialysis enhances, but does not normalise,
insulin-mediated glucose disposal (DeFronzo et al. 1978). Similarly correction of
anaemia in CRF, by the use of erythropoietin, improves glucose disposal (Mak 1996),
as does correction of metabolic acidosis (Reaich et al. 1993). In patients with CRF,
insulin-mediated suppression of hepatic gluconeogenesis is reduced (Schmitz 1985).
In many patients the effect of insulin resistance is offset by increased insulin secretion
by the pancreatic P cells (Mak 1985), but if there is no increased insulin secretion,
then overt glucose intolerance occurs. Hyperparathyroidism is known to reduce
insulin secretion by the pancreas in uraemia; parathyroidectomy for secondary
hyperparathyroidism increases insulin secretion (Mak 1985).
The kidneys are involved in the metabolic clearance of insulin, which is reduced in
renal failure (DeFronzo et al. 1978). Haemodialysis improves the metabolic clearance
of insulin; this is though to be due to an increase in the peripheral clearance of insulin
(Gin et al. 1994).
Other factors also affect glucose tolerance in patients with renal failure; renal
transplant patients receiving steroids have a further risk factor for glucose intolerance
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(Fennel et al. 1983), and glucose tolerance during childhood is also described as being
affected by age and by obesity (Deschamps et al. 1977; Mak et al. 1983; Amiel et al.
1986).
Growth Hormone and Glucose Metabolism
It is well recognised that patients with acromegaly and those with GH-secreting
tumours can develop glucose intolerance and overt diabetes (Sonksen et al. 1967;
Rizza et al. 1982). The effects of GH on glucose metabolism can also be inferred both
from the study of patients with GHD, and by looking at the effects of GH
administration in normal subjects. Children with complete GHD develop
hypoglycaemia when fasted (Hopwood et al. 1975). This is due to reduced hepatic
gluconeogenesis and possibly also reduced glycogenolysis (Haymond et al. 1976),
possibly mediated by an increase in the net effect of insulin in a setting of reduced GH
antagonism. In GHD, insulin secretion is reduced (Underwood et al. 1973).
In an experimental setting, administration of large doses of intravenous GH to normal
subjects results in inhibition of peripheral glucose uptake, but no increase in hepatic
glucose production (Rizza et al. 1982, Rabinowitz et al. 1965). Patients with
acromegaly have both reduced peripheral uptake and increased hepatic synthesis of
glucose (Karlander et al. 1986). The effects of GH are however countered by an
increase in insulin secretion which occurs with either GH excess or GH administration
(Salomon et al. 1989). A diabetogenic effect of GH is only seen if this compensatory
mechanism fails.
In childhood GHD, GH replacement has been shown to restore glucose production to
normal and to increase insulin secretion (Underwood et al. 1973). Growth hormone
treatment of short normal children does not change glucose turnover nor does it affect
glucose tolerance and sensitivity to insulin remains intact (Walker et al. 1989). There
was however an increase in insulin secretion for the duration of treatment (Walker et
al. 1989). Similar results have been reported with GH replacement in adults with
GHD (Salomon et al. 1990).
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Chronic renal failure patients are already at risk of glucose intolerance, and it is
therefore important to determine whether rhGH treatment can be tolerated or whether
it further aggrevates the situation.
Methods
Fasting glucose and HbAlc levels were measured in all groups of patients. Fasting
insulin was available only in the infant, CRI and transplanted groups. The insulin data
were skewed and therefore the median rather than the mean values are reported.
Results
Glucose
At the start of the study, there were several children in each subgroup who had fasting
glucose levels above the normal range, as shown in Figure 10.1. There were no
differences between the groups at baseline, and no significant changes in fasting
glucose during the first year of rhGH treatment in any group (Table 10.1, Figures
10.2 and 10.3). Within the transplanted group there was no difference between the
control and treatment groups during the first year of study (Figure 10.4). In the CRI
group, fasting glucose level prior to treatment was best predicted by age (r2 = 0.134,
p = 0.028).
Insulin
At the start of the study, there was a trend for higher fasting insulin values in the
transplanted group, where several children had values outwith the normal range,
compared with the infant group where only 2 children had values above the expected
range (p = 0.07), and the CRI group, where only one child had a value above normal
(p = 0.08), Table 10.1, Figure 10.5. Median values for fasting insulin are given. In the
CRI group at baseline, fasting insulin was correlated with age (p = 0.043) and height
SDS (p = 0.011), Figure 10.6. There was no relation to GFR, WFH or PTH. Fasting
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insulin was unrelated to the variables tested in the transplant group (prednisolone
dose, GFR, WFH, HVSDS, height SDS).
During rhGH treatment, fasting insulin values were elevated at 1 week in both the
transplanted (p = 0.02) and CRI groups (p = 0.01), but returned toward baseline
during the first year of rhGH treatment, Table 10.1, Figure 10.7. Insulin values in the
transplanted control and treatment groups are shown in Figure 10.8. There was
considerable variation, but an increase was seen after 1 week (p = 0.03), 3 months (p
= 0.04), and 6 months (p = 0.05) in the treatment group, whilst there was no change
in the control group at any of these time points.
HbAlc
HbAlc at the start of treatment is shown in Figure 10.9. Mean HbAlc in the
transplanted group was higher than in the CRI group (p = 0.003), and the combined
dialysis group (p < 0.0001). Using multiple regression analysis, HbAlc at baseline in
the CRI group, was directly correlated with weight for height (p = 0.006) and
inversely correlated to HVSDS (p = 0.025). There was no relation to age, GFR nor
PTH. In the transplanted group, HbAlc was inversely correlated with HVSDS (p =
0.003). There was no correlation with prednisolone dose, age, GFR, WFH nor PTH.
There was no significant change in HbAlc during treatment in any of the groups.
Discussion
Chronic Renal Insufficiency
In keeping with the known occurrence of glucose intolerance in uraemia, 4 out of 27
children in the CRI group had an elevated fasting glucose above the normal range at
baseline. These children were indistinguishable from the rest of the group in terms of
renal function, but within the group, fasting glucose was strongly correlated with age.
Insulin sensitivity in normal children has previously been shown to be influenced by
age (Amiel et al. 1986), with older children showing greater degrees of glucose
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intolerance. Other authors have also found glucose tolerance to be related to age in
children with CRF (Mak et al. 1983; Haffner et al. 1998b).
In the CRI group, fasting insulin at baseline was positively correlated with height
SDS, and in both the CRI and transplanted groups HbAlc was inversely correlated
with HVSDS. Assuming that HbAlc is a marker of the degree of insulin resistance or
insulin lack, these results are consistent with the known anabolic effects of insulin.
Haffner reported the results of oral glucose tolerance tests (OGTT) in children with
CRF before and after rhGH. Prior to starting rhGH treatment, 3 out of 29 patients on
conservative management had an impaired OGTT, and in accordance with our results,
there was no change in fasting glucose or OGTT during rhGH treatment for up to 5
years (Haffner et al. 1998b). Saenger also reported no change in glucose tolerance
during 5 years of rhGH treatment in CRI (Saenger et al. 1996).
In the CRI group, fasting insulin levels were also mildly elevated. There was a small
but significant rise in fasting insulin during rhGH treatment. Haffner studied CRI
patients receiving rhGH for up to 5 years; fasting insulin at baseline was higher than
control values, and rose during rhGH treatment, but this only became significantly
different after 3 years of treatment (Haffner et al. 1998b). Fine, reporting a two year
placebo controlled study of rhGH in CRI, found no change in fasting glucose with
rhGH compared to placebo, but fasting insulin increased in the rhGH treatment group
compared to the control group (Fine et al. 1994). Continued follow up of these
patients found that after 5 years of rhGH treatment insulin remained significantly
increased compared to baseline, and HbAlc increased from 5.3% at baseline to 6.1%
(p = 0.003) (Fine et al. 1996b). This is in contrast to the CRI data reported by
Haffner, where there was no change in HbAlc after 5 years of rhGH treatment
(Haffner et al. 1998b).
There were no changes in HbAlc in our patients, and Van Es reported no change in
HbAlc during 2 years of rhGH treatment in 31 patients with CRI (Van Es et al.
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1991). It is likely that the differences between these studies reflect individual patient
variation in terms ofGFR, body mass, nutrition, age and other factors.
The glucose and insulin data in the CRI patients are consistent with rhGH treatment
increasing insulin secretion, but leaving glucose turnover unchanged. Whilst it may be
reassuring that rhGH does not result in insulin resistance, prolonged
hyperinsulinaemia could turn out to be an unwanted longterm cardiovascular risk
factor for these children.
Dialysis
At baseline, fasting glucose in the dialysis arm of the study was no different to the
CRI or transplanted groups, and there was no change in fasting glucose, nor of
HbAlc during rhGH treatment. Of potential concern during peritoneal dialysis,
children absorb approximately 2-3 g/kg/day of glucose from the peritoneal fluid, and
the amount is even greater when hypertonic dialysate is used to increase fluid
removal. However glucose tolerance appears to be no worse in patients receiving
peritoneal dialysis compared to haemodialysis, and has even been reported to improve
following the institution of peritoneal dialysis (Heaton et al. 1989). Perhaps
surprisingly HbAlc levels at the start of treatment were higher in the transplanted
group than in the combined dialysis groups; a finding also reported by Haffner
(Haffner et al. 1998b). Steroids would appear to have more of a detrimental effect on
glucose intolerance than uraemia, however data regarding the metabolic effects of
rhGH in dialysis patients are more limited than for other groups of CRF patients, as
most paediatric dialysis patients only remain on dialysis for a short period of time
before receiving a renal transplant.
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Renal Transplantation
Four of 21 transplanted children also had an elevated fasting glucose at baseline, but
there was no change in mean fasting glucose during rhGH treatment. Before
treatment, there was a tendency for fasting insulin to be higher in this group compared
with the CRI group, and whilst there was an increase in fasting insulin during
treatment, this was not sustained.
It is well established that glucose tolerance is abnormal in children with renal
transplants. Fennell was one of the first authors to report that glucose tolerance was
adversely affected by steroid treatment (Fennell et al. 1983). In 1991, Van Dop
reported the results of OGTT in 15 children with renal transplants; 3 of these children
had abnormal OGTT results. During the OGTT, the integrated glucose concentration
was directly correlated with adiposity and indirectly correlated with prednisolone
dose, whilst the integrated insulin concentration was directly correlated with
prednisolone dose and age. Integrated glucose and insulin concentrations were
unaltered by 12 months of rhGH treatment in 10 of these children (Van Dop et al.
1991). In our patients neither fasting glucose nor insulin levels were related to
prednisolone dosage.
Likewise Guest has reported similar findings (Guest et al. 1998). Of 49 children with
renal transplants who were tested, 44 had normal glucose tolerance and 5 had
impaired OGTT. Eleven children had evidence of insulin resistance. In this study
fasting glucose was proportional to fasting insulin (p = 0.04). These children were
then entered into a controlled trial of rhGH treatment. During the first year, both the
treatment and control groups had an increase in fasting glucose and insulin, and the
increase was of similar magnitude in both groups (Guest et al. 1998). There was no
mention of a relationship between the OGTT results and steroid dose.
Haffner has also reported on glucose tolerance in children with renal transplants,
before and during rhGH treatment (Haffner et al 1998b). He found that at baseline
fasting glucose, insulin and HbAlc levels were higher in transplanted patients
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compared to controls, and that fasting insulin levels were higher in the transplanted
patients compared to CRI and dialysis patients. In this study fasting glucose was
directly correlated with the dose of steroid, but fasting insulin was not. There was no
change in glucose tolerance in transplanted patients receiving rhGH treatment, but
insulin levels rose and remained elevated for up to 5 years (Haffner et al. 1998b).
It is difficult to explain the discrepancy between these three studies: baseline insulin
values increased during rhGH treatment in Haffner's study; in our patients levels
increased then returned to baseline; whilst in the study of Van Dop insulin was
unchanged by treatment. Patient variation, in terms of steroid dose (total dose and
frequency), other immunosuppressants, age, nutritional status, pubertal status, and
other factors may play a part.
Perhaps a better measure is the effect of rhGH treatment on HbAlc in renal transplant
patients. In our study, baseline HbAlc was higher in the transplanted group compared
to the CRI group (p = 0.003) and to the combined dialysis groups (p < 0.0001). There
was however no change in HbAlc during rhGH treatment in the transplanted group.
In Haffner's study HbAlc was unchanged after 3 years of rhGH treatment (Haffner et
al 1998b). HbAlc was not measured in the other studies described above (Van Dop
et al. 1991; Guest et al. 1998), but has been reported elsewhere to be unchanged by
rhGH treatment after renal transplantation (Van Es et al. 1991; Jabs et al. 1993).
One child in the transplanted arm of our study developed glucose intolerance nine
months after starting rhGH. Glucose tolerance returned to normal when rhGH was
discontinued, however she later went on to develop diabetes mellitus requiring insulin
treatment some months after stopping rhGH treatment. There have been other case
reports of patients with renal transplants developing diabetes or glucose intolerance
during rhGH treatment (Ingulli et al. 1993).
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Conclusion
The data presented here show an increase in insulin secretion with rhGH treatment in
CRF, but there was no effect on fasting glucose and no change in glycosylated
haemoglobin levels in any of the groups. These results are similar to those reported
for other groups of patients with CRF receiving rhGH, and indeed are similar to
results during rhGH treatment of short normal patients and those with GHD. The
duration of increased insulin secretion appears to be variable. Undoubtedly some CRF
patients already have a degree of insulin insensitivity before treatment, and these
patients may be at risk of overt glucose intolerance during rhGH treatment. Long-
term follow up is necessary in CRF patients receiving rhGH treatment.
II. LIPIDS
Patients with CRF have an increased risk of developing cardiovascular disease in later
life. This is thought to be due in part to abnormalities in lipid metabolism, which are
known to be present in childhood (Querfeld 1993). Little is known of the natural
history of uraemic dyslipidaemia in childhood, but lipid levels are often significantly
elevated and treatment of hyperlipidaemia may be of therapeutic benefit. As discussed
above, children with CRF also have insulin resistance, which is another risk factor for
cardiovascular disease. As GH has actions on lipid metabolism as well as on
carbohydrate metabolism, it is important to determine the effect of rhGH treatment on
lipid profiles in children with CRF.
Growth hormone deficiency is characterised by reduced free fatty acid release by
adipose tissue causing diminished ketogenesis. Growth hormone replacement restores
lipolysis and ketone production. Administration of intravenous GH to normal subjects
increases release of free fatty acids from adipose tissue (Rabinowitz et al. 1965),
however two years of rhGH treatment in short normal children had no effect on
fasting free fatty acids, triglyceride or cholesterol levels (Lesage et al. 1991). In this
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study, fasting triglyceride and cholesterol levels before and during rhGH treatment
were measured in different groups ofCRF patients.
Methods
Fasting triglyceride and cholesterol were measured before treatment, after 1 week of
rhGH treatment, then three monthly for one to two years in the patients attending the
London centres, and three monthly in all other patients.
Results
Cholesterol and triglyceride levels during treatment in the different patient groups are
shown in Table 10.3.
Cholesterol
At the start of treatment, mean cholesterol levels were at or just above the upper limit
of the normal range in each group (Figure 10.13). The highest values were in the PD
group, where the values were significantly higher than in the HD group (p < 0.001);
69% of PD patients had a cholesterol level above the normal range, compared with
11% of children in the HD group. Cholesterol was also higher in the transplanted
group compared to the HD group (p = 0.02). Twenty-seven percent of transplanted
children had a baseline cholesterol above normal, as did 21% of the CRI group and
33% of the infants. There were no significant differences between the groups.
Cholesterol levels were unchanged during treatment in the CRI, infant and dialysis
groups, but there was a significant fall in cholesterol during the first year of rhGH
treatment in the transplanted group as a whole (Figures 10.14 and 10.15). When the
transplanted group was analysed by comparing the treatment and control groups,
cholesterol levels fell in both groups, but not significantly so (control group p = 0.27;
rhGH group p = 0.45, ANOVA), Figure 10.16. There was no difference between the
fall in cholesterol in these groups, but interestingly, the decrease in cholesterol in the
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control group during the year of rhGH (2nd year) was greater when compared with the
first year of no treatment (p = 0.002), suggesting that rhGH had some effect on
cholesterol levels.
Triglyceride
Mean fasting triglyceride was at or above the upper limit of the normal range in each
group at the start of treatment (Figure 10.17). Seventy-eight percent of infants, 21%
of CRI, 56% of PD, 86% of HD and 14% of transplanted patients had fasting
triglycerides above the normal range. The highest values were found in the PD group;
these were significantly higher than the CRI (p = 0.034) and the transplanted (p =
0.0016) groups. There was no difference between the PD and HD groups (p = 0.42),
but mean triglyceride was lower in the transplanted group than in the HD group (p =
0.002). During treatment mean triglyceride rose in the CRI group (p = 0.004), but
was unchanged in all the other groups (Figure 10.18 - 10.20).
Discussion
Abnormalities in lipid profile were evident in the majority of patients before treatment.
The findings are similar to those found in adult patients on renal replacement therapy
(Oda and Keane 1998). Cardiovascular and cerebrovascular disease are major causes
of mortality in HD patients (US Renal Data System 1995), and death from
cardiovascular disease is a major cause of graft loss in renal transplant patients
(Lindholm et al. 1995). Whilst children on renal replacement therapy do not exhibit
overt cardiovascular disease, it is likely that its origins start in childhood (Kari et al.
1997). The literature relating to lipid abnormalities in children on dialysis (Querfeld
1993) and after transplantation is limited (Sharma et al. 1994; Singh et al. 1998;
Silverstein et al. 2000).
The main abnormality in CRF is decreased lipoprotein catabolism resulting in reduced
clearance of intermediate particles and diminished formation of high density
lipoproteins (Chan JK et al. 1981). This is due to reduced lipoprotein lipase and
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hepatic triglyceride lipase activies (Chan et al. 1984). This is likely to be multifactorial
in origin, but insulin resistance, hyperparathyroidism and uraemic inhibitors have been
proposed as possible mechanisms.
The lipid abnormalities were most pronounced in the PD group, as is found in the
adult CRF population (Oda and Keane 1998). Hypercholesterolaemia and
hypertriglyceridaemia were both common in our patients; 69 % of the PD patients had
a cholesterol value greater than the upper limit of normal, and 56% had a triglyceride
value above normal. This compares with values of 74% and 50% quoted for the adult
population (Oda and Keane 1998), and of 69% and 90% for paediatric PD patients in
another study (Querfeld et al. 1988). This suggests that lipid abnormalities in CRF do
start early in life, and raises the question of therapeutic intervention at this stage, even
before signs of cardiovascular disease are evident (Fried et al. 1999). Even in the CRI
group who have residual renal function, 21% had a raised cholesterol and 25% a
raised triglyceride. Perhaps ofmore concern, 33% of the infants with CRI had a raised
cholesterol, and 78% a raised triglyceride. These children were young with a mean
age of only 1.9 years. Similar high results in young children have been reported
previously (Querfeld et al. 1988).
Risk factors for hyperlipidaemia during PD include absorption of glucose from, and
protein loss (including apoproteins), into the dialysate (Querfeld et al. 1991). In small
children the surface area of the peritoneum relative to body size is greater than in
older children and adults, and may contribute to the abnormalities found. Furthermore
to sustain growth in children with CRF, high calorie feeds are administered. Often
significant proportions of the calories in these feeds are derived from fat which is
likely to be another contributing factor. The lipid profile of children treated with PD
are of an atherogenic nature, with high concentrations of total cholesterol and
triglycerides and an increase in very low and low density lipoproteins, with normal
high density lipoproteins (Querfeld et al. 1991).
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In the HD population, hypertriglyceridaemia was more of a problem than
hypercholesterolemia. Eighty-six percent ofHD patients had raised triglycerides, and
11% raised cholesterol. Comparable figures for the adult population are 49% and
39% respectively (Oda and Keane 1998), and virtually identical results to ours have
been reported previously in paediatric haemodialysis patients (Pennisi et al. 1976).
The pathogenesis of the marked and consistent hpertriglyceridaemia that is reported in
patients on haemodialysis is due to a combination of increased production of ApoB
lipoprotein and reduced lipoprotein lipase activity (Kasiske and Keane 1991).
Treatment with rhGH had little effect on lipid levels. There was an increase in
triglyceride in the CRI group during the year of rhGH treatment (p = 0.004,
ANOVA). This was evident by 3 months and persisted through the year. In the
absence of a control group it is difficult to know the significance of this finding, which
may be due to an effect of time alone. Reports from other groups however report that
rhGH has little effect on lipid profiles (Hokken-Koelega et al. 1991; Fine et al. 1994;
Haffner et al. 1998b). The paper by Fine in 1994 reported a placebo controlled study
of patients with CRI; there was no change in cholesterol or triglyceride in either group
during the initial 2 years of the study (Fine et al. 1994). A later follow up report
confirmed no change in cholesterol or triglyceride after 5 years of rhGH treatment
(Fine et al. 1996b).
There are fewer data available for dialysed patients; rhGH treatment had no effect on
lipid levels in the PD patients reported here. Similar data have become available since
(Haffner et al. 1998b).
The transplanted patients exhibit a different pattern of dyslipidaemia, with
hypercholesterolaemia being more of a problem. The potential risk factors in this
population are immunosuppressive therapy, proteinuria and obesity, and there is
increased lipoprotein production by the liver (Cattran et al. 1979). The proportion of
our paediatric patients with hypercholesterolaemia was 32%, compared with 79% of
adult renal transplant recipients (Oda and Keane 1998). One study of paediatric renal
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transplant recipients at a mean time of 7.4 years post transplantation, found that 17 of
33 (52%) patients had hypercholesterolaemia (Sharma et al. 1994), another reported
an incidence of hypercholesterolaemia of 51% (Pennisi et al. 1976). In both of these
studies cholesterol levels correlated with the dose of prednisolone. In our study, we
found no correlation with GFR (r = -0.157), prednisolone dose (r = 0.255), weight for
height (r = 0.326, p = 0.14) nor with insulin (r = -0.112).
Yet another paediatric study reported that 52% of 62 transplanted patients had
hypercholesterolemia (Silverstein et al. 2000). In this study the risk factors for having
high cholesterol levels were pre-transplant hypercholesterolemia and years since
transplantation. This study also reported triglyceride levels (Silverstein et al. 2000).
Fifty-two percent of pediatric renal transplant recipients had elevated triglycerides,
with the only demonstrable risk factor being reduced GFR (Silverstein et al. 2000).
Oda reported similar data for adult renal transplant recipients, with 46% of the
patients studied having high triglyceride levels (Oda and Keane 1998). Only 18% of
our patients had a high plasma triglyceride level. It is difficult to explain these
differences; one possiblity could be the more frequent use of alternate day steroids in
our patients, age, nutritional status, renal function or perhaps racial differences
between the populations studied.
There was little change in lipid profiles in the transplanted group during rhGH
treatment. There was a reduction in cholesterol, but when this was analysed further
there was a fall in the control group as well as the treatment group, implying at least
some effect due to time alone. Other groups have reported the effects of rhGH on
lipid profiles in patients with renal transplants. All reported no change in either
cholesterol or triglceride levels (Fine et al. 1991b; Bartosh et al. 1992; Haffner et al.
1998b). Two years of rhGH treatment in short normal children had no effect on either
cholesterol or triglyceride (Lesage et al. 1991).
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Conclusion
Prior to treatment, significant numbers of children in each of the subgroups of the
study had elevated cholesterol and triglyceride levels. During treatment with rhGH
there was a rise in triglyceride levels in the CRI group but no other definitive changes
were seen.
III. RENAL BONE DISEASE
Endogenous GH stimulates longitudinal bone growth both directly and through the
actions of its mediator IGF-I as outlined in Chapter 1. Growth hormone treatment
results in an increase in the number and activity of osteoblasts (Ernst and Froesch
1988), increasing bone length and bone mineral deposition. Growth hormone
deficiency is associated with reduced longitudinal bone growth, reduced final adult
height and reduced bone mineral content (Lu el al. 1992; Saggese et al. 1993). A
significant proportion of accumulated bone mass occurs during puberty, such that
normal duration and timing of puberty are required for this to be accomplished
successfully.
As renal function declines there is reduced activation of vitamin D within the kidney,
causing a fall in plasma calcium. If this is not corrected, the patient develops
osteopenia. Flypocalcaemia (and hyperphosphataemia due to CRF) stimulate secretion
of PTH; if left unchecked, hyperparathyroidism develops. Hyperparathyroidism will,
with time, lead to osteitis fibrosa cystica (Hruska 2000). In the growing skeleton these
consequences of CRF eventually lead to renal rickets. Furthermore, GH is involved in
bone remodelling and children with CRF exhibit a degree of GH resistance (Chapter
8). Children with CRF also have a delayed and shortened puberty, when bone mass
accrual is significant. Yet another risk factor for some of these children is the use of
steroids. The effects of rhGH treatment on bone in CRF have not been fully evaluated.
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Methods
Calcium, phosphate, and ALP were measured before, after one week of rhGH, then 3
monthly in the London patients. In all other patients, calcium, and ALP were
measured 3 monthly; phosphate was recorded 3 monthly in the infants, CRI and
transplanted patients. Parathyroid hormone was measured 3 monthly in all patients.
Analysis of change in parameters during the study was by ANOVA.
Results
Data for calcium, phosphate, ALP and PTH are given in Tables 10.4 and 10.5.
Calcium
There was no difference between plasma calcium in the different subgroups at the
start of treatment (Figure 10.21). There was no significant change in calcium during
the study in any of the patient groups (Figure 10.22 - 10.24).
Phosphate
Phosphate results are available for the infants, CRI and transplanted patients.
Phosphate was significantly lower in the transplanted group than the CRI group (p =
0.04), Figure 10.25. There were significant increases in phosphate levels during rhGH
treatment in the CRI and transplanted patients that were both highly significant
(Figure 10.26). Comparing the transplant control and treatment groups, an increase
was seen in the treatment group (p = 0.02) but not the control group (p = 0.41),
Figure 10.27.
Alkaline Phosphatase
Alkaline phosphatase data are shown in Figures 10.28 - 10.31. At the start of the
study, ALP was highest in the dialysis groups and lowest in the transplanted group.
There was a highly significant increase in ALP in the transplanted group during rhGH
treatment (p < 0.0001), Figure 10.29. Comparing the transplant control and treatment
groups, an increase was seen in the treatment group (p < 0.0001) but not the control
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group (p = 0.55), Figure 10.31. A significant increase in ALP was also seen in the PD
group, but not in any of the other groups.
Parathyroid Hormone
Results for PTH are given in Table 10.5 and Figures 10.32 - 10.35. Before treatment,
PTH was highest in the HD group, being significantly higher than the CRI (p <
0.001), the infant (p = 0.03), the transplanted (p < 0.001), and the PD (p = 0.001)
groups, Figure 10.32. The mean PTH in the CRI group was above the normal range,
whilst that in the transplanted group was within the normal range, but there was only
a trend for higher levels in the CRI compared to the transplanted group (p = 0.09).
Parathyroid hormone levels in the infant group were higher than in the CRI (p =
0.005), the transplanted (p < 0.001) and the PD groups (p = 0.04).
During rhGH treatment, PTH increased in the CRI group (p - 0.01), and decreased in
the infant group (p = 0.03). Parathyroid hormone increased in the treatment group in
the transplant arm of the study (p = 0.05), but not in the control group (p = 0.35).
When PTH was analysed in all transplanted children during their first year of rhGH,
there was however no significant change (p = 0.13).
Discussion
Abnormal renal function has a deleterious effect on bone metabolism giving rise to
hyperparathyroidism and renal osteodystrophy. In the growing child renal
osteodystrophy can result in renal rickets. Severe renal osteodystrophy may retard
growth, and correction of renal osteodystrophy has been reported to improve growth
by some (Chan ICM et al. 1981) but not other authors (Chesney 1985). The question
arises as to whether rhGH treatment is effective in the presence of renal




There was a significant increase in serum phosphate in the CRI patients. Growth
hormone acts on the renal tubule to increase the tubular reabsorption of phosphate
(Corvilian el al. 1962). However in renal failure there is already an accumulation of
phosphate due to reduced tubular phosphate secretion so a further increase in
phosphate might not have been expected. There was a small increase in PTH which
could be secondary to the increase in phosphate. Nearly all of these children were on
activated vitamin supplements at the start of the study.
There was no significant change in ALP in the CRI group, which is contrary to other
published studies. Fine reported a two year placebo controlled trial of rhGH in CRI.
In his study, there was no change in either calcium or phosphate, but after 1 year ALP
was increased in the treatment group compared to the control group, but by 2 years
there was no significant difference (Fine et al. 1994). Parathyroid hormone levels
were not reported. Increase in ALP has been shown to be a good indicator of the
growth response to treatment in other groups of children treated with rhGH,
particularly if the bone ALP isoform is measured (Crofton et al. 1995).
There are several assays used for the measurement of ALP, so it is difficult to
compare different studies. The ALP results in our CRI group are high compared to
normal children and may explain why there was no further increase. There was
however a trend for an increase, and the results are skewed by one patient who had a
very high ALP at the start of the study.
Dialysis
The growth response in the dialysis groups was less than that seen in the CRI or
transplanted groups. Despite a high ALP at baseline, a further increase was seen
during rhGH treatment in the PD group. There was no significant change in PTH in
either the PD or HD group. These children have more disturbed bone metabolism,
which may be one reason for the poorer growth response to GH. One of the children
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in the prepubertal PD group was withdrawn from the study after 11 months of rhGH
treatment because ofworsening renal bone disease. His calcium, phosphate, ALP and
PTH were all within normal limits at the start of the study but increased steadily
during rhGH treatment. It is possible that rhGH treatment was responsible, although
this cannot be proven. Unfortunately no follow up data are available.
Transplantation
In the transplanted patients, there were small but significant increases in phosphate,
PTH and ALP during rhGH treatment. The majority of patients with renal transplants
have better renal function than patients with CRI, and phosphate, PTH and ALP were
lower at baseline in this group compared to the other groups. They would therefore
be expected to have less marked renal osteodystrophy, but virtually all of these
patients receive treatment with steroids, which may have a detrimental effect. Patients
with normal renal function who receive rhGH treatment show a marked increase in
ALP which is said to correlate with the magnitude of the growth response (Crofton el
al. 1995). There are few data reporting the effect of rhGH on PTH in normal children.
The increase in phosphate and ALP are not unexpected. The increase in PTH is
slightly concerning, however when all 22 of the transplanted children were analysed
during their first year of rhGH treatment, there was no longer any significant change
in PTH. Hokken-Koelega reported similar data; in a placebo controlled trial of rhGH
in prepubertal renal transplant recipients, ALP increased in the group receiving
treatment but not in the control group. Parathyroid hormone was unchanged in both
groups (Hokken-Koelega et al. 1996). Tonshoff reported a rise in ALP during the
first year of rhGH treatment in 13 patients with renal transplants, but ALP was no
different from baseline in the 10 patients who were followed for 3 years (Tonshoff et
al. 1993).
Nine children in this study received rhGH for 2 years. There was no difference in
phosphate [day l:1.35(0.42)mmol/l; 2 yrs: 1.4(0.31), p = 0.33], ALP [dayl:
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227(75)U/1; 2 yrs: 273(97), p = 0.12] and PTH [dayl: 4.8(3.4)pmol/l; 2 yrs:5.6(3.7),
p = 0.55] after 2 years of rhGH treatment in these 9 children.
Renal Bone Disease
Other abnormalities of bone are also reported in CRF and following renal
transplantation, namely slipped capital femoral epiphysis (Mehls et al. 1975) and
avascular necrosis of the femoral head (Catterall and Roberts 1971; Mehls et al.
1981). There is also an increased risk of both of these conditions in patients with
GHD. The effects of rhGH treatment on the course of these two conditions is unclear
at present. There has been no systematic study of slipped capital femoral epiphysis or
avascular necrosis in renal patients either before or during rhGH treatment. These
conditions have been diagnosed during rhGH treatment of patients with CRF
(Watkins 1996), but in many patients there were no x-ray films available from before
treatment for comparison. The present study did not set out to address this particular
issue.
BoneMineral Content
There are two recent published studies reporting the effect of uraemia on bone
mineral content. One study reported 13 prepubertal patients with CRI who were
found to have reduced bone mineral content and bone mineral density compared to
controls, and who had an increase in both of these parameters following 1 year of
rhGH treatment (Lanes et al. 1996). Another study found bone mineral density to be
no different to controls in 36 prepubertal children with CRF. Growth hormone
treatment had no effect on bone mineral density in this group of patients (Boot et al.
1996). A recent abstract has compared children with CRI with both height- and age-
matched controls, before and after 1 year of rhGH treatment (Gyssels et al. 2000).
Before treatment total bone mineral content, but not total bone mineral density, was
lower than age-matched controls, whereas there was no difference compared to
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height-matched controls. After 1 year of rhGH treatment, there was an increase in
both bone mineral content and bone mineral density (Gyssels et al. 2000).
Conclusion
There was, as expected, evidence of abnormal bone metabolism in all groups of
patients at the start of the study. There were transient increases in phosphate and ALP
in nearly all groups and an increase in PTH in the CRI group. There were no major
changes in bone metabolism as a result of rhGH treatment, but continued follow up is
required. One child in the dialysis group developed biochemical evidence of marked
renal osteodystrophy during rhGH treatment.
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Figure10.1astingbloodgl cosetthstartfudyinCRI,nfant,r n plan ed,perito aldi lys (PD)andhaemodialysisHgroup .Theupperli itfnormalisn catedbts line.
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Figure 10.2 Fasting blood glucose during rhGH treatment in the CRI,




Figure 10.3 Fasting blood glucose during rhGH treatment in the
peritoneal dialysis and haemodialysis groups.
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Treatment
Figure 10.4 Fasting blood glucose during the first year of study in the
transplanted control and treatment groups.
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Figure 10.7 Fasting insulin during rhGH treatment in the CRI,
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Figure 10.8 Fasting insulin during the first year of study in the transplant
control and treatment groups. *p = 0.04 vs. day 1,
* *
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Day 1 3 Mths 6 Mths 9 Mths 1 Yr
Figure 10.12 HbAl c during rhGH treatment in the transplant control and
treatment groups.
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Figure 10.14 Fasting cholesterol during rhGH treatment in the CRI, infant
and transplant groups. * Mean cholesterol decreased during













Day 1 3 Mths 6 Mths 9 Mths 1 Yr
Figure 10.15 Fasting cholesterol during rhGH treatment in the




Figure 10.16 Fasting cholesterol during the first year of study in the transplant
control and treatment groups. There was no difference between the
change in cholesterol in the two groups.
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Figure 10.18 Fasting triglyceride during rhGH treatment in the CRI, infant
and transplanted groups. * Triglyceride levels increased during




Figure 10.19 Fasting triglyceride during rhGH treatment in the




Figure 10.20 Fasting triglyceride during the first year of study in the














Figure10.21Plasmacalciumtthstartoft dyinCRI,inf nt,transplanted,perito ealdi lysis(PD) andhaemodialysis(HD)groups.Theupperli itfnormalsindicat dbts lili e.
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Figure 10.22 Plasma calcium during rhGH treatment in the CRI,
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Figure 10.23 Plasma calcium during rhGH treatment in the peritoneal
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Figure 10.24 Plasma calcium during the first year of study in the
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Figure 10.26 Plasma phosphate during rhGH treatment in the CRI, infant and
transplanted groups. * Phosphate increased during treatment
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Figure 10.27 Plasma phosphate during the first year of study in the transplant control
and treatment groups. * Phosphate increased in the treatment group
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Figure 10.29 Alkaline phosphatase (ALP) during rhGH treatment in the CRI,
infant and transplant groups. * An increase in ALP was seen in




Figure 10.30 Alkaline phosphatase (ALP) during rhGH treatment in the
peritoneal dialysis (PD) and haemodialysis groups. * ALP




Figure 10.31 Alkaline phosphatase (ALP) during the first year of study in the
transplant control and treatment groups. * ALP increased in the
treatment group (p < 0.0001, ANOVA), but not the control group
(p = 0.55, ANOVA).
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Figure 10.33 Parathyroid hormone (PTH) during rhGH treatment in the CRI,
infant and transplanted groups. * PTH increased during treatment
in the CRI group(p = 0.12, ANOVA), and ** decreased in the




Figure 10.34 Parathyroid hormone during rhGH treatment in the
peritoneal dialysis and haemodialysis groups.
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Figure 10.35 Parathyroid hormone (PTH) during the first year of study in the
transplant control and treatment groups. PTH increased in the
treatment group (p = 0.05, ANOVA), but not in the control group
(p = 0.35, ANOVA).
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Chapter 11: Concluding Remarks
Short stature is a problem in CRF and in children with renal transplants. All of the
groups of children studied had significant short stature (Figure 11.1A). The greatest
increase in height SDS was seen in the infant group, with the poorest response being
seen in the dialysis groups (Figure 11.1B). Increase in height SDS was greater the
younger the child in the infant, CRI and transplanted groups. In the transplanted
group, A height SDS was also negatively correlated with the dose of prednisolone.
Height velocity increased in all groups of patients during rhGH treatment (Figures
11.2 A and B). The greatest increase in HV was seen in the children who were
growing most slowly in the infant, CRI and combined dialysis groups.
Growth hormone was well tolerated in the majority of patients. However two serious
adverse effects occurred during the trial. One child developed benign intracranial
hypertension from which she made a full recovery. Another child developed glucose
intolerance requiring withdrawal from the study. A further child developed
biochemical evidence of renal osteodystrophy, and several of the transplanted children
had presumed episodes of rejection, however for these children it is not possible to be
certain if growth hormone treatment was responsible.
In the short to medium term, rhGH appears to be an effective treatment for short
stature of CRF and renal transplantation. Growth hormone treatment however is not
without side-effects, albeit rare side-effects, and due consideration needs to be taken
before commencing treatment, paticularly in the transplanted patient. The potential
problems need to be explained to the family, and the development of symptoms such
as headaches needs to be taken seriously. The effect of rhGH treatment on final height
is not yet clear, but final height data are awaited with anticipation.
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(A) Height SDS Before rhGH Treatment
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Infant CRI PD HD Transplant
Figure 11.1 (A) Height SDS at the start of the study in the infant, CRI, PD, HD
and transplanted groups. (B) Increase in height SDS during the first
year of rhGH treatment in the same groups of children.
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(A) HV Before rhGH Treatment
12 T
Infant CRI PD HD Transplant











Figure 11.2 (A) Height velocity in the year before the study in the infant, CRI,
PD, HD and transplanted groups. (B) Height velocity during the first
year of rhGH treatment in the same groups of children.
Infant CRI PD HD Transplant
291
Bibliography
Abassi V, Bellanti JA. Humoral and cell-mediated immunity in growth hormone-
deficient children: effect of therapy with human growth hormone. Pediatr Res 1985;
19: 299-301
Abitol CL, Zilleruelo G, Montane B, Strauss J. Growth of uraemic infants on forced
feeding regimens. Pediatr Nephrol 1993;7:173-177
Adelman RD, Holliday MA. Improved growth in dwarf uraemic rats with calorie
supplementation. Pediatr Res 1974;8:378 abstract
Albertsson Wikland K, Niklasson A, Karlberg P. Birth data for patients who later
develop growth hormone deficiency: preliminary analysis of a national register. Acta
Paediatr Scand 1990;370(suppl): 115-120
Allen DB, Fogo A, El-Hayek R, Langhough R, Friedman AL. Effects of prolonged
growth hormone administration in rats with chronic renal insufficiency. Pediatr Res
1992;31: 406-410
Alvestrand A. Carbohydrate and insulin metabolism in renal failure. Kidney Int 1997;
52(suppl):S48-S52
Amiel SA, SherwinRS, Simonson DC, Lauritano AA, TamborlaneWV. Impaired
insulin action in puberty. N Engl J Med 1986;315:215-219
Aron DC, Rosenzweig JL, Abboud HE. Synthesis and binding of insulin-like growth
factor I by human glomerular mesangial cells. J Clin Endocrinol Metab 1989;68:585-
591
Aron DC. Insulin-like growth factor I and erythropoiesis Minireview. Biofactors
1992;3:211-216
Arnold WC, Danford D, Holliday MA. Effects of calorie supplementation on growth
in children with uraemia. Kidney Int 1983;24:205-209
Arnquist HJ, Ballermann BJ, King GL. Receptors for and effects of insulin and IGF-I
in rat glomerular mesangial cells. Am J Physiol 1988;254:C411-416
Astarabadi TM, Essex HE. Effect of hypophysectomy on compensatory renal
hypertrophy after unilateral nephrectomy. Am J Physiol 1953;173:526-534
Badolato R, Bond HM, Valeria G, Petrella A, Morrone G, Waters MJ. Differential
expression of surface membrane growth hormone receptor on human peripheral blood
lymphocytes by dual fluorochrome flow cytometry. J Clin Endocrinol Metab 1994;79:
984-990
292
Ballard F, Baxter R, Binoux M, Clemmons D, Drop S, Hall K, Hintz R, Rechler R,
Rutanen E, Schwander J. On the nomenclature of IGF binding proteins. Acta
Endocrinol (Copenh) 1989;121:751-752
Baroni CD, Fabris N, Bertoli G. Effects of hormones on development and function of
lymphoid tissues. Synergistic action of thyroxin and somatotropic hormone in
pituitary dwarf mice. Immunology 1969;17:303-314
Bartosh S, Kaiser B, Rezvani I, Polinsky M, Schulman S, Palmer J. Effects of growth
hormone administration in pediatric renal allograft recipients. Pediatr Nephrol 1992;
6:68-73
Baumann G. Circulating binding proteins for human growth hormone. In: Muller EE,
Cocchi D, Locatelli V (eds) Advances in growth hormone and growth factor research.
Pythagora Press, Rome, Springer, Berlin, Heidelberg, New York 1989:69-83
Baxter JB, Blalock JE, Weigent DA. Characterization of immunoreactive insulin-like
growth factor-I form leukocytes and its regulation by growth hormone. J Endocrinol
1991; 129; 1727-
Baxter RC, Martin JL. Radioimmunoassay ofgrowth hormone-dependent insulin-like
growth factor binding protein in human plasma. J Clin Invest 1986;78:1504-1512
Baxter R.C. Insulin-like growth factor (IGF) binding proteins: the role of serum
IGFBP's in regulating IGF availability. Acta Paediatr Scand 1991;372(Suppl): 107-114
Beaurain G, Naret C, Marcon L, Grateau G, Drueke T, Urena P, Nelson DL, Bach J-
F, Chatenoud L. In vivo T cell preactivation in chronic uraemic haemodialysed and
non-haemodialysed patients. Kidney Int 1989;36:636-644
Benfield MR, Parker KL, Waldo FB, Overstreet SL, Kohaut EC. Treatment of
growth failure in children after renal transplantation. Transplantation 1993;55:305-
308
Benfield MR, Vail A, Waldo FB, Bucy RP, Kohaut EC. The effect of recombinant
human growth hormone on responses to alloantigens in the pediatric transplant
patient. Pediatr Nephrol 1996;10:280-282
Berard E, Crosnier H, Six-Beneton A, Chevallier T, Cochat P, Broyer M on behalf of
the French Society of Pediatric Nephrology. Recombinant human growth hormone
treatment of children on haemodialysis. Pediatr Nephrol 1998;12:304-310
Bereket A, Lang CH, Blethen SL, Fan J, Frost RA, Wilson TA. Insulin-like growth
factor binding protein-3 proteolysis in children with insulin-dependent diabetes
mellitus: a possible role for insulin in the regulation of IGFBP-3 protease activity. J
Clin Endocrinol Metab 1995;80:2282-2288
293
Berg U, Bohlin AB. Renal function following kidney transplantation in children
treated with cyclosporine. Pediatr Nephrol 1992;6:339-344
Berger EY, Farber SJ, Earle DP. Comparison of the constant infusion and urine
collection techniques for the measurement of renal function. J Clin Invest 1948;
27:710-716
Betts PR, Magrath G. Growth pattern and dietary intake of children with chronic
renal insufficiency. BMJ 1974;1:189-193
Betts PR, Magrath G, White RHR. Role of dietary energy supplementation in growth
of children with chronic renal insufficiency. Br Med J 1977;1:416-418
Blum WF, Jenne EW, Reppin F, Kietzmann K, Ranke MB, Bierich JR. Insulin-like
growth factor I (IGF-I)-binding protein complex is a better mitogen than free IGF-I.
Endocrinology 1989;125:766-772
Blum WF, Ranke MB, Kietzmann K, TonshofFB, Mehls O. Growth hormone
resistance and inhibition of somatomedin activity by excess of insulin-like growth
factor binding protein in uraemia. Pediatr Nephrol 1991;5:539-544
Blum WF, Albertsson-Wikland K, Rosberg S, Ranke MB. Serum levels of insulin-like
growth factor I (IGF-I) and IGF binding protein 3 reflect spontaneous growth
hormone secretion. J Clin Endocrinol Metab 1993;76:1610-1616
Boot AM, Nauta J, de Jong MC, GroothoffJW, Lilien MR, vanWijk JA, Kist-van
Holthe JE, Hokken-Koelega AC, Pols HA, de Muinck Keizer-Schrama SM. Bone
mineral density, bone metabolism and body composition of children with chronic renal
failure, with and without growth hormone treatment. Clin Endocrinol 1998;49:665-
672
Bosque M, Munian A, Bewick M, Haycock, Chantler C. Growth after renal
transplants. ArchDis Child 1983;58:110-114
Bozzola M, Cisternino M, Valtorta A, Moretta A, Maghnie M, Larizza D, Severi F.
Effects of biosynthetic methionyl growth hormone (GH) therapy on the immune
function in GH-deficient children. Horm Res 1989;31:153-156
Bozzola M, Valtorta A, Moretta A, Cisternino M, Biscaldi I, SchimpfFRM. In vitro
and in vivo effect of growth hormone on cytotoxic activity. J Pediatr 1990:117:596-
599
Bozzola M, Valtorta A, Moretta A, SchimpfFRM. GH, GHRH and the immune
system. Growth Growth Factors Curr Med Lit 1991;6:135-139
Brenner BM. Nephron adaptation to renal injury or ablation. Am J Physiol
1985;249:F324-F337
294
Brewer ED, Holmes S, Tealey J. Initiation and maintenance of growth in infants with
end-stage renal disease managed with chronic peritoneal dialysis and nasogastric tube
feedings. Kidney Int 1986;29:230 abstract
British Association for Paediatric Nephrology (BAPN). The provision of services in
the United Kingdom for children and adolescents with renal disease: report of a
working party ofBAPN March 1995. British Paediatric Association.
Broyer M, Kleinknecht C, Loirat C, Marti-Henneberg C, Roy MP. Growth in children
treated with long-term haemodialysis. J Pediatr 1974;84:642-649
Broyer M, Guest G, Gagnadoux MF. Growth rate in children receiving alternate day
steroid treatment after kidney transplantation. J Pediatr 1992;120:721-725
Broyer M, Ehrich, Jones E, Selwood N. Five year survival of kidney transplantation in
children: data from the European (EDTA-ERA) registry. Kidney Int 1993;44(suppl):
S22-S25
Broyer M, Guest G, Crosnier H, Berard E on behalf of the Societe Francaise de
Nephrologie Pediatrique. Recombinant growth hormone in children after renal
transplantation. Lancet 1994;343:539-540 (letter)
Broyer M on behalf of the Pharmacia & Upjohn Study Group. Results and side-effects
of treating children with growth hormone after kidney transplantation - a preliminary
report. Acta Paediatr 1996;417:76-79
BurchWM, Correa J, Shively JE, Powell DR. The 25-kilodalton insulin-like growth
factor (IGF)-binding protein inhibits both basal and IGF-I-mediated growth of chick
embryo pelvic cartilage in vitro. J Clin Endocrinol Metab 1990;70:173-180
Caldas A, Fontoura M. Effects of chronic metabolic acidosis (CMA) in 24-hour
growth hormone secretion. Pediatr Nephrol 1994;8:C40 abstract
Caruana RJ, Leffell MS, Lobel SA, Campbell HT, Cheek PL. Chronic T-lymphocyte
activation in chronic renal failure: a study of haemodialysis, CAPD and pre-dialysis
patients. Int J ArtifOrgans 1992;15:93-98
Casanova S, Repellin AM, SchimpffRM. Production of interleukin-la and
interleukin-2 by mononuclear cells from children with growth delay in relation to the
degree of growth hormone deficiency: Effects of substitutive treatment. Horm Res
1990:34:209-214
Cattran DC, Steiner G, Wilson DR, Fenton SSA. Hyperlipidemia after renal
transplantation: natural history and pathophysiology. Ann Intern Med 1979;79:554-
559
295
Challa A, Krieg RJ, Thabet MA, Veldhuis JD, Chan JCM. Metabolic acidosis inhibits
growth hormone secretion in the rat: Mechanism of growth retardation. Am J Physiol
1993a;265:E547-E553
Challa A, Chan W, Krieg RJ, Thabet MA, Lui F, Hintz RL, Chan JCM. Effect of
metabolic acidosis on the expression of insulin-like growth factor and growth
hormone receptor. Kidney Int 1993b;44:1224-1227
Chan JCM, KodrofTMB, Landwehr DM. Effects of l,25-Dihydroxyvitamin-D3 on
renal function, mineral balance, and growth in children with severe chronic renal
failure. Pediatrics 1981;6:559-571
Chan JK, Varghese Z, Moorhead JF. Lipid abnormalities in uraemia, dialysis and
transplantation. Kidney Int 1981;19:625-637
Chan MK, Persaud J, Varghese Z, Moorhead JF. Pathogenic roles of post-heparin
lipases in lipid abnormalities in hemodialysis patients. Kidney Int 1984;25:812-818
Chan W, Valerie KC, Chan JCM. Expression of insulin-like growth factor-I in uremic
rats: Growth hormone resistance and nutritional intake. Kidney Int 1993; 43:790-795
Chang D, Nagamoto G, SmithWE. Benign intracranial hypertension and chronic renal
failure. Cleve Clin J Med 1992;59:419-422
Chantler C, Lieberman E, Holliday MA. A rat model for the study of growth failure in
uraemia. PediatrRes 1974;8:109-113
Chantler C. Nutritional assessment and management of children with renal
insufficiency. In Fine RN, Gruskin AB, eds. End-stage renal disease in children.
Philadelphia: WB Saunders 1984:193-208
Chavers BM, Doherty L, Nevins TE, Cook M, Sane K. Effects of growth hormone on
kidney function in pediatric transplant recipients. Pediatr Nephrol 1995;9:176-181
Chesney RW : Renal osteodystrophy in children . In Cummings NB, Klahr S eds:
Chronic renal disease: causes, complications and treatment. New York. Plenum.
1985:321-331
Christiansen JS, Gammelgaard J, Frandsen M, Parving HH. Increased kidney size,
glomerular filtration rate and renal plasma flow in short-term insulin-dependent
diabetes. Diabetologia 1981;20:451-456
Christiansen JS, Gammelgaard J, Orskov H, Andersen AR, Telmer S, Parving HH.
Kidney function and size in normal subjects before and during growth hormone
administration for one week. Eur J Clin Invest 1991; 11:487-490
296
Claris-Appiani A, Bianchi ML, Bini P, Ballabio G, Caraceni MP, Funari C, Terzi F,
Romeo L, Rusconi R. Growth in young children with chronic renal failure. Pediatr
Nephrol 1989;3:301-304
Claris-Appiani A, Ardissino GL, Dacco V, Funari C, Terzi F. Catch-up growth in
children with chronic renal failure treated with long-term enteral nutrition. J Parenter
Enteral Nutr 1995;19:175-178
Clark R. The somatogenic hormones and insulin-like growth factor-I: stimulators of
lymphopoiesis and immune function. Endocr Rev 1997;18:1-23
Conover CA, Kiefer MC, Zapf J. Posttranslational regulation of insulin-like growth
factor binding protein-4 in normal and transformed human fibroblasts: insulin-like
growth factor dependence and biological studies. J Clin Invest 1993;91: 1129-1137
Corvilian J, Abramow M, Bergans A. Some effects of human growth hormone on
renal haemodynamics and on tubular phosphate transport in man. J Clin Invest 1962;
4:1230-1235
Cox GN, McDermott MJ, Merkel E, Stroh CA, Squires CH, Gleason TM, Russell D.
Recombinant human insulin-like growth factor (IGF) binding protein-1 inhibits
somatic growth stimulated by IGF-I and growth hormone in hypophysectomized rats.
Endocrinol 1994;135:1913-1920
Crist M, Peake GT, Mackinnon LT, SibbittWL, Kraner JC. Exogenous growth
hormone treatment alters body composition and increases natural killer cell activity in
women with impaired endogenous growth hormone secretion. Metab 1987;36:1115-
1117
Crist M, Kraner JC. Supplemental growth hormone increases the tumour cytotoxic
activity of natural killer cells in healthy adults with normal growth hormone secretion.
Metab 1990;39:1320-1324
Crofton PM, Stirling HF, Kelnar CJ. Bone alkaline phosphatase and height velocity in
short normal children undergoing growth-promoting treatments: longitudinal study.
Clin Chem 1995;41:672-678
Dalton RN, Turner C. A sensitive and specific method for the measurement of inulin.
Ann Clin Biochem 1987;24(suppll):Sl-231
Darendeliler F, Hindmarsh PC, Preece MA, Cox L, Brook CGD. Growth hormone
increases the rate of pubertal maturation. Acta Endocrinol (Copenh) 1990;122:414-
416
Davies SC, Wass JAH, Ross RJ et al. The induction of a specific protease for insulin¬
like growth factor binding protein 3 (IGFBP-3) in the circulation during severe illness.
J Endocrinol 1991;130:469-473
297
Davis ID, Chang P-N, Nevins TE. Successful renal transplantation accelerates
development in young uraemic children. Pediatrics 1990;86:594-600
D'Ercole AJ, Stiles AD, Underwood LE. Tissue concentrations of somatomedin C:
further evidence for multiple sites of synthesis and paracrine or autocrine mechanisms
of action. Proc Natl Acad Sci 1984;81:935-939
DeFronzo RA, Tobin JD, Rowe JW, Andres R. Glucose intolerance in uraemia:
Quantification of pancreatic beta cell sensitivity to glucose and tissue sensitivity to
insulin. J Clin Invest 1978;62:425-435
DeFronzo RA, Alvestrand A, Smith D, Hendler R, Hendler E, Wahren J. Insulin
resistance in uraemia. J Clin Invest 1981;67:563-568
Deschamps I, Giron BJ, Lestradet H. Blood glucose, insulin, and free fatty acid levels
during oral glucose tolerance tests in 158 obese children. Diabetes 1977;26:89-93
Dinkel E, Ertel M, Dittrich M, Peters H, Berres M, Schulte-Wissermann H. Kidney
size in childhood: sonographical charts for kidney length and volume. Pediatr
Radiology 1985;15:38-43
Doi T, Striker LJ, Quaife C, Conti FG, Palmiter R, Behringer R, Brinster R, Striker
GE. Progressive glomerulosclerosis develops in transgenic mice chronically
expressing growth hormone and growth hormone releasing factor but not in those
expressing insulin-like growth factor-I. Am J Pathol 1988; 131:398-403
Doi T, Striker LJ, Kimata K, Peten EP, Yamada Y, Striker GE. Glomerulosclerosis in
mice transgenic for growth hormone. Increased mesangial extracellular matrix is
correlated with kidney mRNA level. J Exp Med 1991;173:1287-1290
Drachman R, Schlesinger M, Shapira H, Drukker A. The immune status of uraemic
children/adolescents with chronic renal failure and renal replacement therapy. Pediatr
Nephrol 1989;3:305-308
Duquessnoy RJ. Immunodeficiency of the thymus-dependent system of the Ames
dwarfmouse. J Immunol 1972;108:1578-1589
Edwards CK III, Ghiassudin SM, Schepper JM, Yunger LM, Kelley KW. A newly
defined property of somatotropin: priming ofmacrophages for production of
superoxide anion. Science 1988;239:769-771
Ernst M, Froesch ER. Growth hormone dependent stimulation of osteoblast-cells in
serum-free culture via local synthesis of insulin-like growth factor-I. Biochem Biophys
Res Commun 1988;151:142-147
Eshet R, Manheimer S, Chobsieng P, Laron Z. Human growth hormone receptors in
human circulating lymphocytes. Horm Metab Resl975;7:352-353
298
Ettenger RB, Rosenthal JT, Marik J, Grimm PC, Nelson P, Malekzadeh MH, Fine
RN. Long-term results with cyclosporin immunosuppression in paediatric cadaver
renal transplantation. Transplant Proc 1991;23:1011-1012
Etzioni A. Immune function in growth hormone-deficient children treated with
biosynthetic growth hormone. ActaPaediatr Scand 1988;77:169-170
Fagin JA, Melmed S. Relative increase in insulin-like growth factor I messenger
ribonucleic acid levels in compensatory renal hypertrophy. Endocrinology 1987;
120:718-724
Fabris N, Pierpaoli W, Sorkin E. Hormone and immunological capacity, III. The
immunodeficiency disease of the hypopituitary Snell-Bagg dwarfmouse. Clin Exp
Immunol 1971;9:209-225
Fennell RS, Van Deusen J, RileyWL. Steroid-induced diabetes in paediatric renal
transplants. Int J Pediatr Nephrol 1983;4:103-107
Fennell RS, Orak JK, Hudson T, Garin EH, Iravani A, Van Deusen WJ, Howard R,
PfaffWW, Walker RD, Richard GA. Growth in children with various therapies for
end-stage renal disease. Am J Dis Child 1984;138:28-31
Fine RN, Mehls O. CAPD/CCPD in children: four years' experience. Kidney Int
1986;30(suppl):S7-S10
Fine RN Ettenger RB. Renal transplantation in children. In Morris PJ, ed. Kidney
transplantation: principles and practice. 3rd ed. Philadelphia: WB Saunders,
1988:635-691
Fine RN, Pyke-Grimm K, Nelson PA, Boechat MI, Lippe BH, Yadin O, Kamil E.
Recombinant human growth hormone treatment of children with chronic renal failure:
long-term (1- to 3-year) outcome. Pediatr Nephrol 1991a;5:477-481
Fine RN, Yadin O, Nelson PA, Pyke-Grimm K, Boechat MI, Lippe BH, Sherman
BM, Ettenger RB, Kamil E. Recombinant human growth hormone treatment of
children following renal transplantation. Pediatr Nephrol 1991b;5:147-151
Fine RN, Yadin O, Moulten L, Nelson PA, Boechat I, Lippe BH. Extended
recombinant human growth hormone treatment after renal transplantation in children.
J Am Soc Nephrol 1992;2(suppl):S274-S283
Fine RN, Kohaut EC, Brown D, Perlman AJ. Growth after recombinant human
growth hormone treatment in children with chronic renal failure: report of a
multicentre randomised double-blind placebo-controlled study. J Pediatr 1994;
124:374-382
299
Fine RN, Attie KM, Kuntze J, Brown DF, Kohaut EC. Recombinant human growth
hormone in infants and young children with chronic renal insufficiency. Pediatr
Nephrol 1995;9:451-457
Fine RN, Brown D, Kuntze J, Wooster P, Kohaut E for the Genentech Cooperative
Study Group. Growth after discontinuation of recombinant human growth hormone
therapy in children with chronic renal insufficiency. J Pediatr 1996a; 129:883-891
Fine RN, Kohaut E, Brown D, Kuntze J, Attie KM. Long-term treatment of growth
retarded children with chronic renal insufficiency, with recombinant human growth
hormone. Kidney Int 1996b;49:781-785
Finkelstein JS, Neer RM, Biller BM, Crawford JD, Klibanski A. Osteopenia in men
with a history of delayed puberty. N Engl J Med 1992;326:600-604
Fleisher TA, White RM, Broder S, Nissley PS, Blaese RM, Mulvihill JJ, Olive G,
Waldmann TA. X-linked hypogammaglobulinaemia and isolated growth hormone
deficiency. N Engl J Med 1980;302:1429-1434
Flyvbjerg A, Kessle U, Dorka B, Funk B, Orskov H, Kiess W. Transient increase in
renal insulin-like growth factor binding proteins during initial kidney hypertrophy in
experimental diabetes in rats. Diabetologia 1992;35:589-593
Fried L, Hutchison A, Stegmayr B, Prichard S, Bargman JM. Recommendations for
the treatment of lipid disorders in patients on peritoneal dialysis. Perit Dial Int
1999;19:7-16
Frystyk J, Dinesen B, and Orskov H. Non-competitve time resolving
immunofluorimetric assay for determination of human insulin-like growth factor I and
II. Growth Regulation 1995;5:47-62
Gargosky SE, Pham HM, Wilson KF, Liu F, Giudice LC, Rosenfeld RG.
Measurement and characterization of insulin-like growth factor binding protein-3 in
human biological fluids: discrepancies between radioimmunoassay and ligand blotting.
Endocrinology 1992;131:3051-3060
Geffner ME, Bersch N, Lippe BM, Rosenfeld RG, Hintz RL, Golde DW. Growth
hormone mediates the growth of T-lymphoblast cell lines via locally generated insulin¬
like growth factor I. J Clin Endocrinol Metab 1990;71:464-469
Gelato MC. Growth hormone-insulin-like growth factor I and immune function.
Trends Endocrinol Metab 1993;4:106-110
Gershberg H, Heinemann HO, StumpfHH. Renal function studies and autopsy report
in a patient with gigantism and acromegaly. J Clin Endocrinol Metab 1957; 17:377-
385
300
Gin H, Combe C, Rigalleau V, Delafaye C, Apacicio M, Aubertin J. Effects of low-
protein, low phosphorus diet on metabolic insulin clearance in patients with chronic
renal failure. Am J Clin Nutr 1994;59:663-666
Glaser NS, Shirali AC, Styne Dm, Jones KL. Acid-base homeostasis in children with
growth hormone deficiency. Pediatrics 1998;102:1407-1414
Golde DW, Bersch N, Li CH. Growth hormone: species specific stimulation of
erythropoiesis in vitro. Science 1977;196:1112-1113
Green WH, Campbell M, David R. Psychosocial dwarfism: critical review of the
evidence. J Am Acad Psychiatry 1984;23:39-48
Grushkin CM, Fine RN. Growth in children following renal transplantation. Am J Dis
Child 1973;125:514-516
Guest G, Broyer M. Growth after renal transplantation: correlation with
immunosuppressive therapy. Pediatr Nephrol 1991;5:143-146
Guest G, Berard E, Crosnier H, Chevallier T, Rappaport R, Broyer M. Effects of
growth hormone in short children after renal transplantation. Pediatr Nephrol 1998;
12:437-446
Guidice LC, Farrell EM, Pham H, Lamson G, Rosenfeld RG. Insulin-like growth
binding proteins in maternal serum throughout gestation and in the puerperium:
effects of a pregnancy-associated serum protease activity. J Clin Endocrinol Metab
1990;71:806-816
Guler HP, Eckardt KU, Zapf J, Bauer C, Froesch ER. Insulin-like growth factor I
increases glomerular filtration rate and renal plasma flow in man. Acta Endocrinol
1989;121:101-106
Gupta D, Fikrig SM, Noval MS. Immunological studies in patients with isolated
growth hormone deficiency. Clin Exp Immunol 1983;54:87-90
Guy JR, Day AL, Glaser JS. Pseudotumour cerebri in chronic renal failure. Neurology
1987;37(suppl 1):289 abstract
Gyssels A, Van Dyck M, Proesmans W, Eeckels R. Recombinant human growth
hormone (rhGH) improves bone mineral content (BMC) and bone mineral density
(BMD) in children with chronic renal failure (CRF). Pediatr Nephrol 2000; 14:
CI03 abstract
Haffner D, Zacharewicz S, Mehls O, Heinrich U, Ritz E. The acute effect of growth
hormone on GFR is obliterated in chronic renal failure. Clin Nephrol 1989;32:266-269
301
Haffner D, Wuhl E, Schaefer F, Nissel R, TonshofFB, Mehls O. Factors predictive of
the short- and long-term efficiacy of growth hormone treatment in prepubertal
children with chronic renal failure. The German Study Group for Growth Hormone
Treatment in Chronic renal failure. J Am Soc Nephrol 1998a;9:1899-1907
Haffner D, Nissel R, Wuhl E, Schaefer F, BettendorfM, TonshoffB, Mehls O and
members of the German Study Group for Growth Hormone Treatment in Chronic
renal failure. Metabolic effects of long-term growth hormone treatment in prepubertal
children with chronic renal failure and after renal transplantation. Pediatr Res 1998b;
43:209-215
Hammerman MR, Rogers SA. Distribution of IGF receptors in the plasma membrane
of proximal tubular cells. Am J Physiol 1986;253:F841-F847
Hammerman MR. The growth-hormone-insulin-like growth factor axis in the kidney.
Am J Physiol 1989;257:F503-F514
Hammerman MR. The growth hormone-insulin-like growth factor axis in the kidney
re-visited. Nephrol Dial Transplant 1999;14:1853-1860
Hanna JD, Challa A, Chan JCM, Han VKM. Insulin-like growth factor-I gene
expression in the tibial epiphyseal growth plate of the acidotic and nutritionally limited
rat. Pediatr Res 1995;37:363A abstract
Hardouin S, Hossenlopp P, Segovia B, Seurin D, Portolan G, Lassarre C, Binoux M.
Heterogeneity of insulin-like growth factor binding proteins and relationships between
structure and affinity. I. Circulating forms in man. Eur J Biochem 1987; 170: 121-132
Haymond MW, Karl I, Weldon VV, Pagliara AS. The role of growth hormone and
cortisone on glucose and gluconeogenic substrate regulation in fasted hypopituitary
children. J Clin Endocrinol Metab 1976;42:846-856
Heaton A, Taylor R, Johnson D, Wilkinson R, Alberti K. Hepatic and peripheral
insulin action in chronic renal failure before and during continuous ambulatory
peritoneal dialysis. Clin Sci 1989;77:383-388
Hindmarsh PC, Bridges NA, Brook CGD. Wider implications for treatment with
biosynthetic human growth hormone in children. Clin Endocrinol 1991;34:417-427
Hirschberg R, Rabb H, Begamo R, Kopple JD. The delayed effect of growth hormone
on renal function in humans. Kidney Int 1989;35:865-870
Hirschberg R, Kopple JD, Blantz RC, Tucker BJ. Effects of recombinant human
insulin-like growth factor I on glomerular dynamics in the rat. J Clin Invest 1991 ;87:
1200-1206
302
Hirschberg R, Brunori G, Kopple JD, Guler H-P. Effects of insulin-like growth factor
I on renal function in normal men. Kidney Int 1993;43:387-397
Hodson EM, Brown AS, Roy LP, Rosenberg AR. Insulin-like growth factor-I,
growth hormone-dependent insulin-like growth factor-binding protein and growth in
children with chronic renal failure. Pediatr Nephrol 1992;6:433-438
Hokken-Koelega ACS, Stijnen T, de Muinck Keizer-Schrama SMPF, Wit JM, Wolff
ED, de Jong MCJW, Donckerwolcke RA, Abbad NCB, Bot A, Blum WF, Drop SLS.
Placebo-controlled, double-blind, cross-over trial of growth hormone treatment in
prepubertal children with chronic renal failure. Lancet 1991;338:585-590
Hokken-Koelega ACS, van Zaal MAE, van Bergen W, de Ridder MAJ, Stijnen T,
WolffED, de Jong RCJW, Donckerwolcke RA, de Muinck Keizer-Schrama SMPF,
Drop SLS. Final height and its predictive factors after renal transplantation in
childhood. PaediatrRes 1994a;35:323-328
Hokken-Koelega ACS, van Zaal MAE, de Ridder MAJ, WolffED, de Jong RCJW,
Donckerwolcke RA, de Muinck Keizer-Schrama SMPF, Drop SLS. Growth after
renal transplantation in prepubertal children: impact of various treatment modalities.
PaediatrRes 1994b;35:367-371
Hokken-Koelega ACS, Stijnen T, de Jong MCJW, Donckerwolcke RA, de Muinck
Keizer-Schrama SMPF, Blum WF, Drop SLS. Double-blind trial comparing the
effects of two doses of growth hormone in prepubertal patients with chronic renal
insufficiency. J Clin Endocrinol Metab 1994c;79:1185-1190
Hokken-Koelega ACS, Stijnen T, de Ridder MAJ, de Muinck Keizer-Schrama SMPF,
WolflfED, de Jong MCJW, Donckerwolcke RA, Groothoflf, Blum WF, Drop SLS.
Growth hormone treatment in growth-retarded adolescents after renal transplantation.
Lancet 1994d;343:1313-1317
Hokken-Koelega ACS, Stijnen T, de Jong MCJW, Donckerwolcke RA, Groothoflf
JW, WolffED, BlumWF, de Muinck Keizer-Schrama SMPF, Drop SLS. A placebo-
controlled double-blind trial of growth hormone treatment in prepubertal children with
renal allografts. Kidney Int 1996;49(Suppl53):S128-134
Holliday MA. Calorie intake and growth in uraemia. Kidney Int 1975;7: S73-S78
Holly JMP, Coulson VJ, Davies SC, Cotterill AM et al. The presence of a circulating
enzyme which specifically modifies the main carrier protein for insulin-like growth
factors (IGFs) in GH-deficient and GH-resistant subjects. J Endocrinol 1993; 131
(suppl):Abstract 8
Holmes SJ, Economou G, Whitehouse RW, Adams JE, Shalet SM. Reduced bone
mineral density in patients with adult onset growth hormone deficiency. J Clin
Endocrinol Metab 1994;78:669-674
303
Hopwood NJ, Forsman PJ, Kenny FM, Drash AL. Hypoglycaemia in hypopituitary
children. Am J Dis Child 1975; 129:918
Hossenlopp P, Seurin D, Segovia-Quinson B, Hardouin S, Binoux M. Analysis of
serum insulin-like growth factor binding proteins using Western blotting: Use of the
method for titration of the binding proteins and competitive binding studies. Anal
Biochem 1986;154:138-143
Hossenlopp P, Segovia B, Lassarre C, Roghani M, Bredon M, Binoux M. Evidence
of enzymatic degradation of insulin-like growth factor-binding proteins in the 15OK
complex during pregnancy. J Clin Endocrinol Metab 1990;71:797-805
Hruska K. Pathophysiology of renal osteodystrophy. Pediatr Nephrol 200; 14:636-640
Hyams JS, Carey DE, Leichtner AM, Goldberg BD. Type I procollagen as a
biochemical marker of growth in children with inflammatory bowel disease. J Pediatr
1986;109:619-624
Ikkos D, Ljunggren H, Luft R. Glomerular filtration rate and renal plasma flow in
acromegaly. Acta Endocrinol 1956;21:226-236
Ingelfinger JR, Grupe WE, Harmon W, Fernbach SK, Levey RH. Growth acceleration
following renal transplantation in children less than seven years of age. Pediatrics
1981;68:255-259
Ingulli E, Singh A, Moazami S, Tejani A. Prednisolone inhibits the efficacy of
recombinant human growth hormone in paediatric renal transplant recipients. Kidney
Int 1993;44(suppl):S65-S70
Isaksson OGP, Jansson JO, Gause JAM. Growth hormone stimulates longitudinal
bone growth directly. Science 1982;216:1237-1239
Isaksson OGP, Lindahl A, Nilsson A, Isgaard J. Mechanism of the stimulatory effect
of growth hormone on longitudinal bone growth. Endocr Rev 1987;8:426-438
Jabs K, Van Dop C, Harmon WE. Growth hormone treatment of growth failure
among children with renal transplants. Kidney Int 1993;44(suppl 43):S71-S75
Janssen F, van Damme Lambaerts R, Van Dyck M, Hall M, Proesmans W, Goos G,
Kinneart P. Effects of recombinant human growth hormone on graft function in renal-
transplanted children and adolescents: the three-year experience of a Belgian study
group. Transplantation Proc 1993;25:1049-1050
Janssen F, van Damme-Lambaerts R, Van Dyck M, Hall M, Schurmans T, Herman J,
Hooghe L, Van Damme B. Impact of growth hormone treatment on a Belgian
population of short children with renal allografts. Pediatr Transplant 1997; 1:190-196
304
Johansson G, Sietniks A, Janssens F, Proesmans W, Vanderschueren-Lodeweyckx M,
Holmberg C, Sipila I, Broyer M, Rappaport R, Albertsson-Wikland K, Berg U, Jodal
U, Rees L, Rigden SPA, Preece MA . Recombinant human growth hormone
treatment in short children with chronic renal disease, before transplantation or with
functioning renal transplants: an interim report on five European studies. Acta
Paediatr Scand 1990;370(suppl):36-42
Jones R, Rigden SPA, Barratt TM, Chantler C. The effect of chronic renal failure in
infancy on growth, nutritional status and body composition. Pediatr Res 1982;16:784-
791
Joss E, Zuppinger K, Schwartz HP, Roten H. Final height of patients with pituitary
growth failure and changes in growth variables after long term hormonal therapy.
Pediatr Res 1983;17:676-679
Kari JA, Donald AE, Vallance DT, Bruckdorfer KR, Leone A, Mullen MJ, Bunce T,
Dorado B, Deanfield JE, Rees L. Physiology and biochemistry of endothelial function
in children with chronic renal failure. Kidney Int 1997;52:468-472
Karlander S, Vranic M, Efendic S. Increased glucose turnover and glucose cycling in
acromegalic patients with normal glucose tolerance. Diabetologia 1986;29:778-783
Kasiske BL, Keane WF. Causes, consequences, and treatment of hyperlipidaemia in
patients with renal disease. In: Andreucci VE, Fine LG, eds. 1991 International
Yearbook ofNephrology. Kluwer Academic, Boston; 1991:179-196
Kassem M, Mosekilde L, Eriksen EF. Growth hormone stimulates proliferation of
normal human bone marrow stromal osteoblast precursor cells in vitro. Growth Regul
1994;4:131-135
Kawaguchi H, Katsumi I, Mori H, Hayashi Y, Makino S. Renal pathology in rats
bearing tumour-secreting growth hormone. Pediatr Nephrol 1991;5:533-538
Kelley KW. The role of growth hormone in modulation of the immune response. Ann
NY Acad Sci 1990;594:95-103
Kiess W, Holtmann H, Butenandt O, Eife R. Modulation of lymphoproliferation by
human growth hormone. Eur J Pediatr 1983:140;47-50
Kiess W, Butenandt O. Specific growth hormone receptors on human peripheral
mononuclear cells: expression, identification and characterisation. J Clin Endocrinol
Metab 1985;60:740-746
Kiess W, Malowzowski S, Gelato M, Butenandt O, Doerr H, Crisp B, Eisl E, Maluish
A, Belohradsky BH. Lymphocyte subset distribution and natural killer cell activity in
growth hormone deficiency before and during short-term treatment with growth
hormone releasing hormone. Clin Immunol Immunopathol 1988;48:85-94
305
Klare B, Strom TM, Hahn H, Engelsberger I, Meusel E. Remarkable long-term
prognosis and excellent growth in kidney transplant children under cyclosporin
monotherapy. Transplant Proc 1991;23:1013-1017
Kleinknecht C, Broyer M, Gagnadoux M-F, Marti-Henneberg C, Dartois A-M,
Kermanagh C, Pouliquen M, Degoulet P, Usberti M, Roy MP. Growth in children
treated with longterm dialysis. A study of 76 patients. Adv Nephrol 1980;9:133-163
Kleinknecht C, Broyer M, Hout D, Marti-Henneberg C, Datois A-M. Growth and
development of nondialyzed children with chronic renal failure. Kidney Int 1983;
24(suppl):S40-47
Koch VH, Lippe BM, Nelson PA, Boechat MI, Sherman BM, Fine RN. Accelerated
growth after recombinant human growth hormone treatment of children with chronic
renal failure. J Pediatr 1989; 115:365-371
Kohaut EC, Whelchel J, Waldo FB, Diethelm AG. Aggressive therapy of infants with
renal failure. Pediatr Nephrol 1987;1:150-153
Koller EA, Stadel BV, Malozowski SN. Papilloedema in 15 renally compromised
patients treated with growth hormone. Pediatr Nephrol 1997; 11:451-454
Kurtz A, Zapf J, Eckhardt K-U, demons G, Froesch ER, Bauer C. Insulin-like
growth factor I stimulates erythropoiesis in hypophysectomised rats. Proc Natl Acad
Sci USA 1988;85:7825-7829
Lajara R, Rotwein P, Bortz JD, Hansen VA, Sadow JL, Betts CR, Rogers SA,
Hammerman MR. Dual regulation of insulin-like growth factor I expression during
renal hypertrophy. Am J Physiol 1989;257:F252-F261
Lam CN, Arneil GC. Long-term dwarfing effects of corticosteroid treatment for
childhood nephrosis. Arch Dis Child 1968;43:589-594
Lamson G, Giudice LC, Rosenfeld RG. A simple assay for proteolysis of IGFBP-3. J
Clin Endocrinol Metab 1991;72:1391-1393
Lanes R, Gunczler P, Orta N, Bosquez M, Scovino R, Dominguez L, Esaa S,
Weisinger JR. Changes in bone mineral density, growth velocity and renal function of
prepubertal uremic children during growth hormone treatment. Horm Res 1996;46:
263-268
Ledermann SE, Randall M, Shaw V, Trompeter RS. Enteral nutrition in the infant and
young child. Pediatr Nephrol 1994;8:C35 abstract
Ledermann SE, Shaw V, Trompeter RS. Long-term enteral nutrition in infants and
young children with chronic renal failure. Pediatr Nephrol 1999;13:870-875
306
Ledermann SE, Scanes ME, Fernando ON, Duffy PG, Madden SJ, Trompeter RS.
Long-term outcome of peritoneal dialysis in infants. J Pediatr 2000;136:24-29
Lee D-Y, Cohen P, Krensky AM, Rosenfeld RG, Yorgin PD. Insulin-like growth
factor binding protein-3 protease activity in the urine of children with chronic renal
failure. Pediatr Nephrol 1993;7:416-423
Lee PDK, Hintz RL, Sperry JB, Baxter RC, Powell DR. IGF binding proteins in
growth-retarded children with chronic renal failure. Pediatr Res 1989;26:308-315
Lee PDK, Conover CA, Powell DR. Regulation and function of insulin-like growth
factor binding protein 1. Proc Soc Exp Biol Med 1993;204:4-29
Lesage C, Walker J, Landier F, Chatelain P, Chaussain JL, Bougneres PF. Near
normalization of adolescent height with growth hormone therapy in very short
children without growth hormone deficiency. J Pediatr 1991; 119:29-34
Lindahl A, Isgaard J, Nilsson A, Isaksson OGP. Growth hormone potentiates colony
formation of epiphyseal chondrocytes in suspension culture. Endocrinology 1986; 118:
1843-1848
Lindholm A, Albrechtsen D, Frodin L, Tufveson G, Persson NH, Lundgren G.
Ischaemic heart disease: a major cause of death and graft loss after renal
transplantation in Scandinavia. Transplantation 1995;60:451-457
Linne T, Bang P, Karlsson E, Ritzen M. Recombinant human growth hormone
treatment gives improved growth also in uremic children below two years of age.
Pediatr Nephrol 1992;6:C 118 abstract
Linne T, Bang P, Karlsson E, Ritzen M. Six-year follow-up of two growth-retarded
uraemic boys in whom growth hormone treatment was initiated before 2 years of age.
Acta Paediatr 1996;417(suppl):130 abstract
Lippe B, Fine RN, Koch VH, Sherman BM. Accelerated growth following treatment
of children with chronic renal failure with recombinant human growth hormone
(Somatrem): a preliminary report. Acta Paediatr Scand 1988;343(suppl): 127-131
Lu PW, Cowell CT, Moore B, Craighead A, Howman-Giles R, Briody J. Spine bone
mineral density and growth hormone treatment. Acta Paediatr Suppl 1992;383:95
abstract
McCarthy TL, Centrella M, Canalis E. Cortisol inhibits the synthesis of insulin-like
growth factor -I in skeletal cells. Endocrinology 1990;126:1569-1575
McGraw ME, Haka-Ikse K. Neurologic-developmental sequelae of chronic renal
failure in infancy. J Pediatr 1985;106:579-583
307
McSherry E. Acidosis and growth in nonuraemic renal disease. Kidney Int 1978;
14:349-354
Mak RHK, Haycock GB, Chantler C. Glucose intolerance in children with chronic
renal failure. Kidney Int 1983;24(suppl):22-26
Mak RHK. The influence of hyperparathyroidism on glucose metabolism in uraemia. J
Endocrinol Metab 1985;60:229
Mak RHK, DeFronzo RA. Glucose and insulin metabolism in uraemia. Nephron
1992;61:377-382
Mak RHK. Effect of recombinant human erythropoietin on insulin, amino acid, and
lipid metabolism in uraemia. J. Pediatr 1996;129:97-104
Malluche HM, Faugere M-C, Renal osteodystrophy. N Engl J Med 1989;5:317-319
Malozowski S, Tanner LA, Wysowski D, Flemming GA. Growth hormone, insulin¬
like growth factor-I, and benign intracranial hypertension. N Engl J Med 1993;
329:665-666
Malozowski S, Tanner LA, Wysowski D, Flemming GA, Stadel BV. Benign
intracranial hypertension in children with growth hormone deficiency treated with
growth hormone. J Pediatr 1995;126:996-999
Maor G, Hochberg Z, von der Mark K, Heinegard D, Silberman MM. Human growth
hormone enhances chondrogenesis and osteogenesis in a tissue culture system of
chondroprogenitor cells. Endocrinology 1989;125:1239-1245
Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in girls. Arch
Dis Child 1969;44:291-303
Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch
Dis Child 1970;45:13-23
Maxwell H, Maheshwari HG, Canosa I, Buchanan CR, Norman W, Rees L. Children
with chronic renal failure have low serum growth hormone binding protein. Pediatr
Nephrol 1991 ;5:C53 abstract
Maxwell H, Nair DR, Rees L. Comparison of glomerular filtration rate as measured
by constant infusion of inulin with and without urine collections. Pediatr Nephrol
1994;8(suppl):C58 abstract
Maxwell H, Nair DR, Dalton RN, Rigden SPA, Rees L. Differential effects of
recombinant human growth hormone on glomerular filtration rate and effective renal
plasma flow in chronic renal failure. Pediatr Nephrol 1995;9:458-463
308
Maxwell H, Rees L on behalf of the British Association for Paediatric Nephrology.
Recombinant human growth hormone treatment in infants with chronic renal failure.
Arch Dis Child 1996a;74:40-43
Maxwell H, Dalton RN, Nair DR, Turner C, Saunders AJS, Rigden SPA, Rees L. The
effects of recombinant human growth hormone on renal function in children with renal
transplants. J Pediatr 1996b;128:177-183
Maxwell H. Recombinant human growth hormone treatment of infants and young
children with chronic renal failure. Br J Clin Pract 1996c;S65:64-65
Maxwell H. The use of recombinant human growth hormone in pubertal patients with
renal disease. Br J Clin Pract 1996d;S65:10-11
Maxwell H, Haffner D, Rees L. Catch up growth following renal transplantation in
children of pubertal age. J Pediatr 1998a; 133:43 5-440
Maxwell H, Rees L on behalf of the British Association for Paediatric Nephrology.
Controlled trial of recombinant human growth hormone in prepubertal and pubertal
renal transplant recipients. Arch Dis Child 1998b;79:481-487
Maxwell H, Rees L, Amlot P. Growth hormone and markers of immune function in
children with renal transplants. Pediatr Nephrol 2000;14:473-475
Mehls O, Ritz E, Krempien B, Gilli G, Link K, Willich E, Scharer K. Slipped
epiphyses in renal osteodystrophy. Arch Dis Child 1975;50:545-554
Mehls O, Ritz E, Gilli G, Wangdak T, Krempien B. Effect ofvitamin D on growth in
experimental uraemia. Am J Clin Nutr 1978;31:1927-1931
Mehls O, Ritz E. Skeletal growth in experimental uraemia. Kidney Int 1983;
15(suppl):S33-S62
Mehls O, TonshoffB, Blum WF, Heinrich U, Seidel C. Growth hormone and insulin¬
like growth factor I in chronic renal failure; pathophysiology and rationale for growth
hormone treatment. Acta Pediatr Scand 1990;370(suppl):28-34
Merchaw S, Tatarsky J, Hochberg Z. Enhancement of human granulopoiesis in vitro
by biosynthetic insulin-like growth factor 1/ somatomedin C and human growth
hormone. J Clin Invest 1988;81:791-797
Miell JM, Taylor AM, Jones J, Holly JM, Gaillard RC, Pralong FR, Ross RJ, Blum
WF. The effects of dexamethasone treatment on immunoreactive and bioactive
insulin-like growth factors (IGFs) and IGF binding proteins in normal male
volunteers. J Endocrinol 1993;136:525-533
309
Miller SB, Hansen VA, Hammerman MR. Effects of growth hormone and IGF-I on
renal function in rats with normal and reduced renal mass. Am J Physiol 1990;259:
F747-F751
Monafo V, Maghnie M, Terracciano L, Valtorta A, Massa M, Severi F. X-linked
agammaglobulinaemia and isolated growth hormone deficiency. Acta Paediatr Scand
1991;80:563-566
Murphy WJ, Durum SK, Anver MR, Longo DL. Immunologic and haematologic
effects of neuroendocrine hormones - studies on DW/J dwarfmice. J Immunol
1992;148:3799-3805
Najarian JS, Frey DJ, Matas AJ, Gillingham KJ, So SKS, Cook M, Chavers B, Mauer
SM, Nevins TE. Renal transplantation in infants. Ann Surg 1990;212:353-365
Nash MA, Torrado AD, Greifer I, Spitzer A, Edelman CM. Renal tubular acidosis in
infants and children. J Pediatr 1972;80:738-748
Neilsen PK, Feldt-Rasmussen U, Olgaard K. A direct effect in vitro of phosphate on
PTH release from bovine parathyroid tissue slices but not from dispersed parathyroid
cells. Nephrol Dial Transplant 1996;11:1762-1768
Nevins TE. Transplantation in infants less than 1 year of age. Pediatr Nephrol 1987; 1:
154-156
Nilsson A, Carlsson B, Isgaard J, Isaksson OGP, Rymo L. Regulation by GH of
insulin-like growth factor-I mRNA expression in rat epiphyseal growth plate as
studied with in-situ hybdridization. J Endocrinol 1990;125:67-74
Nilsson A, Swolin D, Enerback S, Ohlsson C. Epression of functional growth
hormone receptors in cultured human osteoblast-like cells. J Clin Endocrinol Metab
1995;80: 3483-3488
Oda H, Keane WF. Lipid abnormalities in end stage renal disease. Nephrol Dial
Transplant 1998;13(suppl l):45-49
Offner G, Hoyer PF, Juppner H, Krohn HP, Brodehl J. Somatic growth after kidney
transplantation. Am J Dis Child 1987;141:541-546
Offner G, Aschendorff C, Brohedl J. Growth after renal transplantation: an update.
Pediatr Nephrol 1991;5:472-476
Ohlsson C, Bengtsson B-A, Isaksson OG, Andreassen TT, Slootweg MC. Growth
hormone and bone. Endocr Rev 1998;19:55-79
310
Ordonez FA, Santos F, Martinez V, Garcia E, Fernandez P, Rodriguez J, Fernandez
M, Alvarez J, Ferrando S. Resistance to growth hormone and insulin-like growth
factor-I in acidotic rats. Pediatr Nephrol 2000;14:720-725
O'Shea MH, Miller SB, Hammerman MR. Effects of IGF-I on renal function in
patients with chronic renal failure. Am J Physiol 1993;264:F917-F922
Pantelakis SN, Sinaniotis CA, Sbirakis S, Ikkos D, Doxiadis SA. Night and day
growth hormone levels during treatment with corticosteroids and corticotrophin. Arch
Dis Child 1972;47:605-608
Parving HH, Noer I, Mogensen CE, Svendsen PA. Kidney function in normal man
during short-term growth hormone infusion. Acta Endocrinol 1978;89:796-800
Pennisi AJ, Heiser ET, Mickey M, Lipsey A, Malekzadeh MH, Fine RN
Hyperlipidaemia in pediatric haemodialysis and renal transplant patients. Am J Dis
Child 1976;130:957-961
Pennisi AJ, Costin G, Phillips LS, Uittenbogaart C, Ettenger RB, Malekzadeh MH,
Fine RN. Linear growth in long-term renal allograft recipients. Clin Nephrol
1977;8:415-421
Petersen BH, C, Moore WV. Effect of treatment with biosynthetic human growth
hormone (GH) on peripheral blood lymphocyte populations and function in growth
hormone-deficient children. J Clin Endocrinol Metab 1990;70:1756-1760
Phadke A, MacKinnon K, Dossetor J. Male infertility in uraemia: restoration by renal
allografts. Can Med Assoc J 1970;102:607-608
Phillips LS, Kopple JD. Circulating somatomedin activity and sulphate levels in adults
with normal and impaired kidney function. Metabolism 1981;30:1091-1095
Phillips LS, Fusco AC, Unterman TG, Delgreco F. Somatomedin inhibitor in uraemia.
J Clin Endocrinol Metab 1984;59:764-772
Pierpaoli W, Sorkin E. Hormones and immunological capacity. I. Effect of
heterologous anti-growth hormone (ASTH) antiserum on thymus and peripheral
lymphatic tissue in mice. J Immunol 1968;101:1036-1043
Polinsky MS, Kaiser BA, Stover JB, Frankenfield M, Baluarte HJ. Neurologic
development of children with severe chronic renal failure from infancy. Pediatr
Nephrol 1987;1:157-165
Polito C, Greco L, Totino SF, Oporto MR, La Manna A, Strano CG, Di Toro R.
Statural growth of children with chronic renal failure on conservative treatment. Acta
Paediatr Scand 1987;76:97-102
311
Potter DE, Greifer I. Statural growth of children with renal disease. Kidney Int
1978;14:334-339
Potter DE, Luis ES, Wipfler JE, Portale AA. Comparison of continuous ambulatory
peritoneal dialysis and haemodialysis in children. Kidney Int 1986;30(suppl):Sl 1-S14
Powell DR, Rosenfeld RG, Baker BK, Liu F, Hintz RL. Serum somatomedin levels in
adults with chronic renal failure: the importance ofmeasuring insulin-like growth
factor I (IGF-I) and IGF-II in acid-chromatographed uraemic serum. J Clin
Endocrinol Metab 1986;63:1186-1192
Powell DR, Rosenfeld RG, Sperry JB, Baker BK, Hintz RL. Serum concentrations of
insulin-like growth factor (IGF)-l, IGF-2 and unsaturated somatomedin carrier
proteins in children with chronic renal failure. Am J Kid Dis 1987;10:287-292
Powell DR, Liu F, Baker BK, Lee PDK, Belsha CW, Brewer E, Hintz RL.
Characterization of insulin-like growth factor binding protein-3 in chronic renal failure
serum. Pediatr Res 1993;33:136-143
Powell DR, Liu F, Baker BK, Hintz RL, Lee PDK, Durham SK, Brewer ED, Frane
JW, Watkins SL, Hogg RJ for the Southwest Pediatric Nephrology Study Group.
Modulation of growth factors by growth hormone in children with chronic renal
failure. Kidney Int 1997a;51:1970-1979
Powell DR, Liu F, Baker BK, Hintz RL, Durham SK, Brewer ED, Frane JW,
TonshoffB, Mehls O, Wingen AM, Watkins SL, Hogg RJ, Lee PD. Insulin-like
growth factor binding protein-6 levels are elevated in serum of children with chronic
renal failure: a report of the Southwest Pediatric Nephrology Study Group. J Clin
Endocrinol Metab 1997b;82:2978-2984
Powell DR, Durham SK, Brewer ED, Frane JW, Watkins SL, Hogg RJ, Mohan S.
Effects of chronic renal failure and growth hormone on serum levels of insulin-like
growth factor binding protein-4 (IGFBP-4) and IGFBP-5 in children: a report of the
Southwest Pediatric Nephrology Study Group. J Clin Endocrinol Metab 1999;84:596-
601
Proyer H, Thelander H. Abnormally small head size and intellect in children. J Pediatr
1968;73:593-598
Quaife CJ, Mathews LS, Pinkert CA, Hammer RE, Brinster RL, Palmiter RD.
Histopathology associated with elevated levels of growth hormone and insulin-like
growth factor I in transgenic mice. Endocrinology 1989;124:40-48
Querfeld U, Salusky IB, Nelson P, Foley J, Fine RN. Hyperlipidemia in pediatric
patients undergoing peritoneal dialysis. Pediatr Nephrol 1988;2:447-452
312
Querfeld U, Le BoeufRC, Salusky IB, Nelson P, Laidlaw S, Fine RN. Lipoproteins in
children treated with continuous peritoneal dialysis. Pediatr Res 1991 ;29:155-159
Querfeld U. Disturbances of lipid metabolism in children with chronic renal failure.
Pediatr Nephrol 1993;7:749-757
Rabinowitz D, Klassen GA, Zierler KL. Effect of human growth hormone on muscle
and adipose tissue metabolism of the forearm ofman. J Clin Invest 1965;44:51
Ranke MB, Guilbaud O. Growth response in prepubertal children with idiopathic
growth hormone deficiency during the first year of treatment with human growth
hormone. Analysis of the Kabi International Growth Study. Acta Paediatr Scand
1990;S370:122-130
Rapaport R, Oleske J, Ahdieh H, Salomon S, Belfaus C, Denny T. Suppression of
immune function in growth hormone deficient children during treatment with human
growth hormone. J Pediatr 1986; 109: 434-439
Rapaport R, Petersen B, Skuza KA, Heim M, Goldstein S. Immune functions during
treatment of growth hormone-deficient children with biosynthetic human growth
hormone. Clin Pediatr 1991;30:22-27
Reaich D, Channon SM, Scrimgeour CM, Daley SE, Wilkinson R, Goodship THJ.
Correction of acidosis in humans with CRF decreases protein degradation and amino
acid oxidation. Am J Physiol 1993;265:E230-E235
Reed EE, Roy LP, Gaskin KJ, Knight JF. Nutritional intervention and growth in
children with chronic renal failure. J Ren Nutr 1998;8:122-126
Rees L, Greene SA, Adlard P, Jones J, Haycock GB, Rigden SPA, Preece M,
Chantler C. Growth and endocrine function after renal transplantation. Arch Dis Child
1988;63:1326-1332
Rees L, Rigden SPA, Ward GM. Chronic renal failure and growth. Arch Dis Child
1989;64:573-577
Rees L, Rigden SPA, Ward G, Preece MA. Treatment of short stature in renal disease
with recombinant human growth hormone. Arch Dis Child 1990;65:856-860
Rees L, Maxwell H. Factors influencing the response to growth hormone in short
children with chronic renal failure and renal transplants. Pediatr Nephrol 1996a; 10:
337-339
Rees L, Maxwell H. The hypothalamo-pituitary-growth hormone- insulin-like growth
factor axis in children with chronic renal failure. Kidney Int 1996b;49(suppl 53):S109-
S114
313
Rees L, Ward G, Rigden SP. Growth over 10 years following a 1 year trial of growth
hormone therapy. Pediatr Nephrol 2000;14:309-314
Reichel H, Diebert B, Schmidt-Gayk H, Ritz E. Calcium metabolism in early chronic
renal failure. Implications for the pathogenesis of hyperparathyroidism. Nephrol Dial
Transplant 1991;6:162-169
Ritvos O, Ranta T, Julkanen J, Suikkari A-M, Voutilainen R, Bohn H, Rutanen E-M.
Insulin-like growth factor (IGF) binding protein from human decidua inhibits the
binding and biological action of the IGF-I in cultured choriocarcinoma cells.
Endocrinology 1988;122:2150-2157
Rizza RA, Mandarino JL, Gerich JE. Effects ofgrowth hormone on insulin action in
man: Mechanisms of insulin resistance, impaired suppression of glucose production,
and impaired stimulation of glucose utilization. Diabetes 1982;31:
663-669
Rizzoni G, Basso T, Setari M. Growth in children with chronic renal failure on
conservative management. Kidney Int 1984;26:52-58
Rizzoni G, Broyer M, Brunner FP, Brynger, Challah S. Combined report on regular
haemodialysis and transplantation in Europe, 1985. Proc EDTA 1986a;23:55-83
Rizzoni G, Broyer M, Guest G, Fine RN, Holliday MA. Growth retardation in
children with chronic renal disease: scope of the problem. Am J Kid Dis 1986b;7:256-
261
Rizzoni G, Ehrich JHH, Brunner FP, Geerlings W, Fassbinder W, Landais P, Mallick
N, Margreiter R, Raine AEG, Selwood NH, TufVeson G. Combined report on regular
dialysis and transplantation of children in Europe, 1990. Nephrol Dial Transplant
1991 ;6(suppl): 31 -42
Rochiccioli P, Pienkowski C, Bouissou F, Sablayrolles B, Barthe P. Partial
somatropin deficiency in a case of chronic renal insufficiency with renal
transplantation. Efficacy of treatment with human growth hormone. Arch Fr Pediatr
1986;43:1-3
Rodger RSC, Morrison L, Dewar JH, Wilkinson R, Ward MK, Kerr DNS. Loss of
pulsatile luteinising hormone secretion in men with chronic renal failure. Br Med J
1985;291:1598-1600
Roe JH, Epstein JH, Goldstein NP. A photometric method for the determination of
inulin in plasma and urine. J Biol Chem 1949;178:839-845
Rogers SA, Hammerman MR. Growth hormone activates phospholipase C in
proximal tubular basolateral membranes from canine kidney. Proc Natl Acad Sci USA
1989;86:6363-6366
314
Rose GA. Measurement of glomerular filtration rate by inulin clearance without urine
collection. Br Med J 1969;2:91-93
Rosenfeld RG, Pham H, Cohen P, Fielder P, Gargosky SE, Muller H, Nonoshita L,
Oh Y. Insulin-like growth factor binding proteins and their regulation. Acta Paediatr
Suppl 1994;399:154-158
Rotundo A, Nevins TE, Lipton M, Lockman LA, Mauer SM, Michael AF.
Progressive encephalopathy in children with chronic renal insufficiency in infancy.
Kidney Int 1982;21:486-491
Roy S, Arant B. Hypokalaemic metabolic alkalosis in normotensive infants with
elevated plasma renin activity and hyperaldosteronism: role of dietary chloride
deficiency. Pediatrics 1981;67:423-429
Saenger P, Wiedemann E, Schwartz E, Korth-Schutz S, Lewy J, Riggio R, Rubin A,
Stenzel K, New M. Somatomedin and growth after renal transplantation. Pediatr Res
1974;8:163-169
Saenger P, Attie KM, DiMartino-Nardi J, Fine RN and the Genentech Collaborative
Group. Carbohydrate metabolism in children receiving growth hormone for 5 years.
Pediatr Nephrol 1996;10:261-263
Saggese G, Baroncelli GI, Bertelloni S, Cinquanta L, Di Nero G. Effects of long-term
treatment with growth hormone on bone and mineral metabolism in children with
growth hormone deficiency. J Pediatr 1993;122:37-45
Saggese G, Baroncelli GI, Bertelloni S, Barsanti S. The effect of long-term growth
hormone (GH) treatment on bone mineral density in children with growth hormone
deficiency. Role ofGH in the attainment of peak bone mass. J Clin Endocrinol Metab
1996;81:3077-3083
Salomon F, Cuneo RC, Hesp R, Sonksen PH. The effect of treatment with
recombinant human growth hormone on body composition and metabolism in adults
with growth hormone deficiency. N Engl J Med 1989;321:1797-1803
Salomon F, Cuneo RC, Umpleby AM, Sonksen PH. Effect of growth hormone
treatment on glucose metabolism in growth hormone deficiency. Diabetologia 1990;
33:A218
Samaan N, Freeman R. Growth hormone levels in severe renal failure. Metabolism
1970;19:102-113
Schoenle E, Zapf J, Hauri C, Steiner T, Froesch ER. Comparison of in vivo effects of
insulin-like growth factors I and II and of growth hormone in hypophysectomized
rats. Acta Endocrinol 1985;108:167-174
315
Schaefer F, Gilli G, Scharer K. Pubertal growth and final height in chronic renal
failure. In: Scharer K ed. Growth and endocrine changes in adolescents and young
adults with chronic renal failure. Paediatric and adolescent endocrinology. Basel:
Karger, 1989:59-69
Schaefer F, Seidel C, Binding A, Gasser T, Largo RH, Prader A, Scharer K. Pubertal
growth in chronic renal failure. Pediatr Res 1990;28:5-10
Schaefer F, Walther U, Ruder H, Huber W, Marr J, Scharer K. Reduced spermatuna
in adolescent and young adult patients after renal transplantation. Nephrol Dial
Transplant 1991a;6:840
Schaefer F, Andre JL, Krug C et al. Growth and skeletal maturation in dialysed
children treated with rh-erythropoietin - a multicentre study. Pediatr Nephrol
1991b;5:C6 abstract
Schaefer F, Hamill G, Stanhope R, Preece MA, Scharer K. Pulsatile growth hormone
secretion in peripubertal patients with chronic renal failure. J Pediatr 1991c; 119:568-
577
Schaefer F, Mehls O. Endocrine, metabolic and growth disorders. In: Holliday MA,
Barratt TM, Avner ED, Paediatric Nephrology 3rd edition. Baltimore Williams and
Wilkins 1994:1241-1286
Schaefer F, Wuhl E, Haffner D, Mehls O, and the German study group for growth
hormone treatment in chronic renal failure. Stimulation of growth by recombinant
human growth hormone in children undergoing peritoneal or haemodialysis treatment.
AdvPerit Dial 1994;10:321-326
Schaefer F, Haffner D, Wuhl E, Mehls O. Long-term experience with growth
hormone treatment in children with chronic renal failure. Perit Dial Int 1999;
19(suppl2): S467-472
Scharer K, Schaefer F, Trott F, Kassman K, Gilli G. Pubertal development in children
with chronic renal failure. In: Scharer K ed. Growth and endocrine changes in
adolescents and young adults with chronic renal failure. Paediatric and adolescent
endocrinology. Basel: Karger, 1989:151-168
Scharer K. Study Group on Pubertal Development in chronic renal failure. Growth
and development of children with chronic renal failure. Acta Paed Scand 1990;
366(suppl):90-92
Schlechter NL, Russell SM, Spencer EM, Nicoll CS. Evidence suggesting that the
direct growth-promoting effect of growth hormone on cartilage in vivo is mediated by
local production of somatomedin. Proc Natl Acad Sci USA 1986;83:7932-7934
316
Schmitz O. Insulin mediated glucose uptake in non-dialyzed and dialyzed uremic
insulin-dependent diabetic subjects. Diabetes 1985;34:1152-1159
Schoenle E, Zapf T, Foresch ER. Insulin-like growth factor I stimulates growth in
hypophysectomised rats. Nature 1982;296:252-253
Schwartz GJ, Haycock G, Edelman C, Spitzer A. A simple estimate of glomerular
filtration rate in children derived from body length and plasma creatinine. Pediatrics
1976;58:259-263
Schwartz ID, Warady BA. Cadaveric renal allograft rejection after treatment with
recombinant human growth hormone. J Pediatr 1992;121:664-665
Seidel C, Schaefer F, Walther U, Scharer K. The application of knemometry in renal
disease: preliminary observations. Pediatr Nephrol 1991;5:467-471
Sharma AK, Myers TA, Hunninghake DB, Matas AJ, Kashtan CE. Hyperlipidaemia in
long-term survivors of pediatric renal transplantation. Clin Transpl 1994;8:252-257
Sicuro A, Mahlbacher K, Hulter HN, KrapfR. Effect of growth hormone on renal and
systemic acid-base homeostasis in humans. Am J Physiol 1998;274:F650-F657
Silverstein DM, Palmer JA, Polinsky MS, Braas C, Conley SB, Baluarte HJ. Risk
factors for hyperlipidemia in long-term pediatric renal transplant recipients. Pediatr
Nephrol 2000;14:105-110
Simopoulos AP. Growth characteristics in Bartter's syndrome. Nephron 1979;23:130-
135
Simmons JM, Wilson CJ, Potter DE, Holliday MA. Relation of calorie deficiency to
growth failure in children on haemodialysis and the growth response to calorie
supplementation. N Engl J Med 1971;285:653-656
Singh A, Tejani C, Benfield M, Tejani A. Sequential analysis of the lipid profile of
children post renal transplantation. Pediatr Transpl 1998;2:216-223
Smal J, Closset J, Hennen G, De Meyts P. Receptor-binding and down-regulatory
properties of 22 000-M human growth hormone and its natural 20 000-M variant on
IM-9 human lymphocytes. Biochem J 1985;225:283-289
Smith D, DeFronzo RA. Insulin resistance in uraemia is mediated by postbinding
defects. Kidney Int 1982;22:54-62
Smith HW, Finkelstein L, Aliminosa L. The renal clearance of substituted hippuric
acid derivatives and other aromatic acids in dog and man. J Clin Invest 1954;24:388-
404
317
Smith PE. The effect of hypophysectomy upon the involution of the thymus in the rat.
AnatRec 1930;47:119-129
Snow EC, Feldbush TL, Oaks JA. The effect ofgrowth hormone and insulin upon
MLC responses and the generation of cytotoxic lymphocytes. J Immunol 1981; 126:
161-164
So SKS, Chang P-N, Najarian JS, Mauer SM, Simmons RL, Nevins TE. Growth and
development in infants after renal transplantation. J Pediatr 1987;110:343-350
Sonksen PH, Greenwood FC, Ellis JP, Lowy C, Rutherford A, Nabarro JDN.
Changes of carbohydrate tolerance in acromegaly with progress of the disease and in
response to treatment. J Clin Endocrinol Metab 1967;27:1418
Spadoni GL, Rossi P, Ragno W, Galli E, Cianfarani S, Galasso C, Boscherini B.
Immune function in growth hormone-deficient children treated with biosynthetic
growth hormone. Acta Paediatr Scand 1990;80:75-79
Stablein DM, Tejani A. Five-year patient and graft survival in North American
children: a report of the North American Pediatric Renal Transplant Cooperative
Study. Kidney Int 1993;43(suppl):S16-S21
Stickler GB, Bergen BJ. A review: short stature in renal disease. Pediatr Res
1973;7:978-982
Strife CF, Quinlan M, Mears K, Davey ML, Clardy C. Improved growth of three
uraemic children by nocturnal nasogastric feedings. Am J Dis Child 1986;140:438-443
Tanaka T, Komatsu K, Takada G, Miyashita M, Ohno T. Prediction of adult height in
healthy Japanese children. Acta Paediatr Scand 1996;417suppl:57-60
Tang MLK, Kemp AS. Growth hormone deficiency and combined immunodeficiency.
Arch Dis Child 1993;68: 231-232
Tanner JM, Whitehouse RH, Takaishi M. Standards from birth to maturity for height,
weight, height velocity and weight velocity: British children 1965. Arch Dis Child
1966;41:613-635
Tanner JM, Goldstein H, Whitehouse RH. Standards for children's height at ages 2-9
years allowing for height of parents. Arch Dis Child 1970;45:755
Tejani A, Butt KMH, Rajpoot D, Gonzalez R, Buyan N, Pomrantz A, Sharma R.
Strategies for optimizing growth in children with kidney transplants. Transplantation
1989;47:229-233
Tejani A, Fine R, Alexander S, Harmon W, Stablein D. Factors predictive of sustained
growth in children after renal transplantation. J. Pediatr 1993;122:397-402
318
Thomlinson PA, Smellie JM, Prescod N, Dalton RN, Chantler C. Differential
excretion of urinary proteins in children with vesicoureteric reflux and reflux
nephropathy. Pediatr Nephrol 1994;8:21-25
TonshoffB, Schaefer F, Mehls O. Disturbance ofgrowth hormone - insulin-like
growth factor axis in uraemia. Pediatr Nephrol 1990a;4:654-662
TonshoffB, Mehls O, Heinrich U, Blum WF, Ranke MB, Schauer A. Growth-
stimulating effects of recombinant human growth hormone in children with end-stage
disease. J Pediatr 1990b; 116:561 -566
TonshoffB, Dietz M, Haffner D, Tonshoff C, Stover B, Mehls O. Effects of two
years of growth hormone treatment in short children with renal disease. Acta Pediatr
Scand 1991a;379(suppl):33-41
TonshoffB, Heinrich U, Mehls O. How safe is the treatment ofuraemic children with
recombinant human growth hormone? Pediatr Nephrol 1991b;5:454-460
Tonshoff B, Tonshoff C, Mehls O, Pinkowski J, Blum WF, Heirich U, Stover B,
Gretz N Growth hormone treatment in children with preterminal chronic renal failure:
no adverse effect on glomerular filtration rate. Eur J Pediatr 1992;151:601-607
TonshoffB, Haffner D, Mehls O, Dietz M, Ruder H, Blum WF, Heirich U, Stover B.
Efficacy and safety of growth hormone treatment in short children with renal
allografts: three year experience. Kidney Int 1993;44:199-207
TonshoffB, Eden S, Weiser E, Carlsson B, Robinson ICAF, Blum WF, Mehls O.
Reduced hepatic growth hormone (GH) receptor gene expression and increased
plasma GH binding protein in experimental uraemia. Kidney Int 1994;45:1085-1092
TonshoffB, BlumWF, Wingen A-M, Mehls O. Serum insulin-like growth factors
(IGFs) and IGF binding proteins 1,2 and 3 in children with chronic renal failure:
relationship to height and glomerular filtration rate. J Clin Endocrinol Metab 1995a;
80:2684-2691
TonshoffB, Powell DR, Zhoa DL, Domene HM, Blum WF, Moore LC, Kaskel FJ.
Decreased hepatic insulin-like growth factor (IGF)-I and increased IGF binding
protein (IGFBP)-l and -2 gene expression in experimental uraemia. J Am Soc
Nephrol 1995b;6:1032 abstract
TonshoffB, Blum WF, Mehls O. Serum insulin-like growth factors and their binding
proteins in children with end-stage renal disease. Pediatr Nephrol 1996;10:269-274
TonshoffB, Cronin MJ, Reichert M, Haffner D, Wingen AM, Blum WF, Mehls O.
Reduced concentration of serum growth hormone (GH)-binding protein in children
with chronic renal failure: correlation with GH insensitivity. The European study
group for nutritional treatment of chronic renal failure in childhood. The German
319
study group for growth hormone treatment in chronic renal failure. J Clin Endocrinol
Metab 1997;82:1007-1013
Tucker SM, Boyd PJR, Thompson AE, Price RG. Automated assay ofN-acetyl-b-
glucosaminidase in normal and pathological human urine. Clin Chim Acta 1975;62:
333-339
Tyden G, Berg U, Reinholt F. Acute renal graft rejection after treatment with human
growth hormone. Lancet 1990;336:1455-1456
Underwood LE, Van Den Brande JL, Antony GJ, Voina SJ, Van Wyk JJ. Islet cell
function and glucose homeostasis in hypopituitary dwarfism: Synergism between
growth hormone and cortisone. J Pediatr 1973;82:128
Unterman TG, Phillips LS. Glucocorticoid effects on somatomedins and somatomedin
inhibitors. J Clin Endocrinol Metab 1985;61:618-626
US Renal Data System. 1999 Annual Data Report. Bethesda: National Institutes of
Health, National Institute of Diabetes and Digestive and Kidney Diseases, April 1999
Vaccarello MA, Diamond FB, Guevara-Aquirre J, Rosenbloom AL, Fielder PJ,
Gargosky SE, Cohen P, Wilson KF, Rosenfeld RG. Hormonal, metabolic, and
pharmacokinetic effects of recombinant insulin-like growth factor-I in growth
hormone receptor deficient (GHRD) syndrome. J Clin Endocrinol Metab 1993;
77:1683-1689
van Diemen-Steenvorde R, Donckerwolcke RA, Brackel H, WolffED, de Jong
MCJW. Growth and sexual maturation in children after kidney transplantation. J
Pediatr 1987;110:351-356
Van Dop C, Donohoue PA, Bock GH, Ruley J. Enhanced growth with growth
hormone therapy after renal transplantation. Pediatr Nephrol 1989;3:468-469
Van Dop C, Donohoue PA, Jabs KL, Bock GH, Fivush BA, Harmon WE. Glucose
tolerance in children with renal allografts and effect of growth hormone treatment. J
Pediatr 1991;118:708-714
Van Dop C, Jabs KL, Donohoue PA, Bock GH, Fivush BA, Harmon WE.
Accelerated growth rates in children treated with growth hormone after renal
transplantation. J Pediatr 1992;120:244-250
Van Dyck M, Bilem N, Proesmans W. Conservative treatment for chronic renal
failure from birth: a 3-year follow-up study. Pediatr Nephrol 1999;13:865-869
Van Es A on behalf of the European Study Group. Growth hormone treatment in
short children with chronic renal failure and after renal transplantation: combined data
from European clinical trials. Acta Paediatr Scand 1991;379(suppl):42-48
320
Vest M, Talbot NB, Crawford JD. Hypocaloric dwarfism and hydronephrosis in
nephrogenic diabetes insipidus. Am J Dis Child 1963;105:175-181
Vihervuori E, Sipila I, Siimes MA. Increases in haemoglobin concentration and iron
needs in response to growth hormone treatment. J Pediatr 1994;125:242-245
Vijayan A, Franklin SC, Behrend T, Hammerman M, Miller SB. Insulin-like growth
factor I improves renal function in patients with end-stage chronic renal failure. Am J
Physiol 1999;276:R929-R934
Walker J, Chaussain J-L, Bougneres P-F. Growth hormone treatment of children with
short stature increases insulin secretion but does not impair glucose disposal. J Clin
Endocrinol Metab 1989;69:253-258
Warady BA, Kriley M, Lovell H, Farrell SE, Hellerstein S. Growth and development
of infants with end-stage renal disease receiving long-term peritoneal dialysis. J
Pediatr 1988;112:714-719
Warshaw B, Shaw M, Fine RN. Growth preservation after briefgrowth hormone
therapy in chronic renal insufficiency. Pediatr Nephrol 1997;11:82-83
Wass VJ, Barratt TM, Howarth RV, Marshall WA, Chantler C, Ogg CS, Cameron
CS, Baillod RA, Moorhead JF. Home haemodialysis: report of the London children's
home dialysis group. Lancet 1977;i:242-246
Wassner SJ. The effect of sodium repletion on growth and protein turnover in
sodium-depleted rats. Pediatr Nephrol 1991;5:501-504
Watkins SL. Bone disease in patients receiving growth hormone. Kidney Int 1996;
49(suppl 53):S126-S127
Wehrenberg WB, Janowski BA, Piering AW, Culler FL. Glucocorticoids: potent
inhibitors and stimulators of growth hormone secretion. Endocrinology 1990; 126:
3200-3203
Weidermann CJ, Neidermuhlbichler M, Geissler D, Beimpold H, Braunsteiner H.
Priming of normal human neutrophils by recombinant human growth hormone. Br J
Haematol 1991;78:19-22
Weigent DA, Blalock JE. The production of growth hormone by subpopulations of
rat mononuclear leukocytes. Cell Immunol 1991a;135:55-65
Weigent DA, Riley JE, Galin FS, LeBoeufRD, Blalock JE. Detection of growth
hormone and growth hormone -releasing hormone-related messenger RNA in rat
leucocytes by the polymerase chain reaction. Proc Soc Exp Biol Med 199lb; 198:
634-638
321
Werther GA, Haynes KM, Barnard R, Waters M. Visual demonstration and
localisation of growth hormone receptors on human developing growth plate
cartilage. I Clin Endocrinol Metab 1990;70:1725-1731
West CD, Smith WC. An attempt to elucidate the cause ofgrowth retardation in renal
disease. Am J Dis Child 1956;91:460-476
Wilton P. Treatment with recombinant human insulin-like growth factor-I of children
with growth hormone receptor deficiency (Laron syndrome). Acta Paediatr 1992;
383(suppl): 137-141
Wilton P. Growth promotion with recombinant human insulin-like growth factor-I in
Laron syndrome. Acta Paediatr 1993;391(suppl):20
Wingen A-M, Fabian-Bach C, Mehls O. European study group for nutritional
treatment of chronic renal failure in childhood. Low-protein diet in children with
chronic renal failure-1 year results. Pediatr Nephrol 1991;5:496-500
Winick M, Rosso P. Head circumference and cellular growth of the brain in normal
and marasmic children. J Pediatr 1969;74:774-778
Wit JM, Drayner NM, Walenkamp MJ, Hackeng WHL, Tyssen JFIH, Van den Brande
JL.Total deficiency of the growth hormone and prolactin, and partial deficiency of
thyroid stimulating hormone in two Dutch families: A new variant of hereditary
pituitary deficiency. Hormone Res 1989;32:170-177
Wit JM. Growth hormone treatment of idiopathic short stature in KIGS. In: Ranke
MB, Wilton P (eds) Growth hormone therapy in KIGS - 10 years' experience. Edition
J & J im J A Barth Verlag, Mannheim, Heidelberg, 1999:225-243
Wood WI, Cachianes G, Henzel WJ, Winslow GA, Spenser SA, Hellmiss R, Martin
JL, Baxter RC. Cloning and expression of the growth-hormone dependent insulin-like
growth factor binding protein. Mol Endocrinol 1988;2:1176-1185
Wuhl E, Haffner D, TonshoffB, Mehls O and the German Study Group for growth
hormone treatment in chronic renal failure. Predictors of growth response to rhGH in
short children before and after renal transplantation. Kidney Int 1993;44(suppl):S76-
S82
Wuhl E, Haffner D, TonshoffB, Mehls O and the German Study Group for growth
hormone treatment in chronic renal failure. Short dialyzed children respond less to
growth hormone than patients prior to dialysis. Pediatr Nephrol 1996;10:294-298
Yang CW, Striker LJ, Pesce C, Chen WY, Peten EP, Elliot S, Doi T, Kopchick,
Striker GE. Glomerulosclerosis and body growth are mediated by different portions of
bovine growth hormone. Lab Invest 1993;68:62-70
322
Pediatr Nephrol (1995) 9: 458-463
© 1PNA 1995 Pediatric
Nephrology
Original article
Differential effects of recombinant human growth hormone
on glomerular filtration rate and renal plasma flow
in chronic renal failure
Heather Maxwell1, Devati R. Nair2, R. Neil Dalton3, Susan P. A. Rigden3, and Lesley Rees1
1 Paediatric Nephrology and - Renal Research Unit, Royal Free Hospital, Pond Street, Hampstead, London NW3 2QG. UK
3 Children's Renal Unit, Evelina Children's Hospital, Guy's Hospital, London SEI 9RT, UK
Received April 24, 1994; received in revised form October 25, 1994 accepted January 12, 1995
Abstract. In normal subjects recombinant human growth
hormone (rhGH) increases glomerular filtration rate (GFR)
and effective renal plasma flow (ERPF) through the action
of insulin-like growth factor-I (IGF-I). We have measured
clearance of inulin and para-aminohippuric acid in 18
children with chronic renal failure (CRF) during their 1st
year of rhGH treatment to look at the immediate (first 3 h),
short-term (1 week) and long-term (1 year) effects of
treatment. On day 1 mean (range) age was 9.1 (4.9-13.9)
years. GFR 19 (9-58) and ERPF 77 (34-271) ml/min per
1.73 m2. During treatment height velocity increased from
4.5 (1.7-6.5) to 9.5 (4.8-12.7) cm/year (PcO.OOOl). Two
children required dialysis after 0.75 years and I child was
electively transplanted after 0.5 years. There were no other
serious adverse events. GFR and ERPF were unchanged in
the 3 h following rhGH. GFR remained constant on day 8,
22 (6-56) and after 1 year, 20 (9-59) ml/min per 1.73 m2.
ERPF increased to 96 (33-276) ml/min per 1.73 m2 on day
8 (P=0.005), and remained elevated, but not significantly
so, at 99 (24-428) ml/min per 1.73 m2 at 1 year. Fasting
IGF-I increased from 147 (46-315) ng/ml to 291 (61 -673)
by day 8 (P<0.003), and to 341 (101-786) ng/ml at 1 year.
There was no correlation between the change in IGF-I and
renal function. Blood pressure, albumin excretion and di¬
etary protein intake were unchanged by treatment. The
significance of increased ERPF after 1 week of rhGH in
CRF is unclear, but long-term follow-up of renal function is
indicated.
Key words: Recombinant human growth hormone -
Insulin-like growth factor-I - Chronic renal failure -
Glomerular filtration rate - Effective renal plasma flow
Introduction
Several studies have shown that recombinant human
growth hormone (rhGH) is effective in the treatment of
short stature of chronic renal failure (CRF) [I -3]. What is
not so clear at present is the safety of its use. Of particular
concern is the effect on renal function: rhGH, when given
experimentally to adults with normal renal function, in¬
creases glomerular filtration rate (GFR) and effective renal
plasma flow (ERPF). This effect occurs after several hours,
at a time when growth hormone (GH) levels have returned
to normal but levels of the GH mediator, insulin-like
growth factor-I (IGF-I), are elevated [4-7], Indeed, ad¬
ministration of recombinant human IGF-I (rhIGF-I) in¬
creases GFR and ERPF [8,9]. rhGH increases IGF-I levels
in CRF [1], but no changes in GFR have been found, either
in adults given rhGH experimentally [10] or in children in
therapeutic trials of the use of rhGH in short stature of renal
disease [11-13].
The effects of rhGH on ERPF in CRF in man have not
been reported. Recently however rhIGF-I has been shown
to increase both GFR and ERPF in adults with moderate
CRF [14]. If hyperfiltration is a mechanism for progression
of CRF in man, as appears to be the case in small mammals
[15], then rhGH treatment in children with CRF may lead
to a deterioration in renal function. We have therefore
looked at the effects of 1 week and 1 year of rhGH treat¬
ment on renal function and levels of IGF-I in children with
CRF. In addition, we have looked at the immediate effects
of rhGH in the 3-4 h following a subcutaneous injection.
Patients and methods
Correspondence to: H. Maxwell. Paediatric Office. 6th Floor. Royal
Free Hospital. Pond Street. Hampstead, London NW3 2QG, UK
Eighteen children with CRF have been studied. All were regularly
attending CRF clinics. At the start of the study, mean age was 9.1
(4.9-13.9) years, mean GFR, as measured by inulin clearance, 19
(9-58) ml/min per 1.73 m: and mean height standard deviation score
-3.0 (-4.8 to -1.8) using the Tanner and Whitehouse standards for
British children [16], Aetiology of renal disease was congenital
structural problems in 15 children and focal segmental glomerulo¬
sclerosis (FSGS) in 3. All were prepubertal, except 1 boy who pro-
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erased from pubertal stage I! to III during the year of study. rhGH
(Genotropin. Pharmacia. Stockholm) was given for 1 year, at a dose of
I IU/kg per week, as a daily subcutaneous injection every evening.
Written informed consent was obtained in all cases, and ethical ap¬
proval obtained from the participating hospitals.
The children were examined on day 1 and day 8, then at 3-monthly
intervals. Height, weight and blood pressure were recorded, blood
drawn (approximately 12 h after the previous dose of rhGH) for
estimation of GH and IGF-I. a full blood count and biochemical
profile, including plasma creatinine, urea and electrolytes. On each
dav an early-morning urine sample was obtained for measurement of
rr.icioalbumin. Three-day dietary assessments were made 6 monthly
(2 children received overnight nasogastric feeds).
GFR and ERPF were estimated by clearance of inulin (Inutest
25%, Laevosan-Gesellschaft. Linz/Donau) and para-aminohippuric
acid (PAH) (aminohippurate sodium 20%, Merck, Sharp and Dohme,
West Point. USA) respectively, using a standard clearance with urine
collection technique, described below. This procedure was carried out
on day 1. day 8 and at 1 year; on days 1 and 8 rhGH was given at
midday rather than in the evening. On day 1, eight urine collections
were made; the first three to establish baseline clearance. Immediately
the third collection was complete, the first subcutaneous injection of
rhGH was given and the urine collections continued without interrup¬
tion. On day 7 rhGH was given in the evening as usual, then exactly
the same procedure as above was carried out the following morning
(day 8), before and after the eighth injection of rhGH. Baseline
clearances (pre) were taken as the average of the first three collections
and compared with the average of the last three collections (nos. 6-8)
(post) to look for an immediate effect of rhGH. At 1 year, four 40-min
urine collections were carried out, 12 h after the last injection of rhGH.
Baseline clearances on day 1, day 8 and after a year were compared, to
look at the short- and long-term effects of rhGH. Four of the younger
children had baseline clearance tests only on each of the 3 days, four
-■ nin urine collections before rhGH on dayl, and at least 12 h after
tnc previous dose on day 8 and at 1 year.
The procedure was carried out after an overnight fast. A cannula
was inserted in each arm. a fasting blood sample withdrawn, then a
bolus of 50 mg/kg inulin and 5 mg/kg PAH in 50 ml of normal saline
given over 3-4 min. This was followed by infusion of a maintenance
solution of inulin and PAH in 0.45% saline, calculated to maintain a
plasma inulin level of approximately 250 mg/1 (mg inulin/min = 250/
1.000 x GFR) and 25 mg/1 PAH (mg* PAH/mfn = GFR/0.2 x 25/1,000).
The maintenance solution was infused at 100 ml/h. by constant rate
infusion pump (1MED Volumetric Pump 960. IMED. Albington,
ford. UK). Diuresis was induced by encouraging the child to
..mk water. 20 ml/kg for the 1st h. then 10 ml/kg per hour thereafter.
As the study lasted for several hours, the child was allowed to eat small
non-protein, non-fructose-containing snacks. After 1 h. steady state
was assumed and the bladder emptied. Eight 40-min urine collections
(collections 1-8) were made with the child being encouraged to
completely empty the bladder on each occasion. A sample of blood
was drawn, from the second cannula, at the midpoint of each collection
for inulin, PAH and GH. IGF-I was measured during collections 3 and
8. rhGH (0.14 IU/kg) was given by subcutaneous injection on comple¬
tion of the third collection.
Inulin was measured spectrophotometrically using a resorcinol
method [17], PAH was determined by the Bratton Marshall reaction
[18], creatinine by an enzymatic method using an RA1000 autoana-
lyser (Technicon Instruments, Basingstoke. UK) and IGF-I by radio¬
immunoassay after acid-ethanol extraction. It is recognised that this
method of extraction does not completely remove IGF-binding pro¬
teins [19], which can then interfere in the assay. The extent of
interference appears to depend on the particular antibody being used.
In our assay, acid chromatography (AC), when compared with acid-
ethanol (AE) extraction, gave comparable results in CRF (r - 0.979,
P< 0.0001) with AE giving slightly lower results [AE = (0.906 x AC)
-0.049]. GH was measured by immunoradiometric assay. Urinary
microalbumin was measured by an immunoturbidimetric method
(Technicon method, Bayer Diagnostics. UK). Urinary creatinine was
measured enzymatically on the same urine samples, and the results
expressed as the albumin/creatinine ratio.
Statistical analysis was performed using a paired Student's t-test
(and confirmed using a Wilcoxon matched pairs signed rank sum test).
A P value of <0.05 was taken as indicating a statistically significant
difference. Analysis of repeated measurements at different time points
in the same individual was by two-way analysis of variance. Correla¬
tion was performed by Pearson's correlation and multiple regression
analysis. Results are given as mean (range) unless otherwise indicated.
Results
Of the 18 children, 15 completed 1 year of treatment; 2
required dialysis after 9 months of treatment and the other
received a pre-emptive transplant after 6 months. Data from
these children, whilst they were in the trial, have been in¬
cluded and their height velocities on treatment annualised.
There were no other serious adverse events. Height velocity
increased from 4.5 (1.7-6.5) cm/year in the year before
treatment to 9.5 (4.8-12.7) cm/vear whilst on treatment
(P< 0.0001).
Table 1. Glomerular filtration rate (GFR). effective renal plasma flow (ERPF). insulin-like growth factor-I (IGF-I) and growth hormone (GH)
before and after recombinant human GH (rhGH) on days I and 8a-b
Day I Day 8
= 14 pre post pre post
>. iFR 22 (17) 21 (16) 23 (14) 25 (15)
tml/min per 1.73 m:) (9-60) (10-60) (6-5S) (7-53)
ERPF 81 (64) 80 (55) 99 (67)* 104 (72)*
(ml/min per 1.73 m:) (35-281) (35-247) (42-272) (38-272)
IGF-I 145 (67) 129 (61) 238 (141)*** 236 (141)***
(ng/ml) (51-255) (32-222) (59-546) (S9-590)
GH 12.2 (12.0) 105.9 (35.3)** 14.0 (11.2) 163.6 (75.9)**
i mU/I) (0.5-35.8) (33-166.8) (1.8-34.7) (80-291)
P <0.03 day I vs. day 8; ** P <0.001 post vs. pre; *** P <0.005 day 1 vs. day 8
Mean (SD) and range
h Pre rhGH IGF-I and GH values were taken 20 min before injection of rhGH; post rhGH values were taken 3 h after injection
460
Table 2. GFR, ERPF. filtration fraction and blood pressure (BP) during the year of rhGH treatment3
All patients after 1 week Patients completing study
Day 1 Day 8 Day 1 1 Year
(n = 18) (n = 18) (" = 15) (n = 15)
Baseline 19 (13) 22(13) 19 (14) 20 (16)
GFR (9-58) (6-56) (9-58) (9-59)
Baseline 77 (54) 96 (62)* 78 (58) 99 (111)
ERPF (34-271) (33-276) (34-271) (24-428)
Filtration 0.26 (0.07) 0.25 (0.09) 0.25 (0.07) 0.24 (0.08)
fraction (0.15-0.40) (0.11-0.41) (0.15-0.40) - (0.11-0.38)
Systolic 97 (6) 97 (6) 97 (6) 98 (11)
BP (90-110) (87-109) (90-110) (75-120)
Diastolic 58 (8) 59 (7) 59 (8) 64 (6)
BP (40-70) (45-70) (40-70) (40-85)
* P - 0.005 day 1 vs. day 8
a Mean (SD) and range
Fig. 2. Clearance of inulin [glomerular filtration rate (GFR)] in
individual patients on day 1. day 8 and after 1 year of recombinant
human growth hormone (rhGH) treatment. The mean value on each





Day 1 Day 8 3 6
Time (months)
Fig. 1. Mean (SEM) fasting insulin-like growth factor-I (IGF-t) and
growth hormone (GH) during the year of study
Fourteen children had clearance studies before and after a
subcutaneous injection of rhGH on days 1 and 8. Results
are given in Table 1. GH increased approximately ten-fold
in the 3-4 h follow ing rhGH on both days 1 and 8. There
was no change in IGF-I. GFR or ERPF during this time on
either day.
Results at I week
Eighteen patients had baseline clearances before and after
1 week of rhGH (Table 2). Mean fasting GH and IGF-I
were elevated at 1 week (Fig. 1). There was no change in
mean GFR (Fig. 2) but there was a significant increase of
approximately 25% in mean ERPF (Fig. 3). In individual
patients the increase in ERPF was in the order of 69c-30%
in 8. and between 32% -1319c in a further 6 patients. Three
patients showed a decline in ERPF (of 3%. 49c and 22%)
and in 1 patient there was no change. There was no re¬
lationship between day 1 GFR or ERPF and the change in
ERPF. Four patients showed an increase in GFR in addition
to an increase in ERPF. This subgroup was not dis¬
tinguished by baseline renal function, aetiology of renal
disease, basal IGF-I or increase in IGF-I after 1 week. In
-the group as a whole, there was a downward trend in fil¬
tration fraction, but this was not significant. Plasma urea
decreased significantly after 1 week. 18.2 (9.5-30) mmol/1
on day 1 and 13.9 (5.3-22.5) mmol/1 on day 8
(P< 0.0002), but returned to pre-treatment values by
3 months. Creatinine was unchanged after 1 week [274
(66-472) pmol/l on day 1: 279 (69-486) itmol/1 on day 8].
and there was no change in mean weight [22.2
(13.3-37.0) kg on day 1: 22.3 (13.4-36.8) kg on day 8] or
blood pressure during this time (Table 2).
Results at I year
Fifteen children completed 1 year of treatment; the results
are shown in Table 2 and Figs. 2-4. Mean IGF-I and GH
remained elevated during treatment (Fig. 1). GFR did not
change during the study, however there was a significant
401
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Day 1 Day 8 1 Year
Fig. 3. Clearance of para-aminohippuric acid [effective renal plasma
flow (ERPF)] in individual patients on day 1, day 8 and after 1 year of
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4. Mean (SEM) GFR and mean creatinine during rhGH treatment
increase in creatinine (PcO.001) (Fig. 4). Mean ERPF
remained elevated after a year when compared with day 1,
but this was not statistically significant. At 1 year ERPF
was markedly elevated in 1 child, was higher than day 1 in
4, remained constant in 4, and declined by 20%-50% in 6.
There was a downward trend in filtration fraction, but in¬
dividually there was much variation; the decrease was not
significant.
There was no correlation between baseline GFR, ERPF
and the change in GFR and ERPF at 1 week or after 1 year.
There was no correlation between absolute IGF-I (or IGF-I
corrected for age and sex) and GFR or ERPF on day 1, day
8 or at 1 year, nor was there a relationship between the
change in GFR or ERPF and the increase in IGF-I.
Mean systolic and diastolic blood pressures were un¬
changed by 1 year of rhGH (Table 2). Weight increased to
25.7 (15.5-39.2) kg after 1 year of treatment (P< 0.0001).
Microalbuminuria, measured as an albumin (mg/l)/creati-
line (mmol/1) ratio, was unchanged during the study mean
±SD (0.08 ±0.08 on day 1; 0.05 ±0.05 on day 8: and
0.10±0.12 at 1 year) in the 15 children with congenital
structural problems. The 3 children with FSGS had marked
proteinuria.
Dietary intake of protein did not change during the study
period: 2.1 (1.2-2.5) g/kg body weight protein on day 1;
1.9 (1.4-2.9) at 6 months; and 1.8 (1.4-2.1) at 1 year.
Energy intake (MJ/kg body weight) was not affected by
treatment: 0.36 (0.18-0.59) on day 1; 0.33 (0.27-0.47) at
6 months; and 0.36 (0.31-0.41) at 1 year.
Discussion
Many children with CRF grow poorly [20] despite elevated
GH levels [21], which suggests that there is resistance to
the actions of GH. Pharmacological doses of rhGH appar¬
ently overcome this and can effectively improve growth in
these children [1-3]. However prolonged exposure to
consistently high GH levels, such as are found in acrome¬
galy and diabetes, results in an elevation of ERPF and GFR
[22, 23], This may be beneficial in CRF, but if hyperfil-
tration is a mechanism for progression of CRF in man [15],
then rhGH treatment may in the longer term have a dele¬
terious effect on renal function in CRF. However, patients
with acromegaly do not go on to develop renal disease (in
the absence of diabetes and hypertension) [24], whereas
rodents exposed to prolonged elevation of GH levels de¬
velop glomerular sclerosis [25, 26],
In our patients there was no change in GFR during rhGH
treatment, confirming a study in seven adults with CRF,
none of whom showed any change in inulin clearance 24 h
after 3 days of rhGH [10]. It also supports the findings of
the rhGH trials in children with CRF [11 -13], where GFR,
as measured by single-injection inulin clearance, was un¬
changed after 6 months and 1 year [12], and where the
change in calculated creatinine clearance after 24 months
was no different on rhGH than placebo [13].
It is difficult to disentangle the long-term effects of
rhGH treatment on renal function from the natural pro¬
gression of CRF. Two children reached end-stage disease
during treatment and required dialysis. It is not known if
rhGH treatment affected their clinical course. Both children
had FSGS and a rising creatinine before starting treatment.
One child showed a 50% increase in ERPF after 1 week of
rhGH; the other showed little change in ERPF. Four chil¬
dren reached end-stage disease in the year following the
trial, so perhaps it was surprising that there was not a de¬
cline in mean GFR during the study.
Measurement of GFR by standard inulin clearance with
urine collections in children can be difficult. It is not ethical
to use bladder catheterisation, yet without it one cannot be
sure that the child has completely emptied their bladder.
Ensuring a high urine flow rate with the use of an oral
water diuresis makes it easier to empty the bladder, and so
reduces the risk of error. None of our children had bladder
dysfunction. To verify the adequacy of bladder emptying,
we also calculated baseline (pre GH) clearance of inulin by
the constant infusion without urine collection method; at
steady state the amount of inulin infused equals the amount
cleared in the urine [27]. There was close correlation be¬
tween these methods in our patients [28], confirming that
bladder emptying was complete.
Plasma creatinine rose significantly despite a consistent
IFR (Fig. 3), and presumably reflects an increase in
luscle bulk. Fractional excretion of creatinine was un¬
hanged by rhGH treatment (results not shown), therefore
te increase in plasma creatinine was not due to a reduction
t tubular secretion of creatinine. From our data it is clear
tat creatinine alone is an inadequate marker of GFR in
hildren with CRF during rhGH treatment.
None of the previously mentioned studies [10-13] have
>oked at the effects of rhGH on ERPF in CRF in man.
.fter 1 week of treatment we demonstrated an increase in
lean ERPF, to a degree similar to that seen in individuals
ith normal renal function (approximately 257c) [7],
hree-day dietary assessments confirm that increased
RPF was not due to an increase in protein intake during
le trial. Mean systolic and diastolic blood pressure did not
lange, therefore the increase in ERPF represents a de¬
cease in renal vascular resistance.
In 4 children there was also an increase in GFR. It was
at possible to predict the renal response to rhGH from
iseline characteristics and in the group as a whole there
as no relationship between the increase in circulating
}F-I and the changes in GFR and ERPF. Autocrine and
rracrine actions of IGF-I within the kidney may be as, or
■en more, important than circulating IGF-I in mediating
e renal effects of rhGH [29],
Our results are supported by a recent study of four adults
ith moderate CRF, all of whom showed an increase in
FR and ERPF in response to subcutaneous twice daily
jections of rhIGF-I for 5 days [14]. GFR increased be-
,-een 409f-70%, with a larger increase in ERPF, such that
tration fraction decreased in each of the four patients,
le degree of renal insufficiency was less than in our pa-
:nts. In two of these patients clearance of PAH remained
evated 10-12 days after stopping rhIGF-I. which the
sthors suggest may be due to glomerular hypertrophy, as
rculating IGF-I had returned to normal. GFR had. how-
er. returned to baseline. The renal response to rhGH and
IGF-I in CRF in man appears to be variable.
Micropuncture work in normal rats infused with rIGF-I
vealed an increase in GFR and ERPF due predominantly
an increase in efferent arteriolar dilatation and an in¬
case in the ultrafiltration coefficient [30]. The relevance
these changes in CRF [31. 32] and their application to
in are not clear, but it is interesting to speculate that
anges within the glomerulus in CRF. dependent on the
verity and aetiology of renal disease, may determine the
tponse, if any. to rhGH or rhIGF-I. Alternatively, as a
iuction in renal mass stimulates IGF-I production during
mpensatory hypertrophy in rodents [33. 34], there may
eady be increased IGF-I expression in the kidney in CRF
tich results in a different response to exogenous rGH or
JF-I. Renal hypertrophy per se may be important in the
.ponse to prolonged rGH exposure.
Whilst the evidence to date suggests that the renal ef¬
ts of rGH are likely to be due to an effect of IGF-I on
imerular haemodynamics. it is not inconceivable that
H increases secretion of PAH by the proximal tubule,
lile this cannot be discounted from our data, neither can
ie the whole explanation.
In small mammals, prolonged administration of GH
results in glomerular hypertrophy and glomerular sclerosis,
as has been shown in normal mice [25] and in renally
impaired rats [32], Interestingly prolonged exposure to
IGF-I causes hypertrophy but not sclerosis of the glomer¬
ulus in transgenic mice [25, 35], Micropuncture work has
shown that glomerular capillary pressure is not raised in
response to IGF-I in the normal rat [30], so perhaps
sclerosis is due to an action of GH which is not mediated
via IGF-I-induced haemodynamic changes [36]. As men¬
tioned before, patients with acromegaly do not develop
renal disease, despite exposure to high levels of GH. The
renal response to GH in man would appear to be different
from that in rodents; indeed the rodent reduced renal mass
model may not be representative of CRF in man.
In conclusion, during a 1-year study of the use of rhGH
in CRF, there was little change in mean GFR in those
children completing treatment. Of the 18 children, 2 pro¬
gressed to end-stage disease. After 1 week of treatment
there was a significant increase in ERPF, and in some
children ERPF remained elevated after 1 year. Whilst the
mechanism and indeed the significance of the response is
speculative at present, further study is needed to determine
if rhGH affects the progression of CRF in children.
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Recombinant human growth hormone treatment
in infants with chronic renal failure
H Maxwell, L Rees
Abstract
Poor growth is a particular problem for
children with congenital renal disease. A
one year trial of the use of recombinant
human growth hormone (rhGH) in eight
infants and young children with chronic
renal failure is reported here. At entry
bone age was less than 2 years, mean
(range) chronological age 1-9 (T3-2-7)
years, and glomerular filtration rate
(GFR) was 17 (9-42) ml/min/1-73 m2.
Height standard deviation score (SDS)
was -3-3 (-4-6 to -2-0) and height veloc¬
ity SDS was -1-3 (-3-1 to 0-7). One child
was withdrawn when he received a renal
transplant after 9-5 months. Two children
required dialysis, but remained in the
trial. Treatment with rhGH resulted in an
increase in height SDS to -2-2 (-4-2 to
-0-9), p = 0-0002, and height velocity SDS
to 1-1 (-0-7 to 2-6), p=0-006. There was no
change in GFR and no serious adverse
events. There was no effect on plasma
lipids, calcium, phosphate, intact para¬
thyroid hormone, or glucose. Alkaline
phosphatase rose significantly. Thus
rhGH improved growth in eight infants
with chronic renal failure, with four
children entering the normal range.
(Arch Dis Child 1996; 74: 40—43)
Keywords: chronic renal failure, infants, growth,
growth hormone.
deficiency are shorter and lighter than
normal.10
Recombinant human growth hormone
(rhGH) improves growth in older children
with chronic renal failure.11 12 We present here
the results of a one year study of the use of
rhGH in infants and young children with
chronic renal failure, who were not growing
despite good conservative management.
Methods
Criteria for entry to the study were: (1) chronic
renal failure with a glomerular filtration rate
(GFR) of less than 50 ml/min/T73 m2; (2) a
bone age of less than 2 years; (3) height less
than —2 SD or a declining height standard
deviation score (SDS) and no improvement in
growth despite correction of fluid and elec¬
trolyte and acid-base balance, bone disease,
and diet (including a trial of tube feeding when
necessary); (4) absence of uncontrolled renal
bone disease; (5) age less than 1 year at
presentation of disease; (6) two previous height
measurements in the last 6 months.
Children were excluded if there were other
severe congenital abnormalities or if there had
been a previous malignancy.
Growth hormone (Genotropin) (Pharmacia,
Stockholm) was given as a daily subcutaneous
injection (0-14 IU (0-05 mg)/kg/d, equivalent
to 1 IU/kg/week) in the evening for one year.
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Poor growth is a particular problem for
children with congenital renal disease.1
Growth in the first two years of life is greater
than at any other time; by the age of 2 years
children have attained half of their final adult
height.2 Ill health at this time results in a loss of
height potential. While subsequent growth in
the preschool and early school years is often
normal in these children, catch up is rarely
seen.3
Optimum conservative management, in¬
cluding provision of adequate energy, cor¬
rection of electrolyte disturbance and
acid-base abnormalities, and prevention of
renal osteodystrophy goes some way towards
improving growth, but many children remain
below the normal range.13"7 Nasogastric or
gastrostomy feeding to ensure adequate nutri¬
tion improves growth in some,3 8 but not all
children.3 9
Growth in the first two years of life is
strongly influenced by nutrition. It is now
appreciated that the influence of growth hor¬
mone is also important at this age; infants who
are later diagnosed as having growth hormone
PATIENTS
Eight children (three girls, five boys) were
enrolled. Mean (range) chronological age was
1-9 (1-3-2-7) years. Six children had congenital
structural problems, one had congenital nephro¬
sis, and another had bilateral neonatal renal vein
thrombosis. Calculated GFR13 at the start of
treatment was 17 (9-42) ml/min/1-73 m2.
Birth weight was 3-19 (2-24-4-50) kg at a
mean gestational age of 36-7 (34-41) weeks.
Five of the eight infants had a birth weight
within the normal range; one child was small
for dates and one of the two premature infants
had a weight above that expected for gesta¬
tional age. Growth data for the six months pre¬
ceding the trial were recorded. At the time of
entry to the trial, height SDS was -3-3 (-4-6
to -2-0). Height velocity SDS in the previous
six months was -1-3 (-3-1 to 0-7).
MEASUREMENTS
The growth standards of Tanner et al were
used to calculate the height and height velocity
SDS.2























Figure 1 Height standard deviation score six months
before, on day 1, and after one year of rhGH.
Children were seen three monthly, at which
time blood was drawn for estimation of urea,
creatinine and electrolytes, calcium, phos¬
phate, intact parathyroid hormone (PTH),
fasting glucose, insulin, cholesterol, and
triglyceride. Height, weight, blood pressure,
and adverse events were recorded.
Results are given as the mean (range).
Statistical analysis was performed using a
paired r test. Analysis of variance for repeated
measures was used to compare multiple mea¬
surements in the same individuals.
Results
Seven of the eight children completed one year
of treatment: one child was withdrawn when
he received a renal transplant after 9-5 months
of rhGH. Data from this child have been
included in the analysis. Two children reached
end stage renal failure and were begun on peri¬
toneal dialysis, one after four months the other
after 10 months. These children completed the
study and their 1 year growth data have been
included.
Height SDS increased from -3-3 (-4-6 to
-2-0) to -2-2 (-4-2 to -0-9) (p = 0-0002),
fig 1; height velocity SDS increased from —1-3
(-2-7 to 0-7) to 1-1 (-0-7 to 2-6) (p = 0-006),
fig 2. Height SDS calculated six months before
the study was -3-2 (-4-7 to -2-1), giving a
mean increase in height SDS during treatment
of 1-1 (0-4 to 1-7) compared to 0-08 (-0-6 to
0-6) in the preceding six months (p = 0-0016).
Response to rhGH in this group of patients
was unrelated to GFR. The greatest increment
in height SDS was seen in the youngest
children (r=— 0-794, p = 0-019) (fig 3).
There was no change in blood pressure
(table 1). Weight increased from 9-5
(7-5—13-8) kg to 10-6 (8-3—12-9) at six months
and 11-7 (8-9-13-8) after one year (p = 0-008
v dayl). Weight, expressed as per cent of the
ideal weight for height, was 98% (79-18) at the
Pre rhGH On rhGH
Figure 2 Height velocity standard deviation score before
and during rhGH treatment.
start of the study, and 96% (79-127) after one
year.
Calculated GFR (ml/min/1-73 m2) in the
children remaining on conservative manage¬
ment was unchanged by rhGH treatment, at
17 (9-42) on day 1 and 17 (6-34) after treat¬
ment. Results for creatinine, urea, and blood
pressure are shown in table 1. There were no
significant changes in any of these variables.
There were no consistent changes in plasma
calcium, phosphate, intact PTH, triglyceride,
or cholesterol (table 2). Alkaline phosphatase
was raised after six months (p=0-05) and
remained raised at one year (table 2). Plasma
glucose remained constant, but there was a
trend for an increase in fasting insulin (table
2). This was not statistically significant, pre¬
sumably because the sample number was
small.
No serious adverse events occurred during
the trial.
Discussion
In renal disease poor growth in the first two
years of life can result in a significant loss of
height potential.19 Growth thereafter in the
preschool and early school years is often
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Figure 3 Increment in height standard deviation score
during treatment plotted against age at start of treatment.
Table I Values for urea, creatinine, and blood pressure (BP) before and after recombinant
human growth hormone (rhGH) treatment (mean and range)
Day 1 6 Months After rhGH
Creatinine (mmol/l) 213 (70-320) 259(95-488) 276 (100-555)
Urea (mmol/l) 13 3 (4-19-2) 1-1-6 (1-7-20-4) 12 6 (1-4-21-9)
Systolic BP 99 (84-116) 103 (85-126) 93 (80-110)
Diastolic BP 65 (51-85) 61 (50-71) 54 (46-60)
but well below the third centile.34 Catch up
growth at this time is rare.3
At entry to the trial, mean height SDS was
-3-3 despite a mean age of just under 2 years.
A prospective study of growth in infancy in
chronic renal failure reported that the major
loss in height and weight SDS occurred within
the first six months9; this loss can be as great as
0-6 SD per month.5 Delay in diagnosis can
therefore result in a significant loss of growth
potential. Optimum conservative manage¬
ment, with correction of electrolytes, acid-base
status, and calcium metabolism and provision
of adequate nutrition improves growth in
some3 8 but not all children with chronic renal
failure.9 12 Improvement is more common in
children who present to a paediatric nephrolo-
gist below the age of 2 years than those who
present at an older age.3
Traditionally, it has been thought that
growth in infancy is influenced primarily by
nutrition, but recently growth hormone has
been recognised as a contributing factor at this
age.10 The use of energy supplements in
infants with chronic renal failure, by naso¬
gastric or gastrostomy feeding if necessary,
does not consistently improve growth.3 8 9 In a
placebo controlled trial, rhGH has been shown
to improve growth in older prepubertal
children with chronic renal failure,14 and to
maintain an improved growth velocity for up to
3 to 5 years, but there is little published data of
its use in infants and young children.1' The
results of rhGH treatment in two boys aged
less than 2 years with chronic renal failure was
reported in abstract form (Linne et al, Pediatr
Nephrol 1992; 6: CI 18). Both showed a good
response to treatment.
Height SDS did not change in the six
months before the trial, while it increased
from -3-3 to -2-2 during rhGH treatment.
Each child showed an improvement, with four
children entering the normal range. The incre¬
ment in height SDS represents good catch up
growth, and interestingly the greatest
improvement was seen in the youngest
children (fig 3).
The dramatic changes in height velocity in
the first two years of life make interpretation of
growth data difficult within this age group.
Height velocity SDS has been used to allow
comparison between height velocities at differ¬
ent ages. Ideally comparison should be with a
placebo control group, but ethically this is dif¬
ficult. With the small number of children
involved in this study, it was decided to treat all
children. Height SDS was used as the criterion
for entry to the trial. Annualisation to compare
height velocity at this age can be misleading
because of the changing velocity, yet observing
growth for one year to obtain an accurate
velocity measurement will only lead to a delay
in treatment.
Despite the low height SDS before treatment,
mean height velocity SDS was within the
normal range. This suggests that reduction in
height SDS had indeed started early.
Furthermore remarkable catch up growth on
rhGH was seen despite relatively normal height
velocity SDS values during rhGH treatment
(most values were within the normal range,
albeit in the upper half rather than the lower).
Although this is partly an auxiological phenom¬
enon resulting from the high rates of growth
seen in infancy, it appears to be easier to achieve
catch up growth at this time compared with
later childhood,11 12 15 a situation which is aiso
reported following renal transplantation.16 17
Growth after infancy, in the late preschool
and early school years, is often normal in
chronic renal failure3 6; it remains to be deter¬
mined whether or not children treated in
infancy with rhGH can maintain their position
within the normal range without further rhGH
treatment. Perhaps a short course of treatment
in infancy can achieve as much benefit as a
longer course later in childhood. The benefits
have to be weighed against the potential trauma
of daily injections in this age group. However
these children may need to remain on rhGH to
maintain a height within the normal range.
There was no change in calculated GFR in
the children who remained on conservative
management. Patients with acromegaly have
large kidneys that hyperfilter,13 and rhGH
increases GFR and effective renal plasma flow
(ERPF) when given to subjects with normal
kidneys.19 We have previously shown that one
year of rhGH treatment has no effect on GFR,
although there is an increase in ERPF after one
week, which is no longer evident at one year.20
The long term implications of these findings
are unclear. Two of the children were started
on dialysis; it is not known whether rhGH
treatment was implicated. The group included
several children with severely reduced renal
function; one child was withdrawn from the
study when he received a renal transplant.
Table 2 Plasma biochemical variables before and after recombinant human growth hormone (rhGH) treatment (mean
and range)








































*p=0-05 v day 1.
It has been much debated whether growth is
related to GFR per se. It has been reported by
one group1 that growth declines when the GFR
falls below 25 ml/ min/1-73 m2, and by others
that good growth can be achieved in some
children even at a very low GFR values.5 6 We
were unable to find a relation between growth
rate and GFR either before or after rhGH
treatment, although it is noted that our group
of patients is small. The two children who were
started on peritoneal dialysis had the smallest
increase in height SDS.
No adverse events were reported during the
trial. There was no significant change in serum
calcium, phosphate, or PTH, but there was an
increase in alkaline phosphatase during rhGH
treatment, as had been reported previously
during accelerated growth in older children on
rhGH.11 Baseline values of cholesterol and
triglycerides were variable, with no consistent
changes during treatment. There was a trend
towards an increase in fasting insulin during
rhGH, but no change in fasting glucose. The
same findings have been reported previously
with the use of rhGH in chronic renal failure;
fasting insulin returned to baseline during the
second year of treatment.14
In summary, one year of rhGH resulted in a
marked improvement in height SDS in a group
of infants and young children with chronic
renal failure. Two children reached end stage
disease and required dialysis. GFR in the
remaining children was unaffected by rhGH
treatment. There were no serious adverse
events. Further study is necessary to determine
the role and optimum timing of rhGH treat¬
ment in renal disease.
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Effects of recombinant human growth
hormone on renal function in children
with renal transplants
H. Maxwell, BSc. MBChB. mrcp. R. N. Dalton, ma, D. R. Nair, mbbs,
C. Turner, A. J. S. Saunders, mbbs, S. P. A. Rigden, mbbs, frcp,
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pital. Pond Street, Hampstead, London, and the Children's Renal Unit, Evelina Children's
Hospital, and the Department of Radiology, Guy's Hospital, London, United Kingdom
Objective: To provide accurate measurement of renal function during treatment
with recombinant human growth hormone (rhGH).
Methods: We measured glomerular filtration rate and effective renal plasma flow
by clearance of inulin and para-aminohippuric acid before rhGH therapy, after
1 week, and then at 6-month intervals for up to 2 years of treatment in 16 children
(mean (SD) age =13.1 (2.2) years; glomerular filtration rate = 52 (27) ml/min per
I.73 m2). The mean (SD) time from transplantation was 6.5 (3.6) years.
Results: Linear growth velocity during rhGH therapy increased from 4.0 (1.8) to 8.8
(2.6) cm/yr (p <0.0001). One child was withdrawn after 9 months because of ab¬
normal glucose tolerance, and another child received a second renal transplant
after 18 months. Glomerular filtration rate increased to 57 (29) ml/min per 1.73 m2
at 1 week (p = 0.004), remained improved at 6 months (63 (30); p = 0.013), but was
not significantly better at 1 year (59 (33)). Effective renal plasma flow on day 1 was
237 (127) ml/min per 1.73m2 and was unchanged on day 8 (244 (123)), at 6 months
(271 (149)), and after 1 year (269 (157)). During the study there was no significant
change in filtration fraction, blood pressure, or kidney volume, and excretion of
microalbumin and N-acetylglucosaminidase was unaltered. There was one
rejection episode per 14.8 patient-months in the year before treatment, 1 per 18.9
patient-months during the first year of treatment, and 1 per 13 patient-months
during the second year of rhGH therapy.
Conclusion: Treatment with rhGH improves growth in children with renal trans¬
plants. Glomerular filtration rate was increased after 1 week and 6 months of rhGH
therapy but returned to baseline values thereafter. The data indicate the need for
long-term follow-up of children with renal transplants who are receiving rhGH. (J
Pediatr 1996;128:177-83)
Recombinant human growth hormone has been shown to
improve growth in children with renal transplants, and its use
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is now becoming more widespread. However, there are con¬
cerns regarding the effect of rhGH on graft function. Patients
with acromegaly have large kidneys that hyperfilter.1 When
given to adults with normal renal function, rhGH increases
glomerular filtration rate and effective renal plasma flow.2
Growth hormone may also affect the immune system.3
thereby increasing the incidence of transplant rejection.4
Published reports give conflicting results of the effect of
rhGH on graft function.5"13 It is important to ensure that re¬
nal function is not compromised at the expense of improved
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ERPF Effective renal plasma flow
GFR Glomerular filtration rate
GH Growth hormone
IGF-I Insulin-like growth factor I
PAH Para-aminohippuric acid
rhGH Recombinant human growth hormone
growth, not least because graft function itself has been shown
to have an effect on growth.14 We have studied the effects
of rhGH on GFR, ERPF, kidney volume, blood pressure, and
the excretion of microalbumin and /V-acetylglucosaminidase
in 16 children with renal transplants, after 1 week and then
at 6-month intervals for up to 2 years of treatment. Seven
children acted as their own control subjects in the year be¬
fore treatment.
METHODS
Sixteen children (four girls) from two pediatric nephrol¬
ogy centers in London were entered into the study, which
lasted for 2 years and was part of a large international mul-
ticenter trial that is still in progress. More detailed renal
function studies were performed in this subgroup of patients,
who are therefore described separately. In the First year,
children were randomly selected either to receive treatment
or to have no treatment; in the second year, all children re¬
ceived rhGH. Results for all 16 children during the year of
rhGH therapy are reported and are compared with data from
the previous year. Patient details are given in Table I.
All children had either a height less than the 3rd percen¬
tile and a linear growth velocity less than the 75th percentile
or a height less than the 25th percentile and a linear growth
velocity less than the 25th percentile during the preceding
year. They had received their grafts more than 1 year previ¬
ously and had had stable graft function for the 6 months be¬
fore the trial. The initial diagnosis was congenital structural
problems in 9 children and congenital nephrotic syndrome
in 3. and the remaining 4 children had cystinosis, atypical
hemolytic-uremic syndrome, nephronophthisis, and unde¬
termined glomerulopathy, respectively. Two grafts were
from living related donors; 12 were first grafts. 3 were sec¬
ond grafts, and 1 was a third transplant.
Nine children received triple immunosuppression consist¬
ing of azathioprine, 60 mg/nr per day, cyclosporine (at a
dose sufficient to maintain plasma levels between 50 and 100
ng/ml). and prednisolone; seven children received only aza¬
thioprine and prednisolone. Prednisolone was given at a
mean dose of 9.8 (range, 5.2 to 20.1) mg/nr on alternate days
to 15 children; one child received 7.6 mg/nr daily. Recom¬
binant human GH (Genotropin, from Pharmacia) was given
at a dose of 0.14 IU/kg per day (equivalent to 1 IU/kg per
week or 0.35 mg/kg per week) as a subcutaneous injection
every evening.
Retrospective growth data and creatinine values were
available for all children for the year preceding entry into the
trial. Approval was granted by ethics committees at both
centers. Written informed consent was obtained from the
parents after verbal consent was given by the children.
Children were seen on day 1 (before treatment), day 8
(after 1 week of rhGH therapy), every 3 months for up to 1
year, and then every 6 months thereafter. On each occasion,
and while the children were in the fasting state, blood was
sampled for estimation of urea, creatinine, GH. and insulin¬
like growth factor 1 values. With the exception of day 1, these
samples were drawn approximately 12 hours after the pre¬
ceding dose of rhGH. Height was measured with a wall-
mounted stadiometer by the same observer. Blood pressure
was measured in the sitting position.
On days 1 and 8 and then at 6-month intervals, GFR and
ERPF were estimated by clearance of inulin (Inutest 25%,
Laevosan-Gesellschaft GmbH, Linz/Donau, Germany) and
para-antinohippuric acid (aminohippurate sodium, 20%;
Merck, Sharp & Dohme, West Point, Pa.), respectively, with
the use of a standard clearance with urine collection
technique, as described previously.15 Briefly, a dose of in¬
ulin and PAH was given, followed by an infusion of both;
the concentration of this solution was calculated so as to
achieve constant plasma levels. After I hour, four40-minute
urine collections were obtained. The GFR and ERPF values
were calculated from the average of the four collections.
Kidney volume was measured yearly by one of us
(A.J.S.S.), using either an ATL Mark IV (Advanced Tech¬
nology Laboratories, Inc., Bothell, Wash.) or an Acuson 128
(Acuson, Inc., Mountain View, Calif.) ultrasound machine,
with 3.5 or 5 MHz sector probes. When the whole length of
the kidney could not be included in the image, a stand-off gel
block was used. Repeated measurements of renal length
were made until a maximum was reached. Multiple depth
and width measurements were taken and averaged. Kidney
volume (measured in milliliters) was estimated by means of
the formula for an ellipse.16
Rejection episodes were diagnosed by the clinician in
charge, and were assumed to have occurred when there was
an increase in the baseline creatinine value ofmore than 10%
on two occasions, in the absence of a high cyclosporine level
(120 ng/ml; therapeutic range, 50 to 100 ng/ml), dehydration,
infection, or obstruction. Treatment consisted of a 3-day
course of orally administered prednisolone (3 mg/kg per
day). A renal biopsy was performed if the creatinine value
did not return to baseline after this treatment.
Inulin was measured enzymatically,17 PAH was deter¬
mined by the Bratton Marshall reaction,18 creatinine by an
enzymatic method using an RA1000 automatic analyzer
(Technicon Instruments Co., Ltd., Basingstoke, United
Kingdom), and IGF-I by radioimmunoassay after acid-eth-
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anol extraction. This last method of extraction does not
completely remove IGF binding proteins,19 which can then
interfere in the assay. The extent of interference appears to
depend on the particular antibody being used. In our assay,
acid chromatography, when compared with acid-ethanol ex¬
traction, gave comparable results in chronic renal failure
(?• = 0.979; /xO.OOOl). and acid-ethanol gave slightly lower
results (v = 0.906.V - 0.049). Growth hormone was measured
by a two-site immunoradiometric assay.
Ten children had urine samples analyzed for microalbu-
min by a two-site ("sandwich") enzyme-linked immun¬
osorbent assay.20 Polyclonal rabbit anti-human albumin im¬
munoglobulin was used both as the capture antibody and,
when conjugated to horseradish peroxidase, as signal anti¬
body (Dako Corp.. High Wycombe, United Kingdom). In-
traassay and interassay coefficients of variation were 4.2%
and I 1.9% at 10 mg/L, respectively. The reference range of
0 to 10 mg/mmol creatinine was obtained from healthy chil¬
dren.20
iV-Acetylglucosaminidase was measured by an automated
spectrophotometric method with /?-nitrophenyl-(3-D-glu-
cosaminide as substrate (Sigma. Poole, Dorset. United
Kingdom).21 Intraassay and interassay coefficients of vari¬
ation were 2.5% and 5.8%, respectively, at 3.9 pmol
/?-nitrophenol per hour per millimole of creatinine. The ref¬
erence range of 0 to 100 pmol /?-nitrophenol per hour per
millimole of creatinine was obtained from healthy chil¬
dren.20
Three-day dietary assessments were made at 6-month in¬
tervals.
Control data. Seven children were randomly selected to
receive no treatment in the first year. Their results during this
year will be summarized briefly.
Statistical analysis was performed with a paired Student
1 test; significance was confirmed with a Wilcoxon paired
rank sum test. Comparison of different groups was per¬
formed with an unpaired / test. Two-way analysis of variance
was used to compare repeated measurements in the same
group of patients.
RESULTS
Fifteen children completed I year, seven completed 18
months, and six have completed 2 years of rhGH treatment.
Fasting hyperglycemia developed in patient 6, in association
with a raised concentration of hemoglobin Ak after 9
months, at which time rhGH treatment was stopped.
Two children (patients 7 and 11) had poor graft function
at the start of the trial; both had biopsy-proven chronic re¬
jection. Patient I I received a second graft after 18 months
of treatment with rhGH; patient 7 completed 2 years of rhGH
therapy but required hemodialysis 6 months after completion
of the trial. Patient 13 had pyelonephritis after 18 months of
Table I. Patient details (N = 16)
Value (range)
Age (yr) 13.1 (9.4-16.4)
GFR (ml/min/1.73 nr) 52(18-1 17)
Time from transplantation (yr) 6.5(2.0-1 1.8)
HtSDS on day 1 -2.9 (-4.5 to -1.6)
HtSDS at 1 yr -2.4 (-4.3 to -0.9)*
GV (cm/yr) before rhGH therapy 4.0(0.8-8.1)
GV (cm/yr) during rhGH therapy 8.3(3-12.5)1
HtSDS, Heigh! standard deviation score; GV. [linearl growth velocity.
*/> <0.001 versus day I.
t/> <0.0001 versus before rhGH therapy.
rhGH and had a permanent deterioration of graft function
during this episode. Patient 16 had hypertension and hy¬
ponatremia after oral water diuresis during the inulin clear¬
ance study on day I; subsequent measurement of renal func¬
tion was by single-injection inulin clearance only.
Growth. Linear growth velocity doubled in the group re¬
ceiving rhGH. and was associated with a significant im¬
provement in the height standard deviation score (Table I).
Growth velocity during treatment was positively correlated
with GFR at the start of treatment (r = 0.637;/; = 0.006). Five
patients were pubertal at the start of rhGH therapy; Tanner
stage was 2 to 3 at the start of rhGH therapy and 2 to 4 after
I year. The other 11 children were prepubertal at the start of
the trial; I child progressed into puberty during treatment.
Glomerular filtration rate. The GFR increased from 52
(range, I 8 to I 17) to 57 (20 to 118) ml/min per 1.73 rrr after
I week of rhGH therapy (/z = 0.004). The GFR remained
improved at 6 months to 63 (18 to 133) ml/min per 1.73 m2
(p = 0.013) but not at I year (59 [15 to 113]) (Fig. I). By
analysis of variance, there was a significant increase in GFR
with time (/? = 0.036). There was no further significant
change in GFR in those children treated for 2 years; 53 (17
to 65) ml/min per 1.73 nr at 18 months (n = 7), and 38 (11
to 51) at 2 years (n = 5). Despite an increase in GFR, there
was an increase in plasma creatinine concentration from 110
(range. 43 to 221) pmol/L to 139 (64 to 317) after 1 year of
treatment (p = 0.028) (Table II), presumably because of an
increase in muscle bulk. The blood urea concentration
decreased after 1 week of rhGH therapy but returned to pre-
treatment values by-.3 months (Table II).
Effective renal plasma flow. There was no change in
ERPF, as measured by clearance of PAH, between day 1
(237 [82 to 495] ml/min per 1.73 nr) and day 8 (244 [88 to
539]). There was no significant change after 6 months (271
[95 to 572];/? = 0.065) or after 1 year (269 [56 to 538]). There
was no significant change in F.RPF in those children who
received rhGH for 2 years: 285 (54 to 598) ml/min per 1.73
m2 at 18 months (n = 7), and 219 (41 to 469) at 2 years
(n = 5). There was nochange in filtration fraction: 0.23 (0.14































Figure. GFR and ERPF during the year of rhGH treatment. Results are shown as mean and SE.
Table II. Results during rhGH treatment
Day 1 Day 8 At 3 mo At 6 mo At 9 mo At 1 yr
Creatinine (pmol/L) 110(43-221) 111(37-248) 114 (33-235) 114(37-240) 126 (47-252) 133 (47-317)*
Urea (mmol/L) 12.1 (6.0-26.7) 10(3.0-22.0)4 10.8(2.7-22.5) 11.9 (3.0-33.1) 1 1.6(3.2-22.2) 12.4(5.3-29.5)
GH (mU/L)i 6.2(1.1-14) 23.0 (5.0-52.1 )t 13.1 (1.5-30.6) 17.6(3.7-43.6) 12.8(1.0-43.6) 20.5 (0.7-59.3)
IGF-I (ng/ntL)§ 242 (95-410) 540(117-1002)t 613(166-903) 590(105-891) 649 (89-958) 681 (424-948)
Blood pressure (mm Hg)
Systolic 110(100-124) 114(100-128) III(95-130) 114(105-125) 108 (90-125) 115 (100-130)
Diastolic 70 (50-80) 76(50-95) 71(51-100) 75 (60-90) 68 (60-80) 69(60-80)
Values are mean (range).
*p = 0.03 versus day I.
ip < 0.001 versus day 1.
+Fasting GH: normal range is less than 10 mU/L.
§IGF-I: norma! range is age related.
to 0.42) on day 1, 0.25 (0.14 to 0.48) at 1 week, 0.25 (0.13
'o 0.36) at 6 months, and 0.24 (0.15 to 0.32) at 1 year.
Kidney volumes. Kidney volume was measured in 10
patients before and during rhGH treatment. Mean volume
was 128 (range. 57 to 221) ml on day 1 and 133 (57 to 227)
after 1 year (p = 0.14). The change in kidney volume was no
different from that seen in five children studied during the
year of no treatment: 114 (76 to 148) ml on day 1 and 123
(99 to 150) after 1 year {p = 0.38).
Blood pressure. There was no significant change in sys¬
tolic or diastolic blood pressure during rhGH treatment (Ta¬
ble II).
Transplant dysfunction. There was no increase in the
incidence of transplant dysfunction during rhGH treatment;
there was 1 episode per 14.8 patient-months in the year be¬
fore rhGH therapy; 1/18.9 patient-months during the first
year of rhGH therapy, and 1/13 patient-months during the
second year of rhGH therapy (Table III). In the first treatment
year there were 10 episodes of increase in serum creatinine
concentration, which were assumed to be related to rejection
and were treated accordingly. Six episodes occurred during
the second year.
Urinary protein excretion. Three patients had elevated
microalbumin excretion before starting rhGH treatment.
There was no significant change in albumin excretion dur¬
ing therapy: on day 1 the mean (SE) value was 17.3 (11.6)
mg/mmol creatinine; at 6 months, 13.8 (6.7); and at 1 year,
13.1 (6.1). There was also no change in the pattern of uri¬
nary /V-acetylglucosaminidase excretion: on day 1 it was 106
(27) pmol p-nitrophenol per hour per millimole creatinine;
at 6 months, 120 (20); and at 1 year. 123 (26). On day 1, four
patients had elevated levels that persisted with treatment.
Dietary assessments. There was no significant change in
mean (SE) dietary protein intake: 1.3 (0.2) gm protein N per
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kilogram of body weight on day 1,1.1 (0.3) at 6 months, and
1.3 (0.1) at 1 year. Energy intake was likewise unchanged:
37.9 (5.3) kcal/kg on day I, 31.6 (5.8) after 6 months, and
41.5 (7.7) at I year.
Growth hormone and insulin-like growth factor I. Se¬
rum GH and IGF-I levels increased after 1 week of rhGH
therapy and remained elevated thereafter (Table II). There
was no relationship between baseline IGF-I or increase in
IGF-1 and the changes in renal function in individual
patients.
Control data. Values for GFR. ERPF, creatinine, and
urea did not change in the seven children studied during their
year of no treatment (data not shown). Blood pressure, pro¬
tein excretion, and kidney volume were also unchanged.
Linear growth velocity was 4.5 (2.8 to 7.8) cm/yr during the
year before the trial, 4.1 (1.4 to 5.6) during the year of no
treatment, and 8.5 (5.3 to I I. I) during the first year of rhGH
therapy (p <0.004 vs year of no treatment).
DISCUSSION
We found that rhGH treatment in children with renal
transplants resulted in an increase in GFR after I week and
6 months, with a return to pretreutment values by 1 year.
There was no significant change in ERPF or in kidney vol¬
ume. There are a number of mechanisms whereby rhGH
could affect renal function. First, GH, through the action of
IGF-I. increases GFR and ERPF in the normal kidney: mi-
cropuncture studies in the rat demonstrate that this is due to
an effect on glomerular hemodynamics.22 Second, altered
renal function could be related to hypertrophy of the kidney;
prolonged exposure to GH causes renal enlargement, as seen
in acromegaly23 and in transgenic mice secreting high levels
of GH.24 Hypopituitary mice undergoing unilateral nephre¬
ctomy have reduced hypertrophy of the remaining kidney.23
Third, transgenic mice with prolonged exposure to GH (but
not to IGF-I) have glomerulosclerosis and renal failure.24
Finally. rhGH may have an effect on the immune system, and
in renal transplantation could precipitate acute rejection or
cause progression of chronic rejection.3
It is difficult to differentiate among these mechanisms. We
looked at the effects of rhGH after I week to see whether
there is a rise in GFR and ERPF, such as that seen in normal
adults. This is the case for GFR but not for ERPF. The in¬
crease in GFR was still evident at 6 months, in health it has
been proposed that this may be due to an alteration in glo¬
merular hemodynamics, as demonstrated by micropuncture
studies in rats.22 This may also be the explanation in our
children, because it is unlikely that any of the other mech¬
anisms outlined above would be acting at 1 week. At 6
months, increased GFR could still be due to altered hemo¬
dynamics. or possibly also to hypertrophy. With time, how¬
ever, other influences, such as progression of chronic rejec-
Table III. Episodes of transplant dysfunction
Year before First year Second year
Patient No. rhGH of rhGH of rhGH
I 0 0 0
2 0 0 0
3 0 0
4 1 0 0
5 0 0
6 0 0
7* 0 0 1
8 0 0
9 5 1 -)
10 2 1
11* 1 3 2
12 0 0




* Biopsy-proven chronic rejection before rhGH therapy.
tChronic rejection on biopsy during rhGH therapy.
tion, have to be taken into account. Despite the increase in
GFR, there was also an increase in the serum creatinine
concentration, presumably reflecting increased muscle bulk.
We previously showed a similar phenomenon in children
with chronic renal failure receiving rhGH.'"1
Few studies have formally measured GFR during rhGH
therapy. One reported no significant change in GFR. as
measured by single-dose inulin clearance,5 and the other13
reported no significant changes in GFR as measured by in¬
ulin clearance. Other studies of rhGH therapy after renal
transplantation quote changes in creatinine clearance or
changes in the slope of an inverse creatinine (I/creatinine)
plot; however, changes in the creatinine value do not always
reflect a change in GFR. Calculated GFR26 takes some ac¬
count of this; a multicenter European study10 showed no
significant change in calculated GFR after 1 year. Another
study7 showed no significant change in creatinine concen¬
tration in 19 children after 1 year, another reported a decrease
in creatinine clearance in 5 of 9 patients,12 and yet another
reported a decrease in calculated GFR in 3 but an increase
in the other 2 patients.9 Interpretation of these studies is
hampered both by the lack of formal measurement of GFR
and by the heterogeneity within patient groups. Slowly
growing children tend to have poorer renal function to start
with (in one study a rise in the creatinine value of 90 pmol/L
was associated with a decrease in the height standard devi¬
ation score of —0.17l4). Moreover, GFR decreases with the
number of rejection episodes and with the time since trans¬
plantation,27 so changes in GFR during studies such as these
may be related to factors other than rhGH.
It is more difficult to determine the effects of rhGH on the
1 8 2 Maxwell et al. The Journal of Pediatrics
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incidence of rejection episodes. Transplant dysfunction that
appears clinically to be rejection is treated in our centers with
a 3-day course of high oral doses of prednisolone; we pro¬
ceed to a biopsy only if there is no response to this treatment.
This does not allow assessment of the true incidence of re¬
jection. but a similar policy was used in both centers before
and during the trial. The incidence of transplant dysfunction
was not different during rhGH treatment in comparison with
the year before. From the literature, the use of rhGH has been
associated with biopsy-proven acute rejection in children
with previously stable graft function at variable times after
commencing rhGH therapy,8, l0,28,29 and also with the pro¬
gression of chronic rejection.7,12 In one report, two children
with previously diagnosed chronic rejection had an increase
in the serum creatinine concentration after the use of rhGH.
The creatinine level decreased when rhGH therapy was
stopped, which suggests a functional effect rather than irre¬
versible changes.30
Treatment with rhGH could also have an effect on tubular
function, as well as glomerular function; there are receptors
for GH on proximal tubular cells.31 To investigate this effect,
we measured urinary excretion of /V-acetylglucosaminidase.
a renal tubular enzyme. Excretion was unchanged during
rhGH treatment, as was the excretion of albumin.
We conclude that there was an increase in GFR after 1
week and after 6 months of rhGH therapy in children with
renal transplants; GFR returned to baseline by 1 year. We
found no change in ERPF, kidney volume, or rate of clinical
rejection episodes, and no change in urinary protein excre¬
tion. Therapy with rhGH had an acute effect on graft func¬
tion, which has not been demonstrated previously; whether
this is important in terms of long-term graft function remains
to be determined. The results of large multicenter trials, in
progress at the moment, may provide the answer.
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RECOMBINANT HUMAN GROWTH HORMONE
(rhGH) TREATMENT OF INFANTS AND YOUNG
CHILDREN WITH CHRONIC RENAL FAILURE
H MAXWELL, Lecturer in Paediatric Nephrology, Royal Free Hospital, London
SUMMARY Infants with chronic renal failure often grow badly despite medical
management. rhGH treatment results in good catch-up growth and should be used in
infants who do not respond to conservative management.
Growth can be a significant problem in renaldisease, particularly for children with con¬genital renal problems.1 Growth is fastest in
the first two years of life, and ill-health at this time
will result in the child's height rapidly falling away
from the centiles.2 Nasogastric or gastrostomy
feeding improves growth in some, but not all, of
these children,3 and this has lead to interest in the
use of rhGH in this age group/
There were nine infants with chronic renal fail¬
ure in the UK trial of recombinant human growth
hormone (rhGH) in renal disease, and data from
these children were analysed separately.5
PATIENT DETAILS
Criteria for entry to the study included a GFR
of <50ml/min/l,73m2, a bone age of less than
two years and a height less than the 3rd centile
or a declining height SDS, despite correction of
electrolyte and acid-base balance, bone disease
and the provision of adequate calories (by na¬
sogastric or gastrostomy feeding where neces¬
sary). All children had developed renal failure
before the age of one year. rhGH
(1 IU/kg/week) was given as daily subcutaneous
injection in the evening for one year.
Mean (SD) age was 2.0 (0.5) years, range
1.3-2.7 years, and mean height SDS was -3.3
(0.9). As height velocity changes dramatically dur¬
ing the first two years of life, change in height
velocity SDS (HVSDS) was used in preference to
height velocity. HVSDS in the year before the trial
was -1.3 (1.2). Calculated GFR was 17
(12)ml/min/1.73nr at the start of treatment.
RESULTS
Seven children completed a full yearof rhGH treat¬
ment. Two children received renal transplants dur¬
ing the study, and two others required peritoneal
dialysis. Annuaiised data from all nine children
have been included in the analysis.
HVSDS increased to 1.4 (1.1) during treatment
(p=0.004), and height SDS to -2.1 (1.0) (p<0.001)
(Figure 1). GFR at one year was unchanged at 16
(II). The best response to treatment was seen in the
youngest children (r = -0.864; p=0.002) (Figure 2).
DISCUSSION
HVSDS increased in all nine patients and was
associated with a marked improvement in height
Figure 1. Height SDS six months before, at the
start of, and after one year of rhGH treatment
n=9
-2 -
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Figure 2. Incease in height SDS, plotted
against age at start of treatment
SDS (1.2SD), with four children entering the nor¬
mal range. Fine et al reported similar findings in a
two-year study of rhGH in infants with CRF; mean
height SDS increased from -3.0 to -1.1.4
Growth is fastest during infancy and early child¬
hood. and while nutrition improves growth in some
children, this is not universal. Mean height SDS at
the start of treatment was -3.3, despite a mean age
of only 1.9 years and despite optimum conservative
management, showing that children with congeni¬
tal renal disease can rapidly fall away from the
centiles at this time.
Although growth rate after early childhood is
often normal in chronic renal failure patients,
catch-up growth is rare. It will be interesting to see
if infants treated with rhGH can maintain their
height SDS or if they require continuing rhGH
treatment. Whatever, rhGH treatment at this time
results in good catch-up growth and it should be
used in those infants who do not respond to conser¬
vative management.
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USE OF RECOMBINANT HUMAN GROWTH
HORMONE (rhGH) IN PUBERTAL PATIENTS WITH
RENAL DISEASE
H MAXWELL, Lecturer in Paediatric Nephrology, Royal Free Hospital, London
SUMMARY Growth during puberty in renal failure and following renal transplantation
is often poor. Treatment with rhGH improved height SDS in 13 pubertal children with
renal disease.
Recombinant human growth hormone(rhGH) is now being used for short staturedue to renal disease. Efficacy in prepubertal
children has been widely reported,1'4 but efficacy in
pubertal children is less clear. Growth during pu¬
berty is often poor in children with renal disease.5
In the combined UK trial of rhGH in renal disease,
13 children were in early puberty at the start of the
study; we present their data here.
METHODS
Children were classified as chronic renal failure
(CRF). dialysis, or post-renal transplantation. The
CRF group had a glomerular filtration rate (GFR)
of <50ml/min/1.73nr (for at least one year), and
the children in the dialysis group had all been on
either haemodialysis or peritoneal dialysis formore
than six months. The transplant group had stable
graft function and a minimum GFR of
20ml/min/1.73m\
Early puberty was defined in boys as a testicular
volume >4ml and <10ml. and in girls as Tanner
breast stage 2 or 3.
Mean patient details (range) are given in Table 1.
The transplant group received prednisolone 8.2
(0-15.2)mg/trr on alternate days. The children were
treated with rhGH at a dose of 1 IU/kg/week. given as
Table 1. Patient details
Age (years)
a daily subcutaneous injection in the evening. Re¬
nal function, rejection episodes and adverse events
were monitored.
RESULTS
Height velocity (Figure l) and height SDS (Figure
2) increased significantly during treatment. There
was no change in calculated GFR in the CRF group
(19 (10—30)ml/min/ 1.73m2 on day one; 18(11-26)
at one year), or in inulin clearance in the transplant
group (48 (32-78)ml/min/1.73nr on day one; 48
(27-84) after one year).
There were five rejection episodes in three of the
seven transplant children during the study. In the
year before the trial, there were four such episodes
in two (of the same three) children.
DISCUSSION
Height velocity increased in 11 of the 13 children
during rhGH therapy, corresponding to an increase
in height SDS of 0.5, p=0.004. In this group of
children. rhGH had no effect on renal function or
rejection rate.
While these results are encouraging, it is difficult
to differentiate the effects of rhGH from those of
the endogenous pubertal growth spurt in pubertal
HV (cm/yr) HtSDS
CRF (n=3) 13.8(13.0-14.4) 4.7(3.4-5.8) -3.1 (-4.2 to-2.3)
Dialysis (n=3) 14.5(12.4-15.7) 4.6(0.3-8.4) -2.8 (-4.8 to-1.0)
Transplant (n=7) 15.2(12.4-19.8) 4.2(1.3-8.1) -2.5 (-4.5 to-1.6)
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Figure 1. Height velocity during the year
before and the year of rhGH treatment
Figure 2. Height SDS one year before the trial,
on day one and after one year of rhGH
treatment
patients. A controlled trial is needed, but unfortu¬
nately, in any one study, the numbers are too small.
The transplant children are part of a multicentre
controlled study which should provide two-year
growth data. It is only when these children reach
final adult height, however, that the efficacy of
rhGH during puberty can be definitively deter¬
mined.
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Abstract. The effects of age, height velocity over the
preceding year, glomerular filtration rate (GFR) and pred¬
nisolone dose on growth response have been assessed by
single and multiple linear regression analysis in 23 pre¬
pubertal children [age, mean (SD), 8.2 (2.5) years] with
chronic renal failure (CRF) and 16 prepubertal children
[12.1 (2.3) years] with renal transplants treated for 1 year
. ith recombinant human growth hormone (rhGH), 30 U/m2
per week. Height velocity [mean (SD), cm/year] increased
from 4.7 (1.3) to 9.7 (2.1) (P <0.0001) in the CRF group
and 3.1 (1.6) to 7.3 (2.8) (P <0.0001) in the transplant
group. In the CRF group, there was a correlation between
age and height velocity, both in the pretreatment year
(r = -0.755, P <0.0001) and during treatment (r = -0.421,
P - 0.045). There was no correlation between pretreatment
height velocity or GFR and response to rhGH. In the
'.-unsplanted children height velocity during the treatment
car correlated with age (r = -0.647, P - 0.007), prednis¬
olone dose (r - -0.689, P = 0.003), GFR (r = 0.542,
P = 0.030) and pretreatment height velocity (r = 0.655,
P - 0.006). Multiple regression analysis showed predniso¬
lone dose and age to be the most important predictors of
response.
Key words: Recombinant human growth hormone —
Chronic renal failure - Transplant - Growth - Prednisolone
Table 1. Clinical details of the children treated with recombinant
human growth hormone (rhGHR
Age HtSDS GFR Height velocity
(years) (cm/year)
pre rhGH during rhGH
CRF 8.2 (2.5) -2.9 (0.6) 20 (12) 4.7(1.3) 9.7(2.1)*
(« = 23)
Transplanted 12.1 (2.3) -3.2 (0.9) 57 (30) 3.1 (1.6) 7.3 (1.8)*
(n = 16)
HtSDS, Height standard deviation score; GFR. glomerular filtration
rate; CRF, chronic renal failure
* P <0.0001 compared with pretreatment year
a Mean (SD)
hormone (GH) resistance in chronic renal failure (CRF) led
to the rationale for trials of recombinant human GH
(rhGH), which have proved to be successful, at least in the
short term. However, in every series there are children who
do not grow as well as would be predicted. We have ana¬
lysed the factors influencing the growth response to rhGH
in children with CRF and with renal transplants.
Patients and methods
Introduction
Over the last few years there has been considerable de¬
velopment in the understanding of the endocrinology of
growth failure in renal disease. The identification of growth
Correspondence to: L. Rees, Paediatric Office, 6th floor,
Royal Free Hospital NHS Trust, Pond St. Hampstead.
London N\V3 2QG. UK
We have treated with rhGH 16 prepubertal (Tanner stage 1) children
(12 boys) with renal transplants and 23 children (17 boys) with con¬
servatively managed CRF, as pan of two studies of the use of rhGH in
renal disease [1-3]. Only 4 children on dialysis have been treated,
therefore they have not been included in the analysis. Pubertal children
and those entering puberty (i.e. progressing beyond stage 1 for genital,
breast or pubic hair) during treatment have also been excluded, as
interpretation of growth during this time is confounded by the pubertal
growth spurt. All the children were over 3 years of age, with height
standard deviation scores (SDS) of more than 2 SD below the mean, or
height velocity SDS more than 1 SD below the mean. All had attended
the clinic for at least 18 months so that metabolic control had been
optimised and there were reliable height data for comparison of growth
velocity over the year before treatment with the year of rhGH treat¬
ment. None had diabetes, uncontrolled bone disease or abnormal liver
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Fig. 1. Effect of age at the start
of 1 year of treatment with re¬
combinant human growth hormone
(rhGH), 30 U/m- per week, on
height velocity during the treatment
year in: a 23 prepubertal children
with chronic renal failure (CRF)
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b Prednisolone (mg/m2) on alternate days
Fig. 2. Effect on height velocity
during I year of treatment with
rhGH (30 U/m: per week) in
17 prepubertal transplanted chil¬
dren of: a the glomerular filtration
rate (GFR) at the Stan of the year
and b the mean steroid dose over
the year
in Table 1. The mean (SD) prednisolone dose used for immuno¬
suppression was 12.5 (4.0)mg/m3 on alternate days, given as a single
dose in the morning. In the first 12 children studied, glomerular fil¬
tration rate (GFR) was calculated using the Schwartz formula [4]; in
the following 27 it was measured by inulin clearance. rhGH (Phar¬
macia) was given at a dose of 30 U/m: per week in daily doses sub-
cutaneously. Results over the 1st year of treatment have been analysed.
Student's r-tests and single and multiple linear regression were used for
analyses. P <0.05 was accepted as significant.
Results
Rate of growth increased significantly over the year of
rhGH treatment compared with the previous year in chil¬
dren with CRF (P <0.0001) and post transplant
(P <0.0001) (Table 1).
Transplanted children
Over the year before rhGH, there was no correlation be¬
tween height velocity and either age or GFR, but there was
with prednisolone dose (r = -0.603, P = 0.013). During the
year of rhGH, there was a correlation between height
velocity and age (r - -0.647, P = 0.007, Fig. 1 b), GFR
(r = 0.542, P = 0.030, Fig. 2 a), prednisolone dose
(r = -0.6S9, P = 0.003, Fig. 2 b) and height velocity during
the year before rhGH (r = 0.655, P - 0.006). There was no
correlation between GFR and prednisolone dose. Using
multiple regression, only prednisolone dose and age had a
significant effect on growth response; GFR and pretreat-
ment growth velocity no longer had a significant influence.
CRF patients
Over the year before rhGH, there was a correlation of
height velocity with both age (r = -0.755, P <0.0001) and
GFR (r = 0.467, P = 0.025). During rhGH therapy, height
velocity correlated with age (r = -0.421, P = 0.045)
(Fig. 1 a) but not GFR. There was no correlation between
age and GFR, or between height velocity before and during
rhGH treatment.
Discussion
Factors influencing the response to rhGH have been studied
in children treated with rhGH for many differing reasons. In
all cases, there seems to be an age-dependent effect, with
younger children responding the best [5]. A positive cor¬
relation between age and response to rhGH has also been
demonstrated in renal disease [6]. This relationship extends
from infancy [7] to puberty [6], and has been confirmed in
this study in both CRF and after transplantation.
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Another important factor influencing the response to
rhGH is the pretreatment growth velocity. In short normal
children, growth rate rather than absolute size is related to
endogenous GH secretion, and those with the lowest height
velocity and therefore the lowest endogenous GH secretion
have the best response to rhGH [5]. We were unable to find
such a relationship in our patients; indeed in the trans¬
planted children, the slower growing children had the
poorer response to rhGH, although when the results were
standardised for age, there was no correlation between the
height velocity SDS over the pretreatment year and the
increment in height velocity SDS. Whereas Wuhl et al. [6]
found a negative correlation between prestudy height ve¬
locity SDS and increment in height velocity SDS, this
correlation was positive in the study by Hokken-Koelega et
al. [8]. The reasons for the different findings are unclear,
but may be due to the small number of patients studied. If
there is a positive correlation between height velocity at a
given age and response to rhGH, this may reflect the dif¬
ferent mechanism of growth failure in renal disease, rather
than GH deficiency, there is GH resistance which is pre¬
sumably the most severe in the most slowly growing.
Children with renal disease have many factors that
might be expected to affect their response to rhGH, such as
the severity of their renal failure, their nutritional state,
accompanying metabolic abnormalities and, in transplanted
children, the dose of steroids. Although a correlation be¬
tween GFR and response to rhGH has not been demon¬
strated in CRF in both this and other studies [6] (and
varying control of these metabolic factors may be one
reason for this), children on dialysis do less well than those
on conservative management [9], A correlation between
growth response and GFR was seen, however, in our pa¬
tients after transplantation, although this correlation was no
longer significant when the effects of steroid dose and age
were taken into account. The most important factor to af¬
fect growth response in the transplanted children appears to
be the dose of prednisolone, even in children on an alter¬
nate-day regimen.
The growth-suppressing effects of steroid therapy are
well recognised. As part of the cause is a depressant effect
on GH secretion, there are theoretical reasons why trans¬
planted children might respond better than children with
CRF. who have normal or high GH levels [10]. However,
although most studies have shown an improvement in
growth, this is not usually to the same extent as children
with conservatively managed CRF [1. 7J. Our patients, like
those in the study of Wuhl et al. [6], responded equally well
to rhGH whether they were transplanted or in CRF.
In conclusion, children with conservatively managed
CRF respond better to rhGH the younger they are. After
transplantation, young age, good renal function, higher
pretreatment growth velocity and low-steroid dose are as¬
sociated with a better response to rhGH. However, age and
dose of prednisolone are the most significant predictors of
response. Therapeutic options for improving growth in the
older transplanted child on prednisolone therapy, with a low
GFR and a low pretreatment growth velocity, are currently
limited.
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The hypothalamo-pituitary-growth hormone insulin-like growth
factor 1 axis in children with chronic renal failure
Lesley Rees and Heather Maxwell
Department of Paediatric Nephrology, The Royal Free Hospital NHS Trust, London, England, United Kingdom
The hypothalamo-pituitary-growth hormone-IGFl axis in children with
chronic renal failure. Growth hormone (GH) levels are high in children
with chronic renal failure (CRF), and there is increased hypothalamic
sensitivity to the factors that normally modulate GH secretion. GH
binding protein (GHBP) is decreased, which may reflect decreased GH
receptor activity. IGFBP3 levels are normal in both CRF and transplanted
children when measured by immunoradiometric assay, but intact IGFBP3
is low in transplanted children with an excess of small fragments,
measured by Western immunoblotting. These fragments may interfere
with IGF1 bioactivity.
Normal growth depends on the complex interaction of genetic
influences, adequate nutrition, intact endocrine control, and
tissue responsiveness. Over the last few years there have been
considerable developments in our understanding of the hypo¬
thalamo-pituitary-growth hormone (GH)-insulin-like growth fac¬
tor (IGF) axis, both in health and disease. This paper will review
these developments.
The hypothalamo-pituitary-GH-IGF axis in health
The hypothalamus produces GH releasing hormone (GHRH)
and GH release inhibiting hormone (GHRIH) which together
modulate the secretion of GH so that it is released in pulses from
the pituitary (Fig. 1). The pulsatility of GH release seems to be
necessary for normal growth.
Approximately half of the GH circulates bound to a specific
high affinity binding protein, growth hormone binding protein
(GHBP). GHBP contains amino acid sequences that are identical
to the extracellular GH-binding domain of the GH receptor, and
it is thought that GHBP arises by proteolytic cleavage from the
GH receptor. The avidity and specificity of GHBP is similar to
that of the GH receptor itself. It is thought, therefore, that GHBP
may reflect GH receptor activity [1],
As well as modulating the interaction of GH with tissue
receptors. GHBP holds the pulse of GH in the circulation and in
the extracellular space and decreases its clearance [1],
The circulating GH-GHBP complex acts in two ways: firstly by
a direct effect on the chondrocyte, resulting in local production of
IGFI, which through a paracrine mechanism causes the clonal
expansion of differentiated chondrocytes, thus leading to bone
growth; and secondly it stimulates the liver to produce IGFI and
its insulin-like growth factor binding protein (IGFBP). It is
© 1996 by the International Society of Nephrology
believed to be free, rather than bound, IGFI that is able to
interact with chondrocytes. The relative importance of the endo¬
crine, paracrine and autocrine activities of IGFI remains specu¬
lative.
IGFBP3 is the major IGFBP in serum. The IGFBPs extend the
half-life of the IGF peptides, transport them to target cells and
modulate their interaction with surface membrane receptors.
IGFBP3 reflects GH secretion and sensitivity [2].
IGFBPs inhibit IGF action, both in tissue culture and in vivo.
This is thought to be due to competition with IGF receptors for
IGF peptides. IGFI binds to the IGFBP3 with higher affinity than
with its receptor. Recently specific receptors for IGFBPs on the
cell membranes have been demonstrated, suggesting a potential
mechanism for direct IGFBP action [2],
There are proteases that degrade IGFBP3 into fragments which
have decreased affinity for IGFI, but the physiological significance
of protease activity is not clear.
Disorders of growth may, therefore, result from abnormalities
at the hypothalamus, the anterior pituitary, the GH receptor, and
the interaction of IGFs with chondrocytes in epiphyseal growth
cartilage.
The hypothalamic control ofGHRH and GHRIH in CRF
Original studies of GH in CRF showed fasting GH levels to be
high, with an exaggerated and prolonged response to hypoglyce¬
mia, arginine and GHRH [3], Administration of somatostatin
causes a rapid decrease of plasma GH [4], These findings suggest
that in CRF there is an increased hypothalamic sensitivity and
responsiveness to the usual stimuli that induce GH secretion.
The pituitary
GH peaks are normal in frequency in CRF but increased in
amplitude with high basal levels. The worsening of CRF is
associated with a rise in GH baseline levels, and flattening of
peaks, presumably due to decreased renal clearance and pro¬
longed half life of GH (Fig. 2) [5],
The GH receptor
We have measured GHBP in 13 children with CRF. All the
children had been attending clinic for at least a year so that there
was reliable height data for that period, and metabolic control had
been optimized. The mean calculated GFR was 17 with a range of
6 to 36 ml/min/1.73 m2.
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Fig. 1. Current theory for growth in health.
Age 9.8 years
GFR 20 ml/min/1.73 m2
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Fig. 2. Overnight GH secretion in two boys in
CRF.
They were matched for age and height SDS with a group of 11
short normal children who were attending the growth clinic (Table
!)•
A sample of blood was collected in the morning after an
overnight fast. GH and IGFI were measured by radioimmunoas¬
say. GHBP was measured by incubation of serum with hGH
labeled with 125I. The sample was then analyzed by gel filtration.
This results in two peaks, representing the free hGH and the
Table 1. Measurement of GHBP in 13 children with a GFR (mean,
range) of 17 (6-36) ml/min/1.73 m2, and 11 short normal children
CRF Short normal
Age years 8.2(6.1 to 12.0) 8.6 (5.3 to 10.5)
Ht SDS -2.0 (-5.0 to 1.6) -2.3 (-3.3 to -1.1)
cm/year 5.9 (4.0 to 9.2) 4.7 (3.9 to 5.4)
Ht Vel SDS 0.1 (-2.4 to 2.5) -0.8 (-1.9 to 0.0)
Data are mean (range).
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Data are mean (range).
Table 3. Details of the patients treated with rhGH for one year
CRF Transplanted
Age years 8.7(4.1-13.9) 13.1 (9.4-16.4)
GFR 20 (9-58) 52(18-117)
mllmin/1.73 m2
Change in HtSDS 0.8 (0-1.4) 0.5 (-0.2 to 1.3)
during rhGH
Data are mean (range).
Table 4. IGFBP3 during rhGH treatment
Group Day 1 6 Months 1 Year
CRF
IRMA mg/liter 3.8 (0.7) 6.0(1.3)" 6.5 (1.8)"
WLB AU/mm2 102 (74) 139(79)" 182(93)"
Transplant
IRMA mg/liter 4.0(1.0) 5.4(1.5)" 5.5 (1.3)"
WLB AU/mm2 56 (45) 113(103)" 168 (86)"
Fig. 3. GHBP levels in 13 children with CRF and 11 short normal children.
P = 0.03.
bound GH. Binding is expressed as percentage of the total
radioactivity in the higher molecular weight peak [7]. Plasma
hemoglobin, urea, bicarbonate, parathyroid hormone (PTH) were
also measured as markers of metabolic control.
Figure 3 shows the mean and distribution of GHBP in the two
groups of children. GHBP levels were significantly lower in the
children with CRF than the short normal children (P = 0.03).
There was, however, no difference between the two groups for GH
or IGFI (Table 2).
No correlations were found between GHBP and growth, or with
GFR or metabolic control.
GHBP has also been shown to be low in children on dialysis [6].
Low GHBP in CRF may represent decreased GH receptor
expression, and may reflect GH resistance in CRF. Decreased GH
receptor expression may be due to circulating toxins, or to
down-regulation of the GH receptor due to increased circulating
GH levels in CRF.
Results are shown as mean and sd.
a P < 0.001 vs. day 1
The interaction of IGFI with chondrocytes
The predominating current theory for poor growth in renal
disease is that IGFBP3, which is renally excreted, is inadequately
cleared in CRF. This leads to high circulating levels of IGFBP3 and
its fragments, which are also thought to bind IGFI, resulting in less
free IGFI and therefore poor growth [8], However, not all investi¬
gators have been able to find high IGFBP3 levels in CRF [9],
Most investigators who have looked at IGFI bioactivity, mea¬
sured by incorporation of sulphate into cartilage cells in culture,
have found it to be reduced in CRF and in patients on steroid
therapy [8, 10, 11], IGFI measured by radioimmunoassay is
normal in both CRF and renal transplantation [12], Whatever the
mechanism for poor growth in CRF, rhGH increases height
velocity [12],
We have looked in detail at IGFBP3 and its circulating
fragments, at the start and over the course of a year of rhGH
therapy, and also at IGFI measured by radioimmunoassay (Max¬
well et al, submitted for publication).
There were 16 children with transplants and 17 with CRF. The
transplant group had received their grafts a mean (range) of 5.9
(1.9 to 11.8) years previously. The prednisolone dose was 8.8 (5.2
to 9.6) mg/m2 on alternate days. The rhGH dose was 1 p./kg/week.
The transplant group children were slightly older and had better
renal function (Table 3).
Before treatment, IGFBP3 was normal when measured by
immunoradiometric assay (IRMA) [13]. However, when assessed
by Western ligand blotting (WLB) [14], which measures intact
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Fig. 4. Measurement of IGFBP3 and its fragments using Western Immunoblotting in 6 children with CRF (A) and 6 children with renal transplants (BJ in
comparison to controls, and over a year ofrhGH therapy. Symbols are: (gg) intact; (□) 30 kD; (■) fragments. *P < 0.03 vs. controls.
IGFBP3, the levels in the transplant patients were significantly
lower than in CRF. IGFBP3, as measured by both assays, rose
over the year of rhGH treatment, so that IGFBP3 by WLB was
similar in CRF and post-transplant (Table 4). A previous study
using WLB in 7 adolescents on hemodialysis has also found levels
of intact IGFBP3 to be similar to controls, but there was an
increase of smaller fragments [13].
Sera from 6 children with CRF and 6 with transplants were
arbitrarily selected to be analyzed by Western immunoblotting
[15], which detects intact 1GFBP3, the 30 kD fragment and small
fragments of IGFBP3. Again there was no difference between
controls and the CRF patients, but there was an increase in
fragments in the transplant patients in comparison to controls.
The levels of 1GFBP3 increased over the year of rhGH therapy,
and the proportion of fragments decreased so that they did not
differ from the controls (Fig. 4).
For many years it has been recognized that IGFI bioactivity is
decreased in patients on steroid therapy, and it is interesting to
speculate that these 1GFBP3 fragments may be responsible for
the decreased bioactivity, either by interfering directly with the
IGFI receptor, or by binding IGFI.
As steroids are catabolic, we looked to see whether the
presence of circulating fragments could be due to increased
protease activity [16]. However, protease activity in both the CRF
and the transplant group was no different from controls.
IGFI levels increase with age in normal children, and the same
correlation could be found in these children. Although the mean
IGFI was within the normal range. 8 of the 33 children had levels
(converted to SDS) below the normal range. IGFI SDS at the start
of treatment correlated with height velocity SDS in CRF, and with
height velocity in the transplanted children (Fig. 5). IGFI SDS
rose significantly with rhGH therapy in both groups (Table 5).
Administration of rhGH may change the ratio of IGFBP3 to
IGFI, thus altering the proportion of free IGFI and increasing its
bioavailability.
Conclusion
Possible mechanisms of poor growth in CRF are decreased
receptor cell responses to GH and IGFI. The causes remain
unknown. It is possible that the increased circulating 1GFBP3
fragments found in transplant patients may be a result of steroid
therapy. These fragments may interfere with the bioactivity of
IGFI. High basal GH levels with loss of GH pulsatility are caused
by poor renal clearance, but may also, along with increased
hypothalamic sensitivity, be driven by the decreased activity of the
receptor cells.
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Oatch-up growth occurs after renal transplantation
in children of pubertal age
HeatherMaxwell, BSc, MBChB, FRCP, DieterHaffner, AID, and LedLey Reed, AID, FRCP
Objective: Assessment of growth after renal transplantation in children ot pu¬
bertal age by analyzing the annual increment in height standard deviation score
(Ht SDS) in all girls >10years and boys > 1 1 years of age at the time of trans¬
plantation until latest follow-up (minimum 2 years).
Patients: A total of £>9 grafts were placed in 54 recipients (30 boys) between
December 1984 and January 1995. Mean (range) age at transplantation was
13.6years (10.1 to 17.7years). Fifty-one percent had congenital renal disease,
36% acquired renal disease, and 13% had hereditaiy nephropathies. Eighty-
seven percent were first grafts; of these, 29% were performed pre-emptively,
and 23% were from living related donors.
Results: Mean (SD) Ht SDS at transplantation was —1.8 (0.2) and increased
significantly thereafter, such that it was —1.6 (0.2) at 1 year, n = 52; —1.5 (0.2) at
2 years, n = 47; —1.0 (0.2) at 3 years, n = 17; —0.7 (0.3) at 4 years, n = 19; and
—0.6 (0.3), n = 13, at 5 years after transplantation (analysis of variance, P <
.001). The greatest improvement in Ht SDS in the first year was seen in chil¬
dren with the highest glomerular filtration rate (r = 0.429, P = .002) and in those
who were shortest at the time of transplantation (r = —0.356, P = .009).
Conclusion: Catch-up growth occurs in children receiving renal transplants
during the expected time of puberty. (J Pediatr 1998;133:435-40.)
Chronic renal failure frequently results
in poor growth, so that many children
are short at the time of transplanta¬
tion.1,2 Good catch-up growth after
transplantation is related to a number of
factors: young age,3"9 good graft func¬
tion,®'7'9''® significant growth delay at
the time of transplantation,9,' ',12 and the
use of low doses of steroids,'3 particular¬
ly when given on alternate days.12.
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It has been stressed in several studies
that although catch-up growth can be
dramatic in young children, it rarely oc¬
curs in children who undergo transplan¬
tation during the pubertal age range.3"9
However, patients of pubertal age in our
center were observed to have catch-up
growth after transplantation comparable
to that reported in younger children.
Thus this study was designed to assess
the growth of all children of pubertal age
(girls aged >10 years and boys >11
years) at the time of transplantation who
had received a renal transplant in our
center since its inception 13 years ago.
We also looked to see whether other fac¬
tors known to influence post-transplant
growth were affecting the growth of our
patients.
Methods
One hundred thirty-nine renal trans¬
plants were performed in 122 children
over the 10-year period after the initia¬
tion of the transplant program in this
center in December 1984. Fifty-nine of
these grafts (in 54 recipients [30 boys])
were placed in children who were at or
above the expected age for the onset of
puberty (girls >10 years, boys >11
years). Data from these children are
reported.
GFR Glomerular filtration rate
Ht SDS Height standard deviation score
NAPRTCS North American Pediatric Renal Trans¬
plant Cooperative Study
From 1992 onwards, data were collect¬
ed prospectively; before 1992, data were
collected from review of the case notes.
Age, diagnosis, treatment modality, num¬
ber of human leukocyte antigen mis¬
matches between donor and recipient,
and height at the time of transplantation
were noted. After transplantation, height
and GFR by clearance of chromium eth-
ylenediaminetetraacetic acid were mea¬
sured after 6 months, 1 year, and then
yearly. Prednisolone dose adjusted for
surface area was noted at the end of each
post-transplant year.
Immunosuppression consisted of aza-
thioprine (60 mg/m2), cyclosporin A
(dose adjusted to maintain serum levels
of 50 to 150 ng/mL), and prednisolone.
Steroid equivalent to prednisolone 60
mg/m2/day divided into 2 doses was
given intravenously initially, then orally
when tolerated. This dose was tapered at
intervals of 3 to 4 days to a dose of 10
mg/m2/day by 4 to 6 weeks after trans¬
plantation. Over the next 4 weeks the
dose was reduced at approximately
43S
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Table I. Growth data for 5 years after renal transplantation
Time from Increase in HtSDS Cumulative increase
transplantation Height SDS No. from previous year in HtSDS
Day 1 -1.8 (-5.5 to 1.4) 52 0 0
1 Year -1.6 (-5.0 to 1.1) ° 52 0.19 (0.07) 0.19 (0.07)
2 Years -1.5 (-4.5 to 1.2) e 47 0.10 (0.07) 0.35 (0.12)
3 Years -1.0 (-4.5 to 1.8) * 27 0.16 (0.08) 0.67 (0.20)*
4 Years -0.7 (-2.5 to 1.9) * 19 0.15 (0.08) 0.91 (0.24)*
5 Years -0.6 (-2.3 to 2.0) e 13 0.19 (0.07) 1.15 (0.31)5
Results are given as the mean (range) or mean (SE).
°P < .01 vs day 1.
tP = .047 vs increase in FltSDS after 2 years.
ip = .057 vs increase in HtSDS after 3 years.
= .02 vs increase in HtSDS after 4 years.
weekly intervals to 5 mg/m2/day and
then gradually converted, again at week¬
ly intervals, to a dose of 10 mg/m" on al¬
ternate days by 10 to 12 weeks after
transplantation. One year after trans¬
plantation the mean (SE) dose of pred¬
nisolone was 8.5 (0.6) mg/m2 on alter¬
nate days; after 2 years 7.8 (0.5); after 3
years 7.5 (0.5); after 4 years 7.6 (0.6);
and after 5 years 7.0 (0.6) mg/m2 on al¬
ternate days.
Rejection episodes in the first 6 weeks
after transplantation were treated with
intravenous methylprednisolone (600
mg/m2 daily for 3 days); thereafter treat¬
ment consisted of oral prednisolone (3
mg/kg daily for 3 days). Steroid-resistant
rejection was treated with antithymocyte
globulin (Merrieux, France).
Of the 54 children, 51% had congenital
renal disease, 36% had acquired renal dis¬
ease, and 13% had hereditary
nephropathies. Fifty-one of the 59 grafts
were first grafts, 6 were second, and 2
were third. Of first grafts, 29% were pre¬
emptive transplants, and 23% were from
living related donors. One of the second
grafts was from a living related donor. The
mean age at transplantation was 13.6years
(range 10.1 to 17.7years). Only one child
received recombinant human growth hor¬
mone after transplantation. Only growth
data for the 18 months before recombinant
human growth hormone was started is in¬
cluded for this child. Three children re¬
ceived recombinant human growth hor¬
mone before transplantation.
Pubertal staging data were available for
those children who received transplants
from 1990 onwards (37 children). Of
these children, 19 of 37 were pubertal
(Tanner stage 2 or greater) at the time of
transplantation, and 18 were prepubertal
(Tanner stage 1). Nine of the 18 prepuber¬
tal children progressed into puberty dur¬
ing the study period after transplantation.
Growth data for 1 or more years was
available for 51 children (52 grafts); 3 grafts
were lost before 9 months, growth details
were unavailable for 3 of the first grafts in
patients who subsequently underwent re-
transplantation, and 1 child moved from the
area. Correlation between the increase in
Ht SDS during the first post-transplant
year and age, Ht SDS at transplantation,
pubertal stage, GFR, prednisolone dose,
donor source, number of human leukocyte
antigen mismatches, and number of rejec¬
tion episodes was performed.
ANOVA was used to compare data
from the same children at different lime
points. A paired Student t test was used
to compare the same groups at 2 differ¬
ent times; an unpaired t test was used to
compare 2 different groups. A P value of
< .05 was considered significant.
Results
One-year patient and graft survival
rates were 100% and 93%, respectively;
5-year patient and graft survival rates
were 98% and 75%, respectively.
Growth
One-year growth data were available
for 51 patients (52 grafts). Mean Ht
SDS increased from —1.8 (—5.5 to 1.4)
before transplantation to —1.6 (—5.0 to
1.1) after 1 year, P = .007. Ht SDS after
each year of the study is given in Table I.
Individual patients' Ht SDS at yearly
intervals after transplantation is shown
in Fig 1, A for boys and Fig 1, B for girls.
GFR
The mean GFR was 53 (20 to 103)
mL/min/1.73 m2 at 6 months, 52 (12 to
103) at 1 year, 45 (12 to 89) at 2 years, 44
(19 to 75) at 3 years, 42 (26 to 63) at 4
years, and 48 (28 to 81) at 5 years. These
values did not differ significantly.
Predictor,i of Growth Rate in the
Firot Po.it-tranop/ant Year
The greatest increase in Ht SDS dur¬
ing the first post-transplant year was
seen in those children with the best renal
function (r = 0.429, P = .002) (Fig 2). In¬
crease in Ht SDS was also related to Ht
SDS at transplantation (r = —0.356, P =
.009) (Fig 3) but not to age at transplan¬
tation (r = 0.217, P = .12), dose of pred¬
nisolone (r = —0.080, P = .59), or pubertal
stage (r = 0.095, P = .60). Increase in Ht
SDS in the first post-transplant year was
also unrelated to pre-emptive transplan¬
tation, donor source, degree of human
leukocyte antigen mismatching, and
number of rejection episodes.
The strongest predictor of increase in
Ht SDS in the first year was GFR
(mL/min/1.73 m2) at 1 year. Two factors
were related to GFR. One was the num¬
ber of rejection episodes; children with 2
or fewer rejection episodes had a higher
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Boys
A Time Post Transplantation (Years)
Girls
B Time Post Transplantation (Years)
Fig 1. Individual patients' Ht SDS at yearly intervals for boys (A) and girls (B).
GFR than those with 3 or more rejection
episodes in the first post-transplant year
(63.8 [18.2] VS 46.6 [19.0], P = .003). The
second factor was treatment modality be¬
fore transplantation; children who had re¬
ceived a pre-emptive renal transplant had
a higher GFR than those children who
were receiving dialysis at the time of trans¬
plantation (64.4 [20.3] vs 47.0 [21.2], P =
.015). GFR was unrelated to donor status.
During the second post-transplant
year there was a trend for increase in
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Fig 2. Increase in Ht SDS in first post-transplant year plotted against GFR at I year Increase in Ht SDS




Fig 3. Increase in Ht SDS in first post-transplant year plotted against Ht SDS at time of transplantation.
Children who were most stunted had greatest increase in Ht SDS.
Ht SDS to be greater in those children
who had received a pre-emptive renal
transplant (0.33 [0.14] vs 0.06 [0.08]
SD, P = .06) and those with a higher
GFR at 1 year (P = .07). In the third
post-transplant year increase in Ht SDS
was greatest in older children (JP = .05)
and in those who had received a pre¬
emptive transplant (0.36 [0.15] vs 0.04
[0.08] SD, P = .06).
Discussion
We have demonstrated that significant
catch-up growth can occur after renal
transplantation in children of pubertal
age. Indeed, Ht SDS increased signifi¬
cantly for up to 5 years, by which time
nearly all of the children had a height
within the normal range.
Such improvement in height after
transplantation is contrary to published
data in children of this age.3"9 The large
American database, North American Pe¬
diatric Renal Transplant Cooperative
Study, describes catch-up growth for up
to 2 years after transplantation in chil¬
dren <6 years but little or no change in Ht
SDS in 6- to 13-year-olds and a decrease
in Ht SDS in children 13 to 18years old.9
Only 6% of 13- to 18-year-olds had
The Journal of Pediatrics
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catch-up growth after 2 years, and after 5
years the proportion was little changed at
9%.15
The reports mentioned previously have
studied children of slightly different age
ranges.3"9 We chose age ranges of greater
than or equal to 10 years in girls and 11
years in boys to ensure inclusion of all
chddren going through puberty; in fact,
76% of children were in or entered pu¬
berty during follow-up. The NAPRTCS
group used different age ranges for
growth analysis9; if we include only chil¬
dren aged 13 years or over, so as to allow
comparison with NAPRTCS, the mean
(SE) increase in Ht SDS after 2 years in
our cohort is 0.57 (0.16), n = 28, com¬
pared with -0.21 (0.08) for NAPRTCS
and 1.1 (0.28), n = 15, after 3 years com¬
pared with -0.29 (0.13) for NAPRTCS.
It is not clear why our adolescents are
growing so well. Factors known to affect
post-transplant growth positively are
young age3"9 and Ht SDS at the time of
transplantation, with the most stunted
showing the best response.9,11'12 Howev¬
er, the mean (SE) Ht SDS at transplan¬
tation was —1.9 (0.19) in our patients,
which is similar to that in other studies:
NAPRTCS -2.41 (0.09),9 -1.62,6 -2.6
(0.40),11 and-2.41.12
Growth after transplantation is nega¬
tively affected by declining graft func¬
tion.®'7'9,19 Publications from the
NAPKINS database quote mean creati¬
nine clearance values of 68 and 65
mL/min/1.73 m2 for living related donor
and cadaveric grafts after 1 year in chil¬
dren >12 years at the time of transplanta¬
tion.16 The mean GFR in all of our pa¬
tients after 1 year was 52 mL/min/1.73 m2
(20 -103) as measured by the clearance of
chromium ethylenediamine tetraacetic
acid. Creatinine clearance can overesti¬
mate GFR and may explain the higher
values in NAPRTCS. However, it is clear
that our results cannot be explained on
the basis of better graft function.
A possible explanation for our results
is the early use of low-dose steroid thera¬
py. Growth after transplantation is re¬
ported to be influenced by total dose of
steroid,13 although no such correlation
was found in this study. This may be due
to the narrow dose range used or per¬
haps could be explained by a recent re-
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port that was able to relate growth after
renal transplantation to exposure to
prednisone (area under the curve) but
not to the dose per kilogram.'7
In addition to using a low dose of
steroids, we also favor early conversion
to an alternate day regimen. The same
total dose of steroid given on alternate
days is less growth-suppressive than
when given daily for juvenile chronic
arthritis,18 ulcerative colitis, asthma, and
nephrotic syndrome.'9 In children with
renal transplants there are uncontrolled
reports of normal'2,20 and poor
growth11-21,22 w|lJ1 prednisolone doses of
30 mg/m2 or less on alternate days. Broy-
er et al.14 compared 17 children who
were changed from daily to alternate day
prednisone 1 to 2 years after transplanta¬
tion, with 18 who remained on the same
total dose given daily. Ht SDS increased
by 0.5 SD in the alternate day group but
decreased by 0.1 SD in the daily group.
In our patients prednisolone was ta¬
pered to 10 mg/m2 on alternate days by
12 weeks after transplantation. The
NAPRTCS database reports doses of
prednisone of 0.31 mg/kg/day 6 months
after transplantation and 0.19 mg/kg/day
after 30 months.23 Although these total
doses are not dissimilar to ours, the dif¬
ference is that only 12% to 33% of the
NAPRTCS children were treated with
alternate day steroids. In other studies in
which older children showed poor
growth, most received daily steroids in
relatively high dose5, ; when children re¬
ceived alternate day steroids, they re¬
ceived a high dose.4,10 The NAPRTCS
database has also reported improved
growth in those children receiving alter¬
nate day steroids.24
The reason for the continuing use of
daily steroids is the fear of transplant re¬
jection. Although a number of studies de¬
scribe the benefits of alternate day
steroids or steroid withdrawal on
growth,25"27 many report an increased in¬
cidence of rejection.27"29 Acute rejection
rates of between 39% and 56% have been
described after stopping steroids,28,29 and
rates of up to 30% after conversion to al¬
ternate day regimens have been report-
ecj 12,14,20,27 jn sjucJy by Broyer et
ah,14 no increase occurred in the number
of rejection episodes in the group con¬
verted to alternate day steroids. Although
we do not have control data with which
to compare our rejection rate, our overall
graft survival data are no different from
those of other published series,15 and
GFR at 5years is well maintained. There¬
fore good growth in our patients is not at
the expense of loss of graft function.
GFR in the first year after transplanta¬
tion was greater in those children who
had received a pre-emptive transplant;
the difference was more than could be
explained by native renal function. In¬
crease in Ht SDS in the second and third
years after transplantation was greater in
patients who had received pre-emptive
transplants. The number of pre-emptive
transplants performed in our center may
possibly have a bearing on our results.
In conclusion, we have shown that
renal transplantation during the pubertal
age range can result in improved growth
for up to 5 years. Catch-up growth at this
age is contrary to published data, and we
postulate that it may be related to the
consistent and early use of alternate day
prednisolone. Such a steroid regimen
was not associated with increased graft
loss nor with a poor prediction for GFR
at 5 years in our patients.
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Abstract
Aims—To evaluate the efficacy (height
velocity (HV), change in height standard
deviation score (AHSDS)), and safety
(glomerular filtration rate (GFR), inci¬
dence of rejection, and calcium and
glucose metabolism) of recombinant
human growth hormone (rhGH) treat¬
ment after renal transplantation.
Design—A two year randomised control¬
led trial.
Subjects—Fifteen prepubertal and seven
pubertal children: mean (SD) age, 13.0
(2.6) and 15.2 (2.4) years, respectively;
mean (SD) GFR, 51 (30) and 48 (17) ml/
min/1.73 m2, respectively. Six prepubertal
and three pubertal children were controls
during the first year; all received rhGH in
the second year.
Results—In the first year, mean (SE) HV
and AHSDS in the prepubertal treated
group increased compared with controls:
8.1 (0.9) v 3.7 (0.6) cm/year and 0.6 (0.1) v
—0.3 (0.2), respectively. In the pubertal
treated group, mean (SE) HV and AHSDS
were also greater: 10.1 (0.6) v 3.9 (1.3) cm/
year and 0.6 (0.1) v -0.1 (0.2), respectively.
Comparing all treated and control chil¬
dren, there was no significant change in
GFR: treated group, mean (SE) 9.9
(5.4) ml/min/1.73 m2 v control group, -1.6
(7.6) ml/min/1.73 m2. There were also no
differences in the incidence of rejection in
the first year: eight episodes in 13 patients
v five episodes in nine patients, respec¬
tively. Phosphate, alkaline phosphatase
(ALP), parathyroid hormone (PTH), and
fasting insulin concentrations rose during
the first year of treatment, but not
thereafter. In the second year of treat¬
ment, HV remained above baseline.
Conclusion—Treatment with rhGH im¬
proves growth in prepubertal and puber¬
tal children with renal transplants, with
no significant change in GFR or the
incidence of rejection. Phosphate, ALP,
PTH, and insulin increased during the
first year of treatment.
CArch Dis Child 1998;79:481-487)
Keywords: recombinant human growth hormone;
growth; renal transplantation; renal function; transplant
rejection
Recombinant human growth hormone (rhGH)
improves short term growth in children with
chronic renal failure,1 2 and has been shown in
preliminary studies to improve growth in chil¬
dren with renal transplants.13-5 We report a two
year, prospective controlled trial of rhGH in
children after renal transplantation.
The use of rhGH after transplantation
requires close monitoring. There is potential
for rhGH to have an adverse effect on: renal
function,6 the incidence of transplant
rejection,7 renal bone disease,8 and glucose
metabolism.9 In view of this, glomerular filtra¬
tion rate (GFR), rejection rate, and indices of
calcium and glucose metabolism were followed
in our study.
Our study group included both prepubertal
and pubertal children, and the growth data for
these two groups are reported separately. Some
of the children remained on rhGH treatment
after the trial was complete and data from these
children are also reported.
Methods
Twenty two children with renal transplants
were enrolled into a two year, open labelled,
prospective and controlled trial of the use of
rhGH. Patients from three paediatric nephrol¬
ogy centres in the UK were stratified according
to pubertal stage, and then randomised to
rhGH (treatment group) or no treatment (con¬
trol group) in the first year of the trial, with all
children receiving rhGH in the second year. Six
children continued on rhGH treatment after
completion of the trial; data from these
children are also reported (follow up data).
Ethical approval was obtained from the centres
involved, and written consent was obtained
from the parents.
The children were seen on day 1, day 8, and
then at three monthly intervals for two years.
On each occasion, height, weight, blood press¬
ure, and blood biochemistry including urea,
creatinine, calcium, phosphate, alkaline phos¬
phatase (ALP), intact parathyroid hormone
(PTH), glucose, insulin, and glycosylated
haemoglobin (HbAlc) were checked. The
growth standards of Tanner and Whitehouse10
were used to calculate height standard devia¬
tion score (HSDS). Per cent ideal weight for
height (WFH) was calculated six monthly.
For the duration of the trial, the occurrence
of adverse events was noted. Every six months,
GFR was measured by clearance of inulin,
using a constant infusion and urine
collections.2 A rejection episode was defined as
an episode of transplant dysfunction treated
with three days of high dose oral prednisolone.
The diagnosis was made by the managing
clinician.
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Table 1 Height velocity and height velocity SDSfor the treatment and control groups
Height velocity (cm/year) Height velocity SDS
Patients -1 Year Year 1 Year 2 -1 Year Year 1 Year 2
Prepubertal
Treatment group (n = 9) 3.9 (1.7) 8.1 (2.7) 5.7 (2.9)f -0.8 (1.8) 5.3 (5.0) 3.0 (5.8)f
Control group (n = 6) 4.9(1.8) 3.7(1.5) 8.5 (1.6)f -1.1(3.0) -1.6(2.1) 3.0(4.6)*
p < 0.005 p < 0.01
Pubertal
Treatment group (n = 4) 4.5(2.5) 10.1(1.2) 6.4(2.1) -2.8(2.1) 5.5(3.9) 3.6(1.9)
Control group (n = 3) 2.7(1.6) 3.9(2.3) 6.1(4.7) -3.0(2.6) -0.2(1.0) 4.9(5.9)
p < 0.005 p = 0.06
Values are mean (SD). *p < 0.05; fp < 0.005 compared with the previous year.
Recombinant human growth hormone
(Genotropin; Pharmacia and Upjohn, Stock¬
holm, Sweden) at a dose of 0.14 IU (0.05 mg)/
kg/day (equivalent to a dose of 4 IU/m2/day)
was given as a subcutaneous injection each
evening by the child or a parent.
INCLUSION CRITERIA
Children were considered eligible for entry to
the trial if they fulfilled the following criteria:
height less than the third centile for age and sex
or a height velocity (HV) < 25th centile; normal
thyroid function. All had been transplanted for
at least one year, and had aminimum calculated
GFR of 20 ml/min/1.73m2."
EXCLUSION CRITERIA
Children were excluded from, the trial for the
following reasons: HV > 75th centile during
the preceding six months, treatment with any
form of growth hormone in the past year, a
previous malignancy, a severe congenital ab¬
normality, diabetes mellitus, or uncontrolled
renal bone disease.
The prepubertal group was defined by a tes¬
ticular volume of < 4 ml in boys and breast
development less than Tanner stage B2 in
girls.12 Children who were in the early stages of
puberty were enrolled into the pubertal group
(testicular volume & 4 ml and $ 10 ml, breast
stage B2 or B3).
23-78) ml/min/1.73m2. Eleven of the prepu¬
bertal children had renal failure secondary to a
congenital structural problem, two had
glomerulonephritis, one cystinosis, and the
other had atypical haemolytic uraemic syn¬
drome. In the pubertal group, three had
congenital structural problems, two glomeru¬
lonephritis, one congenital nephrotic syn¬
drome, and one had haemolytic uraemic
syndrome. HSDS at baseline, and HV and
height velocity standard deviation score
(HVSDS) during the preceding year are given
in tables 1 and 2. Immunosuppression con¬
sisted of azathioprine (60 mg/m2), pred¬
nisolone (10 mg/m2 on alternate days), and
cyclosporin A. Cyclosporin A dose was ad¬
justed to maintain plasma trough levels be¬
tween 50 and 150 ng/ml.
FOLLOW UP DATA
Fourteen children have been followed up for
two years, three for three years, two for five
years, and one child has been treated for six
years. HV and calculated GFR were measured
during this time. In addition, the first year of
rhGH treatment in all patients was compared
with the growth rate during the preceding year.
Age, pretreatment HV and HSDS, GFR, and
steroid dose were correlated with the increase
in HV and HSDS during the first year of treat¬
ment.
PATIENTS
Fifteen prepubertal (two girls) and seven
pubertal patients (two girls) were enrolled and
randomised to receive either rhGH or no rhGH
in the first year. Nine prepubertal and four
pubertal children received rhGH in the first
year (treatment group); all 22 children received
rhGH in the second year.
In the prepubertal group, the mean age was
13.0 (range, 9.4-16.5) years and mean GFR
was 51 (range, 13-117) ml/min/1.73m2. The
respective values in the pubertal group were
15.2 (range, 12.4-19.8) years and 48 (range,
Table 2 Height SDS atyearly intervals for the treatment and control groups
-1 Year Day 1 Year 1 Year 2
Prepubertal
Treatment group (n = 9) -3.4 (0.7) -3.6 (1.0) -3.0 (l.O)f -2.6 (1.3) *
Control group (n = 6) -3.0 (0.7) -3.0 (0.8) -3.3 (1.0) -2.8 (1.0)4:
Pubertal
Treatment group (n = 4) -2.1 (1.2) -2.4 (1.4) -1.9 (1.3) * -0.9 (0.4)
Control group (n = 3) -2.3 (0.1) -2.6 (0.2) -2.7 (0.5) -2.3 (0.8)
Values are mean (SD).
*p = 0.02 compared with day 1 ;fp = 0.001 compared with day 1; - 0.02 compared with year
1, within the same groups,
STATISTICAL ANALYSIS
Results are expressed as mean (range) or mean
(SD). Within and between group results were
compared using the paired or unpaired Stu¬
dent's t test, respectively. Comparison of
change within the treatment and control
groups was made by calculating and comparing
the mean (SE) change. Frequencies were com¬
pared using the x2 test. Analysis of multiple
results within the same group over time was
performed by analysis of variance (ANOVA).
Correlations were performed using Pearson's
correlation coefficient, and regression by both
single and multiple linear regression analyses.
Significance was set at a p value of < 0.05.
Results
TREATMENT GROUP (NINE PREPUBERTAL AND
FOUR PUBERTAL CHILDREN)
Two prepubertal children stopped rhGH; one
child returned to dialysis after 11 months, the
other developed glucose intolerance after nine
months of treatment. Two children stopped
treatment during the second year; one prepu-
rhCG in renal transplant recipients
bertal child had started the trial with poor graft
function and received a second graft after 18
months of rhGH, the other pubertal child had
an increase in creatinine.
CONTROL GROUP (SIX PREPUBERTAL AND THREE
PUBERTAL CHILDREN)
One pubertal child was withdrawn after 18
months because of a poor response to six
months of rhGH treatment.
GROWTH
Prepubertal group (n - 15)
During the first year of the study, HV and
HVSDS were greater in the treatment group
than the control group (table 1). The mean
(SE) increase in HSDS (AHSDS) during the
first year of study was 0.6 (0.1) in the treatment
group and -0.3 (0.2) in the control group;
p < 0.001 (table 2).
In the treatment group, there was no
difference between AHSDS in the first and
second years of treatment; 0.6 (0.1) v 0.4 (0.2),
respectively (p = 0.34). HV and HVSDS were
lower in the second year compared with the
first year of treatment (table 1). The increase in
mean (SE) HSDS during the second year in
the treatment group was greater than that in
the first year in the control group (0.4 (0.2) v
-0.3 (0.2); p = 0.003), but HV and HVSDS
were not significantly different (p = 0.16 and
0.09, respectively). In the control group, HV,
HVSDS, and AHSDS were greater in the sec¬
ond year of rhGH treatment than in the first
year (tables 1 and 2).
Pubertal group (n — 7)
The results in the pubertal group were similar
to those in the prepubertal group; however, the
numbers of children in the treatment and con¬
trol groups were small. During the first year of
the trial, HV and AHSDS were significantly
greater in the treatment group than the control
group; the corresponding p value for HVSDS
was p = 0.06 (tables 1 and 2).
In the treatment group, HV, HVSDS, and
AHSDS remained above pretreatment values
in the second year of the study, but were lower
than the respective values in the first year of the
trial. Comparing the first and second year data
in the control group, HV, HVSDS, and
AHSDS were greater in the second year than in
the first year, but the values were not significant
(tables 1 and 2).
Pooled follow up data for all prepubertal children
during rhGH treatment
When data are pooled for all 15 prepubertal
children during their first year of rhGH
treatment, mean HV increased significantly
from 3.8 (range, 0.8-6.9) cm/year in the year
before treatment to 8.2 (range, 3.0-12.5) cm/
year; p < 0.001. The corresponding values for
HVSDS were —1.1 (range, -4.7 to 2.1) and 4.4
(range, -2.7 to 13.6; p < 0.001). Mean HSDS
decreased from -3.2 (range, -5.1 to -2.0) to
-3.5 (-5.8 to -1.9; p = 0.015) in the year
before treatment, and subsequently rose to
-2.9 (-5.0 to -1.3) after one year of treatment
(p < 0.001).
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Ten prepubertal children received rhGH for
at least two years. In these children, HSDS
increased from -3.4 (-5.8 to -1.9) on day 1, to
-2.4 (-4.4 to —1.2) after two years
(p = 0.002). Mean HV was 3.9 (range, 0.8-
6.9) cm/year in the year before treatment, 8.2
(range, 3.0-10.7) cm/year in the first year
(p < 0.0002 compared with the previous year),
and 6.1 (range, 0.1-8.8) cm/year during the
second year (p = 0.012 compared with the year
before treatment). The mean gain in height was
14.8 (range, 3.1-18.5) cm in two years. Three
children received three years of rhGH treat¬
ment; mean height gain was 22.1 (range, 21.8-
22.4) cm in three years. One child received
rhGH for five years and another for six years;
HVSDS remained above pretreatment values
during this time.
Pooled follow up data for all pubertal children
during rhGH treatment
Considering all seven pubertal children, mean
HV increased from 4.2 (range, 1.3-8.1) cm/
year in the year before treatment to 8.4 (range,
1.8-11.7) cm/year (p < 0.05) during the first
year of treatment. Mean HSDS was -2.3
(range, -3.8 to —1.2) one year before starting
treatment, -2.5 (range, -4.5 to -1.6) at the
start of treatment, and -2.0 (range, -3.7 to
-0.9) after one year (p < 0.05). Five of the
seven patients completed the study, but elected
to stop treatment. Four children received two
years of rhGH: mean HV was 5.2 (range, 3.5-
8.1) cm/year before treatment, 9.3 (range,
5.3-11.7) cm/year in the first year of treat¬
ment, and 5.8 (range, 4.1-8.7) cm/year in the
second year of treatment, values very similar to
the prepubertal group. The average height gain
during two years of rhGH was 15.0 (range,
9.5-19.3) cm.
Regression analysis
There was no significant difference in the
increase in HSDS and HV in the first year of
treatment between the prepubertal and puber¬
tal groups. Combining the prepubertal and
pubertal groups, HV before and during rhGH
was related to age (r = -0.417; p = 0.05 and
r = -0.463; p = 0.03, respectively). Multiple
regression analysis revealed that prednisolone
dose (p = 0.028) and age (p = 0.049) were the
strongest negative predictors of AHSDS. Using
single regression analysis, HV during treatment
was positively correlated with GFR (r = 0.429;
p = 0.016), but this relation became non¬
significant when the effects of age and
prednisolone dose were taken into account.
There was no significant association between
AHSDS and HSDS on day 1 (r = 0.034) or
between AHSDS and HV (r = 0.265) before
treatment.
Weight for height
At the start of treatment, all children had a
WFH > 100%. The two lowest values (105%
and 108%) were in the two children who
received no prednisolone treatment. Mean
WFH decreased during the first year of
treatment from 133% (range, 105-171%) at
the start of treatment, to 125% (range,
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Figure 1 Glomerularfiltration rate (GFR) as measured by inulin clearance in individual
patients at six monthly intervals during the first two years of rhGH treatment.
99-152%) at six months (p < 0.001), and
122% (range, 96-152%) at one year
(p < 0.001). WFH remained significantly re¬
duced after two years 120% (range, 88-168%;
p = 0.016).
non-significant (n = 20; p = 0.12). There was
no further change in GFR during the second
year of rhGH treatment. Calculated GFR in
the children who continued on treatment after
the study was complete did not change (data
not shown).
Mean serum creatinine in the treated and
control groups did not differ at baseline:
control group, 100 (range, 49-152) pmol/1 and
treated group, 114 (range, 46-220; p = 0.46).
The mean (SE) change in creatinine during the
first year appeared to be greater in the treated
group (30.1 (11.7) pmol/l) than in the control
group (3.8 (6.2) pmol/1), but was not signifi¬
cantly different (p = 0.11). Mean creatinine at
one year in the treated group was 146 (range,
64-317) pmol/1 (p = 0.013 compared with day
1) and did not increase further during the sec¬
ond year of treatment; mean creatinine at two
years was 146 (range, 70-402) gmol/l. Urea
decreased slightly after one week of rhGH
treatment, but was unchanged thereafter (data
not shown).
RENAL FUNCTION
Results for the prepubertal and pubertal
children were combined; GFR at baseline was
comparable in the treatment and control
groups (p = 0.12). The mean (SE) change in
GFR during the first year was 9.9 (5.4) ml/
min/ 1.73m2 in the treated group (n = 12) and
— 1.6 (7.6) ml/min/1.73m2 in the control group
(n = 9; p = 0.22). One child in the treatment
group was withdrawn during the first year
because ofgraft failure. Setting his GFR to zero
at the one year visit does not significantly alter
the change in GFR during the first year: treated
group mean (SE) GFR 7.2 (6.0) ml/min/
1.73m2 (p = 0.36).
Individual GFR values for all children
during their first year of rhGH treatment are
shown in fig 1. Mean GFR increased signifi¬
cantly during rhGH treatment: 49 (range,
13-117) ml/min/1.73m2 on day 1 and 58
(range, 14-133) ml/min/1.73m2 after six
months (n = 22; p = 0.01). In those children
who completed a full year of rhGH, GFR
remained higher at one year; 51 v 59 ml/min/
1.73m2 (n = 19; p = 0.04). However, if a value
of zero is included for the child who lost his
graft, then the change in GFR becomes
Table 3 Indices of calcium and glucose metabolism in the treatment and control groups
Presumed rejection episodes
In the first year of the trial there were eight
presumed rejection episodes in 13 patients in
the treatment group and in nine patients in the
control group (p > 0.10). In the control group,
there were no differences between the numbers
of episodes in the first and second years of the
trial; five episodes in nine patients in each year.
Combining the data from all 22 children, there
were 15 episodes in 22 patients in the first year
of treatment, which was no different from the
year before rhGH treatment (11 episodes in 22
patients; p > 0.10).
ADVERSE EVENTS
A 10 year old girl had raised fasting glucose,
insulin, and HbAlc concentrations after nine
months of rhGH treatment. These values
returned to normal when rhGH was stopped.
Several years before, while on dialysis, she had
pancreatitis and required a partial pancreatec¬
tomy. Glucose tolerance tests before and after
withdrawal from the trial were normal. She
went on to develop insulin dependent diabetes,
and chose to restart rhGH treatment once
established on insulin replacement.
Control group Normal range Day 1 3 months 6 months 1 year
Calcium (mmol/1) 2.10-2.60 2.43 (0.09) 2.45 (0.04) 2.44 (0.08) 2.46 (0.08)
Phosphate (mmol/1) 0.8-1.50 1.23 (0.23) 1.29 (0.21) 1.20 (0.23) 1.32 (0.16)
ALP (units/1) 130-520 231 (81) 212 (89) 240 (145 214 (126)
PTH (ng/1) < 65 43.7 (35.3) 64.6 (48.1) 69.0 (46.0) 61.1 (44.9)
Glucose (mmol/1) 2.5-5.3 5.0 (0.6) 4.7 (0.8) 5.0 (0.8) 5.0 (0.7)
Insulin (units/1) 3-17 12.7 (6.1) 13.2 (4.8) 21.2 (19.8) 18.8 (15.2)
HbAlc (%) 2.8-4.9 4.7 (0.9) 4.9 (1.1) 4.5(1.2) 4.9 (0.8)
Treatment group Day 1 Day 8 3 months 6 months 1 year 18 months 2 years
l (W.IOJ (U.OO) 2HU (U.Zl)Calcium (mmol/1) 2.39 (0.14) 2.42 (0.16) 2.40 (0.17) 2.41 (0.14)
Phosphate (mmol/l) 1.35 (0.39) 1.39 (0.35) 1.63 (0.33)** 1.55 (0.21)* 1.57 (0.27)* 1.49 (0.28) 1.44 (0.31)
ALP (units/1) 201 (80) 152 (44) 313 (89)** 305 (87)** 275 (77)** 236 (72) 273 (97)
PTH (ng/1) 38.1 (15.2) 37.1 (24.7) 50.8 (29.7) 58.1 (39.4)* 61.7 (35.5) 50.7 (24.9) 58.6 (63.6)
Glucose (mmol/1) 4.8(0.9) 5.5(0.7) 5.3(0.8) 4.8(0.6) 5.0(1.2) 5.0(0.7) 4.6(0.6)
Insulin (units/1) 15.0 (7.8) 38.9 (30.7)* 36.6 (30.3)* 24.4 (12.4)* 18.1 (10.2) 36.2 (23.9) 18.9 (7.4)
HbAlc (%) 4.4(0.8) - 4.3(1.0) 4.4(0.9) 4.4(1.1) 4.8 (0.8)_ 4.6(0.8)
All values except normal ranges are mean (SD).
*p < 0.05, **p < 0.01 compared with day 1.
rhCG in renal transplant recipients
A 13 year old boy in the control group devel¬
oped worsening of a pre-existing idiopathic
scoliosis during rhGH treatment, which re¬
quired surgical correction the following year.
RENAL OSTEODYSTROPHY
Mean serum calcium, phosphate, ALP, and
PTH are shown in table 3. Phosphate, ALP,
and PTH increased significantly during the
first year of rhGH treatment, but did not
change significantly thereafter. No child devel¬
oped overt renal osteodystrophy.
GLUCOSE
Glucose, insulin, and HbAlc values are shown
in table 3. In the treatment group, there was a
trend for glucose to increase after one week
(p = 0.10), but not thereafter.When the results
for all children during rhGH treatment were
considered, there was a significant increase in
glucose after one week: 4.8 (0.9) on day 1 and
5.4 (0.7) on day 8 (p < 0.005). Fasting insulin
was raised in the treatment group after one
week of rhGH treatment and remained so until
six months, returning toward baseline there¬
after. HbAlc was unchanged in the treatment
group.
Discussion
This is one of the few controlled trials of rhGH
treatment in children with renal transplants to
date. This group of children were a subgroup of
a large multicentre European study. We have
established that rhGH improves growth in both
prepubertal and pubertal patients with trans¬
plants, that the growth response was equal in
the two groups, and that improved growth per¬
sisted during the second year of treatment.
Comparing the control and treatment groups,
there was no apparent adverse effect on graft
function.
There are several possible mechanisms
whereby rhGH or its mediator, insulin-like
growth factor-I (IGF-I), might affect graft
function: (1) rhGH increases renal plasma flow
and GFR in adults with normal renal
function613; (2) there are known interactions
between rhGH and the immune system, which
could potentially cause an increase in the rate
of rejection episodes14; and (3) rhGH could
have a direct effect on the kidney, because there
are growth hormone receptors on mesangial
cells and IGF-I receptors on proximal tubular
and mesangial cells.1'' Because of the relation
between rejection episodes and GFR, it is very
difficult to study the effects of rhGH on these
parameters in isolation.
We have reported previously that children
with renal transplants respond to rhGH with a
transient increase in GFR,16 similar to the nor¬
mal adult kidney.6 In renal impairment, an
increase in GFR might hasten the progression
of decline in GFR, the so called hyperfiltration
theory.17 There is no evidence that rhGH
adversely affects GFR in children with chronic
renal failure,2 18 but few studies of rhGH in
renal transplantation have formally assessed
GFR. Most studies report changes in creati¬
nine or calculated GFR, and an analysis of
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these trials has been inconclusive." Our data
suggest that two years of rhGH treatment does
not adversely effect graft function.
However, two children were withdrawn from
the study because of a deterioration of renal
function. For one patient there was suspicion of
non-adherence to immunosuppression, while
the other child had an acute rejection episode
after six months of treatment. His GFR at one
year was little changed from baseline, but one
week later he had a further increase in
creatinine and was withdrawn from the study.
A third child received a second renal transplant
after 18 months of rhGH. His renal function
had shown a gradual deterioration before and
during the trial. The small number of patients,
the variability of the clinical course after trans¬
plantation, and the expected decline in graft
function over time hamper interpretation of the
data.
There was no apparent untoward effect of
rhGH on the incidence of acute rejection.
Some reports suggest that rhGH does not
affect acute rejection,1 3 4 20 while others suggest
that it does.7 21 22 Biopsy proven, acute rejection
has been documented in several children at
varying intervals after starting rhGH
treatment.7 21 23 24 None of these were control¬
led trials. One study suggests that the risk of
rejection is increased by rhGH, but only in
children who have had rejection episodes
before treatment.22 In the first year of rhGH
treatment, seven of our patients had 15
presumed rejection episodes; all but one had
suffered presumed rejection episodes in the
previous year.
The incidence of rejection episodes in our
study is higher than other studies. This is
explained partly by the fact that these were
presumed and not biopsy proven episodes and,
therefore, likely to be an overestimation.
Several patients had chronic rejection at the
start of treatment, and other studies report
increases in creatinine during rhGH when
there is biopsy proven, chronic rejection.21"26 It
is difficult to determine whether rhGH has
decreased GFR, if there has been an increase in
muscle bulk, or if this is the natural progression
of chronic rejection. A recent study of mixed
lymphocyte cultures using lymphocytes from
paediatric renal transplant recipients and
donor cells, showed that overall, the addition of
rhGH to the culture had little effect, although
three patients had an augmented response.
These three patients had biopsy proven,
chronic rejection.27
The best response to rhGH was seen in the
youngest children and in those on the least
steroid, with the strongest predictor being the
dose of prednisolone (p = 0.029). Growth in
children with renal transplants, who are not on
rhGH, has been correlated with age, GFR, and
with steroid treatment.28 29 Children on alter¬
nate day steroids grow better than those on
daily steroids,29 and peak height velocity during
puberty in patients with renal transplants is
inversely correlated with steroid dose,30 so that
the relation between response to rhGH and
steroid dose is not surprising. In another post-
transplant study.23 the change in HSDS was
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greater than 0.4 after one year of rhGH
treatment in five of five children not receiving
steroids and one child on alternate day
steroids, but was only -0.2 (range, -0.6 to 0.3)
in 11 children on daily steroids. Mean
creatinine was the same in both groups. All of
our patients were receiving alternate day
steroids.
Whether rhGH benefits final height, particu¬
larly if it is not started until puberty, has yet to
be determined. In renal failure, puberty is
delayed and the magnitude of the pubertal
growth spurt is attenuated.30 Puberty would
seem to be an appropriate time to use rhGH, to
induce or mimic the endogenous growth spurt,
but there is concern that treatment might
shorten the duration of the pubertal growth
spurt.31 Some reports have suggested that this
might be the case in children with renal trans¬
plants who receive rhGH,25 32 while others have
demonstrated a substantial increase in height
during adolescence.3 20 There was no undue
advancement in bone age in our study (data
not shown), nor in other reported studies.20
The increase in HSDS was similar in the
prepubertal and pubertal treatment groups in
our study, with little or no change in HSDS in
either of the control groups. However, longer
follow up will be necessary to determine if
there is a positive effect on final adult height.
ALP, serum phosphate, and PTH increased
during treatment. rhGH increases phosphate
reabsorption by the renal tubule, and the
increase in serum phosphate stimulates PTH.33
It is important that PTH is monitored regularly
during rhGH treatment. There is a concern
that rhGH treatment might be associated with
an increase in the incidence of slipped capital
femoral epiphyses, avascular necrosis of the
femoral head, or worsening renal osteodystro¬
phy in children with renal failure.8 Routine hip
x rays were not performed in our study, but no
child developed overt renal osteodystrophy.
One of the patients developed glucose intol¬
erance during the study. This is a recognised
complication of acromegaly.9 Patients with
renal disease have peripheral resistance to the
actions of insulin,34 which is aggravated in
patients who have received transplants by the
use of corticosteroids.35 Glucose intolerance
during rhGH treatment after transplantation
has been reported previously.23 Our patient had
undergone a partial pancreatectomy, which
might have been a contributing factor. For the
group as a whole, the increases in fasting
glucose and insulin were transient, and during
two years of rhGH treatment there was no
increase in HbAlc. There would appear to be
no longer term adverse effect on glucose toler¬
ance.
In summary, rhGH improves short term
growth in prepubertal and pubertal children
with renal transplants compared with controls.
Mean HV during the second year of rhGH
treatment remained above the baseline value in
the prepubertal group. In both groups, the
approximate height gain was 15 cm after two
years of rhGH treatment. There was no
increase in the incidence of rejection episodes.
There was a significant increase in GFR during
the first six months of treatment, but not there¬
after. With continued use of rhGH, HVSDS
reduces towards baseline, but growth can
remain above pretreatment values for up to six
years.
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Abstract Lymphocyte subsets and T cell activation
markers were measured in ten children with renal trans¬
plants for up to 1 year before and during their 1st year of
recombinant human growth hormone (rhGH) treatment.
The number of lymphocytes, helper or cytotoxic T cells
or natural killer cells, and the T cell expression of CD25,
CD26 and HLA-DR antigens were not altered by rhGH.
B cell numbers declined both before and during treat¬
ment. There was no difference in lymphocyte subset
numbers between children with and without rejection
episodes.
Key words Recombinant human growth hormone •
Renal transplantation • Growth • Lymphocyte subsets •
T cell activation markers
Introduction
The use of recombinant human growth hormone
(rhGH) in transplanted children is controversial be¬
cause of the possibility of graft rejection. GH enhances
immune function in rodents [1], and there are GH and
insulin-like growth factor 1 (IGF-1) receptors on lym¬
phocytes and macrophages [2]. There are case reports
of acute rejection occurring after the introduction of
rhGH treatment [3. 4J. We studied lymphocyte subsets
.: 'i markers of T cell activation before and during
riiGH treatment in children with renal transplants, to
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see if there were any changes that might predispose to
acute rejection.
Patients and methods
Ten patients (7 boys) who were part of a randomised controlled
trial of rhGH post renal transplantation [5] were seen on one to
four occasions in the year before rhGH treatment (control phase)
and 3 monthly during treatment (rhGH phase). Mean (range) age
at entry to the study was 12.3 (9.4-15.2) years, glomerular filtra¬
tion rate (GFR) was 61 (26-93) ml/min per 1.73 m:, height
standard deviation score -2.7 (-3.5 to -1.6) and height velocity
4.2 (2.6-5.6) cm/year during the preceding year. The mean time
from transplantation was 5.2 (1.9-10.2) years. Diagnoses were
renal dysplasia in 4 patients, prune-belly syndrome in 2 patients
and 1 case each of cystinosis, haemolytic uraemic syndrome, con¬
genital nephrotic syndrome and idiopathic crescentic glomerulo¬
nephritis.
Immunosuppression was prednisolone [10.2 (7.6-20.2) mg/m-
every other day], azathioprine (60 mg/m: per day) and in seven
children cyclosporin A (trough levels 50-150 ng/ml). No child re¬
ceived recombinant erythropoietin. rhGH (Genotropin. Pharmacia
and Upjohn, Stockholm. Sweden) 0.14 IU (50 pg)/kg per day was
given as a subcutaneous injection each evening. Informed consent
and ethical approval were obtained.
At each visit haemoglobin, platelets, differential white count,
lymphocyte subsets and T cell activation markers were measured.
The number of lymphocytes, T (TCRap). CD4*. CDS*. B and nat¬
ural killer (NK) cells were calculated. The numbers of T cells ex¬
pressing the interleukin-2 receptor (CD25). MHC class II antigens
(HLA-DR) and another marker of T cell activation. CD26 (dipep-
tidy(peptidase), were recorded. These three antigens increase dur¬
ing T cell activation at early, intermediate and late times, respec¬
tively. Episodes of illness and graft rejection (as diagnosed by the
clinician in charge) were recorded.
Lymphocytes were separated on Lymphoprep (Nygaard, Den¬
mark) and incubated with T10B9 (TCRafi receptor) together with
a second antibody (listed below). Staining was performed by dou¬
ble-fluorescence flow cytometry (Facscan flow cytometer. Becton
Dickinson) using phycoerythrin-labelled anti-mouse Ig.M and fluo¬
rescein isothiocyanate-labelled anti-mouse IgG as second layers.
Using the lymphocyte gate determined by forward angle and
side scatter, the percentage total T cells (TCRap). T helper (CD4),
T cytotoxic (CDS). B (CD19) and NK (CD16-CD7-) cells was de¬
termined. The absolute number of each lymphocyte subset was
then calculated from the paired total lymphocyte count. The per¬
centage of T cells expressing CD25, CD26 and HLA-DR antigens
was determined.
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Monoclonal antibodies against CD2 (RFTI1). CD4 (RFT4),
CD7 (RFT2). CDS (RFT8).~CD25 (RFT5). HLA-DR (RFDR2)
were raised in the Department of Immunology. Royal Free and
University College Medical School. The following antibodies
were also used: T10B9 (TCRci(5), a kind gift from Professor
Thompson. Kentucky. USA. CD16 (Leu 11 b. Becton Dickinson)
and CD26 (Ta-1. Coulter).
As lymphocyte counts vary with age, and because it was not
possible to find an exactly matched control group, the patients act¬
ed as their own controls. To allow for day-to-day variation, the av¬
erage value of each subset or activation marker was calculated
during the control and rhGH phases and compared using a paired
Student's r-test. To exclude a difference due to the effects of time
alone, the change in lymphocyte numbers and activation markers
during each phase was calculated and compared. Summary data
are expressed as the mean (SE) Correlations were performed using
multiple regression analysis. A P value of <0.05 was taken to re¬
present statistical significance.
nificant difference between the change in B cell number
during each phase (P=0.72), suggesting an effect due to
time alone.
T cell activation markers (Table 1)
Surface expression of CD25 was variable, but was lower
during the treatment phase (P=0.013). However there
was no significant difference between the change in per¬
centage of CD25+ T cells in the control phase compared
with the rhGH phase (P=0.31), suggesting an effect of
time alone. There was no significant change in expres¬
sion of the CD26 antigen nor of DR antigens on T cells
either during the control or treatment phases.
Results
Nine children completed the study; one required dialysis
after 11 months of rhGH. Height velocity increased to
8.5 (5.3-11.7) cm/year during treatment (P<0.001). GFR
was unchanged: 61 (26-93) ml/min per 1.73 m2on day 1
and 61 (24-109) ml/min per 1.73 m- after 1 year. There
was no increased incidence of infections compared with
the year before the trial (data not shown).
During the year of rhGH treatment, two children had
three and three had one rejection episodes. No anti-
lymphocyte preparations were given. These same five
children had 12 such episodes in the previous year. The
other five children had no episodes of graft dysfunction
before or during treatment.
Lymphocyte subsets (Table 1)
There was no significant difference in the total number
of lymphocytes, nor in T cell (TCRaf}), CD4 or CDS
counts, or CD4/CD8 ratio, between the control and rhGH
phases. The B cell count was lower during rhGH treat¬
ment than during the control phase, but there was no sig-
Table 1 Lymphocyte subsets and T cell activation markers in ten
pediatric renal transplant patients before and after 1 year of re¬
combinant human growth hormone (rhGFL
Con trol phase rhGH phase
Number txlONfi
Total Kmphoevtes I.SS 10.60--3.48) 1.82 (0.57-3.65) P=0.7S
T cells' 1.40 (0.45--2.S!) 1.38 (0.33-2.96) P=0.92
CD4- o.so tO.IS--1.80) 0.80(0.20-1.94) P=0.99
CDS- 0.52 (0.05--1.19) 0.50 (0.07-1.65) P=0.82
Natural killer cells 0.25 (0.01--1.49) 0.11 (0.02-0.27) P=0.33
B cells 0.11 (0.03-0.25) 0.07(0.01-0.17) A=0.015
CD4/CD8 OSS (1.04-•3.78) 2.41 (0.75-7.13) A=0.91
Percentage T cells expres sing
CD25 14.7 (3.4-3S.5) 7.0(0.38-13.5) R=0.013
HLA-DR 25.3 (5.7-8 2.0) 16.0(2.9-63.3) P=0.34
CD26 38.1 (3.7-82.1) 34.5 (8.S-60.5) />=0.65
Correlations
There was no relationship between lymphocyte numbers
or percentage T cell activation markers and rejection epi¬
sodes, GFR or prednisolone dose, either before or during
rhGH treatment.
Rejection episodes
The five children who had rejection episodes were com¬
pared with the five who did not. There were no signifi¬
cant differences in lymphocyte subsets or T cell activa¬
tion markers either before or during rhGH.
Discussion
We have shown that lymphocyte subsets and the surface
expression of T cell activation markers were unchanged
during rhGH treatment of children with renal transplants.
GH is known to interact with the immune system; mice
with hypopituitarism have thymic aplasia [1], and GH
replacement not only improves growth but also restores
immune competence. In man peripheral lymphocytes ex¬
press GH and IGF-I receptors [2], and in vitro studies in¬
dicate a role for GH in lymphopoiesis [2J. as well as the
development of other haematopoietic cell lines [6]. With
rare exceptions [7], children with GH deficiency have
normal indices of immune function [8.9]. GH replace¬
ment may transiently decrease the percentage B cells and
CD4~ cells [9], although not to subnormal levels.
Possible consequences of rhGH treatment in trans¬
planted children are an increase in the incidence of infec¬
tion or rejection. To date there has been no reported in¬
crease in infections with rhGH [5. 10.11], but the risk of
rejection remains unclear. Three multi-centre studies
showed no increased incidence of rejection during rhGH
treatment post renal transplantation [5, 10,11], but sug¬
gested risk factors were the use of alternate-day rather
than daily steroids [10], and the occurrence of rejection
episodes prior to rhGH treatment [11]. All of the patients
475
in our study received alternate-day steroids, but only
those children with rejection episodes in the year before
rhGH had rejection episodes during treatment.
One small study has shown that the response to donor
tissue of rhGH-treated mixed lymphocyte cultures is
augmented in patients with chronic rejection. In our
study, half of the patients had rejection episodes during
rhGH treatment. However, they were indistinguishable
in terms of lymphocyte subsets and T cell activation
markers, either before or during rhGH treatment.
In conclusion, we have not been able to identify any
changes in peripheral T cell numbers or activation that
might predispose to rejection in children with renal
transplants treated with rhGH.
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In chronic nephropathies prolonged
ACE inhibition can induce remission:
dynamics of time-dependent changes in GFR.
investigators of the Gruppo Italiano Studi
Epidemiologici in Nefroiogia (GISEN Group)
J Am Soc Neph.ro! 11999: I1.1 99T-I006
The Ramipri! Efficacy in Nephropathy Core and Follow-lrp Study
found that > or = 36 r.ior.:.-.s of continued ramipri! therapy
decreased substantially the r:>k of end-stage renal failure (ESRF)
in patients w ith chronic nephropathies ar.d a urinary protein excre¬
tion rate > or = 3 e 24 h. Thi- study investigates the time-dependent
. tanges in GFR in these patients and in control subjects who were
. ndomi/ed to conventional therapy during the core period and
switched to ramipril during the follow-up study. Analyses includ¬
ed lot) patients icontinued ramipril: //= 74: switched to ramipril:
i: = 7oi who had at least three GFR measurements (including base¬
line) during the whole observation period and a subgroup of
43 patients (continued ramipril:. it = 26: switched to ramipril:
n = 17) w ho had at least six GFR measurements, including at least
three in the core and at least three in the follow-up study. Ramipril
(1.25 to 5 mg/d) and conventional therapy were targeted a: achiev¬
ing a diastolic BP below 90 mm Hg. The main efficacy variables
were GFR and ESRF (need for dialysis). Analysis was by inten¬
tion to treat. Throughout the study, the mean +'- SEN! rate of GFR
decline (deltaGFRi was significantly lower in patients continued
on ramipril compared to those switched to ramipri! 10.51+.'-0.09
versus 0.76—/-0.10 rnl'min cer l.~3 m- per month. P<0.031. In pa¬
tients on continued rami?::! who had a: leas: six GFR mea-
sured-but not in control subjects-deluGFR progressively im¬
proved with time and. in the cohort with the longest follow-up.
decreased from t in ml. min per 1.73 ru-' per month >: 0.16+/-0.12
(at IS monthsi to 0.I0-/-O.05 (at 60 months). This rate was about
10-foLi slower compared to patients on conventional therapy dur¬
ing the REIN Core study. Analyses of the individual slopes found
that a: the end of the follow-up. 10 of 26 patients on continued
ramipril therapy had a positive deltaGFR and another 10 patients
had an improvement of deltaGFR while on ramipri! therapy.
Delta GFR significantly improved in parallel w ith a significant re¬
duction in proteinuria. Changes in deltaGFR (P = 0.0001) and pro¬
teinuria IP = 0.04) were significantly different in the two groups.
Baseline characteristics and changes in systolic and diastolic BP
and 24-h urine urea and sodium excretion were comparable. The
present results offer evidence that in chronic nephropathies, the
tendency of GFR to decline with time can be effectively halted,
even in patients with remarkably severe disease.
